Manipulation of growth & meat quality by vitamin D and its analogues by Craggs, Lucinda
Craggs, Lucinda (2010) Manipulation of growth & meat 
quality by vitamin D and its analogues. PhD thesis, 
University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/13325/1/523214.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
Manipulation of Growth & 
Meat Quality by Vitamin D 
and its Analogues .. __ 
Lucinda Craggs, Bsc (hons) 
Thesis submitted to the University of 
Nottingham for the degree of Doctor of 
Philosophy, May 2010 
Table of Contents 
- - - - - - - - - - - - - - - - - - - - - - - - - - - ~ - - ~ - - - - - -
Table of Contents 
List of Figures 
List of Tables 
Abstract 
List of Abbreviations 
Funding Acknowledgement 
Acknowledgements 
Publication 
CHAPTER 1: INTRODUCTION 
viii 
xii 
xv 
xvii 
xx 
xxi 
xxii 
Introduction ...........•....................................................................................................................... 1 
1.1 Introduction to Literature Review ......................................................................................... 3 
1.2 Vitamin D ............................................................................. '" ............................................... 3 
1.2.1 Sources, synthesis and deficiency of vitamin D .............................................................. 4 
1.2.2 Action and Regulation of vitamin D production ............................................................. 6 
1.2.3 Vitamin D deficiency ....................................................................................................... 7 
1.2.4 Vitamin D and muscle function ...................................................................................... 7 
1.2.5 Vitamin D signalling ........................................................................................................ 8 
1.2.6 Vitamin D and Muscle: Summary ................................................................................. 13 
1.3 Introduction to muscle metabolism, development and growth and its relevance to meat 
quality .............................................................................................................................................. 13 
1.3.1 Myogenesis ................................................................................................................... 13 
1.3.2 Skeletal Muscle Architecture ........................................................................................ 19 
1.3.3 Muscle Function and Fibre type ................................................................................... 23 
1.3.4 MHC Genes ................................................................................................................... 25 
1.3.5 Muscle growth and fibre type ...................................................................................... 27 
1.3.6 Muscle fibre type control: Summary ............................................................................ 31 
1.4 Meat Quality """""""""."." .. "." ......................................................................................... 32 
1.5 Conversion of Muscle to Meat ............................................................................................ 33 
1.5.1 The Pre-rigor Phase ...................................................................................................... 33 
1.5.2 The Rigor phase ............................................................................................................ 34 
1.5.3 The Tenderisation phase .............................................................................................. 35 
1.5.4 Properties of Meat changed during the conversion ..................................................... 35 
1.6 Proteolysis and Tenderisation ............................................................................................. 36 
1.6.1 The Calpain System ....................................................................................................... 37 
1.6.2 Regulation of calpain activity by calpastatin ................................................................ 39 
1.6.3 Function of the Calpains ............................................................................................... 39 
1.6.4 The calpain system and meat quality ........................................................................... 40 
1.6.5 Evidence for the Il-calpain as major contributing enzyme to post mortem 
tenderization ................................................................................................................................ 41 
1.6.6 Improvement of meat quality by calcium Infusion ...................................................... 43 
1.6.7 Summary of the calpains and meat quality .................................................................. 45 
1.7 Vitamin 0 3 Supplementation and Meat Quality ................................................................. 45 
1.7.1 Summary of vitamin D3 Sheep trials ............................................................................. 49 
1.8 Summary of Literature ......................................................................................................... 50 
1.9 Hypothesis ............................................................................................................................ 51 
1.10 Aims ...................................................................................................................................... 52 
CHAPTER 2: MATERIALS & METHODS 
2.1 Materials used in this study ................................................................................................ 53 
2.1.1 Equipment used at the University of Nottingham ....................................................... 53 
2.1.2 Equipment used in Pfizer Ltd. (Sandwich, Kent, UK) .................................................... 54 
2.2 Experimental Design of Animal Trials ................................................................................. 55 
2.2.1 Animal housing layout .................................................................................................. 55 
2.2.2 Diet Composition .......................................................................................................... 57 
ii 
2.2.3 Standard slaughter procedure ...................................................................................... 58 
2.2.4 Carcass handling ........................................................................................................... 58 
2.2.5 Sample Procedure ........................................................................................................ 58 
2.3 Analysis of Plasma Vitamin D Concentration ..................................................................... 59 
2.3.1 Trial 1 Plasma Samples ................................................................................................. 59 
2.3.2 Trial 2 Plasma Samples ................................................................................................. 59 
2.4 Fat Analysis of Animal Muscle ............................................................................................. 60 
2.4.1 Preparation of LD samples for fat analysis ................................................................... 60 
2.4.2 Extraction of fat using Soxtherm method .................................................................... 60 
2.5 Calcium Ion Concentration Analysis: Atomic Absorption Spectroscopy ........................... 61 
2.5.1 Principle of Atomic Absorption .................................................................................... 61 
2.5.2 Preparing Calcium Standards ....................................................................................... 61 
2.5.3 Preparing Samples ........................................................................................................ 62 
2.5.4 Determining Calcium Concentration ............................................................................ 63 
2.6 Warner-Bratzler Shear Force Assay for Meat Tenderness ................................................. 63 
2.6.1 Preparation of samples-Core preparation .................................................................... 64 
2.6.2 Warner-Bratzler Shear Force Assay .............................................................................. 64 
2.7 Extraction and Measurement of total RNA ........................................................................ 64 
2.7.1 Extraction of total RNA from LD and Kidney ................................................................ 64 
2.7.2 DNAse treatment of total RNA ..................................................................................... 65 
2.7.3 Total RNA Quantification .............................................................................................. 66 
2.7.4 Horizontal Agarose gel Electrophoresis of total RNA ................................................... 66 
2.7.5 Reverse-Transcription (RT) of mRNA ............................................................................ 67 
2.8 Development of sequences for primer and probe design in sheep ................................... 69 
2.8.1 Development of calpain Sequences ............................................................................. 69 
2.8.2 Design of Quantitative (Real-Time) PCR primers and probe ...................................... 70 
2.9 General and Quantitative Polymerase Chain Reaction ...................................................... 70 
2.9.1 General (Semi-Quantitative) PCR ................................................................................. 71 
iii 
2.9.2 Electrophoresis of PCR products .................................................................................. 72 
2.9.3 Quantitative PCR .......................................................................................................... 72 
2.9.4 Normalisation of data to ~ - A c t i n n .................................................................................. 77 
2.10 Measurement of Proteins by Western Blotting technique ................................................ 78 
2.10.1 Extraction of proteins from animal tissues .................................................................. 78 
2.10.2 Determination of Protein concentration by Lowry Assay ............................................ 79 
2.10.3 Protein separation by SDS-PAGE (Sodium Dodecyl Sulphate- Polyacrylamide Gel 
Electrophoresis) ............................................................................................................................ 80 
2.10.4 Western Blot Protein Transfer ...................................................................................... 80 
2.10.5 Ponceau Stain of Membrane ........................................................................................ 81 
2.10.6 Immunodetection of proteins ...................................................................................... 81 
2.10.7 Chemiluminescence detection of proteins ................................................................... 82 
2.10.8 Stripping and re-probing with a second protein antibody ........................................... 82 
2.10.9 Quantification of protein blots ..................................................................................... 83 
2.11 Cell culture methods ............................................................................................................ 83 
2.11.1 Preparation of primary skeletal muscle myoblasts from rat pups ............................... 84 
2.11.2 Culture of skeletal muscle cell lines ............................................................................. 86 
2.12 Cell Culture Experimental Procedures ................................................................................ 87 
2.12.1 Diluting Vitamin D3 ....................................................................................................... 87 
2.12.2 Treatment of primary muscle cells with Vitamin D for microarray analysis ................ 88 
2.12.3 Characterisation of Myosin Heavy Chain Gene expression in skeletal muscle cells .... 89 
2.12.4 Treatment of Skeletal muscle cells with 1aOHD3 for gene and protein expression 
a na lysis ...................................................................................................................................... 90 
2.13 Extraction of RNA and protein from cultured cells ............................................................ 91 
2.13.1 Harvest of mRNA from Primary cells for Microarray analysis ...................................... 91 
2.13.2 RT step with SuperScript III RT enzyme- expression of MHC using PCR ...................... 92 
2.13.3 Microarray .................................................................................................................... 92 
2.13.4 Microarray Analysis ...................................................................................................... 93 
iv 
2.13.5 Harvest oftotal RNA and protein from skeletal muscle cell lines ................................ 93 
2.13.6 Determination of protein concentration by 2-D Quant Kit .......................................... 94 
2.13.7 Western Blotting of C2C12 cell samples ....................................................................... 95 
2.13.8 Real Time PCR using LC480 system .............................................................................. 95 
2.14 Statistical analysis ................................................................................................................ 98 
CHAPTER 3: RESULTS 
3.1 Trial 1: 4 Days Vitamin D ..................................................................................................... 99 
3.1.1 Trial Outline ................................................................................................................ 100 
3.1.2 Meat quality results: Trial 1; 4 days vitamin 03 .......................................................... 101 
3.1.3 Vitamin 0 effects on gene expression: Trial 1; 4 days vitamin 03, ............................. 104 
3.1.4 Trial Summary ............................................................................................................. 107 
3.2 Trial 2: 7 Days Vitamin D & Calcium Bolus ........................................................................ 108 
3.2.1 Trial Outline ................................................................................................................ 108 
3.2.2 Vitamin 0 signalling results: Trial 1; 7 days vitamin 03 + calcium bolus ..................... 113 
3.2.3 Trial Summary ............................................................................................................. 116 
3.3 Summary of Sheep Trials ................................................................................................... 117 
3.4 Microarray to indentify novel targets of l,25(OHhD3 ...................................................... 119 
3.4.1 Trial outline ................................................................................................................. 119 
3.4.2 Quality of RNA used in the microarray ....................................................................... 119 
3.4.3 Analysis of microarray data ........................................................................................ 121 
3.4.4 Genes changed by l,25(OHh03 10-5 M treatment ..................................................... 121 
3.4.5 Genes changed by l,25(OHh03 10-9 M treatment ..................................................... 130 
3.4.6 Summary and discussion of microarray data ............................................................. 135 
3.5 Characterisation of skeletal muscle cells for culture work .............................................. 137 
3.5.1 Outline of work ........................................................................................................... 137 
3.5.2 Expression of MHC in rat derived muscle cells (Rat Primary cells & L6 Aston cell line) ... 
.................................................................................................................................... 138 
3.5.3 Expression of MHC in Mouse Muscle cells ................................................................. 141 
v 
3.5.4 Results and Discussion: Characterisation of skeletal muscle cells for culture work .. 143 
3.6 Treatment of C2C12 cells with vitamin D analogue 1a(OH)D .......................................... 144 
3.6.1 Results: Effects of 1a(OH)D on mouse C2C12 muscle cell line .................................. 146 
3.6.2 Results: Effects of 1a(OH)D on mRNA expression of housekeeping genes during 
proliferation and differentiation of C2C12 myoblasts ............................................................... 149 
3.6.3 Summary of Housekeeping Genes ............................................................................. 154 
3.6.4 Results: Effects of 1a(OH)D on mRNA expression of markers of differentiation during 
proliferation and differentiation of C2C12 myoblasts ............................................................... 155 
3.6.5 Results: Effects of 1a(OH)D on MHC gene expression ............................................... 158 
3.6.6 Effect of dietary vitamin Don MHC expression in sheep trials .................................. 163 
3.6.7 Summary of MHC gene expression ............................................................................ 164 
3.6.8 Results: Effect of 1a(OH)D on transcripts up-regulated by l,25(OHhD3 ................... 165 
3.6.9 Summary 1a(OH)D effects on transcripts which responded to l,25(OHhD3 ............. 169 
3.6.10 Results: Effects of 1a(OH)D on protein signalling ...................................................... 170 
CHAPTER 4: DISCUSSION 
4.1 Effects of dietary Vitamin D on meat quality in Sheep trials ........................................... 177 
4.1.1 Conclusion of effects of dietary Vitamin D on meat quality in Sheep trials ............... 187 
4.2 Effects of direct Vitamin D treatment on muscle cells ..................................................... 187 
4.2.1 Effect of l,25(OHhD3 on muscle gene expression assessed by microarray analysis. 188 
4.2.2 Effect of 1a(OH)D3 on muscle gene expression in proliferating C2C12 myoblasts .... 189 
4.2.3 Effect of 1a(OH)D3 on muscle gene expression in differentiating C2C12 myoblasts. 192 
4.3 General discussion of direct Vitamin D treatment on muscle cells ................................. 195 
4.3.1 Conclusions of effects of 1a(OH)D3 in developing myoblasts .................................... 199 
4.4 Conclusion .......................................................................................................................... 200 
4.5 Further Work ...................................................................................................................... 202 
vi 
APPENDICES 
Appendix A: WBSF Sample Procedure .......................................................................................... 205 
Appendix B: Real-time PCR oligonucelotides designed in sheep ................................................. 207 
Appendix C: Solutions used to create denaturing protein Gels ................................................... 214 
Appendix D: Protein Antibodies .................................................................................................... 215 
Appendix E: Oligonucleotides used in Rat .................................................................................... 216 
Appendix F: Oligonucleotides used in Mouse .............................................................................. 219 
Appendix G: "Assay on Demand" Oligonucleotides {ABI} ............................................................ 223 
Appendix H: C2C12 RNA agarose gel electrophoresis .................................................................. 224 
Appendix I: Trial 2 feed refusal data ...................................................................................... 227 
Appendix J: Real-time PCR data of C2C12 myoblasts ................................................................... 228 
Appendix K: Average Housekeeping gene values for real-time PCR data of C2C12 myoblasts 
across differentiation .................................................................................................................... 229 
Appendix L: Protein data of C2C12 myoblasts across differentiation ......................................... 230 
References ........................................................................................................................................ 231 
List of Figures 
Figure 1.2-1. Structure of vitamin D and its metabolites ....................................................................... 5 
Figure 1.2-2. Summary of overall metabolism, activation and regulation of vitamin D within the body 
................................................................................................................................................................ 5 
Figure 1.2-3. Mechanism for vitamin D signalling via the nuclear vitamin D receptor (VDRnuc) ........ 10 
Figure 1.2-4. RXR forms heterodimers with a number of steroid hormone receptors including the 
vitamin D receptor (VDR), thyroid hormone receptor (TR) and retinoic acid receptor (RAR) ............. 10 
Figure 1.2-5. Schematic diagram of hypothetical mechanism of 1,25(OHhD intracellular signal 
transduction in rapid responses to vitamin D ...................................................................................... 12 
Figure 1.2-6. Schematic diagram of the MAPK signalling cascades from extracellular stimuli to cellular 
response ............................................................................................................................................... 12 
Figure 1.3-1. Schematic diagram of the early stages of myogenesis and the signalling factors 
responsible ........................................................................................................................................... 15 
Figure 1.3-2. Schematic diagram of the structure of the four myogenic regulatory factors (MRFs) ... 15 
Figure 1.3-3. Schematic diagram of the control of muscle cell differentiation by MRFs ..................... 16 
Figure 1.3-4. Structure of muscle from tissue to individual myofribril strand ..................................... 21 
Figure 1.3-5. Proteins within the muscle sarcomere ........................................................................... 22 
Figure 1.3-6. Schematic representation of position of MHC encoding genes on human chromosome .. 
.............................................................................................................................................................. 26 
Figure 1.3-7. Proposed mechanism for calcineurin in activation of the slow muscle fibre program of 
gene expression .................................................................................................................................... 30 
Figure 1.5-1. The post mortem changes in shear force (kg) of lamb longissimus thoracic et lumborum 
muscle .................................................................................................................................................. 34 
Figure 1.6-1. Schematic structure of the calpain enzymes and their inhibitor calpastatin ................. 38 
Figure 1.6-2. Schematic diagram of the proteins of the costamere which are responsible for 
anchoring the myofibrillar structures to the cell membrane ............................................................... 42 
Figure 1.7-1. Changes in serum calcium in beef cattle fed vitamin D3 prior to slaughter ................... 46 
Figure 2.2-1. Pen Layout in the sheep housing .................................................................................... 55 
Figure 2.2-2. Housing layout and diet treatment allocation to animals in dietary vitamin D trials .... 56 
Figure 2.5-1. Calibration curve obtained with calcium standard solutions ......................................... 62 
Figure 2.7-1. Horizontal agarose gel electrophoresis of total RNA extracted from mouse LD and leg 
muscle .................................................................................................................................................. 67 
Figure 2.7-2. Schematic representation of Reverse Transcription of mRNA ....................................... 68 
viii 
Figure 2.9-1. The three repeated cycles of the Polymerase Chain Reaction (PCR) ............................. 71 
Figure 2.9-2. Schematic diagram of the release of the fluorescence signal during quantitative PCR .. 73 
Figure 2.9-3. Amplification plot of standards used to measure Ovine Calpain I expression in sheep LD . 
.............................................................................................................................................................. 75 
Figure 2.9-4. The number of cycles required to reach threshold (Ct) plotted against the log of the 
relative quantity of cDNA in the standard curve .................................................................................. 75 
Figure 2.12-1. Structure of vitamin D3 analogue used in rat primary microarray experiment; la,25-
(OHh vitamin D3 also known as calcitriol. ............................................................................................ 87 
Figure 2.12-2. Structure of vitamin D3 analogue used in muscle cell line experiment; l,a-
hydroxyvitamin D3 also known as alfacalcidiol. .................................................................................... 88 
Figure 2.13-1. Position of unknown sample MHC IIA mRNA expression when measured relative to 2 
cDNA standard curves, mouse LD and C2C12 cell aged 10 days .......................................................... 97 
Figure 3.1-1. Timeline for Trial 1: 4 days vitamin D immediately prior to slaughter ......................... 101 
Figure 3.1-2. Representative blots of the calpain system in LD and vitamin D responsive targets in 
kidney protein extracts from sheep in trial 1: 4 Days vitamin D3 ....................................................... 106 
Figure 3.2-1. Timeline for Trial 2: 7 days vitamin D + calcium bolus immediately prior to slaughter. 
............................................................................................................................................................ 109 
Figure 3.2-2. Representative blots of the calpain system in LD and vitamin D responsive targets in 
kidney protein extracts from sheep in trial 2: 7 days vitamin D3 + calcium ....................................... 115 
Figure 3.4-1. Effects of 1,25 Vitamin D3 on quantity and quality of RNA extracted from rat primary 
muscle cells in culture ........................................................................................................................ 120 
Figure 3.4-2. Molecules changed by l,25(OHhD3 at 10-sM concentration, network 1: Associated with 
Genetic Disorder, Opthalmic Disease, & Cellular Growth and Proliferation ...................................... 125 
Figure 3.4-3. Molecules changed by l,25(OHhD3 at 10-sM concentration, network 2: Associated with 
Cellular Growth and Proliferation, Embryonic Development & Connective Tissue Development and 
Function .............................................................................................................................................. 126 
Figure 3.4-4. Molecules changed by l,25(OHhD3 at 10-sM concentration, network 3: Associated with 
Cancer, Cell Death & Hematological Disease ..................................................................................... 127 
Figure 3.4-5. Molecules changed by l,25(OHhD3 at 10-sM concentration, network 4: Associated with 
Cardiovascular System Development and Function, Cardiovascular Disease & Cell Death ............... 128 
Figure 3.4-6. Molecules changed by l,25(OHhD3 at 10-sM concentration, network 5: Associated with 
Cancer, Cellular Movement & Lipid Metabolism ............................................................................... 129 
Figure 3.4-7. Molecules changed by l,25(OHhD3 at 10-9M concentration, network 1: Associated with 
Tissue Development and Function ..................................................................................................... 132 
ix 
Figure 3.4-8. Molecules changed by l,25(OHhD3 at 10-9M concentration, network 2: Associated with 
Cellular growth and proliferation ....................................................................................................... 133 
Figure 3.4-9. Molecules changed by l,25(OHhD3 at 10-9M concentration, network 3: Associated with 
Cell d ath & DNA I' t' b" d . e rep Ica lon, recom matlon an repair .................................................................. 134 
Figure 3.5-1. Expression of MHC mRNA in rat LD muscle .................................................................. 139 
Figure 3.5-2. Expression of MHC mRNA in rat primary muscle cells at four different ages post 
differentiation .................................................................................................................................... 140 
Figure 3.5-3. Expression of MHC mRNA in the L6 Aston muscle cell line at four different ages post 
differentiation .................................................................................................................................... 140 
Figure 3.5-4. Expression of MHC mRNA in Mouse LD muscle ............................................................ 141 
Figure 3.5-5. Expression of MHC mRNA in the C2C12 muscle cell line at four different ages post 
differentiation .................................................................................................................................... 142 
Figure 3.5-6. Protein expression of MHC fast (MHC-f) and slow (MHC-s) in L6 and C2C12 cell lines at 
three stages post differentiation ........................................................................................................ 142 
Figure 3.6-1. Phase contrast microscopy of C2C12 skeletal muscle cells throughout the process of 
differentiation from 80% confluence (day -1), fusion media added on day 0 and refreshed every 48 
hrs for 9 days ........................................................... '" ................................. , ...................................... 145 
Figure 3.6-2. Schematic time line of la(OH)D treatments directly on C2C12 muscle cells ............... 146 
Figure 3.6-3. Morphology of C2C12 cells following 48 hour treatment with la(OH)D ..................... 148 
Figure 3.6-4. Relative expression of housekeeping genes relative to mouse LD standard curve; ~ ~
actin, cyclophilin A and GAPDH at three stages of differentiation .................................................... 152 
Figure 3.6-5. Relative expression of Myf5, myogenin and desmin at three stages of differentiation . 
............................................................................................................................................................ 157 
Figure 3.6-6. Relative expression of Embryonic MHC at three stages of differentiation .................. 161 
Figure 3.6-7. Relative expression of MHC I / ~ , , MHC IIA, MHC IIX and MHC liB at three stages of 
differentiation .................................................................................................................................... 162 
Figure 3.6-8. Representative blot of Myosin Heavy Chain fast and slow following SDS-PAGE ......... 164 
Figure 3.6-9. Relative expression of C / E B P ~ , , metallothionein 2A, parvalbumin and c-Myc at three 
stages of differentiation ..................................................................................................................... 167 
Figure 3.6-10. Representative blot of C2C12 proteins analysed by SDS-PAGE after 48 hours treatment 
with la(OH)D at myoblast stage ........................................................................................................ 171 
Figure 3.6-11. Representative blot of C2C12 proteins analysed by SDS-PAGE after 48 hours treatment 
with la(OH)D at three different stages of differentiation ................................................................. 173 
x 
Figure 3.6-12. Effect of level of phosphorylation of two protein targets in C2C12 myoblasts after 48 
hours treatment with 1a(OH)D at three different stages of differentiation ..................................... 174 
Figure 4.3-1. Hypothesised routes of the biologically active form of vitamin D signalling within the 
muscle cell .......................................................................................................................................... 200 
Figure 4.5-1. Proposed mechanism and outcomes of intracellular signalling of biologically active 
vitamin D isoforms within muscle cells .............................................................................................. 204 
Figure 4.5-2. Schematic diagram of possible novel gene targets of 1a(OH)D3 and 1,25(OHhD3 
discovered in this thesis ..................................................................................................................... 204 
xi 
List of Tables 
Table 1.3-1. Muscle phenotypes observed in mice lacking expression of MRFs ................................. 17 
Table 1.3-2. Physiological properties in each muscle fibre type .......................................................... 24 
Table 1.3-3. Myosin protein isoforms, gene name and associated tissue types ................................. 25 
Table 1.6-1. Physical properties of the calpain enzymes ..................................................................... 38 
Table 1.6-2. Changes in activity of m- and 11- calpain expressed as % values in control and over-
expressed calpastatin transgenic mice ................................................................................................. 42 
Table 1.6-3. Efficacy of calcium chloride (CaCI2) infusion in improving shear force in lambs fed ~ ~
adrenergic agonists (BAA) .................................................................................................................... 44 
Table 1.7-1. Changes in calcium status in beef cattle fed vitamin D3 prior to slaughter ..................... 47 
Table 1.7-2. Changes in shear force of longissimus dorsi steaks from beef cattle fed vitamin D3 prior 
to slaughter .......................................................................................................................................... 47 
Table 1.7-3. Changes in calcium status in lambs of either callipyge or normal genotype fed vitamin D3 
for 7 days prior to slaughter ................................................................................................................. 48 
Table 2.2-1. Basal diet composition as-fed basis ................................................................................. 57 
Table 2.2-2. Nutritional composition of diets fed during trial period in Triall. .................................. 57 
Table 2.2-3. Nutritional composition of diets fed during trial period in Trial 2 ................................... 57 
Table 2.S-1. Absorbance readings obtained for calcium standard solutions ....................................... 61 
Table 2.7-1. RNA 260/280 ratios from samples used in this thesis ..................................................... 66 
Table 2.8-1. Bovine Sequence used to interrogate NCBI EST non-human, non mouse database and 
retrieved partial length cDNA sheep sequences .................................................................................. 70 
Table 2.8-2. ClustalW alignment of created contiguous Ovine calpain cDNA sequences Vs human and 
bovine sequences indicating the similarity to ovine sequences .......................................................... 70 
Table 2.9-1. Diluting cDNA to create a standard curve for relative quantification of unknown samples 
.............................................................................................................................................................. 74 
Table 2.9-2. Reaction volumes and thermal cycling conditions of two Q-PCR systems used in mRNA 
expression analysis in sheep trials ....................................................................................................... 77 
Table 2.9-3. Effect of Vitamin D3 supplementation on mRNA expression of ~ - A c t i n , , as measured by 
the Fast Taq ABI system, and again in the LD as measured by the Roche LC480 system .................... 78 
Table 2.13-1. Creation of protein standards for 2-D Quant Assay ....................................................... 94 
Table 2.13-2. Summary of gene targets and their sources measured in C2C12 experiment and the 
standard curve and cDNA dilution used for analysis ............................................................................ 96 
xii 
Table 3.1-1. Effect of 4 days vitamin D3 supplementation on animal growth, feed intake and carcass 
characteristics ..................................................................................................................................... 102 
Table 3.1-2. Effect of 4 Days Vitamin D3 Supplementation on plasma Vitamin D, serum and LD 
calcium levels ..................................................................................................................................... 103 
Table 3.1-3. Effect of 4 days vitamin D3 on shear force (Kg) of LD ..................................................... 103 
Table 3.1-4. Effect of 4 Days Vitamin D3 Supplementation on LD Fat Content ................................. 104 
Table 3.1-5. Effect of 4 Days Vitamin D3 supplementation on mRNA and protein expression of calpain 
system in LD ........................................................................................................................................ 105 
Table 3.1-6. Effect of 4 Days Vitamin D3 supplementation on mRNA and protein expression of 
vitamin D targets in kidney ................................................................................................................. 105 
Table 3.2-1. Effect of 7 days vitamin D3 + Calcium supplementation on animal growth, feed intake 
and carcass traits ................................................................................................................................ 111 
Table 3.2-2. Effect of 7 Days Vitamin D3 + calcium bolus on plasma 2s(OH)-vitamin D, serum & LD 
calcium levels ..................................................................................................................................... 112 
Table 3.2-3. Effect of 7 days vitamin D3 + calcium bolus on shear force of LD .................................. 112 
Table 3.2-4. Effect of 7 Days Vitamin D3 Supplementation plus calcium bolus on LD Fat Content ... 113 
Table 3.2-5. Effect of 7 Days Vitamin D3 + calcium on mRNA and protein expression of Calpain 
System in LD muscle ........................................................................................................................... 114 
Table 3.2-6. Effect of 7 Days Vitamin D3 + calcium on mRNA and protein expression of vitamin D 
targets in kidney ................................................................................................................................. 114 
Table 3.4-1. Concentration and integrity of RNA used in microarray ................................................ 120 
Table 3.4-2. Effect of l,2s(OHhD3 treatment on yield of RNA harvested for microarray analysis ... 120 
Table 3.4-3. Top 5 signalling networks containing highest number of molecules changed by 
l,2s(OH)2D3 10-sM treatment ............................................................................................................ 121 
Table 3.4-4. List of genes up regulated with l,2s(OHhD3 10-sM ....................................................... 123 
Table 3.4-5. List of genes down regulated by l,2s(OHhD3 10-sM ..................................................... 124 
Table 3.4-6. Top 3 signalling networks containing highest number of molecules changed by 
l,2s(OH)2D3 10-9M treatment ............................................................................................................ 130 
Table 3.4-7. List of genes up regulated by l,2s(OHhD3 10-9M .......................................................... 130 
Table 3.4-8. List of genes down regulated by l,2s(OHhD3 10-9M ..................................................... 131 
Table 3.4-9. Genes changed in both treatments with l,2s(OHhD3 exhibiting dose responses ........ 136 
Table 3.5-1. Basic PCR primers and predicted product sizes used to characterise rat-derived cells for 
MHC gene expression ......................................................................................................................... 138 
Table 3.5-2. Information for primers used to characterise MHC gene expression of C2C12 cells .... 141 
xiii 
Table 3.6-1. Expression of housekeeping genes in myoblasts treated with 1a(OH)D in growth media 
analysed using q-RT PCR ..................................................................................................................... 150 
Table 3.6-2. Average values of housekeeping genes in myoblasts treated with 1a(OH)D in growth 
media analysed using q-RT PCR .......................................................................................................... 153 
Table 3.6-3. mRNA expression of markers of differentiation in Myoblasts treated with 1a(OH)D in 
growth media ..................................................................................................................................... 155 
Table 3.6-4. Expression of MHC genes in C2C12 myoblasts treated with 1a(OH)D in growth media . 
............................................................................................................................................................ 158 
Table 3.6-5. Effect of two vitamin D feeding regimes immediately prior to slaughter on relative 
expression of mRNA of adult MHC genes .......................................................................................... 163 
Table 3.6-6. Effect of 7 days vitamin D & Ca on MHC fast and slow protein levels in ovine LD ........ 164 
Table 3.6-7. Effect of 1a(OH)D on expression of 1,25(OHhD3 targets in Myoblasts treated within 
growth media ..................................................................................................................................... 166 
Table 3.6-8. Fold changes in C / E B P ~ ~ expression affected by 1a(OH)D treatment relative to DMSO 
controls across the differentiation process ........................................................................................ 166 
Table 3.6-9. Effect of 1a(OH)D treatment on level of phosphorylation on two protein targets in 
proliferating myoblasts ...................................................................................................................... 170 
Table 4.1-1. Effects of vitamin D supplementation in sheep ............................................................. 181 
Table 4.1-2. Effects of vitamin D supplementation in beef steers ..................................................... 182 
Table 4.2-1. Effect of 1a(OH)D3 on muscle gene expression in proliferating C2C12 myoblasts ........ 190 
xiv 
Abstract 
Recent published work indicates a role for pre-slaughter dietary vitamin D supplementation to 
promote post mortem meat tenderization in cattle (Montgomery et 01., 2000; Foote et 01., 2004; 
Montogmery et 01., 2004), pigs (Wilborn et 01., 2004) and sheep (Wiegand et 01., 2001; Boleman et 
01., 2004). The hypothesis being that vitamin D supplementation at supra-nutritional levels is able to 
cause increases in the calcium status of the animals, increasing the activity of the calcium-dependant 
proteolytic enzymes, the calpains, which are responsible for meat tenderization (Koohmaraie & 
Geesink, 2006). Muscle fibre type is a variable factor in muscle and is related to meat quality (Klont 
et 01., 1998). Vitamin D has been suggested to playa role in regulating skeletal muscle function 
through the creation of vitamin D receptor knockout mice models (Endo et 01., 2003) and 
observations that muscle weakness and falling risk in vitamin D deficient patients is linked to a loss 
of fast muscle fibres (Aniansson et 01., 1986; Larsson et 01., 1979; Sorenson et 01., 1979; Sato et 01., 
2005). 
This thesis investigated two vitamin D pre-slaughter diet regimes on their effects on meat quality of 
the most economically important cut of the carcass, the longissimus dorsi (LD) muscle (Molina et 01., 
2005) and the expression of the calpain system. Trial 1 fed sheep vitamin D at 2.0 X 106 IUjday for 
four days prior to slaughter and found that this had no effect on shear force of LD chops. Calcium 
levels were unchanged but mRNA levels of calpain I and II were increased 3.7 and 10% respectively 
(P=0.099 and P=0.014) but there was no effect on calpastatin mRNA nor changes in the calpain 
system at the protein level. Trial 2 fed sheep the same dose of vitamin D for 7 days with an 
additional calcium bolus, resulting in a 10% increase in calcium concentrations of both serum and LD. 
Toughness of LD chops was increased (P<O.Ol), there was no effect on mRNA of the calpain system 
but there was an increase in the protein levels of calpain II and calpastatin by 16 and 17% 
respectively (P=O.Os and P=0.087). 
A microarray study of rat primary myoblasts treated with l,2s(OHhD3 for 24 hours highlighted a 
number of responsive genes significantly up and down regulated 1.5 fold or more (P<O.Os). Pathway 
analysis identified novel targets of l,2s(OHhD3 with a possible relationship to muscle growth and 
function; these included C j E B P ~ , , metallothionein 2A and the MAPK, ERK. Three muscle cell strains, 
the rat primary muscle cells, L6 Aston and C2C12, were assessed for myosin heavy chain (MHC) gene 
expression using semi-quantitative PCR and western blotting analysis. The muscle cell line 
demonstrating the broadest range of MHC genes relevant to mature muscle tissue was used for the 
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final experiments; this was the C2C12 cell line demonstrating expression of the slow MHC I / ~ , , an 
isoform which was absent or showed much lower expression in the other cells. 
C2C12 cells treated with la(OH)D3 for 48 hours at varying stages of development responded in 
changes in myogenic regulatory factors (MRFs), MHCs and novel target gene expression. Real time 
PCR analysis of C2C12 cells treated with the active vitamin D metabolite la(OH)D3 affirmed C / E B P ~ ~
mRNA expression to be upregulated (P<O.OOl) and MAPK ERK 1/2 phosphorylation to be down 
regulated (P<O.OOl) by la(OH)D3 in muscle cells. The effect of la(OH)D3 in myoblasts was reduce 
proliferation and promote differentiation, as myotubes formed the effect of la(OH)D3 was to 
promote MHC gene expression of an intermediate oxidative fibre type, increasing expression of MHC 
1 / ~ ~ and 2A, decreasing MHC 2B. 
In conclusion, there is no apparent benefit of a pre-slaughter dietary vitamin D feeding regime on 
meat quality, but the active metabolites of vitamin D, la(OH)D3 and l,25(OHhD3, exert changes in 
gene expression and MAPK signalling which are likely to affect muscle growth and fibre type, and is 
of relevance in terms of both meat quality and muscle function in the elderly. 
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Introduction 
The overall aim of the work reported in this thesis was to examine the potential for vitamin 0 to 
influence muscle growth and function from an animal production perspective, investigating the 
influence of dietary vitamin 0 on the quality of meat as a product and the biologically active forms' 
effects on gene expression relating to the muscle's capacity to grow. Meat quality is a general term 
used to describe a wide variety of factors which contribute to and define the value of meat as a 
product. These factors can include the composition and conformation of the carcass, the health 
issues associated with meat products e.g. Escherischa Coli 0157 contamination and bovine spong-
iform encaphalopathy (BSE), production methods related to the animal's welfare and environmental 
impact as well as the actual eating experience of the end meat product (Maltin et 01., 2003). All of 
these are factors which affect consumer's decisions when choosing meat products but the most 
influential factor affecting their decision to re-purchase a chosen product is the tenderness of the 
meat, with 94.6% of consumers choosing more expensive meat as long as it had lower shear force 
scores (more tender meat) (Boleman et 01., 1997). Therefore a major focus of the meat industry is to 
gain an understanding of the mechanism of tenderization and thereby improve production methods 
to consistently produce tender meat (Bindon & Jones, 2001). 
Tenderisation is a result of proteolytic activity in the muscle post mortem which acts to degrade the 
protein ultrastructure within the muscles and so reduces the amount of force required to cut the 
meat. It is widely acknowledged that the majority of the tenderisation process is performed by the 
calpain system (Koohmaraie & Geesink, 2006) which is regulated by intracellular levels of calcium 
(Goll et 01., 2003). In order to manipulate the activity of the calpain system during post mortem 
storage, a number of studies demonstrated that infusing carcasses (Koohmaraie et 01., 1988) or 
marinating steaks (Whipple & Koohmaraie, 1993) in calcium chloride solutions is proficient in 
reducing shear force of meat rapidly during the first 24 hours of storage. It has been shown that this 
rapid increase in tenderness with calcium chloride infusion is a result of increased calpain activity 
(Koohmaraie et 01., 1989). Although this treatment of meat post mortem was demonstrated to vastly 
improve the speed and extent of post mortem tenderisation, it required additional procedures to be 
performed in the abattoir and the use of additives in meat products could lead to products which are 
rejected by consumers (Hoover et 01., 1995). In light of these observations, the research work 
described in this thesis set out to examine whether supplementing animal feed with vitamin 0, a 
compound which is metabolised into a hormone responsible for activating calcium absorption from 
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the diet, could produce elevated calcium levels in the muscle and thereby activate the calpains 
during post mortem aging. 
A second variable trait which is reported to influence meat quality is the relative quantities of 
different fibre-types within the muscle (Schiaffino & Reggianni, 1996). These intrinsically differ in 
size, proteolytic and metabolic activity all of which influence tenderisation post mortem (Klont et 01., 
1998). In relationship to manipulation of fibre type, multiple studies in human patients have 
reported a relationship between vitamin D deficiency in elderly patients and the number of falls as a 
result of impaired muscle function, findings which have led several researchers to the suggestion 
that vitamin D could affect transitions in muscle fibre type (Bischoff et 01., 2003; Bischoff-Ferrari et 
01., 2006, Snijder et 01., 2006). Reduced vitamin D status is associated with a reduction in fast fibres 
and this leads to a higher incidence of falling in older patients (Aniansson et 01., 1986; Larsson et 01., 
1979; Sorenson et 01./ 1979; Sato et 01./ 2005). In addition to its responsibility for calcium 
homeostasis, acting through the classical nuclear receptor (Norman et 01., 2002), the vitamin D 
receptor has been found to modulate intracellular signalling pathways which are not predominantly 
associated with calcium homeostasis in muscle cells (Buitrago et 01., 2006; Buitrago et 01., 2001). 
Some of these signalling pathways are associated with effects on proliferation and differentiation of 
cells, with biologically active vitamin D reducing proliferation (De Haes et 01., 2004) and enhancing 
terminal differentiation in non-muscle cell types (Berry & Meckling-Gill, 1999). A fundamental aspect 
of animal production is the enhancement of lean tissue mass which is predominantly associated with 
an increase in fast type muscles. Therefore these general observations suggest that vitamin D may 
have a role as an agent which can modulate both growth and the phenotype of muscle tissue in 
ways which could have relevance to the meat production industry. 
To this end, the latter experiments of this study were designed to investigate the effects of vitamin D 
signalling in muscle cells, particularly changes in fibre type and growth of muscle cells. Overall, these 
findings will improve the understanding of vitamin D as an agent to enhance meat quality both in 
terms of activating proteolysis during post mortem storage, presumably via the calpain system, and 
in changes in fibre type. In addition the studies will help to improve the general knowledge of 
vitamin D's role in muscle growth both in immature muscle through to manipulating muscle function 
in aged muscle tissue. 
2 
Literature Review 
1.1 Introduction to Literature Review 
Vitamin D has been commonly known to prevent rickets and osteomalacia for almost a century, and 
its role in calcium homeostasis to prevent these bone disorders is considered to be the compound's 
primary function (Holick, 1999). Recently, novel roles have been considered for vitamin D in tissues 
unrelated to calcium homeostasis, and this has led to research to further understand its mechanisms 
in "non-classical" tissues. The studies reported in this thesis investigate the effects of vitamin D in 
muscle tissue in both the classical sense of calcium homeostasis and in the more recent role of 
vitamin D's ability to signal using pathways related to growth and differentiation. Therefore this 
literature review aims to provide a background of vitamin D's actions in both calcium and non-
calcium mechanisms, before the process of muscle development and growth is described and finally 
the aspects of muscle tissue which affect the quality of meat as a product are considered. 
1.2 Vitamin D 
Vitamin D is the common term used to describe a group of cholesterol derived compounds which act 
as pro-hormones in the calcium homeostasis mechanism. There are two major forms of vitamin D, 
vitamin D2 and vitamin D3, which are derived from the dietary plant and animals sources respectively 
and are known as the calciferols or simply as vitamin D (Norman & Collins, 2001). Vitamin D2, or 
ergocalciferol, is produced in plants and yeasts from the plant sterol ergosterol and similarly vitamin 
D3, or cholecalfierol, is produced in animals from the vertebrate sterol cholesterol. It is thought that 
both forms can have biological actions in vertebrate animals; however the efficiency of conversion of 
vitamin D2 in the liver is thought to be much less than that of vitamin D3 (Pfeifer et al.; 2002). Both 
vitamin D2 and D3 are seco-steroids, where the second carbon ring in the sterol structure is broken 
open, a process which requires energy from UV light and in most vertebrate species takes place in 
the skin. The actual vitamin D compounds are considered pro-hormones as the molecules need to be 
hydroxylated before they become biologically active, in animals these hydroxylation steps are 
catalyzed by enzymes, firstly in the liver producing 2s-hydroxyvitamin D, or calcidiol, before the 
kidney produces the active vitamin D molecule 1,25 dihydroxyvitamin D (l,2s(OHhD), or calcitriol; 
the structures of the products of these reactions are shown in figure 1.2-1. The biological function of 
vitamin D is traditionally considered to be associated with calcium homeostasis and the formation of 
healthy bones, however in the last decade research has looked towards understanding this 
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hormone's effects in recently discovered targets in non-calceamic tissues including the thyroid cells 
of the immune system, brain and nervous system, liver, lung and many others (Pfeifer et 01.; 2002). It 
is known that vitamin D exerts its effects by binding to its receptor (VDR) and in doing so activates 
the classical calcium mobilisation responses, but more recently the discovery of the VDR in many 
other tissues has led to the realisation that this hormone has a much larger role in tissue 
development and maintenance. The VDR can be located in the membrane where it exerts immediate 
biological effects within minutes of the active vitamin D binding, the major result being increased 
calcium absorption in cells lining the intestine. However, the VDR-vitamin D complex can also 
translocate to the nucleus where transcription of specific genes is regulated, such as the calcium-
binding protein, calbindin D-28K (Norman & Collins, 2001). 
1.2.1 Sources, synthesis and deficiency of vitamin D 
Vitamin D is a fat soluble substance required for normal calcium homeostasis and has few natural 
dietary sources, mainly oily fish and their liver oil and less so the livers of meat animals such as 
cattle, pigs and chickens (Holick, 1999). The largest source of vitamin D for most organisms is in fact 
the exposure to sunlight, where vitamin D can be photosynthesised in the skin using the energy from 
the UVB sunrays to convert the precursor, pro-vitamin D or 7-dehydrocholesterol (7DHC) to the 
subsequent pre-vitamin D and vitamin D compounds. However the ability of animals to produce 
vitamin D this way is variable depending on geographical location, seasonal variation in sunlight, skin 
pigmentation, age, as well fleece shearing and housing practices in animals (Hidiroglou et 01., 1979; 
Hidiroglou & Karpinski, 1989). In terms of farming practices where animals are increasingly being 
raised indoors it is a possibility that routine supplementation of vitamin D may be required to 
prevent deficiency (Montgomery et 01.,2004). 
The natural vertebrate form of vitamin D3 is derived from cholesterol (Voet et 01., 2008). The major 
source of vitamin D to vertebrate species is the photosynthesis of vitamin D during sun exposure 
where vitamin D is metabolised from its steroid precursor 7DHC to pre-vitamin D by action of UVB 
light (wavelength in the region of 295-315nm) which breaks open the second carbon ring of the 
steroid structure (figure 1.2-1). Pre-vitamin D is then converted to vitamin D by a process of 
isomerisation which does not require any enzymatic control. The endogenous vitamin D as well as 
that absorbed from the diet is transported in the circulation by binding to its specific vitamin D 
binding protein (DBP) (Walters, 1992). At the liver the enzyme 25-hydroxylase adds a hydroxyl group 
to the carbon at the C25 position to form 25-hydroxyvitamin D (25(OH)D), before this product is 
again transported in the blood to the kidney tubular cells where the enzyme la-hydroxylase adds 
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another hydroxyl group to the carbo n at C1 position, generating l ,25-dihydroxyv ita min D 
(l,25(OHh D), the biologically active form of vitamin D. 
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Figure 1.2-1. Structure of vitamin D and its metabolites, beginning with vitamin 0, cholecalciferol, which is 
synthesised in the skin before the addition of a hydroxyl group by the liver converts it to 25-
hydroxycalciferol or calcidiol, and finally the kidney produces the active form la,25-dihydroxycholecalciferol 
or calcitriol. From Deeb et al., 2007. 
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The circulating forms of vitamin 0, 2S(OH)0 and l,2S(OHhO, are not equal in concentration as 
circulating levels of the active form l,2S(OHhO are under tight control at the activation step in the 
kidney (Brown et 01., 1999). In light of this, the circulating levels of the 2S(OH)0 are representative of 
bodily stores of vitamin 0 and this metabolite is routinely used to evaluate vitamin 0 status of 
animals (Hidiroglou et 01., 1979). Synthesis of the active form is controlled at the kidney 
hydroxylation step by parathyroid hormone in response to fluctuating calcium and phosphorus levels 
as well as a negative feedback of l,2S(OHhO on the la-hydroxylase. The active metabolite, 
l,2S(OHhO, is produced in response to these stimuli and is transported bound to OBP in the blood to 
its primary target tissues; the small intestine and bone as well as the parathyroid gland (Oeeb et 01., 
2007), depicted in figure 1.2-2. 
"-.2 2 Actio:-! and {egU!ation.:...fvitamirr D ~ r o d u c t i o n n
The active form of vitamin 0 is produced in response to a drop in the circulating levels of calcium 
and phosphorus ions in the blood. A drop in calcium levels is detected by the parathyroid gland and 
this stimulates the glands secretion of parathyroid hormone (PTH) into the bloodstream. PTH then 
increases the synthesis of l,2S(OHhO in the kidney by up-regulating the activity of la-hydroxylase. 
This causes a rise in the circulating levels of l,2S(OHhO which then works to normalise the calcium 
and phosphorus levels in the blood by three mechanisms. Firstly the hormone prevents further loss 
of ions by increasing calcium retention from the urine produced in the kidney (Yamamoto et 01., 
1984) and by reducing the amount of phosphorus lost to the urine indirectly by decreasing PTH 
secretion at the parathyroid gland (Bonjour et 01., 1977). Secondly the hormone increases dietary 
absorption by activating calcium uptake in the epithelial cells of the small intestine. Lastly, when 
dietary supply is insufficient l,2S(OHhO can release calcium and phosphorus from their stores in 
bone, stimulating bone resorptive cells, known as osteoclasts, to release calcium and phosphorus 
back into the blood stream. This response is in turn auto-regulated by action of l,2S-(OHhO which 
down regulates the production of PTH at the parathyroid gland as well as inhibiting la-hydroxylase in 
the kidney. Further, the circulating levels of l,2S-(OHhO are diminished by action of 24-hydroxylase , 
an enzyme which is most abundant in the kidney but is also present in the target tissues. This 
enzyme catalyzes the catabolism of l,2S-(OHhO, converting it to the inactive form l,24,24(OHhO 
(Holick, 1999). The overall metabolism, activation and regulation of vitamin 0 within the body is 
summarised in figure 1.2-2. This is the first step in the catabolism of vitamin 0 and eventually results 
in the formation of calcitroic acid (la, (OH)-24,2S,26,27-tetranor-23-COOH-0 3) which is excreted 
from the body in the bile (Holick, 1999). 
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12.3 Vitamin') deficien(.v 
The symptoms of vitamin D deficiency indicate the hormone's vital role in calcium and phosphorus 
homeostasis and its direct effect on bone formation (Brown et 01., 1999). The appearance of the 
symptoms of vitamin D deficiency is a result of a lifestyle lacking two factors; firstly when exposure 
to sunlight is reduced thereby reducing production in the skin and secondly when the diet is itself is 
lacking in vitamin D (Holick, 1999). The most notable signs of vitamin D deficiency are rickets in 
young animals where the long bones do not form properly, causing stunted growth, in conjunction 
with the classic bone deformities such as knock-knees or bowed legs (Holick, 1999). In adults vitamin 
D deficiency presents with more subtle symptoms since the bones have already formed, and so 
vitamin D deficiency is characterised by osteomalacia (unmineralized bone matrix), usually causing 
pain and weakness in the bones and muscles, and associated osteoporosis (porous bones from 
calcium resorption) where bones are weak and susceptible to fracture (Holick, 1999). 
L2.4 Vitamin D and Lus::.le :uEction 
Vitamin D deficiency has been frequently reported to present with muscle myopathy in addition to 
the well understood bone disorders of osteomalacia in adults and rickets in children (Schott & Willis, 
1976). Eastwood et 01./ (1977) reported that patients with long term kidney failure suffering with 
osteomalacia could be treated with supplementation of 25-hydroxyvitamin D and found, besides the 
effects on bone mineralization; patients also exhibited an increase in the muscle strength with 
vitamin D treatment. The relationship between vitamin D deficiency and loss of muscle function was 
further supported by studies describing an association between vitamin D deficiency and muscle 
pain, weakness and loss of type II fibres ("fast twitch" muscle fibres) in human patients (Russel, 
1994; Ziambaras & Dagogo-Jack; 1999). Direct effects of vitamin D on muscle contractile function 
were reported by Curry et 01. (1974) whose study demonstrated that the sarcoplasmic reticulum (SR) 
of muscle in vitamin D deficient rabbits had a slower uptake of calcium ions compared to the SR of 
muscle from rabbits fed a diet sufficient in vitamin D. This discovery was further investigated by 
Rodman & Baker (1978) who reported that muscles in vitamin D deficient rats had a slower 
relaxation time in comparison to normal animals, a response which is mediated by calcium uptake by 
the SR and in this case the vitamin D effect was found to be independent of calcium and phosphorus 
levels. Further to the evidence for vitamin D's effects on muscle contractile properties, Wassner et 
01. (1983) reported that vitamin D deficient rats showed reduced muscle growth rates with a higher 
rate of myofibrillar protein degradation. A further study into the effects of 25(OH}D on rat 
diaphragm muscle reported an increase in ATP levels and leucine incorporation into protein, again 
demonstrating the possibility for vitamin D metabolites to regulate muscle metabolism and growth 
(Birge & Haddad, 1975). Although these studies provided the insight for the connection between 
vitamin D and muscle function, it was the discovery of the expression of the vitamin D receptor in 
muscle which affirmed the association between vitamin D and a direct effect on muscle tissue. 
Simpson et 01., (1985) first reported the presence of the 1,25(OHhD receptor (vitamin D receptor, 
VDR) in muscle cell lines and found that treatment of cell lines with the active form of vitamin D 
reduced DNA synthesis and inhibited proliferation of muscle cells; thus indicating skeletal muscle as 
a direct target organ of vitamin D and demonstrating that the hormone plays a role in regulating the 
terminal differentiation of muscle cells. Another piece of the puzzle into the hormone's role in 
muscle cell growth and differentiation was supplied by Endo et al.'s study into VDR (-/-) mice (2003) 
whereby the group observed reduced muscle fibre size in muscles of the hind limb and abnormally 
high expression of the muscle growth regulatory genes; Myf5, myogenin and E2A, as well as 
abnormal expression of the embryonic forms of the contractile protein myosin heavy chain (MHC). 
The group performed an additional experiment treating the C2C12 muscle cell-line with vitamin D 
and found treatment with the active hormone metabolite incurred downregulatory changes of these 
genes, suggesting a novel role for the hormone in controlling normal muscle cell growth and 
development. 
1.2.5 Vitamin D signalling 
Activated 1,25(OHhD exerts its actions on target tissues by binding to its specific receptor, the VDR, 
a member of the steroid hormone nuclear receptor family, whose general structure contains 
domains for ligand binding, DNA binding and activation of transcription (Cooper & Haussman, 2007). 
The understanding of the mechanism by which steroid receptors signal begins with the diffusion of 
the steroid hormone across the cell membrane where it binds to the receptor in the cytoplasm. 
Upon binding the ligand-receptor complex dimerizes with another nuclear receptor, the retinoid X 
receptor (RXR), and this 1,25(OHhD-VDR-RXR complex translocates to the nucleus where it directly 
binds DNA and regulates expression of specific genes, depicted in figure 1.2-3. The RXR is required 
for a number of nuclear receptors to exert actions on gene transcription, including the thyroid 
hormone receptor (TR) and retinoic acid receptor (RAR), shown in figure 1.2-4. Vitamin D is able to 
affect transcription of its target genes by the action of the VDR-RXR complex binding to response 
elements (VDREs) in the promoters of its target sequences which subsequently causes activation or 
inhibition of the expression of these genes. Genes which are known to be upregulated by vitamin D 
and its receptor are calcium binding proteins such as calbindin D-9k and -28k, and the 24-
hydroxylase enzyme which catalyzes breakdown of active vitamin D (Minghetti & Norman, 1988). In 
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contrast, genes which are down regulated by vitamin D-VDR-RXR binding are the la-hydroxylase 
enzyme in the kidney and the VDR itself. Response elements for the VDR are typical of steroid 
receptors which recognise their target genes by a code of short sequences of "half-sites" which are 
usually repeated within a short distance of each other (Lewin, 2008). The nucleotide sequences of 
the VDREs were elucidated by Carlberg et 01. (1993) who reported that there were two mechanisms 
for vitamin D to activate gene transcription; firstly they described response elements which were 
responsive to VDRnuc alone, possibly as a homodimer, and finally those which were activated by the 
VDR-RXR heterodimer. The sequences, or half sites, recognised by VDRnuc alone were GGGTGA 
arranged in three specific patterns, either as a direct repeat with a space of 6 nucleotides, as a 
palindrome with no space or as an inverted palindrome with 12 nucleotides between. The half-sites 
required for activated gene transcription by the VDR-RXR heterodimer were direct repeats of pairs 
of 6-nucleotide motifs; GGTCCA, AGGTCA and GGGTGA with a space of 3 nucleotides between the 
repeated motifs e.g. 5'-GGTCCANNNGGTCCA-3', where, for activation of gene transcription, the RXR 
binds the 5' most motif and the VDR binds the 3' motif (Kurokawa et 01., 1993), shown in figure 1.2-
4. 
1.2.5.1 Rapid-responses ofVDR 
More recently, the discovery of the VDR's presence in non-calcaemic tissues has opened the door to 
the elucidation of vitamin D's roles beyond calcium homeostasis, including processes such as cell 
proliferation, differentiation, regulating the immune response and apoptosis (Walters, 2002). The 
realisation that vitamin D was able to stimulate intracellular signalling pathways usually associated 
with membrane receptors was a result of multiple studies reporting vitamin D's ability to increase 
levels of second messenger molecules. Morelli et 01., (1993) were first to report that treatment of 
muscle cells with l,25(OHhD resulted in a rapid increase (seconds after vitamin D administration) in 
inositol 1,4,5-trisphosphate (IP3) and diacylgycerol (DAG); two second messenger molecules 
produced from the hydrolysis of phosphatidylinositol 4,5- bisphosphate (PIP2), a reaction catalyzed 
by activation of the enzyme phospholipase C (PLC). The authors of that study reported the major 
responses of the DAG and PIP2 signal in muscle cells to be the release of calcium from intracellular 
stores, the sarcoplasmic reticulum (SR) by ligand gated Ca2+ channels, and the activation of the 
enzyme protein kinase C (PKC). 
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changes in gene expression via binding of the VDRnuc to the vitamin D response elements (VDREs) in 
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Despite these secondary signalling molecules having well known roles in the signalling of other 
membrane receptors, it was unknown at the time of this study whether the VDR itself was present at 
the membrane of cells. A further report of the rapid signalling effects of vitamin D in muscle was 
produced by Vazquez et al. (1995) who observed changes in intracelullar calcium levels mediated by 
the adenylyl cyclase and cyclic AMP (cAMP) mechanism of second messenger signal transduction, 
again usually activated by membrane receptors. Both these studies provided substantial evidence 
for the presence of a membrane receptor for vitamin D which was capable of inducing rapid 
responses to ligand binding, unrelated to the classical VDR signalling via gene transcription, but had 
not yet elucidated the receptor responsible. The final missing piece of the jigsaw came from Nemere 
et al. (1998) who performed immunohistochemical staining for the VDR in the membrane of 
chondrocytes (bone forming cells) and provided the evidence that was required to show the VDR 
could be present at the cell membrane and was responsible for the activation of PKC by vitamin D. 
Whether or not the VDR that is present at the cell membrane is the same VDR responsible for 
induction of gene transcription is still unclear. Brown et al. (1999) made a clear argument for two 
distinct VDR in their review of literature, however, Capiati et al. (2002) reported that the VDR was 
able to translocate from the cytosol to the plasma membrane within 10 minutes following binding of 
the ligand to the receptor. 
Despite the lack of understanding over the exact form of receptor required for membrane signalling, 
it is now clear that vitamin D is able to mediate responses via a number of intracellular signalling 
pathways beginning with second messenger systems such as cAMP and PIP2 hydrolysis, which lead to 
the activation of intracellular signal transduction pathways such as the mitogen-activated protein 
kinase (MAPK) cascade (Buitrago et al., 2001) and the protein-tyrosine kinase, c-Src (Gniadecki, 
1998; Buitrago et al., 2001) in muscle, schematic diagram presented in figure 1.2-5. There are many 
enzymes which constitute the MAPK system and they respond to physical and chemical stimuli in 
order to coordinate cellular responses in survival and adaptation (Chang & Karin, 2001). Briefly there 
are three tiers to the MAPK pathway, the MAPkinase (MAPK) itself, which is activated by a MAPK 
kinase (MAPKK) which again is activated by a MAPKKkinase (MAPKKK), forming a multi-level cascade 
demonstrated in diagram 1.2-6. Taken together this body of research provides evidence for vitamin 
D's ability to activate intracellular signals which are now understood to be responsible for the 
control of cell growth, differentiation, proliferation and survival (Cooper & Hausman, 2007). 
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1.2.6 Vitamin D and Muscle: Summary 
In light of the studies reported so far, there is a clear role of vitamin D to maintain muscle function 
and strength, as shown by reports of myopathy in vitamin D deficient individuals which can be 
rectified with re-alimentation of vitamin D (Schott & Willis, 1976; Eastwood et 01./ 1977;. Russel, 
1994; Ziambaras & Dagogo-Jack, 1999). In addition, the fact that muscle tissue has been shown to 
express the vitamin D specific receptor, VDR, suggests the effect of vitamin D on muscle to be 
hormone dependant and not only a secondary effect of calcium and phosphorus homeostasis 
(Simpson et 01./ 1985). Finally, in view of the muscle deformities and abnormal expression of the 
myogenic regulatory factors (MRFs) in VDR (-j-) mice there is substantial justification for 
investigations into vitamin D's possible role in this tissue as a regulator of growth and development 
(Simpson et 01./ 1985; Endo et 01.,2003). 
1.3 Introduction to muscle metabolism, development and growth and its 
relevance to meat quality 
Understanding the growth and development of muscle tissue is important in terms of meat 
production for 3 reasons; firstly, the factors which affect the growth of muscle during early muscle 
cell proliferation ultimately affect the yield of meat; secondly, factors controlling the fibre type in 
terms of metabolism and contractile speed (twitch) of the muscle will also affect meat quality and 
finally the mechanisms for muscle growth in adult muscle tissue affects both yield and meat quality 
(Maltin & Plastow, 2004). All these factors will be discussed within this literature review along with 
the definition of meat quality and how it can be influenced, before the hypothesis behind vitamin 
D's possible role in influencing meat quality and overall production are discussed. 
1.3.1 Myogenesis 
Skeletal muscle formation is a highly organised procedure that is controlled by a number of 
transcription factors working together to cause pluripotent stem cells of the embryo to specialise 
and differentiate into the highly organised skeletal muscle tissue described in section 1.3.2. This 
process, myogenesis has three main phases; the first is cell line determination, where cells are 
programmed to become muscle cells, myoblasts, followed by proliferation, which increases the 
population of these muscle destined cells (myoblastsL and lastly differentiation, where the cells 
begin to specialise into the phenotype characteristic of muscle cells (Buckingham M., 1992). This 
programme of cell specialisation is regulated by four transcription factors, known as the muscle 
regulatory factors (MRFsL whose presence at specific times of myogenesis control the expression of 
muscle specific genes (Edmondson & Olson, 1993). 
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1.3.1.1 Initiation and Regulation of Myogenesis 
Muscle tissue is derived from the neural tube of the embryo where the somites form. The somites 
compartmentalize to create the scleratome and the dermamyotome, which eventually give rise to 
bone and cartilage and appendicular muscle respectively. The dermamyotome then divides into the 
myotome and the dermatome; the dermatome leading to the dermis and the myotome producing 
skeletal muscle, schematic diagram of these events is shown in figure 1.3-1 (Buckingham M., 1992, 
Cossu et al., 1996). Initiation for the signal to differentiate into muscle cell lines comes from other 
regions of the embryo via signalling molecules Wnt and Sonic hedgehog (Shh). The dorsal neurotube 
and surface ectoderm release Wnts, which is a positive initiator of MRF expression, in addition to 
Shh released from the notochord and floor plate neural tube (Buckingham M., 2001). Wnts acts via 
its receptor, Frizzled1, and activates its signalling pathway through ~ - c a t e n i n n and T-cell Factor TCF (a 
transcription factor) which, with Shh, induces expression of the early MRFs MyfS and MyoD. 
Negative regulators of the muscle determination pathways also exist to assist in the control of 
embryo development. Notch, a transmembrane signalling receptor between cells (Cooper & 
Hausman, 2008), has been proposed as an antagonist for Wnt signalling (Buckingham M., 2001) and 
similarly Twist and the Id proteins have been shown to be negative regulators of the basic helix-Ioop-
helix (bHLH) transcription factors involved in myogenesis (Yun & Wold, 1996). There are many other 
small signalling molecules released within the embryonic tissues which have been investigated for 
their role in muscle cell line determination and formation, including Pax3, c-met, Lbx1, Dach2, Eya2 
and Sixl. Knockouts of these signalling molecules with and without knockouts of MRFs have all 
shown abnormal muscle development ranging from no muscle in the embryos to specific and 
regional abnormalities (Birchmeier & Brohmann, 2000, Buckingham M., 2001). Some of these 
signalling proteins are required extremely early on in skeletal muscle development, where it has 
been shown that mice lacking Pax3, a transcription factor responsible for activating expression of c-
met, do not have muscles in their limbs (Tajbakhsh et al., 1997). Without Pax3 there is no 
transcription of c-met, which is a kinase enzyme required to regulate the migration of muscle pre-
cursor cells from the somite to the limb buds of the developing embryo, hence animals lacking Pax3, 
c-met or HGF, a ligand of c-met, (hepatocyte growth factor, also known as scatter factor) do not 
develop muscle in the limbs (Buckingham et al., 2003). 
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Figure 1.3-1. Schematic diagram of the early stages of myogenesis and the signalling factors responsible. 
Initial signals for the onset of the myogenic development programme are released as Wnts from the neural 
tube (NT) and Sonic Hedgehog (Shh) from the notochord (NC). Migration of muscle cell precursors from the 
somite to the limb bud is regulated by a number of signalling molecules in addition to the MRFs. In green 
font, delamination from the dermomyotome allows muscle cell precursors to migrate to the limb buds; this 
process is activated by the Pax3 transcription factor which induces c-met expression. The migration of the 
muscle cell pre-cursors to the limb buds, in blue font, requires the presence of both c-met and its ligand HGF 
(hepatocyte growth factor, or scatter). Once cells have migrated, they undergo proliferation to increase 
their population, in purple font, classically regulated by the MRFs MyfS and MyoD, however it is known that 
other signalling proteins are required including Mox2, Msx1 and Six as well as Pax3 and c-met. Pre-cursor 
cells are then determined into the muscle-cell line by MyfS and Myod, in red, and begin to express specific 
muscle cell genes, before they differentiate into multinucleated myotubes under the influence of Myogenin, 
in orange font. Final specifications of specific muscles and fibre type attributes are regulated by further 
signalling molecules. From Buckingham et 01. (2003). 
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1.3.1.2 The Myoregulatory Factors 
The MRF family are members of the basic-helix-Ioop-heli x (bHLH) family of transcription factors with 
similar structures shown in figure 1.3-2, all of which are responsible for the control of cell-type-
specific gene expression in their vary ing tissues (Edmondson & Olson, 1993). The M RFS act to alter 
gene expression by forming homo- and hetero-dimers which bind to DNA at specific nucleotide 
sequences containing the motif CANNTG (where N is any nucleotide), known as E-boxes (Ludolph & 
Konieczny, 1995), present in the control region of most muscle-specific genes as well as other cell-
type specific genes in other t issues (Edmondson & Olson, 1993). All of the four MRFs are required 
throughout the process of myogenesis and experiments investigating the development of MRF 
knockout models in mice have elucidated each MRF's role in myogenesis. As mentioned above, the 
specification of the early cells in the mesoderm into the muscle cell line begins with ear ly signals 
from other regions of the embryo before expression of the MRF family begins within the early 
muscle cells. The first MRFs to be expressed are Myf5 and myoD which act to promote proliferation 
and switch on the muscle-cell specific genes. Myogenin is expressed later in gestat ion and controls 
the process of muscle cell differentiation, whereby single nucleate cells leave the cell cycle and 
elongate before fusing and forming multinucleate myotubes. MRF4 is the last MRF to be expressed 
in the myogenic process and remains the most predominantly expressed following birth . A 
schematic representation of the MRF's involvement in the myogenic programme is shown in f igure 
1.3-3. 
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Figure 1.3-3. Schematic diagram of the control of muscle cell differentiation by MRFs (Ludolph & K o n i e c ~ ~
1995). Specification into the muscle cell line is initiated by early signals from Pax -3 as well as MyoD and 
Myf5. Muscle cell precursors, or myoblasts, proliferate under the influence of MyoD and MyfS until 
differentiation is induced by both extracellular and intracellular signals. Myogemn is the MRF responsible for 
regulating differentiation into fused and multinucleated myotubes until MRF4 becomes the most 
predominant MRF to be expressed in maturing muscle. 
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Table 1.3-1. Muscle phenotypes observed in mice lacking expression of MRFs. 
MRF (-/-) Normal Myogenesis? Deformities? other MRF expression Reference 
MyoD Yes No MyfS l' X 3 Rudnicki et al ., 1992 
MyfS Yes defects in rib region none reported Braun et al .,1992 
MyoD +MyfS No myoblasts present Rudnicki et aI., 1993 
Myogenin Myoblasts are present but no terminal Hasty et al ., 1993, 
differentiation, no functional muscle Nabeshima et al ., 1993 MRF4 Yes mild rib deformities Myogenin l' X 3 Zhang et al., 1995 
MRF knockout studies have contributed immensely to the understanding of each MRF's role in 
regulating skeletal muscle formation, with all this data combined the roles of the MRF family can be 
identified, summarised in table 1.3-1. The first MRF to be investigated in this way was MyoD 
(Rudnicki et al., 1992) where it was observed that mice embryos developed normally without 
abnormalities, however there was an increased expression of Myf5 by three times that in wildtype 
siblings. This was closely followed by a Myf5 knockout model where muscle tissue again appeared to 
progress normally although there were some deformities in the ribs of embryos (Braun et al., 1992). 
These two studies demonstrated the ability for Myf5 and MyoD to compensate for the other's 
absence, but when both Myf5 and MyoD expression was removed there was no muscle cell 
formation at all, demonstrating the requirement for at least one to be present for fetal survival 
(Rudnicki et al., 1993). This information leads to the conclusion that MyoD and Myf5 are required for 
determination of pluripotent cells to the muscle cell lines and without these MRFs there are no 
myoblasts present in the foetus. Following these studies the role of myogenin was investigated by 
the knockout model where mice embryos were observed to survive gestation before dying shortly 
after birth (Hasty et al., 1993, Nabeshima et al., 1993). These myogenin (-/-) mice did have normal 
myoblast populations but showed no terminal differentiation into muscle cells and as a result had no 
functional muscle tissue. This model highlighted the vital role of myogenin to induce terminal 
differentiation of myoblasts into functioning muscle cells. Finally a knockout mouse model for MRF4 
was investigated and found there was no affect on the determination and differentiation of muscle 
and all animals appeared healthy with the exception of some mild rib deformities (Zhang et al., 
1995). These MRF4 (-/-) mice did have increased expression of myogenin in comparison to wildtype 
siblings which gave way to the notion that lack of MRF4 expression is compensated by myogenin and 
that MRF4's role was of importance of after muscle cell development. 
Upon expression, the MRFs up-regulate expression of a number of muscle specific genes, for 
example all MRFs are capable of up-regulating the expression of desmin (Li & Capetanaki, 1994) and 
each MRF is capable of activating its own array of genes, for example MyoD upregulates creatine-
kinase, tropnin I, a-actin and a-acetylinecholine receptor; whereas MRF4 only activates a-actin and 
a-acetylinecholine receptor (Ludoplph & Konieczny, 1995). 
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1.3.1.3 Other factors regulating myogenesis 
As mentioned previously, the MRFs form both homo- and hetero-dimers prior to binding to the E _ 
box of target genes; however, this process is further regulated by the presence of many other HLH 
proteins which are capable of binding with the MRFs and modifying their actions. Of these the MEFs 
and the E proteins are thought to be positive regulators of muscle differentiation whereas the Id 
protein is a negative regulator of muscle differentiation. 
1.3.1.4 Myocyte enhancer factors (MEFs) 
The myoctyte enhancer factor 2 family (MEF2) are a family of transcription factors with similar 
function to the MRFs and are expressed in a broad range of cell types including brain, cardiac and 
visceral tissue where differential gene splicing produces tissue specific isoforms (Ludolph & 
Koneiczny, 1995). The MEF family of transcription factors are members of a larger superfamily of 
MADS transcription factors (MCMl agamous deficiens serum response factors) which all have the 
characteristic MADS box, a 56 amino acid motif responsible for binding to DNA and dimerization 
with other proteins. In addition, the MEF2 family contain another conserved 19 amino acid 
sequence, known as the MEF2 site responsible for binding AT-rich DNA sequences in the regulatory 
regions of many muscle specific genes (Ludolph & Koneiczny, 1995). There are four members of the 
MEF2 family, MEF2A, MEF2B, MEF2C and MEF2D, all of which function by forming homo- and 
hetero-dimers with the MRFS plus other transcription factors, and activate the expression of muscle 
specific genes such as desmin (Li & Capetanaki, 1994), creatine kinase, myosin heavy chain, and 
other MRFs (Ludolph & Konieczny, 1995). 
1.3.1.5 E proteins 
The MRF family of transcription factors are members of the class II of basic helix-loop-helix 
transcription factors and are able to form dimers with members of the ubiquitously expressed E 
proteins which are members of the class I bHLH factor family (Berkes & Tapscott, 2005). The E 
proteins function in a similar way to the MRFs and bind DNA sequences at the E-box due to their 
bHLH domain. The E2A gene is able to encode three different E proteins due to differential splicing 
of mRNA leading to the production of E12, E47 and E2-5, in addition, other similar related proteins 
E2-2 and HEB are encoded by distinct genes (Shirakata 1993). These proteins are able to form 
heterodimers with the MRFs and in doing so, change their affinity for DNA binding. For example, 
when MyoD forms a hetero-dimer with E12, its affinity for binding to the E-box in the creatine kinase 
gene enhancer sequence is much greater than would be for a homo-dimer of MyoD alone {Benezra 
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et aI., 1990). The exact role of the E-proteins in myogenesis is still under debate, and knockout 
studies of specific E-proteins show no effect on the formation of skeletal muscle, demonstrating 
some redundancy in the family (Berkes & Tapscott, 2005). 
1.3.1.6 ld protein 
The Id family of proteins contains three members, Id1, Id2 and Id3, all of which contain the helix-
loop-helix domain but lack the basic region required for DNA binding as seen in the bHLH 
transcription factors MRFs. However, the Id proteins are still able to form dimers and complexes 
with bHLH proteins but in doing so restrict their ability to bind DNA at the E-box, thus inhibiting 
muscle gene expression. In their study in the C2C12 mouse-derived muscle cell line, Jen et 01. (1992) 
demonstrated that overexpression of Id mRNA was capable of inhibiting muscle cell differentiation. 
1.3.1.7 Myogenesis Summary 
The development of muscle cells from the embryo to fully formed specialised muscle cells is a highly 
regulated process and requires the presence of a multitude of signalling factors. The MRFs are 
muscle specific transcription factors which can induce expression of muscle genes in non muscle 
cells and myogenesis does not occur in their absence. Some MRFs are vital such as Myfs and 
Myogenin and can act to oversee myogenesis in the absence of other MRFs in a way that MRF4 and 
MyoD cannot. In addition to the MRFs a large array of proteins are also required and play their part 
from the very beginning of muscle-cell migration to the limb buds through to the maturation of fully 
differentiated, mulitnucleated mature myotubes. 
1.3.2 Skeletal Muscle Architecture 
Skeletal muscle is responsible for allowing the voluntary movement of animals and is a highly 
adapted tissue to perform this function. Skeletal muscle is structured in a hierarchy of components, 
beginning with the overall muscle which is made up of bundles of fibres. Each fibre within the 
bundles, known as a myofibre, is a single muscle cell containing multiple nuclei as a result of many 
cells forming together to create one extremely large muscle cell, which is around sOllm in diameter 
and several centimetres long (Cooper & Hausman, 2007). Each individual cell is further made up of 
many smaller fibres, known as myofibrils, and these each have a distinct sub-structure of proteins 
organised in repeating units along their length. Skeletal muscle is also referred to as striated muscle 
owing to its appearance under the microscope; this striped appearance is a result of many repeating 
protein units known as the sarcomere, which are made of multiple proteins organised into a distinct 
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arrangement, demonstrated in figure 1.3-4. The proteins within the sarcomere are described in 
figure 1.3-5 along with the sub-structures of each region of the sarcomere. 
1.3.2.1 Structure o/the Sarcomere 
The thick filaments are comprised of many molecules of myosin gathering together to form a long 
chain with the reactive large heads of each protein orientated to face outwards. Each molecule of 
myosin is formed from a complex of 6 smaller myosin proteins, consisting of two heavy chains 
(myosin heavy chain, MHC) and two pairs of light chains (regulatory light chain, RLC and essential 
light chain, ELC). These form the much larger myosin molecule which has a long chain which 
associates with other myosin molecules to bind the thick filament and a large globular head where 
the protein can bind to actin in contraction. Actin is a cytoskeletal protein, present in many tissues of 
the body and exists in three forms, a-, ~ ~ and v. ~ ~ and v-actin are expressed by most cell types as 
part of the cytoskeleton whereas a-actin is muscle specific (Au, 2004). Actin in the thin filament is a 
globular protein, noted as G-actin, which polymerises to form a long molecule known as filamentous 
actin or F-actin. The F-actin is formed around 2 molecules of the filamentous cytoskeletal protein 
nebulin, which acts as a "molecule ruler" to regulate the length of the thin filament, and around 
these is another long-chain molecule, tropomyosin, a coiled-coil protein which wraps around the 
thin filament and prevents the myosin heads from the thick filament binding (Au, 2004). In addition 
to tropomyosin, the troponin complex is also associated along the thin filament and it is this complex 
that removes the inhibition of tropomyosin in response to calcium. At rest the tropomyosin is 
positioned over the active sites of the actin proteins, but during muscle innervation calcium ions are 
released which bind to troponin and alter its tertiary structure and in doing so moves tropomysoin, 
revealing the active site for myosin binding and allowing contraction. The interaction between actin 
and myosin requires energy from ATP and the head of the myosin protein is an ATPase able to 
hydrolyse ATP to ADP + P, providing the energy for the interaction between the two filaments. 
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Figure 1.3-4 Structure of muscle from tissue to individual myofribril strand. Each muscle is attached to a 
bone of the skeleton at either end and is used to coordinate animal movement. The muscle Itself s made of 
bundles of fibres which are effectively muscle cells, formed when multiple muscle cell walls break dow,., to 
form larger massive cells with multiple nuclei. Each muscle cell, or myofibre, contains further smaller f bres 
known as myofibrils and within this structure the characteristic protein ultrastructure of the co,.,tractlle 
apparatus is seen. Taken from Randa" et al. (2002). 
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Figure 1.3-5. Proteins within the sarcomere, adapted from Swartz et al. (2000). A) The characteristic bands 
of the sarcomere defined by the overlap of the thick and thin filaments and the space between. B) The thick 
filament is composed of myosin molecules, bundled together in a formation that leaves the reactive globular 
head facing outwards from the filament. C) The thin filament is anchored at the Z-line by CapZ to a-actinin . 
0) The thin filament is comprised of many globular actin proteins polymerising to form a long chain, 
constructed around two molecules of another long filamentous protein, nebulin. E) Titin is the largest 
protein known and spans the length of the sarcomere, preventing over-stretching of muscle fibres. F) The 
actin proteins provide many binding sites along their chain to which myosin heads from the thick filament 
can bind (myosin crossbridge) and facilitate sliding of the filaments past each other. This reaction is 
regulated by the presence of tropomyosin which is associated with troponin complexes along the thin 
filament (0). Together tropomyosin and troponin regulate the binding of myosin to the active sites on the 
thick filament. 
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1.3.3 Muscle Function and Fibre type 
There is great variation in the roles skeletal muscles are required to perform, ranging from 
maintaining posture to powering short, powerful sprints (Bottellini & Reggiani, 2000) and in order to 
perform these roles skeletal muscle can be highly heterogeneous in terms of mechanical and 
metabolic properties (Buckingham, 1992; Schiaffino & Reggiani, 1996). There are two major 
components to muscle protein, the myofibrillar protein fraction involved in muscle contraction and 
movement, and the sarcoplasmic proteins which include enzymes and myoglobin (Peterson et 01., 
1991). After skeletal muscle cells differentiate and fuse into adult myotubes, they can begin to 
express different isoforms of muscle specific genes allowing muscle cells to be able to specialise 
further into fibres with varying degrees of physical properties, such as differing contraction time, 
maximal power, shortening velocity and resistance to fatigue (Bottellini & Reggiani, 2000L and 
metabolic properties; with differing levels of glycogen and lipid in the cells, fibre diameter, colour 
and their oxidative and glycolytic capacities (Chang, 2007). The speed with which the actin and 
myosin crossbridges interact differs as a result of different myosin heavy chain isoforms. The muscle 
fibres can react differently to neural stimuli resulting in slow gradual contraction lasting minutes or 
with a quick contraction which is over in milliseconds (Randall et 01., 2002). The number of calcium-
ATPase enzyme pumps present on the membranes of the SR can affect the speed with which a 
muscle recovers from a contraction (Rodman & Baker, 1978) and the mitochondrial population 
density affects the energy supply required for aerobic respiration. 
Muscle contraction requires energy in the form of ATP and, in order to generate ATP, muscle is able 
to metabolize fuels such as glucose, fatty acids and ketone bodies (Voet et 01., 2008). Choice of fuel 
consumption and energy production varies depending on the duration of work being done. For 
extremely short, rapid contraction muscle produces ATP from the reaction between 
phosphocreatine and ADP, producing creatine and ATP, a reaction which can generate enough ATP 
to fuel around 10 seconds of muscle "work". Following exhaustion of phosphocreatine supplies, 
muscle can utilise glycogen stores in the process of glycolysis, which involves the anaerobic 
respiration of glycogen, resulting in the production of lactate. Human muscle can use glycolysis as an 
energy store for around 2 minutes of exercise before build up of the by-product lactate begins to 
lower pH of muscle and causes muscle fatigue. For longer, sustained muscle use, oxidative 
phosphorylation of fatty acids must be used, a process which produces ATP most efficiently although 
more slowly. Training of athletes can alter the metabolic profiles of muscles so that sprinters rely on 
glycolysis as their major fuel supply whereas long distance runners rely on oxidative metabolism 
(Voet et 01., 2008). Overall, these differences in muscle metabolism allow muscle fibres to be 
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classified depending on two factors, whether they utilize predominantly glycolysis or oxidative 
phosphorylation as their energy source, and secondly, the speed of contraction, i.e. slow or fast 
twitch (Reggiani & Mascarello, 2004). These two factors are the predominant properties used to 
define the three major classes of muscle fibre type. 
Peter et 01. (1972) suggested fibres be classified under three terms based on their twitch speed and 
their metabolism; 1) slow oxidative (SO), 2) fast twitch glycolytic (FG) and 3) fast twitch oxidative 
glycolytic (FOG) which are intermediate fibres using a combination of both oxidative and metabolic 
metabolism. Generally, slow oxidative (SO) fibres have small fibre diameter, low force per cross-
sectional area, slow rate of contraction and low myosin ATPase activity. SO fibres have high 
resistance to fatigue with a large population of mitochondria, along with little capacity for energy 
generation anaerobically by glycolysis. In contrast, fast glycolytic (FG) fibres have a large diameter 
and force per cross-sectional area and have high myosin ATPase activity. FG fibres fatigue quickly 
and have few mitochondria for oxidative respiration due to their high capacity for anaerobic 
glycolysis. Fast oxidative glycolytic (FOG) fibres have properties between SO and FG, where FOG are 
intermediate in size, myosin ATPase activity, resistance to fatigue and enzymes in glycolytic energy 
production. Similar to FG fibres, FOG fibres have a large force per cross-sectional area and a fast rate 
of contraction, but are similar to SO fibres in that they have a large capacity for oxidative 
metabolism due to their large mitochondrial population, summarised in table 1.3-2 (adapted from 
Randall et 01., 2002). 
Table 1.3-2. Physiological properties in each muscle fibre type, adapted from Randall et 0/. (2002). 
Muscle Characteristic 
Fibre diammeter 
Force per cross-sectional area 
Rate of contraction (V max) 
Myosin ATPase activity 
Fatigue resistance 
Mitochondrial capacity for oxidative metabolism 
Enzymes for anaerobic glycolysis 
Slow Oxidative (SO) Fast Oxidative Glycolytic (FOG) Fast Glycolytic (FG) 
Type I Type lIa Type IIx 
Small ~ ~ Large 
Small 
Slow 
Low 
High 
High 
Low 
High 
Fast 
~ ~
~ ~
High 
~ ~
Large 
Fast 
High 
Low 
Low 
High 
Key: ~ ~ = intermediate 
A study in rats (Armstrong & Phelps, 1984) found that within the hind-limb muscle mass of rats the 
collection of fibres was predominantly fast glycolytic (76%) with less fast twitch oxidative (19%) and 
very few slow oxidative fibres (5%). In comparison, a study in the muscle population of sheep (Suzuki 
& Tamate, 1988) found that type I, SO, fibres were much more abundant in sheep muscles, where 
SO fibres accounted for between 50 and 75% in some leg muscles, an observation they linked to the 
species requirement to stand for long periods of time during grazing. 
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1.3.4 MHe Genes 
There are several MHC protein isoforms expressed in mammals as a result of multiple MHC genes in 
the genome and their expression is tissue related, such as the cardiac isoforms in the heart, encoded 
by gene MYH6, and the extraocular in the eye, encoded by gene MYH13. Of these multiple gene 
variants, six isoforms are predominant in skeletal muscle, as summarised in table 1.3-3 (Maccatrozzo 
et al., 2004). All the MHC genes are highly homologous and there is little variation between their 
nucleotide sequences in the highly conserved regions of the protein structure, but in the globular 
head region where the ATP binding region is associated there are differences, culminating in varying 
speeds with which the proteins catalyze ATP to produce energy for actin binding and contraction 
(Schiaffino & Reggiani, 1996, Pette & Staron, 2000). During mammalian embryonic development, the 
primary MHC genes to be expressed in skeletal muscle are the embryonic, neonatal and the I / ~ ~ slow 
isoforms until birth, after which the expression of the embryonic and neonatal isoforms decreases 
and they are replaced by the adult fast isoforms II A, IIX and liB which are expressed through 
adulthood, along with the 1/ ~ ~ slow isoform (Chang, 2007). In small mammals such as dogs and 
rodents{Schiaffino & Reggiani, 1996) there are four major adult MHC isoforms present in varying 
abundances in skeletal muscle, whereas in larger species such as cattle and horses there are only 
three adult isoforms present, 1/ ~ ~ slow isoforms, IIA and IIX (Chikuni et al., 2004; Maccatrozzo et al., 
2004). The organization of the MHC within the chromosome is not related to the spatial expression 
pattern and the 6 skeletal muscle MHC genes are split between two chromosomes in several species 
including human and mice (Weiss et al., 1999). In humans the distribution of the isoforms is the 
same aside from locations in chromosomes 17 and 14, demonstrated in figure 1.3-6. 
Table 1.3-3. Myosin protein isoforms, gene name and associated tissue types. 
MHC Isoform Gene Name Tissue 
MHC la / Cardiac MYH6 Heart 
MHC Extraocular MYH13 Eye 
MHC I f3/Slow MYH7 Heart/ Skeletal Muscle 
MHC lIa MYH2 Skeletal Muscle 
MHC IIx MYH1 Skeletal Muscle 
MHC lib MYH4 Skeletal Muscle 
MHC Embryonic MYH3 Developing Skeletal Muscle 
MHC Neonatal MYH8 Developing Skeletal Muscle 
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Chromosome 17 
protein name 5' EMB lIa IIx lib NED ED 3' 
Gene name MYH3 MYH2 MYHl MYH4 MYH8 MYH13 
Chromosome 14 
protein name 5' I / ~ ~ Slow a/ cardiac 3' 
Gene name MYH7 MYH6 
Figure 1.3-6 Schematic representation of position of MHC encoding genes on human chromosome. Location 
of skeletal MHC genes is conserved between some mammalian species with the lIP slow isoform localized 
with the a-cardiac isoform, in this example of human organization these two genes are situated on 
chromosome 14. The two developmental MHC are located either side of the adult fast isoforms located in 
chromosome 17 in human with the extraocular isoform. Common name for each MHC protein encoded is 
above, gene name is annotated below. Adapted from Maccatrozzo et 01. (2007). 
The variation in each isoform's activity in the ATPase reaction leads to variation in the protein's 
contraction speed and hence types of isoforms expressed in skeletal muscle sarcomeres determines 
their contraction speeds and thereby force. This leads to the classification of muscles in terms of 
their contractile speed; fast or slow. The slow isoform is MHC I, also known as MHC ~ ~ or slow, and is 
associated with a slower muscle contraction in comparison to its faster relatives; MHC IIA, IIX and 
liB. Chang (2007) further defined muscle fibre types in light of the recent discovery of MHC gene 
properties as follows; 1} slow oxidative express slow MHC isoforms, are red in colour due to high 
levels of myoglobin and large numbers of mitochondria which support oxidative respiration, have 
the highest lipid contents and have the most dense capillary networks; 2} fast glycolytic fibres 
predominantly express the fast MHC liB isoforms, have the largest diameter of the fibre types, have 
least myoglobin and mitochondria content, contain a large store of glycogen to fuel their 
predominant metabolism and have low levels of lipid, 3} intermediate fast fibres have a fast twitch 
but use a combination of oxidative and glycolytic metabolism and express the MHC IIA and IIX 
isoforms. 
This variation of fibre type between species and the distribution of these fibre types within an 
animal is related to the requirement of muscles to perform a variety of roles. Slow moving animals 
require more slow oxidative fibres whereas fast moving such as rodents tend to have more fast 
glycolytic. This is reflected in the MHC gene expression profile of animal species whereby large 
animals such as cattle and horses MHC liB are almost exclusively absent, despite being abundant in 
smaller species such as pigs, dogs and rodents (Chang, 2007). Similarly fibre types vary between 
muscles as those involved in posture tend to contain predominantly SO fibres where as those 
muscles involved in movement can contain a variety of fibre types (Suzuki & Tamate, 1988; Ariano et 
al., 1973). Distribution of fibres is also varied within a muscle with studies into a number of species 
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finding agreement that SO fibres tend to aggregate in the deepest regions of the muscle and the 
faster twitch fibres found towards the outer regions of the muscles (Armstrong et 01., 1982; 
Armstrong et 01., 1984; Suzuki & Tamate, 1988, Klont et 01., 1998). The arrangement of the slow 
fibres within the depths of the muscle surrounded by faster fibres is a result of the development of 
the fibres pre-natally. The first fibres to form in the embryo, known as primary fibres, are slow and 
the fast fibres form around them, known as secondary fibres, at the same time as the neural tissue is 
forming (Buckingham et aI., 2003). 
1.3.5 Muscle growth and fibre type 
The development of the differential fibre types begins with the onset of innveration during foetal 
development (Buckingham, 2001) and the control of muscle fibre type beyond birth can be 
manipulated by a number of methods and is of interest to the meat industry as it is known to affect 
meat quality (Klont et 01., 1998). It has been known for some time that muscle contraction 
properties can be altered by altered electrical stimulation applied directly to the muscles, causing 
fast to slow fibre type transitions supported by related expression changes in MHC genes (Pette, 
1998; Jaschinski et 01., 1998). In addition studies have investigated the fibre type changes during 
animals growth and reported that from birth to mature liveweight, fibre type of muscle progresses 
from fast to slow, observed in pigs (Handel & Stickland, 1987L sheep (de Macado et 01., 2000) and 
cattle (Wegner et 01., 2000) and have attributed these changes to the rate of growth of the animals 
whereby increased growth rate leads to increase in slow/fatigue resistant fibres probably due to an 
increased load effected by increased liveweight (Handel & Stickland, 1987). Importantly, these 
studies reported that these changes in properties of muscle fibre types were not due to growth of 
new muscle cells but due to changes within existing fibres. The number of muscle cells present in the 
adult tissue is defined during the early stages of muscle development (myogenesis) and post-natal 
muscle growth involves an increase in the size of those muscle cells (hypertrophyL not an increase in 
number (hyperplasia) (Rehfeldt et 01., 2004). 
An example of agents that have been investigated for their effects in promoting muscle growth in 
the meat industry are ~ - a d r e n e r g i c c agonists (BAA). BAAs are potent promoters of lean muscle 
growth and studies have reported their effects in cattle (Beerman D.H., 2002; Yang & McElligot, 
1989; Vestergard et aI., 1994) and sheep (Koohmariae & Geesink, 1991). The results of these studies 
indicated that the majority of muscle hypertrophy as a result of BAA treatment was specific to fast 
glycolytic fibres, in the case of Verstergard et al.'s study the ratio of FG fibres in the LD of BAA 
treated animals was 71.1% compared to 51.7% in controls. The BAA studies show that the fibre type 
changes seen with BAA treatment are specific to fast glycolytic fibres, and the overall action in 
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muscle is to increase glycolytic potential and reduce oxidative capacity, in addition to increased 
protein synthesis and reduced protein breakdown. While the phenomenon of muscle hypertrophy 
observed with BAA treatment is of great interest to the meat industry in terms of increased 
production, it provides a clear link between changes in fibre type of muscle and the resulting meat 
quality, as there are reported adverse affects of BAA treatment on the tenderisation process post 
mortem (Koohmaraie & Geesink, 1991) and thus the gains of muscle growth are offset with losses in 
product quality. Although the mechanism of fibre type specific hypertrophy observed with BAA 
treatment is of interest to the studies reported in this thesis, the primary aim of this investigation is 
to improve meat quality in terms of tenderness. Thus the following literature review aims to outline 
some of the mechanisms responsible for fibre type switching and the relevance of muscle fibre type 
to meat quality. 
1.3.5.1 Muscle fibre Type Transitions 
It has been known for some time that muscle contraction properties can be altered by altered 
electrical stimulation, causing fast to slow fibre type transitions supported by related expression 
changes in MHC genes (Jaschinski et 01., 1998). In their experiments, Jaschinski et 01. (1998) 
demonstrated that over a long period of chronic electrical stimulation, a fibre transition could be 
seen in muscles from rat expressing predominantly MHC liB to switch to predominantly expressing 
MHC IIX. This was in agreement with another experiment where fibres from rabbit hind limbs 
switched MHC gene expression from predominantly MHC IIX, to MHC IIA and eventually to MHC I / ~ ~
(Leeuw & Pette, 1993). These experiments demonstrate muscle's ability to change gene expression 
and to alter its phenotype in order to meet the demands more efficiently. 
These transitions in MHC genes follow a sequential order, where MHC proteins of the fibre are 
converted from one form to another, in the sequence set out below (Jaschinski et 01., 1998, Pette & 
Staron, 2000), where the change in isoform expression is sequential. For example MHC IIA 
expression must lead to MHC IIX before the final transition to MHC liB, with hybrid fibres in 
between. 
MHC I CP) H MHC IIA H MHC IIX H MHC IIB 
The transformation from one fibre type to another allows muscle to adapt to altered requirements 
and demonstrates plasticity in muscle fibre populations of muscle. The mechanisms for these 
transitions are complex and are regulated in a variety of ways including neuromuscular acitivity, 
hormones and aging (Pette & Staron, 2000). In particular relevance to this study, it has been shown 
that thyroid hormone has been demonstrated to change MHC gene expression, whereby low levels 
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of thyroid hormones (hypothyroidism) results in muscle fibre type changes in a fast to slow 
transition (Nwoye & Mommaerts, 1981), and in contrast, high levels of thyroid hormones 
(hyperthyroidism) the transition is slow to fast (U et 01., 1996). Aging has been related to a loss of 
type II fibres and a subsequent study verified that there is a transition from MHC IIX to MHC I at both 
mRNA and protein levels of expression levels in both men and women during aging (Short et al., 
2005). The signalling mechanisms that regulate fibre type transitions are complex and require a 
change in gene expression of a large variety of proteins, ranging from enzymes involved in energy 
metabolism to the MHC proteins required for contraction. Although still not fully elucidated, a 
number of mechanisms for fibre type changes are considered below. 
1.3.5.2 Mechanisms controlling Fibre type transitions 
1.3.5.3 Calcineurin and NFAT 
Calcineurin, a calcium-calmodulin-regulated protein phosphatase was demonstrated to up-regulate 
the expression of MHC I slow in C2C12 muscle cells and promote muscle cell differentiation (Delling 
et 01., 2000). Calcineurin is an excellent candidate to be mediator of fibre type switching as it is 
responsive to fluctuating levels of calcium and therefore its activity is a reflection of the contractile 
activity of the muscle (Alzuherri & Chang, 2003). Calcineurin is known to be up-regulated by 
increased intracellular calcium levels, as seen in prolonged nerve contraction, and the enzyme 
functions in removing phosphate groups from the nuclear factor of activated T cells (NFAT) family of 
transcription factors, thus activating them to translocate to the nucleus, shown in figure 1.3-7. Once 
in the nucleus the activated NFAT protein can bind DNA and affect gene transcription. It has been 
previously shown that this mechanism is involved in the slow fibre regulation, but that the NFAT 
transcription factors require other muscle specific transcription factors such as the MEF2 family, and 
together these proteins are able to promote slow fibre formation (Chin et 01., 1998). In their study 
Delling et 01. (2000) could demonstrate a role for one of the NFAT protein family members, NFATc3, 
in promoting cell differentiation but not in slow fibre type conversion, however they did not 
investigate the role of other members of the NFAT family and postulated NFATc1 and NFATc2 could 
be involved. A further study by da Costa et al. (2007) demonstrated that calcineurin signalling via 
NFAT was able to upregulate the oxidative fibre phenotype in C2C12 cultures by upregulating the 
expression of the fast but oxidative MHC IIA and downregulating MHCs IIX and liB. 
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Figure 1.3-7. Proposed mechanism for calcineurin in activation of the slow muscle fibre program of gene 
expression leading to increased expression of the MHC I / ~ ~ slow isoform (from Chin et 01., 1998). Neuron 
firing patterns cause fluctuations in intracellular calcium ions. Calcium ions activate the calcium regulated 
calcineurin A (CnA) enzyme which de-phosphorylates the nuclear factor of activated T-cells (NFAT) family of 
transcription factors. NFAT then dimerizes with the MEF2 family of transcription factors and promotes 
transcription of the slow muscle fibre related gene programme. 
1.3.5.4 Protein Kinases 
The exp lanation for the modulation of slow fibre phenotype by calcium fluctuations is further 
supported by the actions of the other calcium regulated signalling molecules within muscle cells, the 
Ca2+/calmodulin-dependant kinases, known as calmodul in kinases, and protein kinase C (PKC) . 
Calmodulin-kinases are a family of phosphorylating enzymes which are activated by increased levels 
of free calcium in the cell as seen in frequent contraction of muscle. Calmodulin kinases are known 
to up-regulate genes involved in oxidative metabolism such as mitochondrial enzymes involved in 
fatty acid metabolism and electron transport, as well as the transcription factors NFAT and PGC-1a, 
which are important regulators of slow muscle fibre phenotypes (Chin, 2005). Meissner et 01., (2007) 
investigated the relationship of calcium and the MAPK signalling pathways in C2C12 muscle cells and 
found the p38/MAPK was associated with MHC IIX expression via recruitment of the transcription 
co-activator CREB-binding protein and MEF2 proteins C and D. Finally, Akt is a member of the 
serine/threonine protein kinases and is act ivated via the phosphatidylinositol -3 kinase (PI3 K) 
pathway, and in an experiment causing over-expression of Akt, type liB fibres were formed and 
glycolytic metabolism was increased (Izumiya et 01., 2008). 
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1.3.5.5 Peroxisome Proli/era tor-A ctiva ted Receptors (PPARs) 
In addition to the role of calcineurin in upregulating the transcription of the MHC I / ~ ~ slow gene, a 
study by Lin et al. (2002) demonstrated that calcineurin activates the transcription factor 
peroxisome proliferator-activated receptor gamma (PPARy) co-activator 1-a (PGC-1a). Upregulated 
PGC-1a was shown to act with the other transcription factors of the MEF2 family and caused fibre 
type changes from the fast to slow isoforms and increased expression of mitochondrial metabolism. 
Schuler et al. (2006) demonstrated that PGC-1a expression was under the control of another 
member of the PPAR family, P P A R ~ , , which is implicated in activating PGC-1a expression via a PPAR 
response gene in the promoter region of the PGC-1a gene. Together these two transcription factors 
were shown to promote slow fibre formation (Schuler et al., 2006). In addition to PGC-1a, other 
members of the peroxisome proliferator-activator receptors (PPARs) family are related to muscle 
fibre type with PPARo overexpression leading an increased proportion of type I fibres in mice (Wang 
et al., 2004), PPARa overexpression in mice causing changes in muscle oxidative metabolism (Finck 
et al., 2005) and mice overexpressing PGC-1a have an increase in the proportion of type I and IIA 
fibres (Lin et al., 2002). In contrast to the PGC-1a promotion of slow oxidative phenotype, Arany et 
al. (2007) demonstrated that the related protein P G C - 1 ~ ~ was involved in transcriptional upregulation 
of the MHC IIX gene, via co-activation with PPARa, and so induced intermediate fast twitch fibres 
with oxidative metabolism. 
1.3.6 Muscle fibre type control: Summary 
Muscle is a heterogenous tissue which is capable of performing a large range of functions. The ability 
of muscle to perform these functions stems from the presence of different fibre types as a result of 
the differential expression of specific isoforms of muscle genes. Mechanisms to improve meat yield 
by increasing muscle growth have been investigated and in particular ~ - a d r e n e r g i c c agonists (BAAs) 
are potent in increasing muscle growth, but adversely affect the quality of the meat produced. There 
is now increasing understanding of the mechanisms involved in the manipulation of fibre type and 
the possibility of a growth promoting agent which could increase muscle mass via hypertrophy of the 
oxidative fibre types known to be associated with tender meat could be of significant advantage to 
the meat industry. 
Sorenson et al. (1979) performed an investigation into vitamin D supplementation and its effects in 
fibre type changes. In their study a vitamin D analogue, 1a-hydroxycholecalciferol or alfacalcidiol, 
plus calcium was administered to elderly female patients with low bone density and found oxidative 
capacity of the muscle as measured by succinate dehydrogenase activity, was low before the 
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supplementation regime and was subsequently increased with treatment. In addition they observed 
an increase in the number of fast oxidative fibres and a decrease in fast glycolytic fibres, providing 
valuable evidence not just for vitamin D and calcium supplementation in improving oxidative 
capacity (resistance to fatigue) as well as inducing fibre type transitions. A final study into vitamin D 
supplementation in muscle fibre type was performed by Sato et 01. (2005) who gave elderly women 
ergocalciferol at 1000 IU/day for 2 years and found falling risk decreased by 59%, muscle strength 
increased and the number and size of type II fibres increased. In addition to vitamin D's effects on 
aged muscle, it has been shown that the hormone could playa role in normal muscle growth and 
development. In a study using knockout VDR (VDR -/-) mice Endo et 01. (2003) found mice born with 
the VDR -/- genotype exhibited abnormal muscle development, with elevated levels of the myogenic 
regulatory factors (MRFs) Myf5 and myogenin, along with the MRF-coactivator E2A. In addition 
these mice expressed higher levels of embryonic and neonatal isoforms of the myosin heavy chain 
genes. The muscle fibres of the VDR -/- mice were 20% smaller than in VDR +/+ control mice. The 
same study followed up these observations using the mouse derived C2C12 skeletal muscle cell-line 
and found the expression of Myf5, myogenin and neonatal MHC were down-regulated in response 
to activated vitamin D treatment and provides evidence for the importance of vitamin D in 
regulating the process of muscle tissue development. 
These studies provide evidence for vitamin D to exert direct effects on muscle tissue and fibre type, 
but have not investigated the molecular mechanisms through which vitamin D could potentially 
signal, and thus the objective of the work performed in this thesis aims to determine the potential 
pathways through which vitamin D might regulate MHC gene expression and muscle fibre type, 
which is of economic relevance to the meat industry through possible improvements in meat quality. 
The final section of this literature review aims to define meat quality, outline what factors affect 
meat quality, with particular reference to the calpain system, and the subsequent hypothesis for 
vitamin D's role in modulating meat quality. 
1.4 Meat Quality 
There are three major contributors to the development of the quality of meat in terms of tenderness 
1) the degree of background toughness, 2) the toughening phase prior to rigor and 3) the 
tenderization phase. Background toughness is a result of the extent of connective tissue, primarily 
collagen, and affects the ease with which unconditioned muscle can be cut (Koohmaraie & Geesink, 
2006). Connective tissue increases with the age of animals and thus in the production of premium 
steak meat it is standard to slaughter animals after their first growth phase before background 
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toughness is significant; culling of elderly animals leads to meat with tougher tendencies. Of the 
remaining contributors to meat quality, the toughening phase is constant in all carcasses which are 
processed the same, however, it is the tenderization phase that is most variable (Koohmaraie & 
Geesink, 2006) and is of interest to meat scientists to manipulate in order to produce meat of 
guaranteed high quality. The major factor in the development of tenderization is the activity of 
proteolytic enzymes post mortem (Koohmaraie & Geesink, 2006) and the manipulation of these 
enzymes has been the focus of many studies in order to understand how production methods can 
optimise meat tenderness. In particular these enzymes are activated by intracellular calcium levels, 
the levels of which are expected to be regulated by vitamin D. It is likely that increases in calcium 
status of meat animals, as regulated by vitamin D, could affect the tenderisation process post-
mortem through activation of the calpains. 
1.5 Conversion of Muscle to Meat 
In order to produce meat of high quality, it is important to understand the reactions that take place 
in muscle post mortem and how they contribute to the development of tender meat that is of 
acceptable quality to the consumer. The conversion of muscle to meat can be defined by three 
phases; the pre-rigor phase, rigor mortis and post rigor tenderization (Sentrandeu et al., 2002). 
1.5.1 The Pre-rigor Phase 
At death, blood circulation ceases and oxygen and nutrient supply to tissues is cut off causing the 
metabolic conditions in the muscle to change and the tissue begins to undergo a series of events 
that ultimately create the end product of meat. The pre-rigor phase in lamb muscle lasts around 12 
hours and in this phase the muscle is still excitable and is still metabolizing available energy sources 
of ATP (Adenosine triphosphate), PC (phosphocreatine) and glycogen (Sentrendau et al; 2002). 
When the muscle is supplied with oxygen and nutrients i.e. during "life", these energy sources are 
primarily used to control the extent of muscle contraction and homeostatic conditions of the cells, 
predominatly keeping free calcium inside the sarcoplasma at low concentrations. There are two 
mechanisms to maintain the low free calcium ion concentration of the sarcoplasma. The first 
mechanism is that which sequesters free calcium ions within the muscle cell into the sacroplasmic 
reticulum (SR) via calcium ATPase, and requires energy in the form of ATP to perform calcium ion 
movement across the membrane. The second mechanism is to constantly remove calcium from the 
internal environment into the extracellular fluid, again a function performed by an ATP-dependant 
calcium pump on the cell membrane. As both these calcium pumps require ATP, it is the eventual 
decrease in this energy source in the muscle post mortem that allows the rise in calcium levels inside 
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the muscle ce ll and leads to the susta ined uncontrolled musc le cont ract ion th at defines th e second 
phase of muscle to meat convers ion; the rigo r phase (Ja ecocke, 1993). 
1.5.2 The Rigor phase 
During rigor the free calcium levels in the sarcop lasma rise, thereby removing troponin inh ibit ion of 
the actin binding sites and initiating muscle contraction, t his phase beg ins in lamb meat around 12 
hours post mortem. In normal muscle cont raction, the release of ca lcium from the sarcolemma 
results in a change in the calcium concentration from the reg ion on 10-7M to 10-sM, and th is calc ium 
is subsequently sequestered back into the sarcoplasmic ret icu lum to allow relaxati on, but post 
mortem the energy supplies become exhausted and t he contract ion is ma inta ined . Jeacocke (1993) 
found calcium levels at onset of rigor to be in the region of 10-4 M, allowing t he much stronger and 
sustained contraction causing the characterist ic increase in toughness of meat at thi s stage, shown 
in the shear force measurements demonstrated in figu re 1.5-1. 
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Figure 1.5-1. The post mortem changes in shear force (kg) of lamb longissimus thoracic et lumborum muscle 
(Wheeler & Koohmaraie, 1994). In lamb, the pre-rigor phase lasts approximately 12 hours before t"e onset 
of rigor, where meat reaches maximum toughness, in this case at 24 ~ o l J r s s The meat the!" begins the 
tenderization phase where shear force is slowly reduced; this process can take UP 0 two weeks in lamb 
muscle. 
A defining characteristic change of muscle t issue during t he co nversion of muscle to meat is t hat of 
the shear force of the meat. Shea r fo rce is the measure ment of the degree of res ista nce wi t h which 
meat shows to being cut when the fibres are shea red transverse ly along the ir length. Changes in 
shear force during the conversion of muscle to meat is shown in f igure 1.5-1 (Wheeler & 
Koohmaraie, 1994), with the peak of rigor begi nning at around 6 hours post mortem and lasting 
around 12 hours. Following t he rigo r phase the meat undergoes a slower, gradual decrease in 
toughness . 
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1.5.3 The Tenderisation phase 
In lamb, the tenderization phase begins at around 24 hours post mortem and is a result of initiation 
of proteolysis (Wheeler & Koohmaraie, 1994). The meat slowly becomes more tender, taking around 
a week to reach ultimate tenderness, but the rate and extent of tenderness development is highly 
variable. It is this phase of meat production, known as conditioning or aging that is of concern in the 
present study. Improving the time taken to reach acceptable meat tenderness would help reduce 
the length of cold storage and reduce costs of meat, in addition to being able to guarantee a tender 
meat product. 
The further development of tenderness during the aging period is catalyzed by the activity of 
proteolytic enzymes in the muscle which break down the muscle ultra-structure. The importance of 
the role of proteases in the tenderization process was demonstrated by Wheeler and Koohmaraie 
(1994) showing that between 24 and 72 hours post mortem the shear force of lamb muscle halved, 
but the length of the sarcomere (the extent of muscle contraction) was not significantly changed. 
This information leads to the conclusion that post-rigor, the development of tenderness is catalyzed 
by proteolytic enzymes and not by further changes in muscle contraction state, which just increases 
the "density" of the structure of the sarcomere causing the increased resistance to cutting i.e. 
toughness. 
1.5.4 Properties of Meat changed during the conversion 
There a number of properties of the meat which change during the conversion process and these are 
key identifiers of aspects which affect the quality of the meat. 
1.5.4.1 Muscle pH 
Tissues can continue to respire aerobically until available oxygen is used up following which they 
respire anaerobically, regenerating adenosine tri-phosphate (ATP) initially from phospho-creatine 
and then for a more prolonged period from glycolysis. When muscle glycogen is metabolised via 
glycolysis the products are pyruvate and ATP, although the amount of ATP produced is much less 
than is seen with aerobic respiration. In a final effort to produce energy anaerobically, pyruvate is 
metabolised into lactate, a by-product which is normally removed by the blood circulation. However, 
in post mortem muscle lactic acid accumulates and causes a decrease from neutral pH 7.5 down to 
pH 5.4-5.7 (Maltin et 01. 2003), known as ultimate pH (pHu). The amount of glycogen available prior 
to slaughter is a large factor in the normal development of post mortem pH. In animals with 
depleted glycogen stores the pH of the carcass does not decrease causing the meat to become dark 
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firm dry (DFD). Thus it is of high importance in the meat industry that animals are not stressed prior 
to slaughter and transport of animals to the abattoir, and conditions therein, must cause minimal 
upset to meat animals (Peterson et al., 1997). 
1.5.4.2 Temperature 
As the muscle ceases to metabolize energy sources and the carcass is dressed, the muscle 
temperature begins to drop to that of the environment. The rate of temperature loss is affected by 
the fat content of the muscle (owing to fat's insulating properties), the size of the carcass and the 
reduction in metabolic activity of the tissues. The rate of temperature change is another contributing 
factor to the final tenderness of meat as rapid cooling prior to rigor can lead to cold- shortening of 
the meat and cause toughness, as a result of irreversible muscle contraction. 
1.6 Proteolysis and Tenderisation 
There are numerous enzymes present in muscle which can potentially contribute to the 
development of tenderization, these are the cathepsins (lysosomal peptidases), the proteasome 
(ubiquitin-marked proteolysis), caspases (apoptotic proteases), matrix metallopeptidases (MMP), 
muscle serine peptidases, and the calpain system (Ca2+-dependant, cysteine proteases) (Sentrandeu 
et aI, 2002). The major enzyme system reported to have effects on meat tenderness are the calcium-
activated protease enzymes the calpains, and in particular the micro calpain (calpain I) isoform 
(Koohmariae & Geesink, 2006). It was the members of the calpain system which were investigated in 
this study. Although other protease enzymes have been attributed to playing some role in post-
mortem proteolysis, the consensus is that the calpains play the major role. There is little activity of 
the ubiquitin-proteasome system in contributing to meat quality development, as the system is ATP-
dependant and such energy stores are already depleted in the early stages post mortem. However 
there is some contribution towards degrading proteins such as troponin-C in the thin filament and 
myosin light chains -2 and -3 of the thick filament (Koohmaraie, 1992). In addition the lysosomal 
enzymes also do not appear to be highly active (Maltin et al., 2003), although the cathepsins are 
capable of degrading a-actinin, actin and myosin (Okitani et al., 1980) which are not substrates of 
the calpain system, but this proteolYSiS does not occur until late post mortem at 7 to 10 days 
(Matsukara et al., 1981). 
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1.6.1 The Calpain System 
The calpains are endogenous cysteine protease enzymes, with optimum activity in neutral pH (pH 
7.2-8.2). There are two calpain isoforms responsible for proteolysis post mortem calpain I, or 11-
calpain, and calpain II, m-calpain. Both enzymes have multiple calmodulin like EF-hand calcium 
motifs within their structure. The levels of calcium required to activate them has given rise to their 
suffixes; Il-calpain requiring calcium levels (Ca2+) in the region of 3-50 11M and m-calpain requiring 
higher levels around 400-800 11M for half maximal activation (Goll et ai, 2003). The enzymes exist as 
heterodimers, composed of two subunits; the larger subunit is around 80 to 75kda in size and the 
smaller around 30kDa. The 80kDa subunit structure can be divided into four major structural 
domains, domains I, II, III and IV, shown in figure 1.6-1. Domain I containing the N-terminal region is 
automatically removed in a process of autolysis upon activation of the enzyme. Domain II of the 
80kDa subunit contains the active site, characteristic of other cysteine proteases, including the 
cathepsins, and domain III may be involved in binding phospholipids at the cell membrane and in 
contributing to folding of the protein. Domain IV contains four Ca2+ binding regions and is 
responsible for the activation of the enzyme, although there are an additional two other potential 
Ca 2+ binding sequences in domain III. The 30kDa subunit has five Ca 2+ binding regions in domain VI, 
similar to domain IV of the 80kDa subunit. The calpain enzyme subunits are encoded by distinct 
genes, with calpain I or Il-calpain and calpain II or m-calpain large subunit being encoded by the 
CAPN1 and CAPN2 genes respectively, however the smaller 30kDa subunit is encoded by a third 
gene, CAPN4 and this subunit is common to both calpain I and II. 
The calpains are situated intracellularly, usually associated with organelles such as the myofibrils in 
skeletal muscle and the cytoskeleton in non-muscle cells. Upon activation by the binding of Ca 2+ ions 
to the calmodulin-like domain IV, the enzyme translocates from the cytosol of the cell to the 
membranes. At the membrane the enzyme performs a further self-activation step whereby it 
removes the N-terminal region in domain I which results in the production of the active 75kDa form 
of the enzyme. This step is significant to the activity of the enzyme as the autolysed form requires a 
lower concentration of Ca 2+ ions for activation, shown in table 1.6-1 (Melloni et 01., 1996). Following 
this autolysis step, the enzyme is then released back into the cytosol of the cell where it can degrade 
its substrates. 
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Figure 1.6-1. Schematic structure of the calpain enzymes and their endogenous inhibitor calpastatin, 
adapted from Sentrendau et 01. (2003). 
The activity of the calpain enzymes are regulated not only by the free calcium concentrat ion in the 
muscle but by the presence of their endogenous inhibitor calpastatin, the structure of wh ich is 
shown in figure 1.6-1. Calpastatin is a polymorphic protein and multiple isoforms exist as a result of 
different promoters in the gene and splicing events (Goll et 01., 2003), which gives rise to proteins 
ranging from 50 to 172kDa (Sentrandeu et 01./ 2002), despite being encoded by a single gene, CAST. 
In each protein there are four domains responsible for calpain inhibition (domains I to IV) and the L-
domain which is the N-terminal of the protein and is variable in size . The binding of calpain to 
calpastatin is calcium-dependant, although in a unique phenomenon the Ca 2+ requirement fo r the 
binding of the inhibitor is less than that required for the enzyme to be activated (Wendt et 01., 2004) , 
shown in table 1.6-1 and discussed further below. 
Table 1.6-1. Physical properties of the calpain enzymes (adapted from Maltin et 01., 2003). AutolysIs of tbe 
calpains reduces the concentration of calcium required for half-maximal activity but also decreases the 
calcium concentration required for binding of calpastatin. 
Property of Ca lpain protease ~ - C a l p a i n n Autolysed ~ - c a l l a i n n m-Cal pain Autolysed m-ca lpain 
Molecular mass 110 99 108 98 
Large subunit 81 78 80 78 
Small subunit 28 20 28 20 
pH optimum 7·5 7·6 7·6 7·4 
Ca 2+ concentration for half-maximal activity ( ~ ~ ) ) 1-50 0·5-2·0 200- 1000 30--150 
Ca 2+ concentration for binding calpastatin ( ~ ~ ) ) 42 0·042 400 24 
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1.6.2 Regulation of cal pain activity by calpastatin 
In their review in 2003, Goll et al. reinforced the significance of the regulation of the calpain enzyme 
activity with their estimation that there are enough calpain enzymes present within in a muscle cell 
to completely degrade all the z-discs within 5 minutes. Calpastatin acts as a reversible inhibitor of 
calpain activity and every calpastatin protein has four calpain binding regions, each capable of 
binding a calpain molecule. Within the four inhibitory domains of the calpastatin molecule there are 
three subdomains A, Band C; of which sub-domain A binds domain IV of the calpain 80kDa subunit 
and sub-domain C binds domain VI of the calpain 30kDa subunit (Wendt et ai, 2004), however, sub-
domain B is vital to inhibitory activity. 
The binding of the calpains to calpastatin is calcium dependent and is reversible so that released 
calpain enzymes can continue to be proteolytically active (Imajoh & Suzuki, 1985), however the 
mechanisms of calpastatin and calpain binding were not clear until recently. Otsuka & Goll (1987) 
reported in their study that the calcium levels required for calpastatin to bind m-calpain was lower 
than that required for m-calpain to be catalytically active, when a calcium concentration of 0.53M 
was sufficient for half-maximum binding to calpastatin in comparison to a calcium concentration of 
0.93M required for half-maximum activity of m-calpain in the absence of an calpastatin. This 
phenomenon was further investigated using both m- and Il-calpain and again found the same result 
(Kapprell & GolI, 1989). From these studies it was concluded that it was impossible for calpain 
enzymes to exist without being bound to calpastatin, until a study by Melloni et al. (2006) has shed 
more light on this phenomenon. In their study Melloni et al. (2006) report that phosphorylation of 
calpastatin by protein kinase C reduces the association between the inhibitor and enzymes. Protein 
kinase C is activated in response to calcium influxes within cells (Voet et al., 2008) and therefore it 
seems likely that this is an additional step in calcium related control of calpain activity. 
1.6.3 Function of the Calpains 
The function of the calpains in living cells is not entirely defined and there has been some research 
into the calpain enzymes functions via knock-out models. A study performed by Azam et al. (2001) 
created mice null for the Il-calpain isoform and observed animals which survived but demonstrated 
altered blood platelet function. In another study Arthur et al. (2000) demonstrated an essential role 
of calpains in foetal survival in their study using knock-out mice lacking the gene for the small 30kDa 
subunit, where animals not expressing the small sub-unit did not survive beyond mid-gestation. 
These studies show the calpains are important in a large variety of functions and both Azam et al. 
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(2001) and Arthur et al. (2000) suggested the essential roles of cell division and migration, cell 
proliferation, apoptosis and cytoskeletal organization. 
1.6.4 The calpain system and meat quality 
The calpain enzymes are the major contributors to the development of tender meat; in particular it 
is Jl-calpain that is largely responsible for the tenderization of muscle (Koohmaraie & Geesink, 2006). 
Wheeler & Koohmariae (1994) reported that as a result of the increased calcium levels during the 
rigor phase there is already detectable activity of the Jl-calpain enzyme at 18 hours post mortem in 
lamb muscle. Lametch et al. (2004) reported that in in vitro post mortem conditions of pH = 5.5 and 
4°C, Jl-calpain retained 24-28% of its activity when compared to that in normal physiological 
conditions of pH=7.5 and 25°C. Further to support their major role in meat tenderisation, the 
calpains have been shown to be capable of degrading a large number of proteins in vitro and a study 
by Lametch et al. (2004) reported proteolytic digestion of a number of important structural proteins 
of the sarcomere including desmin, myosin light chain I, troponin T, tropomyosin al, tropomyosin a4 
and CapZ as well as myosin and actin of the sliding filaments, although not all of these are degraded 
during postmortem proteolysis (Koohmaraie & Geesink, 2006). 
The discovery of the calpains and their activities in myofibrillar turnover was made in the 1970's 
(Dayton et al., 1976) but investigations into their role in postmortem proteolysis began over ten 
years later. Bandman & Zdanis (1988) were some of the first to investigate specific proteins altered 
during post mortem tenderization and found titin was completely degraded within post mortem 
muscle but myosin was unaffected. Hwan & Bandman (1989) then investigated specific protein 
degradation in the Z-line in aging muscle and found desmin was degraded but not a-actinin, which is 
released from the Z-line intact. Taylor et al. (1995) investigated the major structural changes in the 
sarcomere during the early tenderization phase and found that the proteins linking the Z-lines 
together, known as N2 lines, and proteins of the structures known as the costameres, which anchor 
the myofibrils to the membrane, were the major substrates of proteolysis. Members of the 
sarcomere which are degraded by the calpain enzymes include the key regulatory proteins troponin-
T and -I along the thin filament and titin, the largest protein present, being responsible for 
regulating sarcomere length. Huff-Lonergan et al., (1996) demonstrated Jl-calpain was responsible 
for the digestion of five proteins, nebulin and filamin in addition to desmin, titin and troponin-T, and 
further, their study showed that the rate of the extent of the degradation of these proteins was 
correlated with improved tenderness of bovine muscle. 
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1.6.5 Evidence for the Jl-calpain as major contributing enzyme to post mortem 
tenderization 
The large majority of tenderisation develops early post mortem with 65-80% of tenderisation taking 
place between 3 and 4 days of storage at 4°C (Taylor et 01., 1995). During this period there is no 
degradation of actin or a-actinin and no large structural changes in the Z-Iine despite proteins of the 
Z-line being susceptible to degradation by the calpains. In fact this study showed that the major 
substances degraded during this early stage of tenderization are two cytoskeletal structures. Firstly, 
the costa mere, which binds the contractile myofibril structures to the muscle cell membrane 
(sarcolemma), and secondly the structures which form a link between the Z-line and the thin 
filament known as the N2 lines, shown in figure 1.6-2. In fact the majority of this early calpain activity 
is focussed at the costamere, where the enzymes degrade the proteins desmin and vinculin, in 
addition to nebulin and titin of the N2 lines. Association of the loss of the costamere and the N2 lines 
with the large change in tenderness observed early post mortem is evidence to show that calpain 
degradation of these structures is largely responsible for the tenderization mechanism and there is 
little degradation of the actual contractile apparatus (Taylor et al 1995). Further disassembly of the 
sarcomere does take place as calpains are responsible for degrading proteins associated with the 
thin filament such as troponin T and tropomyosin although there is no degradation of the contractile 
proteins myosin and actin. 
In mice over-expressing the calpastatin protein there was a lack of post mortem protein degradation 
as measured by degradation of desmin and troponin-T (Kent, 2004). There was little change in 
activity of m-calpain between control mice and those which over-express calpastatin, where as 11-
calpain activity was significantly affected, table 1.6-2. This suggested that l1-calpain is the major 
protease responsible for post mortem proteolysis and tenderization of meat. Geesink et 01. (2006) 
further strengthened the argument with the use of l1-calpain knock-out mice. Their study compared 
the amount of substrate degradation in Il-calpain -/- against that observed in wild type and found 
that there was little post mortem degradation of key protein substrates of l1-calpain, nebulin, 
dystrophin, metavinculin, vinculin, desmin and troponin-T, despite the presence of m-calpain. These 
observations suggested that Il-calpain is responsible for a vast proportion of the post mortem 
degradation contributing to tenderisation of meat. With this knowledge in mind, it has been the aim 
of a number of studies to promote overall calpain activity post mortem by increased activation via 
increasing free calcium. 
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Figure 1.6-2. Schematic diagram of the proteins of the costamere which are responsible for anchoring the 
myofibrillar structures to the cell membrane. Further,three of these proteins, ankyrin, desmil1 and vinculin, 
extend into the structure to anchor repeating myofibrils laterally at the Z disc. Image from Taylor et al. 1995. 
Table 1.6-2. Changes in activity of m- and j..1- calpain expressed as % values in control and over-expressed 
calpastatin transgenic mice, adapted from Kent et aI, 2004. 
Percent Remaining Activity 
Enzyme Days P.M. Control Mice Transgenic CAST mice 
m-calpain 1 94 96 
3 99 98 
7 93 91 
sem 2.8 2.2 
J.l-calpain 1 81b 9-r 
3 29d 94a 
7 13e 67' 
sem 4.4 3.5 
Other evidence that further supports the role of ca lpa in in meat tenderi sa tion are the obse rvat ions 
that treatment of animals with ~ - a d r e n e r g i c c ago nists (BAA) results in an increase in musc le growth 
as a result of changes in the activity of the calpa in system but with detrimental effects on meat 
quality (Koohmaraie et 01., 1991; Wheeler & Koo hmaraie, 1992) . These agents increase protein 
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synthesis and decrease protein degradation (Bardsley et al., 1992) their predominant effect on the 
calpain system being an increase in mRNA of calpastatin (Parr et al., 2001). The Callipyge breed is an 
example of an inherited trait for increased muscle growth (Rehfeldt et al., 2004), the effect of which 
is a specific increase in the size of muscles associated with the hindlimbs, the muscles of the 
forelimbs showing little increase in muscle mass. Callipyge lambs yield more meat as a result of this 
increased hypertrophy, however, their meat is more tough compared to non-callipyge lambs (Ducket 
et al., 2000). Although their increase in muscle mass is due to increased protein synthesis combined 
with decreased protein degradation, the predominant effect on proteolysis is an increase in 
calpastatin levels which adversely affects the tenderisation process through inhibition of calpain 
activity causing the characteristic toughness of the callipyge meat. Overall the BAAs and the callipyge 
genotype indicate further the calpain system's the role in increasing muscle growth and yield of 
meat, with unwanted subsequent adverse effects on meat tenderisation. If the meat industry wishes 
to improve muscle growth using such agents, then it must find ways to improve the post mortem 
tenderisation effects that are inhibited by over active calpastatin and reduced activity of calpain I. 
1.6.6 Improvement of meat quality by calcium Infusion 
There have been multiple studies investigating the effect of increasing calcium levels in carcasses 
post mortem by infusion of calcium solutions with the objective of increasing calpain activity and 
thereby improving meat quality. An experiment carried out by Koohmaraie et al. (1988) in lamb 
carcasses infused a 0.3M calcium chloride (CaCI2) solution at 10% (w/w) of the liveweight into 
carcasses circulation system via the carotid artery. This provided a 40-fold increase in calcium levels 
in the Longissimus Dorsi (LD) of the infused carcasses and significantly reduced shear force in the 
calcium infused carcasses after 24 hours post-mortem (LD muscle chops shear force was 3.56Kg 
compared to 6.32kg in controls, P<O.OS). This experiment did not evaluate directly the activity of the 
calpain system nor the effects of calcium infusion on eating quality at consumer level. In a second 
calcium chloride infusion study the activity of both m- and Il-calpain activities dropped significantly, 
with Il-calpain activity dropping to immeasurable levels in the 0.3M calcium chloride infusion 
(Koohmaraie et al., 1989). The increased Il-calpain activity caused increased autolysis resulting in 
loss of activity early in the initial 24 hour post mortem period (Koohmaraie et al., 1989). Koohmaraie 
& Shackelford (1991) then went on to investigate whether calcium chloride infusion of carcasses 
post mortem could overcome the reduced tenderisation that is seen in BAA treated animals. They 
found that calcium chloride (CaCh) was able to significantly reduce the shear force of BAA carcasses 
(which had a much higher shear force in comparison to control animals) when compared to BAA 
carcasses without CaCh infusion, causing shear force to be reduced to levels usually observed in 14 
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day aged carcasses of animals fed a control diet, data shown in table 1.6-3. Koohmaraie & 
Shackelford (1991) attributed this much higher rate of tenderisation over 24 hours to increased 
activity of the calpain system, in particular Il-calpain, and demonstrated that this method could be 
applied to overcome known causes of tough meat. 
T a b l ~ ~ 1.6-3. Efficacy of calcium chloride (CaClz) infusion in improving shear force in lambs fed IJ-adrenergic 
agonlsts (BAA). Adapted from Koohmaraie & Shackelford (1991). 
Shear force (kg) 
Diet Treatment CaClz Infusion day 1 day7 day 14 
Control 10.0 7.7 6.9 
Control + 3.0 3.1 2.7 
BAA 11.4 9.6 9.1 
BAA + 6.0 5.2 5.2 
pooled sem 0.7 0.7 0.9 
Significance 
DietTreatment * * * 
CaClzlnfusion * * * 
Interaction N.S. N.S. N.S. 
* refers to significant effect (P<O.OS) 
In 1993, Whipple & Koohmaraie published data showing that meat tenderness could be improved by 
40% when beef steaks were marinated in a calcium containing solution. The steaks were marinated 
in a 150mM calcium solution for 24 and 48 hours, both of which gave significant decreases in 
toughness, although 48 hours gave optimal results. The activities of the calpain system were 
measured and it was found that the activity of both calpastatin and m-calpain were decreased. In 
their study Polidori et 01. (2000) slaughtered meat-age wether lambs and infused the carcasses with 
0.3M CaCI 2 at 10% ratio of the liveweight via the carotid artery immediately post mortem, and found 
the calcium level in the muscle tissue was increased 60-fold by CaCI2 infusion, from 4.451lg/g tissue 
to 265.33Ilg/g. The shear force of treated chops was reduced although not as dramatically as was 
previously reported by previous studies, with control chops displaying shear force values of 5.99kg at 
6 days post mortem in comparison to treated chops of 5.22kg. At 24 hours post mortem the 
treatment significantly reduced m-calpain activity (P<0.01) whilst the activity of II-cal pain had 
dropped to an undetectable level, suggesting its activity was exhausted through autolysis. 
Calpastatin activity was also significantly reduced in treated chops (P<0.05). This drop in activity was 
in agreement with Koohmaraie et 01. (1989), where accelerated post mortem proteolysis had led to 
accelerated autolysis of the calpain enzymes and subsequent loss of activity. 
The evidence presented suggests that meat can be treated with CaCI2 solutions in order to produce a 
guaranteed tender steak, however, it was noted by Hoover et 01. (1995) that there was resistance 
from the meat industry as consumers would not accept meat that had been injected with a 
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substance. In their study in 1995, the taste panel was subjected to restaurant conditions to assess 
the impact of calcium chloride on eating quality. Their study used the lower dose of 0.2M CaCI
2 
solution at a 5% by weight injection rate, and found improvement in perceived tenderness and 
flavour of the treated steaks, although the evaluation was not performed by a trained taste panel. 
1.6.7 Summary of the calpains and meat quality 
The calpains and their endogenous inhibitor, calpastatin, have been shown to playa major role in 
the proteolytic events in the aging process of meat and are important factors in the development of 
tender meat that is acceptable to consumers. The use of growth promoters such as ~ - a d r e n e r g i c c
agonists can increase growth of muscle partly by increasing calpastatin activity which reduces 
calpain-mediated protein degradation, which improves growth of muscle but inhibits tenderisation. 
As the calpain enzymes are calcium-activated, their activity post mortem can be increased by 
infusing, injecting or marinating carcasses with calcium chloride solutions. However, there is 
concern from the industry that this physical manipulation of the carcass or butchered meat has a 
low acceptability to consumers; therefore, if the manipulation of carcass calcium to improve meat 
quality could be achieved through dietary means, this may be more acceptable. As vitamin D is a 
dietary component and is activated into a hormone responsible for calcium homeostasis, this may 
present an opportunity to manipulate this feed component which would subsequently alter calcium 
levels and increase calpain activity post mortem. 
1.7 Vitamin D3 Supplementation and Meat Quality 
There has been a practice in dairy farms to administer vitamin D3 prior to onset of lactation as a 
method of increasing calcium levels in the serum in order to reduce the incidence or severity of 
hypocalcaemia associated with milk fever (Littledike & Goff, 1987). In light of the apparent meat 
quality benefits of increasing calcium concentration in meat post mortem, Swanek et 01. (1999), 
investigated the possibility of increasing calcium status of meat animals pre-slaughter via 
supplementing feed with vitamin D3. In the first experiment of this kind, Swanek et 01. fed vitamin D3 
beef cattle in three experiments. The first experiment investigated the effects of the level of vitamin 
D3 supplementation on calcium status of the animals, feeding vitamin D3 at either 0.0 (control), 2.5, 
5.0 and 7.5 x106 IUjday (n=5 per dose) for 10 days and monitoring calcium levels throughout and for 
5 further days. These levels of vitamin D supplementation are noted as supra-nutritional levels as 
they are up to 1000 times higher than the standard recommended vitamin D intake of meat animals 
(210 IUjday for lambs and 2400 IUjday for cattle (McDonald et 01., 2002), where one IU is around 
0 . 0 2 5 ~ g g vitamin D (Holick, 1999}). The results of Swanek et al.'s study found that serum calcium 
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levels increased linearly (P<0.04) betw een days 6 and 13 in Vitamin D3 groups and found ma ximum 
serum calcium levels appeared at day 9 onwards, with increases from 20 - 40% com pa red to 
controls, figure 1.7-1. 
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Figure 1.7-1. Changes in serum calcium in beef cattle fed vitamin 0 3 prior to slaughter, Swanek et al., 1999. 
Animals were supplemented with one of three levels of vitamin 0; 2.5, 5.0 or 7.5 ><10 6 IU/day (MIU/day) for 
10 days and serum calcium compared to that of control animals, considered to be baseline. Serum calcium 
was highest in animals given 7.5 ><106 IU/day and peaked after 12 days, whereas serum calcium in animals 
fed the intermediate dose of 5.0 xl06 lU/day peaked after 8 days. 
In their two successive experiments beef cattle were supplemented wi t h the two highest doses of 
vitamin D3, 5.0 and 7.5 x10
6 IUjday, fo r 7 and 10 days respect ively. The lower dose of 5.0 x106 IUjday 
was sufficient to significant ly increase both se rum and in musc le calcium (20% increase, P<0.03 and 
30% increase, P<O.OS, respectively, table 1.7-2) and found t hat shea r force was significantly reduced 
after 7 days of aging, compared to control an imals, but no diffe rences were seen with longer storage 
(table 1.7-2) . With the higher dose of 7.5 x106 IUjday supplemented for 10 days, there was a larger 
increase in muscle calcium levels (50% increase, P<0.02, t able 1.7-1) and this translated into 
improved shear force at both 7 and 14 days of condit ion ing (P<0.02 and P<0.07 respect ively, table 
1.7-2) along with significant decreases of both ~ - c c l p p i n n and calpast atin activity after 24 hours post-
mortem (P<O.Os and P<0.04 respectively, table 1.7-2). Th is study showed that feeding vita min D3 to 
beef animals immediately prior to slaughter was sufficient t o alte r calcium status of an im als and 
improve meat quality of the steaks, thus prod ucing an alte rn ative to manipulating carcasses with 
CaCI 2 solutions post mortem in the abatto ir. 
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Table 1.7-1. Changes in calcium status in beef cattle fed vitamin 03 prior to slaughter. Adapted from Swanek 
et 01.,1999. 
Swanek et ai, Dose Vit 0 3 n Time Plasma Ca Musde Ca 
1999 x10 6 1U per group (days) (mg/dL) (Ilg/g) 
Expt 2 0.0 9.23 13.9 59 7 
5.0 12.39* 19.9* 
0.0 14.2 
Expt 3 22 10 N.M. 
7.5 21.3 t 
*P<O.03 * p<o.os 
t P<O.02 
Table 1.7-2. Changes in shear force of longissimus dorsi steaks from beef cattle fed vitamin 03 prior to 
slaughter, Swanek et 01., 1999. 
Swanek et aI, Dose Vit 0 3 Shear Force (kg) Calpain System Activity/g 24hr PM 
1999 x10 6 1U Day 7 Day 14 Day 21 Il-calpain m-calpain calpastatin 
Expt 2 0.0 4.70 4.03 3.58 
5.0 4.12* 3.87 3.60 
0.0 5.13 4.40 4.04 0.56 0.99 4.83 
Expt 3 
7.5 4.21 t 3.81 t 3.44 0.19
t 0.62 4.11 t 
*p< 0.01 P=0.2S P=O.90 
t P< 0.02 t p<0.07 P=O.13 tp<o.os P=O.0729 t p<0.04 
Several further studies have been performed in cattle in light of this original experiment, 
investigating the possibility of improving meat tenderness using shorter vitamin 03 supplemental 
regimes (5 and 7.5 x106 IUjday for 9 days, Montgomery et 01., 2000; 6 x106 IUjday for 4 and 6 days, 
Karges et 01., 2001), using additional calcium supplements (Scanga et 01., 2001), investigating the 
supplementation of vitamin 03 at a variety of doses (0.5, 1.0, 2.5, 5.0 & 7.5 x106 IUjday for 9 days, 
Montgomery et 01., 2002), the efficacy of vitamin 03 supplementation in reducing toughness from 
growth promoters (Reiling & Johnson, 2003), the use of 25-hydroxy vitamin 03 in comparison to 
l,25-dihydroxyvitamin 03 (Foote et 01., 2004), efficacy of vitamin 03 in reducing toughness in meat 
from cull cows (Rider-Sell et 01., 2004) and the differential effects of vitamin 03 in differing cattle 
breeds (Montgomery et 01.,2004). 
Not all of these studies produced shear force data or measured calpain activities, and results 
reported in many of the studies are inconclusive in terms of the effects on these experimental 
outcomes. The proposed mechanism for the benefits of vitamin 03 supplementation prior to 
slaughter is that the calcium status of animals is increased leading to increased activity of the calpain 
system immediately post mortem, thus tenderizing steaks more quickly and reducing the time 
required for conditioning and the cost associated with cold storage. To provide conclusive evidence 
for benefits of vitamin 0 3 in this role there must be an evaluation of each step associated with the 
mechanism; these are calcium status, calpain activity and the shear force of the chops. 
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At the time this study commenced, the majority of work performed into this mechanism was in 
cattle and only two studies had been carried out in sheep and another two in pigs. In 2002 Wiegand 
et 01. investigated levels of 0.25 and 0.5 xl06 IUjday doses of vitamin D3 for their effects on serum 
calcium in pigs and found significant increases with the higher dose which gave a higher calcium rise 
more quickly. This higher dose of 0.5 xl06 IUjday gave a 60% increase by day 4 compared with 0.25 
xl0
6 
IUjday arising in a 40% increase by day 6. Following this initial experiment the group 
investigated effects on calcium status and LD tenderness of a short dose of 0.5 xl06 IU/day for 3 
days immediately prior to slaughter. They found serum calcium was increased by 20% in treated 
animals compared to controls (P<O.Ol) but there were no differences in shear force values. A second 
study performed in pigs (Wilborn et 01., 2004) used lower doses of vitamin D3 of 0.04 and 0.08 xl06 
IUjday but fed for much longer than has previously been investigated, supplementing for 44-51 days 
prior to slaughter. This study did record changes in calcium levels in the blood after 7 weeks of 
supplementation (29% increase compared to controls, P<0.05) but there were no changes in calcium 
concentration of the LD muscle, nor effects on tenderness of the chops. 
In 2001, Wiegand et 01. performed a study investigating the possibility of vitamin D3 
supplementation in reducing the toughness of steaks from callipyge lambs, as noted earlier the 
callipyge breed exhibits hind limb hypertrophy and produces tough meat (Duckett et 01., 2000). The 
study performed a preliminary experiment using two doses of vitamin D3, administering 1.0 and 2.0 
xl06 IUjday for 4 days to determine the optimum dose for calcium status changes. Their second 
experiment administered the higher dose of 2.0 xl06 IUjday for 7 days prior to slaughter and 
recorded the changes in calcium status and shear force of LD chops. In the normal breed genotype of 
sheep, serum calcium increased 8.8% in the vitamin D group compared to controls (P<0.05, table 
1.7-3), and in the callipyge genotype, a 6.1% increase was seen in vitamin D fed animals (P<0.05). 
Table 1.7-3. Changes in calcium status in lambs of either callipyge or normal genotype fed vitamin D3 for 7 
days prior to slaughter; Wiegand et 01., 2001. 
Wiegand et 01 Dose Vit 03 Time n Breed Plasma Ca Muscle Ca 
2001 x106 1U (days) per group (mg/dL) (9mg/dL) 
Normal 9.44 5.38 0 
callipyge 9.29 4.24 
Expt 2 7 8 
Normal 10.27* 7.15 
2 
callipyge 9.89* 4.14 
* P<O.05 
However, these changes in the calcium levels were not transferred to significant changes in the 
muscle calcium levels, nor was there any effect on shear force of LD chops. Callipyge lambs fed the 
control diet did present chops with higher shear force values than the normal genotype lambs 
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(P<0.05) and vitamin D3 supplementation was not able to overcome this. Boleman et al. 2004 
performed another study in sheep, investigating a number of doses of vitamin D3 from 0.25 to 0.75 
x106 IU/day for 4 days to assess the changes in serum calcium before administering the highest dose 
of 0.75 x106 IU/day for 14 days prior to slaughter. There was no effect of this vitamin D3 
supplementation regime on plasma calcium levels. Boleman et al. measured the shear force changes 
in four muscles; longissimus dorsi (LD), biceps femoris (BF), semitendinosus and semimembranosus, 
across an aging period from 5 to 15 days; however there was no effect of vitamin D3 on the shear 
force of chops prepared from these muscles, with the exception of the LD at 15 days conditioning 
which was significantly higher (P<0.05) and the BF which was significantly lower at day 5. Neither of 
these studies performed in sheep were able to give conclusive evidence to support the hypothesis 
that pre-slaughter vitamin D3 feeding regimes improve meat tenderness. 
1.7.1 Summary of vitamin D3 Sheep trials 
Neither of the investigations by Wiegand et al. (2001) and Boleman et al. (2004) measured the 
effects of dietary vitamin D regimes on the activities of the calpain system in lamb and thus these 
studies do not provide clear answers to the vitamin D3 and meat quality question. The changes in 
calcium status in cattle studies are considerable with serum calcium increases around 20 - 50% and 
did report positive changes in shear force of chops which were associated with effects on the calpain 
system (Swanek et al., 1999). The work in sheep has failed to report such clear evidence, while 
Wiegand et al. reported a 14.9% increase in serum calcium when sheep were fed a high dose for 5 
days, there was no clear effect on the shear force of the LD and no direct investigation into 
subsequent calpain system activity. Boleman et al. (2004) did not find any significant changes in 
circulating calcium levels and there was no effect on shear force and no investigation into the 
calpain system activity. It would be expected that the same responses observed in cattle could be 
replicated in sheep. In addition to ascertaining the influence of incorporating this agent in feed on 
meat quality, there is a need to investigate all the components of the hypothesised system, 
measuring calcium levels of the serum and muscle, shear force of the LD as a standard muscle to 
compare between investigations and investigate effects on the calpain enzymes which can be 
related to the shear force of the muscle. 
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1.8 Summary of Literature 
The literature described in this chapter provides an insight into the available evidence indicating the 
potential of vitamin D to enhance meat quality by a variety of mechanisms. The recent work 
supplementing vitamin D to meat age animals in a short but high dose immediately prior to 
slaughter appears to provide a simple mechanism to promote tenderisation of meat post mortem. 
The model proposed in these studies is based on vitamin D's classical role in calcium homeostasis 
and the evidence of work performed in CaCI2 marination studies. It is likely that such treatments will 
greatly influence the development of tenderness post mortem and will reduce the length of cold 
storage required to reach acceptable levels of tenderness through feed manipulation alone. The 
studies investigating these effects in cattle appear to provide evidence to support the functionality 
of the proposed model, however, the work in sheep is not as conclusive and there is a requirement 
for research to investigate optimum duration and level of vitamin D supplementation, and to 
confirm the mechanism affects both shear force and calpain system activity. 
A second potential role for vitamin D in muscle tissue was implicated by the results of Endo et al.'s 
study, providing evidence for vitamin D to control the growth and development of muscle fibres 
from the earliest phase of myoblast development. The results of their study show that the absence 
of VDR results in smaller muscle fibres and abnormal MRF expression, which would be of relevance 
to animal production where muscle growth is a primary aim. In addition their study reported that 
treatment of muscle cells with active vitamin D, l,25(OHhD3, could downregulate expression of 
some genes associated with muscle cell development and therefore further research into this 
mechanism could provide a novel role for vitamin D as an agent to promote muscle growth in animal 
production systems. 
The potential for vitamin D to affect muscle growth has two-fold relevance, the initial gain to the 
industry being increased muscle growth and yield, but secondly the effects of the hormone of fibre 
type could also improve the quality of the meat. It is well known that the use of BAAs in meat 
animals significantly increases lean growth and therefore yield of muscle tissue, but with detrimental 
affects on the tenderness of the meat, as demonstrated in Koohmaraie & Shackelford's experiment 
(1991). This increase of growth observed in BAA treatments is associated with increases in the size 
and number of fast glycolytic fibres (Vestergard et 01., 1994) and it is likely that these fibres are 
responsible for the increased toughness of the meat. However, investigations of vitamin D 
supplementation in human patients reports that vitamin D can increase the size and number of fast 
oxidative fibres and reduce the number of fast glycolytic fibres simultaneously (Sorenson et 01., 
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1979; Sato et 01., 2005). Taken together these studies provide evidence to propose the use of 
vitamin D as an agent to promote muscle growth without the detriment to meat quality which is 
associated with BAA treatment. 
Therefore it is the aim of the experiments in this thesis to investigate the use of vitamin D and active 
metabolites in their capacity to promote muscle growth and to promote the tenderisation of meat in 
the aging period. The results of these experiments will be relevant to the meat industry in terms of 
optimising production methods to produce a greater yield of meat which is likely to be tender, and 
could additionally provide benefit to elderly human patients at risk of falling through loss of fast 
fibres associated with vitamin D deficiency. 
1.9 Hypothesis 
The hypotheses of the work performed in this study are as follows: 
• Supplementation of vitamin D to meat age lambs in the final week immediately prior to 
slaughter will promote tenderisation of meat via activation of the calpain system 
• Administration of active vitamin D metabolites to growing muscle cells will promote muscle 
growth through effects in gene expression and subsequent translated protein, in particular 
those of the MRFs which control early muscle cell growth and development. 
• Administration of active vitamin D metabolites to growing muscle cells will promote fibre 
type changes via mechanisms controlling MHC gene expression. 
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1.10 Aims 
The aims of this thesis are as follows: 
• To clarify and optimise the mechanism through which vitamin D supplementation in the final 
week immediately prior to slaughter will promote tenderisation of lamb meat by assessing 
the three major components ofthis system: 
o Increases in calcium status of the serum and LD 
o Increases in expression/activity of the calpain system in the LD 
o A reduction in shear force of the LD chops 
• To assess targets of vitamin D in muscle which are of relevance to muscle growth and fibre 
type changes in rodent muscle cells, incorporating two experiments: 
o The first experiment will screen for novel gene targets of 1,25(OHhD3 in rat muscle 
cells via microarray analysis. 
o The second experiment, in a mouse derived muscle cell line, will assess the efficacy 
of an active vitamin D analogue, la(OH)D3, to promote gene expression changes of: 
• Novel targets identified by the microarray screen 
• Expression of MRFs and effects on muscle cell growth and development 
• Expression of MHC genes and effects on muscle fibre type. 
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Materials and Methods 
2.1 Materials used in this study 
2.1.1 Equipment used at the University of Nottingham 
• Bench top centrifuge; (volumes below 2ml) Microfuge 22R Centrifuge, Beckman Coulter 
• Bench top centrifuge; (volumes over 2 ml and cell cultureL Centaur 2, MSE 
• Bench Top Shaker; Stuart See-Saw Rocker SSL4, Barloworld Scientific Ltd (Staffs UK) 
• Polytron PT300 homogeniser, Kinematica (Litteu, Switzerland) 
• Basic PCR machine; DNA Engine- Mastercycler, M .J. Research (MA, USA) 
• Quantitative real time PCR machine; LightCycler® 480, Roche Diagnostics (Switzerland) 
• Q-PCR Software, LightCycler® 480 SW V 1.5, Roche Diagnostics GmbH (Germany) 
• SubGell GT tanks for agarose gel electrophoresis, BioRad (Hemel Hempstead, UK) 
• Dri-Block Heat Block, Techne (Cambridge UK) 
• Microplate Reader model 680XR, BioRad, Japan 
• UV /Visible Spectrophotometer, Amersham Biosciences Ultrospec 2100pro, Biochrom Ltd 
(Cambridge, UK) 
• SDS-PAGE 200mm x 100mm vertical dual plate unit, Fischer Scientific (Loughborough, UK) 
• Trans-Blot with plate electrodes, BioRad, (Hemel Hempstead, UK) 
• Texture Analyser Software, Texture Expert Exceed 
• Spectrometer ND-IOOO Nanodrop Products, Thermo Fischer Scientific (Wilmington, USA) 
• DNA gel imager: Gel Doc 2000, BioRad Laboratories (CA, USA) 
• Protein gel imager: Flour-S MAX2, BioRad Laboratories (CA, USA) 
• Software to Ana lyse DNA and protein gels : Quantity One V4.1.1., Bio Rad Laboratories (CA, 
USA) 
Laboratory reagents for work performed in North Laboratory, Sutton Bonington Campus were 
purchased from Fischer Scientific (Loughborough, UKL Sigma Ald ri ch (Poole, UK) and Promega 
(Southampton, UK). Water used in buffers and solutions was either glass distilled or column purified 
using MilliQ Elix®Purification system (Millipore, Watford , UK) . Water for use in nucleic acid work was 
certified RNAse/DNAse free, purchased from Sigma Aldrich . 
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2.1.2 Equipment used in Pfizer Ltd. (Sandwich, Kent, UK) 
• Bench top centrifuge; volumes below 2 ml; Centrifuge 5415R, Eppendorf 
• Bench top centrifuge; cell culture, Centaur 2, MSE. 
• Agarose Gel Tanks; Horizon 11.14 (Large) and Horizon 58 (Small) Horizontal Gel 
Electrophoresis Apparatus, Life technologies, GIBCO BRL 
• Agarose Gel Imager; Universal Hood II, BioRad Laboratories, (Milan, Italy). 
• Agarose Gel Imagine Software; Quantity One V4.6, BioRad Laboratories (CA, USA) 
• Basic PCR machine; T3 Thermocycler, Biometra 
• Quantitative real time PCR machine; 7900HT Fast Real-Time PCR System, Applied Biosystems 
(CA, USA) 
• Quantitative real time PCR software; Sequence Detection Systems V 2.2.2.; 2004 Applied 
Biosystems (Foster City, CA, USA) 
• Spectrometer ND-1000 Nanodrop Products, Thermo Fischer Scientific (Wilmington USA) 
• Agilent 2100 Bioanalyzer, Agilent Technologies 
Laboratory reagents for work performed in Pfizer, Sandwich, were purchased from Fischer Scientific 
(Loughborough, UK) and Sigma Aldrich (Poole, UK) unless otherwise stated. Water used in buffers 
and solutions was either glass distilled or column purified. Water for use in nucleic acid work was 
certified RNAse/DNAse free, purchased from Sigma Aldrich. 
54 
2.2 Experimental Design of Animal Trials 
2.2.1 Animal housing layout 
All animals were male Mule X Charolais lambs approximately 7 months old and we re individually 
housed for the duration of the trials . Animals were weighed weekly to assess weight gain during the 
housing period and were arranged into 3 slaughter groups according to weight approximate ly 3 
weeks prior to the supplementation week, shown in figure 2.2.1. Within each slaughte r group, 
animals were paired with the an imal housed in the pen behind, creating treatment-contro l pairs 
matched for age and weight, and during the supplementation period treatment diets were allocated 
to animals distributed equally within each slaughter group, demonstrated in figure 2.2.2. On the day 
of slaughter, animals were taken to the lairage in groups of four consisting of two treatment pairs, 
and were slaughtered in pair order beginning with vitamin D treated animals . The order of removal 
was sequential, for example in trial 1 slaughter began with the pair 373 and 208, where 373 was 
treated with vitamin D and therefore slaughtered first, followed by its control pair 208, shown in 
figure 2.2.2-A. 
Pen layout in the Metabolism 3 building 
Block 2 Block 3 
Block 1 
Slaughter 
1 ________________ \ unit r-\ ----
Feeding 
a c c e s s ~ - - - - -
access door 
Figure 2.2-1. Pen layout in the sheep housing. Each block possessed equal numbers of treated .,=6) and 
control (n=6) animals and animals were paired with the animal in the pen behind. Block 1 cant a ned 
heaviest animals (n=12) randomly assigned to treatment group; Block 2 contained middle-we ght an ma 
(n=12) and Block 3 contained lightest animals (n=12). 
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A Al location of t reatment group 
Group 3 
263 169 152 462 276 182 258 171 380 
D C D C D D C D C 
310 332 377 464 475 421 474 168 386 
C D C D C C D C D 
Group 2 
361 254 148 486 297 178 209 467 208 
C D C C D D C D C 
364 251 181 330 293 123 333 219 373 
D C D D C C D C D 
Group 1 
DOOR 
B Allocation of treatment group 
Group 3 
232 370 215 490 339 21 2 488 21 3 409 
D C D C D D C D C 
137 144 274 108 338 220 522 515 309 
C D C D C C D C D 
Group 2 
101 228 180 378 455 281 234 308 246 
C D C C D D C D C 
141 450 296 145 478 535 158 518 51 1 
D C D D C C D C D 
Group 1 
Figure 2.2-2. A; Housing layout and diet treatment allocation to Trial 1 animals; B; Housing layout and dIet 
treatment allocation to Trial 2 animals. 
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2.2.2 Diet Composition 
Basal diet composition as fed to animals during housing prior to trial diets and fed as control diet to 
control group during trial periods is shown in table 2.2-1. The diet has no added vitamins or 
minerals. Vitamin D diet was based on this mix with vitamin D3-500 (Rovimix, DSM, Derbyshire UK) 
added prior to pelleting the diet. 
Table 2.2-1. Basal diet composition as-fed basis. 
VegOil 
Barley 
Oats 
Soya 
Grass Nuts 
Nutramol30 (RUMENCO) 
Total 
5 kg 
240 kg 
80 kg 
25 kg 
100 kg 
50 kg 
SOOkg 
2.2.2.1 Vitamin D3 diet formulation 
The supplement D3-500 contains 500,000 IU per g, therefore to supply 2xl06 IU/day vitamin D, 
animals required 4g D3-500/day, given to them in 1.4Kg feed, hence feed supplemented with D3 500 
required 2.86g D3-500 per Kg. For the second trial, basal calcium was calculated as 0.7% calcium by 
Frank Wright Ltd and calcium propionate was added to double the calcium in the vitamin D3 + 
calcium diet. Basal diet supplied 0.7/100x lKg = 7g calcium/Kg. To provide an additional 7g calcium 
per Kg diet, calcium propionate (21% calcium) was added at {21/100*X = 7; X = (7xl00)/21) = 33.3g 
calcium propionate per Kg diet. Final calcium concentrations were confirmed by AA spectrometry by 
Dave Bozon (Nutritional Sciences). Nutritional composition for each diet fed in trial 1 is summarized 
in table 2.2.2 and for trial 2 in table 2.2.3. 
Table 2.2-2. Nutritional composition of diets fed during trial period in Trial 1. 
Trial 1 Diets Basal Diet/Control Vitamin D 
Energy (MJ/Kg) 16.41 16.46 
Nitrogen (%N) 2.21 2.15 
Calcium (mg/g) 15.88 15.82 
Table 2.2-3. Nutritional composition of diets fed during trial period in Trial 2. 
Trial 2 Diets Basal Diet/Control Vitamin D only Vitamin D + Ca 
Energy (MJ/Kg) 16.46 16.79 16.69 
Nitrogen (%N) 1.87 1.78 1.58 
Calcium (mg/g) 15.09 11.71 34.56 
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2.2.3 Standard slaughter procedure 
All animals were slaughtered by electrical stunning to the head, followed by exsanguination, 
performed by a licensed slaughterman in the abattoir at Sutton Bonington Campus, University of 
Nottingham, under conditions designed to replicate those in a commercial unit. Procedures were 
performed as schedule 1 according to DEFRA guidelines and all animal experiments at University of 
Nottingham were first drafted then sent to Home Office inspector for approval to ensure they fell 
outside the Animals (Scientific Procedures) Act 1986 and therefore were not under UK Home Office 
Animal Licence. 
2.2.4 Carcass handling 
Immediately after death, carcasses were dressed and defleeced but not split, and their weight 
recorded, the time to prepare each carcass from stunning to final dressing and weighing was 
consistently 15 minutes. The pH was taken using a puncture electrode (Ingold, Mettler-Toldeo Ltd. 
Leicester, UK) from the left side of the carcass at 45 minutes post mortem and 24 hours after. 
Carcasses were placed in a chiller at 4°C four hours after slaughter and dressing to reduce the 
potential for cold shortening, and then hung overnight by Achilles tendon until sampling at 24 hours. 
At 24 hours post mortem the temperature and pH of the carcasses were measured at the same 
sample site again before the whole LD was removed for aging subsequent to Warner-Bratzler shear 
force (WBSF) analysis, see appendix A for diagram of snap LD, pH and temperature sample sites. 
2.2.5 Sample Procedure 
2.2.5.1 Blood Samples 
Blood samples were collected at exsanguination, whole blood and plasma samples were collected in 
15ml tubes containing ethylenediamine tetraacetic acid (EDTA) to prevent clotting; whole blood was 
stored at -20°C at the end of each slaughter day. Plasma was prepared at the end of the slaughter 
day by spinning tubes at 3000 rpm for 15 minutes at 4°C in a Beckman centrifuge. The straw 
coloured supernatant was removed into eppendorf tubes before storage at -20°C. Serum samples 
were prepared in 50ml tubes which were left to clot overnight in a chiller at 4°C. The following 
morning samples were spun at 3000 rpm for 15 minutes and the supernatant stored in eppendorf 
tubes as before. 
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2.2.5.2 Snap Tissue Samples 
Snap frozen samples of live tissue were prepared by submersion in liquid nitrogen as quickly as 
possible after slaughter. The time of sampling was consistent for each animal and was within 2 
minutes of stunning and exsanguination. Snap samples were taken in the following order; 
Longissimus Dorsi (LD) taken from both the left and right sides through the fleece immediately 
following stunning and exsanguination, between the 10th and 11th rib and Semitendinosus (ST) was 
sampled from the left leg (sample sites shown in Appendix A). Approximately 20g of the kidney 
tissues was then sampled, taken consistently from same side and included both cortices, as the 
carcass was dressed according to standard slaughter procedure. Finally the Psoas (PS) was sampled 
from the left side of the carcass and, once frozen, all samples were stored at -80°C. The carcasses 
were hung overnight in the chiller before snap samples were taken of the LD muscles, both left and 
right, caudal to the initial sample point, 24 hours after slaughter and again stored at -80°C. Snap 
samples were stored at -80°C until protein and total RNA extraction, approximately 6 months later. 
2.2.5.3 LD Chop Samples for Shear Force Analysis 
The remaining part of both sides of the Longissimus Dorsi was dissected 24 hours post mortem and 
prepared into chops 2.54cm thick before vacuum packing in pairs, 2 chops per sample point, left and 
right side chops packed separately. The chops were taken towards the caudal region of the muscle, 
beyond the sample site of the initial snap sample taken at around the 10th_11th rib. The chops were 
labelled according to their distance from the original snap site and numbered from 1 to 4 (1 being 
taken from the 11th rib region down to 4 denoting from the dorsal region), see appendix A for 
diagram of LD chop preparation, numbering of chops and latin square arrangement for ageing 
period. These chops were then aged in a chiller at 4°C for up to 21 days before blast freezing at -
80°C. 
2.3 Analysis of Plasma Vitamin D Concentration 
2.3.1 Trial 1 Plasma Samples 
Plasma samples stored in eppendorfs were sent to Professor Bill Fraser of the Department of Clinical 
Biochemistry, University of Liverpool, for vitamin D analysis by Tandem Mass Spectrometry. 
2.3.2 Trial 2 Plasma Samples 
Plasma samples stored in eppendorfs were sent to Stuart Jones of the Nottingham University 
Hospitals NHS trust, city campus, Nottingham for vitamin D analysis by HPLC. 
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2.4 Fat Analysis of Animal Muscle 
Fat content of LD was performed using the Soxtherm fat extraction method. Analysis of fat content 
on samples by the Soxtherm method is an industry standard procedure and is routinely used to 
measure fat content of meat and other food stuffs (Perez-Palacios et al., 2008). 
2.4.1 Preparation of LD samples for fat analysis 
Crushed LD samples to be used for analysis of fat content were first freeze dried to remove all 
moisture. Samples were weighed and placed in sOml falcon tubes sealed with perforated parafilm 
and placed in freeze drying equipment (Freeze drying System, Edwards, UK). Samples were weighed 
every 24 hours until their weights became constant and were then deemed to have had all water 
removed. 
2.4.2 Extraction of fat using Soxtherm method 
Around l.sg crushed and freeze dried LD muscle was weighed into a crucible, allowing two replicate 
crucibles per sample. The weight of the crucible plus freeze dried muscle tissue was accurately 
recorded before fat was extracted in petroleum ether using Soxtherm Fat Extraction Equipment 
(Gerhardt). The sample was heated with petroleum ether at 150°C for 35 minutes to encourage 
release of the fat component from the sample. The solvent and fat were then removed together into 
another thimble, where the fat extract was recovered from the solvent by drying in an oven at 103°C 
for one hour. The final weight of the extracted fat was then recorded and the fat content of the 
sample was calculated using the following equation: 
Soxhlet Fat % = [Weight of Extract (g) / Sample Weight (g)] x100% 
The average of the two replicates for each sample was calculated and the fat content expressed as a 
percentage value. 
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2.5 Calcium Ion Concentration Analysis: Atomic Absorption Spectroscopy 
2.5.1 Principle of Atomic Absorption 
Atoms consist of a nucleus comprised of protons and neutrons, orbited by electrons in a number of 
"shells" or "energy levels". The number of electrons orbiting the nucleus depends on the element 
and its chemical state. Atoms usually exist in a balanced energy state where the number of negative 
electrons orbiting the nucleus is equal to the number of positive protons on the nucleus, and the 
configuration of the electrons allows for stable orbits. The atom's stable energy state can be 
disturbed by the addition of energy from outside the atom, which can alter the configuration of the 
electrons. Atomic absorption occurs when light energy applied to the atom is absorbed and causes 
electrons to gain enough energy to "jump" from a lower energy level to another. This means the 
atom is in a higher energy state, known as the "excited state". The amount of light energy required 
for this to occur is unique to each element, and thus each element is known to absorb light of a 
specific wavelength (proportional to the energy of the light wave). Calcium absorbs light at 
wavelength 422.7 nm; hence by using a spectrometer to measure the amount of light absorbed at 
this wavelength the calcium ion concentration can be calculated. 
This is the basis for AA spectroscopy; by measuring the amount of light absorbed at a specific 
wavelength, the quantity of an individual element in a sample can be calculated. The more of an 
element present in the sample, the more light energy is absorbed. 
2.5.2 Preparing Calcium Standards 
To calibrate the system, a set of known quantity calcium solutions were made. Calcium chloride was 
dissolved in deionised water at concentrations of 2mgjl, 4mgjl, 6mgjl, 8mgjl and lOmgjl. 
Measurements were made, example absorbance recordings for the standards are shown in table 
2.5.1., and a calibration curve was obtained. The curve is linear across this range and samples were 
diluted to appear in the middle of the curve, shown in figure 2.5-1. 
Table 2.5-1. Absorbance readings obtained for calcium standard solutions. Standard deviation (S.D.) and 
standard error of mean (S.E.M.) are shown. 
Standard Concentration (mgjl) Atomic Absorbance Mean S.D. S.E.M. 
2 2.210 2.196 2.197 2.201 0.0078 0.0045 
4 4.023 4.042 4.005 4.023 0.0185 0.0107 
6 6.101 6.158 6.093 6.117 0.0354 0.0205 
8 8.347 8.234 8.324 8.302 0.0597 0.0345 
10 10.455 10.457 10.393 10.435 0.0364 0.0210 
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Figure 2.5-1. Calibration curve obtained with calcium standard solutions, showing position of example 
unknown serum samples on the curve. 
2.5.3 Preparing Samples 
2.5.3.1 Serum samples 
Frozen serum samples were defrosted at room temperature for 4smins and mixed with a vortex 
mixer for approximately 15 seconds to ensure a completely homogenized sample before dilution and 
analysis. 
2.5.3.2 Muscle samples 
Muscle samples were crushed in liquid nitrogen using a pestle and mortar before approximately 2g 
of tissue was weighed into an acid (HCI) washed crucible and the weight recorded . Samples were 
then ashed overnight in a muffle furnace at 550°C (Muffle Furnace size 2, Gallenkamp) . The 
following morning samples were allowed to cool to room temperature before preparation for 
analysis by Atomic Absorption Spectrometry. When cool, 1ml of 6M HCI was added to the crucible 
and used to rinse the sample into a clean sOml conical flask. Another 1ml HCI was used to digest any 
remaining sample before the crucible was rinsed with lanthanum chloride solution (0 .2% w/v) into 
the flask, then made to a final volume of sOml (a 1:25 dilution) . Once made up to sOml, the solut ion 
was left for an hour to allow for precipitation of the lanthanum phosphate complex before analysed 
in the AA Spectrometer (AAnalyst 100, Atomic Absorption Spectrometer, Perkin Elme r Instruments, 
Norwalk, CT, USA) . 
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2.5.3.3 Diluting Samples 
0.2ml of sample was diluted with 9.8ml 0.1% w/v lanthanum chloride (1:50 dilution) to produce 
samples which could be measured in the linear range of the curve. The lanthanum chloride was used 
to react with any phosphate in the sample to reduce interference from phosphates. 
2.5.4 Determining Calcium Concentration 
The equipment measures absorption of light in triplicate and gives the average of the three 
measurements, with the standard deviation of each set. Any sample with a SO higher than 0.1 was 
repeated. 
An example result 
AA Concentration: 
2.934; 2.932; 2.889 
Mean: 2.919 mg/I SO = 0.0252 
Original Sample Concentration: 2.919 x 50 = 145.95 mg/I 
Standards were used randomly throughout sample determination to check variation of the method. 
The samples were analyzed in reverse slaughter order in Run 1, and then in actual slaughter order in 
Run 2. The results from both runs were then compared for repeatability of the method, and the 
average of the 6 measurements was taken as the final result. 
2.6 Warner-Bratzler Shear Force Assay for Meat Tenderness 
Once the LO had been aged at 4°C for the appropriate time (according to Latin square sample 
arrangement in Appendix A), the vacuum packed LO chops were stored at -70°C until required for 
tenderness analysis, when they were stacked, single layered on ventilated racks in a cold room at 
4°C for 72 hours to allow thorough defrosting. The thickest chop was used for temperature 
monitoring, with an electrical temperature probe placed in the geometric centre. It was assumed 
that the temperature of all other chops would be reflected by temperature changes in this chop. 
Steaks were placed in an 80°C water bath and cooked until the largest chop reached a temperature 
of 78°C then an additional ten more minutes were given for cooking. All chops were removed and 
placed back on the racks at 4°C to cool overnight. 
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2.6.1 Preparation of samples-Core preparation 
Samples were removed from the cold room in polystyrene boxes to prevent large temperature 
changes. Chops were then individually removed from the boxes at random and prepared for 
tenderness analysis. Warner-Braztler shear force analysis requires chops to be prepared into cores of 
certain diameter (1.27 cm) and length (2.5cm) achieved by use of a hand held corer. Each chop was 
removed from its vacuum pack and as many cores were prepared from the steak as possible, 
average core yield per chop was 4. Cores were cut in parallel to the alignment of the muscle fibres 
within the LD, using the back fat as a guide for the orientation of the chop within the muscle. The 
whole of the chop was sampled to reduce any variation in toughness between the outer and inner 
areas of the muscle. All chops were sampled in this way to cover all variation within chops. All cores 
were then analysed for shear force and the average of all cores was taken and assumed to be 
representative of the chop as a whole. 
2.6.2 Warner-Bratzler Shear Force Assay 
Each core was then placed at the centre of a guillotine fitted with a blade of thickness 1.016mm with 
a central v-shaped cutting blade of angle 60° as defined by Wheeler et 01. (1997). The blade is part of 
the TA-XT2i Texture analyser (Stable Micro Systems, Surrey, UK) and was calibrated with a 25kg 
weight, set at a constant speed of 1.7 mm/s. This machine then measures the force required for the 
blade to shear the core whilst maintaining a constant speed using supplied software (Texture Expert 
Exceed). The result is expressed in kg. 
2.7 Extraction and Measurement of total RNA 
All water used in the extraction of RNA, reverse transcription into single standed DNA and further 
PCR reactions was RNAse/DNAse free water (Sigma) and all sample and reaction tubes, pipette tips 
and PCR plates were certified RNAse/DNAse free by manufacturers. 
2.7.1 Extraction of total RNA from LD and Kidney 
Total RNA for real time PCR analysis was extracted from sheep tissues using TRlzol® Reagent 
(Invitrogen, UK), whereby RNA is extracted by phase separation. Animal tissue samples were crushed 
in liquid nitrogen using a pestle and mortar prior to extraction and were stored at -80°C before 
TRlzol® extraction. 1ml TRlzol® reagent was added to 100mg frozen crushed animal tissue before 
homogenisation for two bursts of 30 seconds, and all samples were kept on ice until ready for phase 
separation. The prepared homogenates were left on the bench for 5 minutes to allow dissociation of 
nucleoprotein complexes. 2 0 0 ~ 1 1 chloroform was then added and each sample shaken vigorously for 
15 seconds. This mixture was then incubated for another 3 minutes at room temperature before 
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centrifugation at 12,000 rpm (Microfuge 22R Centrifuge, Beckman Coulter) for 15 minutes at 4°C. 
This separates the mixture into three phases, the top phase being a colourless aqueous solution 
containing the total RNA; it is this top phase that is carefully removed and transferred to a fresh 
tube. The total RNA was then precipitated from solution by addition of 0.5ml isopropanol, the tube 
contents were mixed using a vortex mixer and the solution incubated at room temperature for 10 
minutes. This solution was then centrifuged at 12, 000 rpm for 10 minutes, allowing the total RNA to 
collect as a pellet at the base of the tube. The water/isopropanol supernatant was removed carefully 
and the pellet re-suspended in 1ml 75% v/v ethanol. Finally the total RNA pellet was cleaned of 
remaining traces of TRlzol® reagent constituents using 75% v/v ethanol; the pellet was vortexed 
briefly in 75% v/v ethanol before the pellet was collected again by centrifugation at 12,000 rpm for 
15 minutes. The ethanol supernatant was removed and the pellet air-dried before dissolving in 40111 
RNAse/DNAse free water and storing at -80°C. 
2.7.2 DNAse treatment of total RNA 
To remove possible contamination of genomic DNA in the extracted total RNA, the RNA was treated 
with a DNAse enzyme to digest any DNA present. 5111 DNAse enzyme (Promega, UK; Catalogue 
#M610A) was added with 511110 x DNAse buffer to RNA dissolved in 40111 water. The contents of the 
tube were mixed by vortex mixer and then collected by brief centrifugation (up to 12,000 rpm for 30 
seconds) using a bench top centrifuge (Microfuge 22R Centrifuge, Beckman Coulter). The reagents 
were then incubated at 3rC for one hour. The reaction was then stopped by addition of 150111 water 
with 200111 phenol/chloroform/isoamylalcohol (Ratio 25:24:1; Sigma Aldrich, UK) and the contents 
vortex mixed and spun for 5 minutes at 13,000 rpm at 4°C. This separated the enzyme and reagents 
from the RNA, leaving the total RNA dissolved in the aqueous upper phase. The top layer was 
removed to a clean tube and the RNA precipitated by addition of 375111 ethanol with 15111 3M 
sodium acetate (pHed to 5.2 with HC!). The contents were vortex mixed and left to precipitate at -
80°C overnight. Following precipitation, the samples were vortex mixed for approximately 15 
seconds before the RNA pellet was collected by centrifugation at 13,000 rpm at 4°C for 15 minutes. 
The supernatant was removed and the total RNA washed in 1ml 75% v/v ethanol. The pellet was 
then re-collected by spinning at 13,000 rpm at 4°C for 5 minutes. Finally the ethanol supernatant 
was removed and the total RNA pellet air-dried before dissolving in 40111 water, ready for RNA 
quantification. 
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2.7.3 Total RNA Quantification 
Quantity of extracted total RNA was determined using a Nanodrop spectrophotometer (NO-I000 
Nanodrop Products, Thermo Fischer Scientific, USA). In addition, RNA purity was assessed by ratio of 
absorption at 260nm to 280 nm, thereby giving an indication of the level of protein contamination, 
where a 260/280nm ratio between 1.8 and 2.0 is optimal, where protein contamination reduces the 
ratio from the optimal 2.0; therefore a ratio below 1.8 indicates a sample containing unacceptable 
levels of protein. The average 260/280 ratio and the range of values for each RNA sample set used in 
this thesis is shown in table 2.7-1. Following RNA quantification the samples were all diluted to a 
concentration of 0.1Ilg/1l1 in water and stored until the reverse transcriptase step could be 
performed, approximately 3 months later. Total RNA samples were separated by agarose 
electrophoresis following the storage period to visually check that integrity was maintained. 
Table 2.7-1 RNA 260/280 ratios from samples used in this thesis. Data for sheep tissues is from trial 1 of this 
thesis (trial 2 values were unavailable) n=36, C2C12 cell RNA n=48 and Rat Primary cells n=12. 
Tissue Mean 260/280 Ratio SEM Range 
Minimum Maximum n 
Sheep LO 2.10 0.005135 2.02 2.16 36 
Sheep Kidney 2.03 0.011951 1.81 2.12 36 
Rat Primary Muscle Cells 2.10 0.008657 2.06 2.13 12 
C2C12 Cells 2.08 0.004803 1.96 2.11 48 
2.7.4 Horizontal Agarose gel Electrophoresis of total RNA 
RNA integrity and quality was visualised using non-denaturing agarose gel electrophoresis. 5111 RNA 
at a concentration of 0.11lg/1l1 was loaded with 1 1116 x loading dye (Promega, Cat #G190A) in a 1.5% 
w/v agarose gel made with lx TAE (40mM Tris, ImM ethylenediaminetetraacetic acid (EOTA), 0.12% 
(v/v) acetic acid), the gel was then electrophoresed for approximately 1 hour in 1 x TAE buffer. The 
gel was stained in O.5llg/ml ethidium bromide in 1 x TAE buffer, and visualised using GelOoc system 
and Multi-analyst program (BioRad, Hemel Hempstead, UK). Intact total RNA from animal tissues 
should exhibit three clear bands, the larger 28S and 18S ribosomal RNA molecules, followed by a 
smaller transfer RNA band, and a slight smear of mRNA fragments, as observed in figure 2.7-1. 
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Figure 2.7-1 Horizontal agarose gel electrophoresis of total RNA extracted from mouse LD and leg muscle, 
three distinct bands are visible showing 28S, 18S and tRNA to be intact, markers are lkb and lOObp DNA 
markers (Promega). 
2.7.5 Reverse-Transcription (RT) ofmRNA 
To investigate changes in the expression of genes at the mRNA leve l, the extracted total RNA was 
reverse transcribed into copy DNA (cDNA), which was a template for use in Polymerase Chain 
Reactions (PCR) . Extracted total RNA was reverse transcribed using reverse transcriptase (RT) 
enzymes to generate cDNA. All extracted RNA was diluted to O.1Ilg/1l1 prior to RT step and the 
reverse transcriptase enzyme (Moloney Murine Leukemia Virus-Reverse Transcriptase (MMLV-RT), 
Promega UK) was used to generate cDNA in the sheep studies. The RT reaction used the basic 
principles of heating the RNA to a high temperature to denature the tertiary structures, then cooling 
rapidly to allow annealing of short DNA hexamer primers (single stranded DNA molecules 6 bases in 
length) to the RNA. The hexamers were designed to anneal randomly to RNA and provide a start site 
for the reverse transcriptase enzyme, demonstrated in figure 2.7-2. 
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Figure 2.7-2 Schematic representation of Reverse Transcription of mRNA. 
2.7.5.1 RT using MMLV·RT 
Random primers = 
Reverse Transcriptase = 
Free nucleotides - T-
1111 random primers (Promega, UK) at a concentration of 0.5I1g/111 was added to 0.511g total RNA in a 
thin-walled microfuge tube and the final volume made up to 15 111 with water, the reage nts were 
then vortex mixed and collected by brief centrifugation (up to 12,000 rpm fo r 30 second s). The tube 
was then heated to 70°C for 5 minutes on a PCR heat block, before t ransfe rring quickly t o ice. This 
ensured the primers annealed while the RNA was denatured and preve nts seco nda ry structures 
forming. The sample was left on ice for at least one m inute befo re add it ion of 5111 5x MMLV-RT 
Buffer (250mM Tris-HCI, pH 8.3; 375mM KCI; 15mM MgCI2; 50mM DTI; Promega UK), 1.25 111 
nucleotides mix (dATP,dCTP, dGTP, dTIP, final concentrat ions O.5mM ), 0.5 111 Ribonuclease Inhibitor 
enzyme (25 units; Promega UK), 1 III RT enzyme (200 units) and 2.25 111 water. The contents were 
mixed and collected briefly as before and incubated fo r 5 minutes at room temperature to allow the 
enzyme to extend the primers before transfer to the heat block of t he PCR machine (DNA Eng ine-
Mastercycler, M.J. Research; USA) for one hour at 42°(, The fi na l 25111 of first strand cDNA mixture 
was diluted 1:4 to 100111 with water to be stored as stock cDNA at -20°(, 
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2.8 Development of sequences for primer and probe design in sheep 
At the time of this study there were no available known mRNA sequences for the sheep calpain 
enzymes nor for the calbindin D-28K protein. To overcome this, calpain sequences needed to be 
created using available sheep partial length cDNA sequences in the EST (expressed sequence tag) 
database (National Center for Biotechnology Information (NCBI)). There had been previous work in 
this laboratory to develop and sequence a PCR product of calbindin D-28K in sheep (Miss C. Anike-
Nkweze, University of Nottingham) and the present study used this sequence to develop a set of 
sheep specific primers. Primers and dual labelled fluorescent oligonucleotide probes for sheep 
mRNA measurement were purchased from Sigma Genosys (UK) and primers and probes for use in 
mouse and rat -derived cells and tissues were purchased from MWG (UK). 
2.B.1 Development of calpain Sequences 
There were no existing mRNA sequences for the ovine calpain enzymes I and II, so sequences 
needed to be generated using the EST database of sheep cDNA fragments. To do this the mRNA 
nucleotide sequence of the closest related species was used to search for related ovine sequences, 
which was in this case the bovine sequence. 
Firstly the bovine peptide sequence was found using the "Swissprot" website 
[http://www.expasy.org/sprot/L where a search was performed using the common protein name 
(calpain I or calpain II). This then produced a link to EMBL (European Bioinformatics institute-EMBL) 
for the bovine mRNA nucleotide sequence [http://www.ebLac.uk/embl/].This nucleotide sequence 
for the bovine mRNA of the translated protein was then used to search using the BLAST (basic local 
alignment tool) tool within the NCB I (National Center for Biotechnology Information) website for 
related ovine sequences using the EST-[non-human, non-mouse- others] database. This recovered a 
number of unidentified ovine partial length cDNA sequences with similarity to the initial bovine 
mRNA sequence. 
Each of the collected ovine cDNA sequence fragments were then aligned with the relevant bovine 
calpain I or II sequences using the ClustalW alignment tool within the NCB I website, to ascertain the 
region of the mRNA sequence it was related to. The ovine sequence fragments were organised into 
their order relative to the bovine sequence, aligned and a contiguous cDNA sequence generated. 
The bovine mRNA sequence used to search the sheep EST database and the sequences obtained for 
each gene are shown in table 2.8-1. This final created sequence was then ClustalW aligned back to 
the original bovine and human sequences to assess variation, the results are shown in table 2.8-2. 
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Table 2.8-1 Bovine Sequence used to interrogate NCBI EST non-human, non mouse database and retrieved 
partial length cDNA sheep sequences. 
Ovine Calpain primers Ovine EST Sequence 
Gene Bovine sequence Accession No. Length (bp) 
Calpain I NM_174259 EE820633 710 
DYS0737S 741 
EE814187 557 
DY491370 781 
created sequence 1404 
Calpain II N M_OOll03086 DYS064S9 722 
DYS09248 658 
DYS21444 568 
created sequence 990 
Table 2.8-2 ClustalW alignment of created contiguous Ovine calpain cDNA sequences Vs human and bovine 
sequences indicating the similarity to ovine sequences. Length of created ovine calpain I sequence was 
1404bp, created ovine calpain II was 990bp. 
Ovine Calpain I alignment to Accession # Sequence Length (bp) Similarity 
Bovine Calpain I U07849 286 97% 
Human Calpain I X04366 3007 82% 
Ovine Calpain II alignment to Accession # Sequence Length (bp) Similarity 
Bovine Calpain II U07850 623 96% 
Human Cal pain II M23254 3213 89% 
2.8.2 Design of Quantitative (ReaJ-Time) peR primers and probe 
Intron and exon boundaries were identified using the exon boundaries for equivalent genes in 
bovine genomic DNA sequence as a guide, before primers and probes for real-time PCR were 
designed using Primer Express Software (Vl.5, Applied Biosystems); the resulting sequences and the 
position of the primers and probes are shown in appendix B. 
2.9 General and Quantitative Polymerase Chain Reaction 
cDNA created from mRNA extracts was analysed for gene expression by either semi-quantitative or 
quantitative PCR. General PCR amplifies small quantities of cDNA into larger amounts that can be 
visualized under eithidium bromide staining. This method was used to validate primers and to verify 
expression of genes in different tissues. Quantitative (or real-time) PCR (Q-PCR) allows absolute or 
relative quantification of mRNA transcripts by determining the quantity of PCR amplicon produced 
after each cycle of the PCR reaction. Q-PCR was performed in all studies to quantify changes in gene 
expression at the mRNA level. 
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2.9.1 General (Semi-Quantitative) peR 
AmpliTaq Gold enzyme (Applied Biosystems) was used in general PCR reactions, in a thin-walled 
2 0 0 ~ 1 1 volume microcentrifuge tube; containing 0.25 ~ I I AmpliTaq Gold Enzyme (1.5 units), 5 ~ I I lOx 
PCR Gold Buffer, 3 ~ I I 25mM MgCI2, 1 ~ I I 10mM dNTP mix, 1.25 ~ I I forward primer, 1.25 ~ I I reverse 
primer (both primers at concentration of 1 0 p m o l / ~ l ) ) and 5 ~ I I template cDNA (equ ivalent to 0 . 2 5 ~ g g
RNA), with the final volume adjusted to 50 ~ I I with water. This reaction mixture was then vortex 
mixed and centrifuged briefly to collect at the base of the tube before incubation using a PCR 
thermocycler (DNA Engine- Mastercycler, M.J. Research; USA). The reaction was incubated at 95°C 
for 10 minutes to activate the enzyme before the amplification cycles began . Cycles contained three 
steps; 94°C denaturation step for 30 seconds, 55 to 65°C annealing temperature (primer set 
dependant) for 30 seconds and 72°C elongation for 30 seconds to 1 minute (dependant on length of 
amplicon), summarized in figure 2.9-1. These three steps were repeated 35 times before the final 
elongation step of 7rC for 5 minutes followed by cooling to 4°C. 
1) 
2) 
3) 
Incubate at 94°C to dtmalure cDNA 
t;tX;ondary structure 
Temperature lowered to allow 
product-specific oligonucleotides to 
bind to eDNA, usually between 
55°C- and 65°C 
50' 
Temperature raised to 720C to al10iw 
extension of product by T aq 
Polymerase 
5' 
I: II Ii 
5' 
3' 
I I I I I I I I 
S' 
5 5 ' ~ ~ ~ ~ ~ ~ - ' - ' - r . . __ ~ 3 ' 'I I I I I I I I 
~ - - - - - - : r r
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Figure 2.9-1 The three repeated cycles of t he Polymerase Chain Reaction (PCR). 
Taq Fotymaase = 
O L i . g o n u c k o t i d ~ ~
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2.9.2 Electrophoresis of PCR products 
To validate the primers and check the size of the nucleotide sequence amplified, the semi-
quantitative PCR products were separated by horizontal electrophoresis in agarose gels and 
visualised using eithidium bromide staining. 10111 PCR product was diluted with 2111 loading dye and 
electrophoresed in 1.5% w/v agarose gel made in 1 X TAE buffer at 100V for 1 hour. The separated 
products in the gel were then stained for 20 minutes in 0.5 Ilg/ml ethidium bromide (in 1 X TAE 
buffer) and imaged under UV light using the Gel Doc (Gel Doc 2000) and Multi-Analyst software 
(BioRad Laboratories; CA, USA). 
2.9.3 Quantitative PCR 
Quantitative PCR uses similar thermal cycling conditions as used in the general PCR method, except 
after every cycle of cDNA synthesis; the quantity of cDNA is measured. To measure the quantity of 
cDNA an additional oligonucleotide is included in the reaction mixture, referred to as a dual-labelled 
fluorescent probe due to it being modified with two additional fluorescent dyes conjugated at either 
end of the specific sequence, at the 5' end is the reporter dye and the quencher is situated at the 3' 
end. These two dyes have differential energy properties, the reporter having high energy and the 
quencher having low energy, and so, when the two dyes are in close proximity (i.e. both bound at 
either end of the probe) the quencher absorbs the energy from the reporter and thus there is no 
release of fluorescent energy from the probe. This phenomenon is referred to as Flourescence 
Energy Resonance Transfer (FRET) and is the basis for cDNA quantification during quantitative real-
time PCR using dual-labelled fluorescent probe technology. 
The probe has a higher annealing temperature than the primers and thus binds before the primers 
to a specific sequence in the middle region of the amplicon. The DNA polymerase enzyme used in 
the PCR reaction has 5'nuclease activity which allows it to digest any obstructions in its path, and 
thus will degrade the probe as it copies the template cDNA between the two primers. During the 
quantitative PCR reaction the DNA polymerase copies the template cDNA strand and degrades the 
probe as it comes to find it in its path and due to the orientation of the two dyes, the quencher is 
released first. The removal of the quencher from the 3' end of the probe releases the inhibition on 
the reporter dye's fluorescence and the fluorescence can be detected. This reaction is summarised 
in a schematic diagram in figure 2.9-2. The level of fluorescence after each cycle is proportional to 
the amount of cDNA template being copied and thus the quantity of amplicon copied after every 
amplification cycle can be related to the level of fluorescence released. 
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The theory behind quantifying cDNA using the Polymerase Cha in React ion is that the amount of 
cDNA in the sample should double with each cycle of the reaction, giving an opt imum efficiency of 2. 
The reaction causes an exponential rise in the quantity of the amplified product (ampl icon) and the 
quantitative peR method measures the rise in cDNA after every cycle . After every cyc le the 
polymerase enzyme releases a fluorescent signal from the labelled probe, which is directly 
proportional to the quantity of template present, and it is this signal which was measured by the 
light-cycler equipment. The machine records the number of cycles taken for each sample to reach 
threshold fluorescence (Ct) and this is proportional to the amount of cDNA template at the start of 
the reaction. To quantify the relative concentration of unknown samples a pool of cDNA was diluted 
into a standard curve to be used as a reference for relative quantification, the dilution method is 
outlined in table 2.9-1. 
Po Iymeriza tion ® = Reporter 
Forward @) = Quencher 
Primer 
5' .. 
3' 5" 
5" 3' 
3' ~ ~ 5' @ A evBf'89 Prim-:;r 
Strand displacement 
5' .... 
3' 5' 
5" :3" 
:3(t 4 5' 
Cleavage 
S( ~ ~
3" 5' 
5' 3' 
5" 3' .. @ ... ~ ~.". A . . . ~ ~~ ~ .. ~ ~
, , 
Palymeriza tioll campi eted 
S' .. 
3' 5" 
Figure 2.9-2 Schematic diagram of the release of the fluorescence signal during q u a n t i t a t i ~ e e P ~ ~ . . Image 
from TaqMan® peR Reagent Kit With AmpliTaq Gold® DNA Polymerase Protocol manual Applied Blosy tems 
(2002), 
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Table 2.9-1: Diluting cDNA to create a standard curve for relative quantification of unknown samples 
Standard Curve Relative Quantity 
1 0.75 0.5 
Volume Stock cDNA (!-.tI) 100 75 50 
Volume Water (Ill) 0 25 50 
Dilute these 1:10 (10111 Standard Curve + 90111 water) 
1:10 0.1 0.075 0.05 
1:100 0.01 0.0075 0.005 
1:1000 0.001 0.00075 0.0005 
0.25 
25 
75 
0.025 
0.0025 
0.00025 
The q-PCR machine's software (Sequence Detection Systems V 2.2.2.; 2004 Applied Biosystems, 
Foster City, CAl USA) then calculates the efficiency of the reaction by plotting the number of cycles 
to reach threshold against the relative quantity of cDNA template in the standard curve. Figure 2.9-3 
demonstrates the typical relationship between the fluorescence value generated at each cycle 
number, generated by the amplification of a cDNA standard curve, the threshold value of 
fluorescence is shown as a red line (measured using 7900HT Fast Real-Time PCR System, Applied 
Biosystems) and the corresponding cycle number is the Ct value. The software then calculates the 
equation of the standard curve by plotting the number of cycles required to reach threshold (Ct) 
plotted against the Log 10 of the relative quantity of cDNA in the standard curve, shown in figure 2.9-
4. Assuming that the quantity of DNA doubles after each cycle, the theoretical number of cycles 
required for the amount of cDNA to increase by a factor of 10 is Log2 10, and therefore when the 
standard curve is plotted displaying the relationship between Ct value and loglo value of the 
template quantity (total RNA equivalentsL theoretically the gradient is approximately 3.322 (3 dp) 
when the reaction is near 100% efficiency (DNA quantity doubling per cycle). Most reactions do not 
reach maximum efficiency as a result of a variety of factors, for example different binding capacities 
of the oligos to the cDNA strand. As a result of these factors each primer and probe set was 
evaluated for its efficiency across the standard curve and the unknown sample templates were 
diluted to lie where the reaction had a linear response, an example of unknown samples amplifying 
in the linear phase of the reaction is shown in figure 2.9-4. 
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Figure 2.9-3 Amplification plot of standards used to measure Ovine Calpain I expression in LD. As 
concentration of cDNA in t he starting t emplat e decreases, the time taken to reach threshold detection is 
longer; shown as a red line. 
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Figure 2.9-4 The number of cycles required to reach threshold (Ct) plotted against the log of the relative 
quantity of cDNA in the standard curve. The equation of the standard curve s calculated and the gradient of 
the line describes the efficiency of t he react ion, 3.3 being optimum. The samples, denoted in red crosses, 
were diluted 1:10 and are shown lying across the linear phase of the reaction. 
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2.9.3.1 q-PCR in Sheep Trials 
Expression of calpain system and calbindin -D28K mRNA in sheep trials was quantified using real-
time quantitative PCR using the Fast-Taq system and analysed using Sequence Detection System 
software (SDS) (Applied Biosystems, Foster City, CA, USA). Primers for the ovine calpains, calpastatin 
and calbindin were designed as described in section 2.8 and are summarised in appendix B. The 
myosin heavy chain (MHC) genes were analysed using the LC480 system (Roche) using primers and 
probes designed by Miss Krystal Hemmings (University of Nottingham; Appendix B). A standard 
curve of either LD or kidney was generated from pooled cDNA taken from each trial sample and 
serially diluted to generate a range of dilutions against which the trial samples could be quantified. 
All trial samples of cDNA were diluted 1:10 before measurement to ensure samples were quantified 
against the linear phase of the standard curve. To correct for variation in sample preparation an 
internal control gene expected to be unchanged by vitamin D treatment was also quantified under 
the assumption that expression of this gene was not altered by treatment and that total RNA 
content of samples was constant. For this purpose ~ - A c t i n n was measured and utilised as an internal 
standard for all genes. All sample values were calculated relative to the standard curve in arbitrary 
units and then divided through by the corresponding value for ~ - A c t i n ; ; giving results expressed as a 
ratio to ~ - A c t i n . .
For each reaction, cDNA diluted 1:10 was added into a well of the PCR thermal cycling plate and 
added to it were PCR Mastermix, dual labelled probe and forward and reverse primers before the 
final volume was adjusted with RNAse/DNAse free water, table 2.9-2 summarises the volumes and 
final concentrations of the components of each reaction system and the thermal cycling conditions 
used. For the calpain system analysis, the Applied Biosystems 7900 HT Fast Real-Time PCR system 
was used and the master mix was Taqman Fast Universal PCR 2X mastermix (Applied Biosystems, 
Warrington, UK) and each sample was measured in duplicate reactions in a 96-well reaction plate; 
raw data was analysed using Sequence Detection System (SDS, V2.2.2 ) software. For the analysis of 
the MHC genes the Roche Light Cycler 480 system was used, the master mix was LightCycier ®480 
probes Master 2 X Mastermix (Roche Diagnostics GmbH, Germany) and each sample was measured 
in triplicate reactions in a 384-well plate; raw data produced was analysed using LC480 Software 
(LightCycler® 480 SW V 1.5, Roche Diagnostics, Germany). 
Immediate analysis of the raw data was performed by each system's specific software, whereby the 
relative concentration (an average of replicates) was calculated against the standard curve, followed 
by the export of data to Microsoft Excel (version 2007) for further analysis investigating effects 
between treatment groups prior to statistical analysis performed in Genstat software (Vii). 
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Table 2.9-2. Reaction volumes and thermal cycling conditions of two Q-PCR systems used in mRNA 
expression analysis in sheep trials. 
Reagents 
cDNA Template 
Equivalent RNA ( ~ ) )
Mastermix 
Dual-labelled probe 
Forward primer 
Reverse Primer 
Water 
Total Volume 
Cycling Conditions 
Denaturation 
Amplification 
Cooling 
Q-PCR 7900HTFast Real-Time PCRSystem 
Volume (Ill) Final Concentration (1lM) 
8.3 
0.0415 
12.5 
0.5 0.2 
0.75 0.3 
0.75 0.3 
2.2 
25 
Temperature °C Duration (seconds) 
95 20 
95 1 
60 20 -7 Acquisition 
-7 repeated for 40 cycles 
None 
2.9.4 Normalisation of data to p-Actin 
Q-PCR LightCycier ® 480 System 
Volume (Ill) Final Concentration (1lM) 
2.5 
0.025 
7.5 
0.3 0.2 
0.45 0.3 
0.45 0.3 
3.8 
15 
Temperature °C Duration (seconds) 
95 600 
95 10 
60 50 
72 -7 Acquisition 1 
-7 repeated for 45 cycles 
40 10 
Total RNA samples were normalised for RNA concentration prior to the RT step to ensure each cDNA 
sample was created from similar amounts of total RNA prior to PCR, however, to further correct for 
variation in the sample preparation a house keeping gene was used, which was ~ - A c t i n n in case of the 
ovine experiments. Expression of ~ - A c t i n n at mRNA level was measured using primers and probes 
designed for sheep by Dr. Zoe Daniel (University of Nottingham), for normalisation of the calpain 
genes the data from Fast Taq ABI system was used and for the Myosin Heavy Chain genes the data 
from the Roche LC480 was used. The level of expression of this gene was compared between 
treatment groups using a paired T-test in Genstat software and the data is shown in table 2.9-3. The 
results in table 2.9-3 show that the two real time PCR machines produced similar results for the 
expression of ~ - A c t i n n in LD and kidney in both trials and that there were no effects of dietary 
treatment on ~ - A c t i n n expression in LD and kidney of both trials (P>O.OS in all cases). 
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Table 2.9-3 Effect of Vitamin 0 3 supplementation on mRNA expression of (3-Actin, as measured by the Fast 
Taq ABI system, and again in the LD as measured by the Roche LC480 system. cDNA created from samples 
with constant RNA concentration from either LD or Kidney tissues from animals fed either a control or 
vitamin D supplemented diet. 
Trial 1: 4 Days Vitamin D 
Housekeeping Gene Beta Actin Control Vit D d .f. S.E.D. P 
FastTaq (ABI) (Ilg RNA equivalent) LD 1.631 1.608 16 0.0855 0.766 
Kidney 1.544 1.530 17 0.0389 0.68 
LC480 (Roche) (relative expression) LD 0.1197 0.1066 17 0.0177 0.460 
Trial 2: 7 Days Vitamin D + Ca 
Housekeeping Gene Beta Actin Control Vit D d .f. S.E.D. P 
FastTaq (ABI) (Ilg RNA equivalent) LD 1.358 1.427 17 0.0676 0.234 
Kidney 1.676 1.728 17 0.0716 0.389 
LC 480 (Roche) (relative expression) LD 0.0774 0.0785 17 0.0133 0.897 
2.10 Measurement of Proteins by Western Blotting technique 
Analysis of specific protein levels in samples was performed by denaturing electrophoresis of 
extracted proteins followed by transfer to a nitrocellulose membrane followed by immunoprobing 
with antibodies specific to the protein targets. This method allows relative comparison of protein 
levels between control and treatment groups. 
2.10.1 Extraction of proteins from animal tissues 
Snap tissue samples taken during carcass sampling and stored at -70oe until extraction when 
samples were crushed in liquid nitrogen in a crucible before weighing out 19 (±0.05g) into a 20ml 
sterilin tube. 5ml of extraction buffer with protease inhibitors (containing 100mM Tris-Hel pH 5.5, 
10mM enthylenediamine tetra-acetic acid (EDTA), O.5mM 2-(4-aminoethyl)- benzenesulphonyl 
fluoride (AEBSF), O.OlmM leupeptin and O.OlmM pepstatin) was then added to the crushed sample. 
The extraction buffer contains three protease inhibitors to prevent proteolysis. The mixture was 
then homogenised (Polytron, The Nertherland) using 2 x 30 second bursts, allowing 30 seconds 
between to allow time for the blade to cool. Sterilin tubes were kept in an ice bath to prevent 
heating of the samples during homogenisation. 
Following homogenisation 100111 of the mixture was removed into a 1.5111 tube containing 900111 
O.lM NaOH for protein concentration analysis (Lowry assay, see section 2.10.2). Another 250111 was 
removed and added to an equal volume of SDS-mix DTI (20% v/v glycerol, 12.5% v/v 1M Tris/Hel 
pHed to 6.8, 4% w/v SDS (Sodium Doecyl Sulphate), 15.4% w/v Dithiothreitol (DTI), and a few grains 
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bromophenol blue} for use in SOS-PAGE analysis. This solution contains strong reducing agents 
which denature the tertiary structure of proteins which allows optimum separation of proteins via 
electrophoresis through acrylamide gels. A further two 1.5ml tubes were filled with the homogenate 
and centrifuged at 15,000 rpm (Microfuge 22R Centrifuge, Beckman Coulter) for 15 min in a pre-
cooled centrifuge (4°C). Following centrifugation, 100111 of the supernatant was added to 900111 
a.1M NaOH, and another 250111 supernatant added to 250111 SOS-mix on. These two aliquots of the 
supernatant protein fraction were stored at -20°C for protein quantification and electrophoresis. A 
further aliquot of supernatant was boiled on a 1.5111 tube heater at 100°C for 5 minutes before a final 
centrifugation (15,000 rpm for 15 min at 4°C). The resulting boiled supernatant, containing the 
endogenous calpain inhibitor calpastatin, was aliquoted into 0.1M NaOH and 50S-mix on as 
described for the supernatant above. All prepared extracts were then stored at -20°C until required, 
approximately 6 months later. 
2.10.2 Determination of Protein concentration by Lowry Assay 
The Lowry protein assay (Lowry et 01., 1951) was performed on extracts from sheep samples which 
had been stored in 0.1M NaOH at 1:10 dilution. The assay uses two solutions made up fresh for each 
assay; solution 1 (5ml 2% w/v Na2C03 in 0.1M NaOH, O.5ml 1% w/v CUS04, 0.5ml 2% w/v KNa 
Tartrate) followed by equal volume of solution 2 (5ml 0.1M NaOH and O.sml Folin's Ciocalteau's 
Reagent (FSA Lab Supplies, England). 
In alkaline solution the copper III ions will complex with the proteins, this then reacts with the Folin-
phenol reagent, reducing the acids to tungsten and molybdenum which produce blue solutions. The 
more protein present, the more acids are reduced thus producing a darker blue solution. The 
intensity of colour is detected colorimetrically by absorption at 620 nm. Protein standards were 
made up using Bovine Serum Albumin (BSA); six known concentration solutions were made up, 
containing 0.2, 0.4, 0.6, 0.8, 1.0 and 1.2 mg/ml, stored at -20°C between assays. In a 96 well micro 
titre plate 50111 of each standard solution was added in duplicate. 0.1M NaOH solution was used as 
the a 111 solution for background comparison. Again, in duplicate, 50111 of each sample was pipetted 
onto the plate, before all wells were made up to 200111 with 0.1M NaOH. 50111 of solution 1 
(described above) was added to all wells and left for 5 minutes at room temperature. 50111 of 
solution 2 was then added and the plate incubated at room temperature for 20 minutes before the 
absorption at 620nm was read using the micro titre plate reader Oynatech MRsOOO (Oynatech 
Laboratories Ltd, Guernsey, Channel Islands, UK). The absorption output was used to equate protein 
concentration by Biolinx 1.1a software, (Oynatech UK) comparing the unknown samples to the 
known concentrations of the BSA standards. Following determination of protein content within each 
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sample, those samples stored in 50S-mix on were diluted to constant protein concentrations. A 
standard mix was prepared by taking 20111 of each diluted sample and mixing in a l.5ml tube. This 
standard was then loaded three to five times across gels to measure variation between and within 
gels. 
2.10.3 Protein separation by SDS-PAGE (Sodium Dodecyl Sulphate- Polyacrylamide Gel 
Electrophoresis) 
Prepared denatured protein samples in 50S-mix, as described in section 2.10.1, were separated by 
vertical electrophoresis in Sodium Oodecyl Sulphate Polyacrylamide gels (50S-PAGE). Polyacrylamide 
gels were prepared using variable acrylamide content keeping the ratio of acrylamide to bis-
acrylamide constant (37.5:1 acrylamide:bis-acrylamide), quantities described in Appendix C. 
Appropriate concentrations of acrylamide in the gel were used according to molecular weight (MW) 
of protein to be investigated, varying from 8% w/v for proteins of size 250kOa to 75 kOa, to 12% w/v 
for smaller, 100kOa to 20kOa. Prior to loading, all samples were boiled on a heat block for approx 1 
minute at 100°C to ensure denaturation of proteins and spun in a centrifuge (3 minutes at 15000 
rpm at room temperature) to ensure a homogenous mix. 10111 pre-stained molecular weight marker 
(Biorad, USA) was loaded to demonstrate the distance moved by known molecular weight protein 
standards, ranging in size from 10 to 250kOa. Gels were run at 200V constant until the blue dye of 
the 50S-mix on began to run off the bottom of the main gel, usually around 45 minutes for a 10cm 
long gel. 
2.10.4 Western Blot Protein Transfer 
After running, the gels were laid in western blot buffer (5% (w/v) isopropanol, 0.4M Glycine and 
2.5mM Tris Buffer, all Fischer Scientific Ltd, UK) for 5 minutes. A piece of 0.45 11m nitrocellulose 
membrane (GE Healthcare, UK) was cut to size just larger than the gels, then soaked in distilled 
water for 10 minutes to hydrate before immersion in western blot buffer ready preparation of the 
western blot stack. The stack was prepared on a sponge soaked in western blot buffer, followed with 
a layer of two sheets of Whatman 3MM paper (Fisher scientific, UK) also soaked in western blot 
buffer. The gel was laid on the 3MM paper and western buffer poured over to keep the gel moist 
before the nitrocellulose membrane was laid covering the gel. The layers were rolled with a glass rod 
to ensure no air bubbles were trapped between the gel and membrane. Two more layers of 3MM 
paper were added and a final sponge on top with additional buffer poured over the stack after every 
layer to ensure all components remained wet and rolled with the rod to remove any air bubbles. This 
ensures all proteins migrate evenly across the whole membrane, any air bubble between the gel and 
the membrane prevents protein migration to the membrane. The stack was compressed in a plastic 
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cassette then immersed in an electro-blotting Trans-blot tank (BioRad, Hemel Hempstead, UK) filled 
with western blot buffer. The gel was placed toward the negative electrode as proteins are 
negatively charged and move toward the membrane in the direction of the positive electrode. A 
constant current of 350mA was applied across the stack for 2 hours for the large gels used to run all 
experimental trial samples, and 200mA for 90 minutes for small gels, where fewer samples were 
used for antibody optimisation. 
2.10.5 Ponceau Stain of Membrane 
Following the blotting process the membrane was stained using Ponceau stain (0.5% w/v Ponceau S 
stain, 5% (w/v) trichloroacetic acid) to ensure protein transfer. The membranes were submerged in 
Ponceau stain for approximately 1 minute and washed in distilled water to reveal protein bands. The 
stain was removed using TBS-T (20mM Tris HCI pH 7.5, 150mM NaCI & 0.1% (w/v) Tween 20) once 
transfer of protein was confirmed. At this stage position of the molecular weight markers was 
denoted with a permanent marker. 
2.10.6 Immunodetection of proteins 
Once transferred to the nitrocellulose membrane, specific proteins were visualised using 
immunoprobing technique. The first step of this method removes all possible non-specifc binding 
sites still available on the nitrocellulose membrane. This was done by blocking the membrane in a 
solution of 5% (w/v) non-fat dried milk (Marvel®) in TBS-T for at least 30 minutes on a platform 
shaker at room temperature. Following the initial blocking, the membrane was probed by the 
protein-specific primary antibody overnight at 4°C. After the first antibody incubation, the 
membrane was washed for 30 minutes with 1% (w/v) non-fat dried milk in TBS-T with 6 x 5 minute 
washes using fresh wash solution each time. The membrane was then probed for 1 hour with a 
secondary antibody, usually anti-rabbit or anti-mouse IgG conjugated with horseradish peroxidase 
(HRP) or alkaline phosphatase enzyme, depending on the source of the primary antibody in use. Full 
details of antibodies and conditions used for detection are summarised in Appendix D. Following 
incubation with secondary antibody the membrane was washed again with 1% (w/v) non-fat dried 
milk in TBS-T for a further 30 minutes, again with 6 x 5 minute washes. A final 5 minute wash in TBS-
T was the last step before the chemiluminescence reaction. 
The calpain enzymes were visualized at the protein level using antibodies developed to porcine 
calpains (produced by Tim Parr, University of Nottingham) which were verified to cross react with 
sheep (Sazili, 2003; pp32). All samples were diluted to constant protein concentration of 5 ~ g h . 1 I I
before loading 2 0 ~ 1 1 volume sample to give 1 0 0 ~ g g protein/lane. For the calpain enzymes the 
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proteins in the supernatant fraction were loaded and Calpain II was detected first before the 
membrane was stripped (as described in section 2.10.8) and re-probed with Calpain I antibody. For 
calpastatin detection the whole homogenate fraction was used and again samples were loaded to 
the same constant protein concentration of 51lg/1l1 so that a constant volume of 20111 could be 
loaded, giving a lOOllg protein per lane. The calpastatin protein was detected using a monoclonal 
antibody from Sigma (details in Appendix D) following which the membrane was stripped using 
stripping buffer (Pierce, described in section 2.10.8) and was re-probed with an anti-Desmin 
antibody. 
2.10.7 Chemiluminescence detection of proteins 
If a secondary antibody conjugated with horse radish peroxidase was used, the luminescence 
solution required was EZ-ECL (Biological Industries, Israel), whereas for secondary antibodies 
conjugated with alkaline phosphatase enzyme the developing solution required was CDP star (GE 
Healthcare, UK). For EZ-ECL detection equal volumes of solutions A and B were added together 
depending on the surface area of the membrane (a total volume of 8mls was used for each large 
membrane containing around 25 samples), poured over the protein bound surface of the membrane 
and incubated at room temperature for 1 minute. For CDP-Star 6mls reagent was added per large 
1Dcm gel, left to incubate for 5 minutes. The detection solutions were removed briefly using 3MM 
Whatman blot paper before the membrane was wrapped in cling film before securing into an 
autoradiograph cassette. Application of the detection reagents initiates a light reaction between the 
conjugated enzyme of the secondary antibody and the development solutions, the light emitted 
from this reaction was detected using autoradiography film (hyperfilm, GE Healthcare, UK). Exposure 
of the film to the membrane was dependant on strength of luminescence and usually varied 
between 15 seconds to 5 minutes. The film was then developed in a dark room by immersion in 
Kodak X-ray Developer solution for 2 minutes, a brief rinse in water then fixed by immersion in IIford 
Hypam rapid fixing solution (both solutions were diluted 1 in 5 from stock solution with water, 
supplied by Calumet Photographic Co. (Nottingham, UK) for 2 minutes followed by final wash in 
water. 
2.10.8 Stripping and re-probing with a second protein antibody 
Following immunoprobing with the initial protein specific antibody, membranes were stripped of the 
bound primary and secondary antibodies to allow immunoprobing for a different protein. This 
allowed the same blot to be probed for a number of test proteins without repeating the initial 
electrophoresis and transfer. For all protein work performed using sheep tissue, the membrane was 
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washed in a pre-prepared stripping buffer (Pierce, UK) for 10 minutes followed by a brief wash in 
TBS-T. The blot was then blocked with 5% (w/v) marvel TBS-T and probed with another antibody. 
For membranes used for protein detection in cell culture work where antibodies to both total 
protein and phosphorylated proteins were used to detect bands of the same size, the first antibody 
was removed from the membrane using lOOmis of a stronger stripping buffer (0.09M SDS, 0.6M Tris 
and ~ - M e r c a p t o e t h a n o l l added immediately prior to use to give O.OlM) added for each large 
membrane and heated in a 50 0 e water bath for 30 minutes. The membrane was then washed once 
in distilled water at room temperature on a bench top shaker for 5 minutes and twice in TBS-T 
solution for 5 minutes before the membrane was treated with detection reagents and developed to 
ensure there were no traces of the first antibody remaining. Following the second incubation with 
detection reagents, the membrane was washed again in TBS-T at room temperature to remove any 
remaining developing solutions, before the membrane was ready to be blocked with 5% marvel-TBS-
T solution and re-probed with another primary antibody. 
2.10.9 Quantification of protein blots 
The protein bands on the developed blot were quantified using Bio Rad software (Gel Doc 2000, 
USA) and optical density of bands was measured using Multi Analyst image analysis software 
(BioRad, USA). Variation in signal detection (which included gel and blotting variation) across gels 
was corrected for using the protein standard replicate loaded on gels. Data was expressed as optical 
density of the band per weight of protein loaded per sample. 
2.11 Cell culture methods 
The final experiments of this study were performed in rodent skeletal muscle cell models in culture 
which were treated directly with active forms of vitamin D at differing time points. From these cell 
models total RNA and protein samples were prepared for analysis of vitamin D's direct signalling 
mechanisms within muscle cells. The scheme of this work followed three phases, a microarray 
analysis to identify novel targets of la,25 dihydroxyvitamin D3 using primary skeletal muscle cells, 
selection of available muscle cell types on the basis of their myosin heavy chain gene expression and 
a final vitamin D3 experiment on the chosen cell line to verify targets of the microarray and to 
evaluate the active form of vitamin D's possible role in fibre type maintenance. Primary skeletal 
muscle cell cultures were prepared from neonatal male rat pups as described below. These cells 
were removed directly from newborn rat muscle tissue and were allowed to proliferate in culture 
plates before addition of differentiation media which initiates formation of myotubes. These primary 
cell lines are most closely related to cells in vivo and provide a large number of identical samples 
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which can be treated directly with active vitamin D3. High quality mRNA was extracted from these 
cells following treatment with vitamin D3 and was analysed by microarray for novel targets in 
skeletal muscle tissue. 
Although the microarray experiment was performed in the primary skeletal muscle cells, it was 
necessary to identify the myosin heavy chain genes which were expressed by this model as the 
purpose of the final experiment was to investigate vitamin D's effects in both developing and mature 
adult muscle. For the final experiment the muscle cells needed to express both the fast and slow 
myosin heavy chain genes so that any fibre type switching could be observed. Two other skeletal 
muscle cell models were assessed for their range of MHC expression, these were immortalised cell 
lines derived from rat, the L6 Aston, and from mouse, the C2C12 cell line. After identifying the cells 
which expressed the most appropriate range of MHC genes (see section 3.5 of this thesisL the final 
experiment of treating muscle cells directly with a vitamin D3 analogue was performed at a range of 
doses and time points. 
2.11.1 Preparation of primary skeletal muscle myoblasts from rat pups 
This method of cell preparation generates proliferative myoblasts cultured from muscle tissue taken 
from neonatal male rat pups which can be differentiated into myotubes and treated with agents. 
This element of work was performed within Pfizer Ltd (Sandwich, UK) with the help of Mr Adrian 
Thompson and Dr. Christine Berger. Three day old male Wistar rat pups were killed by cervical 
dislocation and were placed in industrial methylated spirit (IMS) for approximately 1 minute to 
sterilise animal surfaces. Hind legs were then removed from the pups and the muscle tissue 
dissected and placed in falcon tube containing Dulbecco's modified eagle's medium (DMEM) until all 
tissue was harvested. All of the following preparation steps were performed in a sterile laminar flow 
hood using autoclaved equipment and sterile consumables. DMEM was poured off the tissue, and 
then the remaining liquid removed with Pasteur pipette. The tissue was then washed with 40mls 
tissue wash solution (4mls of Antibiotic-Antimycotic solution (Invitrogen Ltd.) added to 36mls of 
sterile phosphate buffered saline (PBS) with 4 0 ~ . d d 1% w/v DNAse solution (deoxyribonuclease I type 
IV (Sigma, Ayrshire, UK) diluted with sterile deionised water to give a 1% w/v solution; stored in 
lOOll1 aliquots at -80°C to be thawed just before each preparation) by inversion three times. The 
tissue wash solution was decanted as before and the tissue washed again in 40mls sterile PBS. Finally 
the PBS was removed and the muscle tissue was poured onto the inverted petri dish lid. Muscle 
tissue was chopped using sterile scalpel blades on the petri dish lid for at least five minutes to break 
up the myofibrils and release single cells. The chopped tissue was then poured into the base of the 
petri dish and 10mls of tissue digestion solution was added (1.5mls Trypsin enzyme (concentration 
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of 25g/L in Hank's balanced salt solution (HBSS) Sigma, UK) was added to 13.5ml sterile PBS with 
15111 1% w/v DNAse solution). The lid was replaced and the dish placed into 3rC incubator for 30 
minutes to allow the enzyme to digest proteins between the cells and release myoblasts further. 
Following the 30 minute incubation period with the tissue digestion solution, the cells were further 
disrupted by passing the solution through a 16G needle into a sterile syringe and dispelling again. 
This action was repeated 7 times each time returning the solution to the petri dish before drawing 
back into the syringe. 
The dish was then returned to the incubator for another 10 minutes before the cells were passed 
through the syringe needle a further 7 times. The cells were then once more incubated for 10 
minutes at 3rC and the syringe step repeated a final time. After the final disruption step the cells 
were retained in the barrel of the syringe, while 10mls of cell growth medium (125mls foetal calf 
serum (FCS) added to 500mls DMEM (20% FCS DMEM) with 7mls Antibiotic-antimycotic solution and 
warmed in a 3rC water bath prior to use) was used to wash the base of the petri dish and also 
drawn into the syringe barrel. This suspended cell solution was then filtered through a Swinnex-47 
filter unit with a fitted wire mesh. The cell mixture was pushed through the filter and collected in a 
50ml falcon tube. Following the cell solution a further 10mls cell growth media was passed through 
the filter unit and again collected in the 50ml falcon tube. This filter step was then repeated using 
another filter fitted with lens tissue, first passing the cell suspension through followed by another 
wash with 10mls cell growth solution, again collected into the final mixture. This solution was 
centrifuged at 1500rpm (Centaur 2, MSE) at 4°C for 5 minutes, before the majority of the 
supernatant was discarded leaving the cells in approximately 5mls media collected in base of the 
tube. A further 5mls of cell growth media was added to the cells and the pellet re-suspended by 
drawing into a pipette and releasing again. 
2.11.1.1 Countingl Diluting and Plating Cells 
1ml of the prepared cell solution was counted using a cell counter (Vi-Cell XR 2.03, Beckman 
Coulter). According to the number of viable cells, the solution was diluted with cell growth media to 
give a concentration of 5 x 104 cells per ml. Cells were then seeded at this density. In a 6-well plate 
format, 2.5mls of the solution was added to each well, giving a total of 12.5 x 104 cells per well, and a 
total of 7.5 x 105 cells per plate. Prepared primary myoblasts were plated into gelatine-coated 6-well 
plates (Biocoat, Becton Dickinson Labware, USA) at the above density and the solution swirled 
around in a figure of 8 to ensure even distribution of myoblasts, before incubation at 3rC with 5% 
CO2 until confluent. 
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2.11.1.2 Fusing Cells 
Once cells had proliferated to almost 90% confluence the cell growth media was substituted for cell 
fusion media (13mls donor horse serum (DHS) was added to 500mls DMEM (2.5% v/v DHS DMEM) 
with 6mls Antibiotic-Antimycotic solution (Sigma, UK) and warmed in a 3rC water bath prior to 
use). Cell growth media was removed with a disposable pipette and the cells washed gently with 
warmed sterile PBS, using 2mls PBS per well. PBS was then removed and the fusion media added, 
allowing 2.5mls per well. Cells were then returned to the incubator until required. 
2.11.2 Culture of skeletal muscle cell lines 
Two cell lines were used during this study, the rat-derived L6 Aston (provided by John Brameld, 
University of Nottingham) and the mouse derived C2C12 cell line (provided kindly by Philip Rhodes, 
University of Nottingham). All media, PBS and trypsin enzyme were warmed in a 3rC waterbath 
before use, unless stated otherwise. All work for cell line culture was performed in a sterile laminar 
flow hood and reagents were sterile and equipment autoclaved. 
2.11.2.1 Thawing cells 
Cells were frozen in lml freezing media (lml dimethyl sulfoxide (DMSO) in 9mls FCS (10% DMSO 
FCS) and were defrosted quickly in a 3rC water bath. Upon thawing the cell solution was added to 
10mls cell-line growth media (50ml fetal calf serum (FCS) into 500ml DMEM (10% FCS DMEM), 
supplemented with 10mls 200mM L-Glutamine and 10ml 10mg/ml Antibiotic/Antimycotic solution, 
Sigma, UK), pipetted up and down to ensure cells were dispersed before leaving to adhere in a 75ml 
flask. Media was changed for fresh cell-line growth media every 48 hours until cells were almost 90% 
confluent at which point cells were ready to be harvested. 
2.11.2.2 Splitting and re-seeding cells 
Cells were allowed to grow to 90% confluence in a 75ml flask before harvesting and re-seeding into 
6-well plates for experiments. To harvest the adhered cells media was removed and cells washed by 
running PBS over the base of the flask. This PBS was removed and 2mls trypsin added to the flask 
before returning to the incubator for approximately 5 minutes. This allowed trypsin to digest the 
proteins which adheres the cells to the surface of the flask so that cells were free to be manipulated 
in suspension. After 5 minutes the flask was removed from the incubator and knocked slightly to aid 
release of cells, examination of the cells under a microscope confirmed cells were dislodged before 
continuation to next step. 
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When almost all cells had been released, 8mls cell-line growth media was added to the flask to 
neutralise the trypsin enzyme and prevent further damage to cells. This cell suspension as then 
moved to a sterile SOml flacon tube and centrifuged at 700rpm (Centaur 2, MSE) at 4°C for 4 
minutes. The supernatant from this step was decanted and cells re-suspended in 2mls fresh cell-line 
growth media. 20111 of this cell suspension was counted in a haemocytometer and the number of 
cells harvested was calculated. Cells were diluted in cell-line culture media and re-seeded at a 
density of 3 x 104 cells per well, requiring 1.8 x 105 cells per 6-well plate. Following passaging, cells 
were left to proliferate, renewing growth media every 48 hours until 90% confluent, at which point 
media was substituted for cell-line fusion media (lOml donor horse serum (DHS) into SOOml DMEM 
(2% v/v DHS DMEM), supplemented with 10mis 200mM L-Glutamine and 10mi 10mg/ml 
Antibiotic/Antimycotic solution) to promote myoblast differentiation. Cells were incubated in 3rC 
incubator with S% CO2 until required. 
2.12 Cell Culture Experimental Procedures 
To investigate the effect of la,2S-dihydroxyvitamin D3 (l,2S(OHhD3) and 1a(OH)-D3 on cultured 
muscle cells, myoblasts of either cell lines or primary cells were required to have been grown in 
growth media until almost 90% confluent. The day of addition of cell fusion media was denoted as 
day 0 of differentiation and all time points post differentiation were counted from this day. 
2.12.1 Diluting Vitamin D3 
Two vitamin D analogues were used in this study; for the microarray primary rat muscle cells were 
treated with the active la,2S-dihydroxyvitamin D3 and in the mouse C2C12 skeletal muscle cell line 
experiment, the analogue la hydroxyvitamin D3 was used. Both forms of vitamin D3 are biologically 
active and were purchased from Sigma (Germany), their structures are shown in figures 2.12-1 and 
2.12-2. 
HO" 
Figure 2.12-1 Structure of vitamin D3 analogue used in rat primary microarray experiment; 1a,2S-(OHh 
vitamin D3 also known as calcitriol. 
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Vitamin D3 used in the rat primary muscle cells to produce mRNA for the microarray experiments 
was the activated form, la,25-dihydroxycholecalciferol, structure shown in figure 2.12-1, purchased 
from Sigma (Germany) and was first suspended in DMSO (lmg supplied, la,25-0H2D3 suspended in 
2 4 9 . 5 ~ 1 1 DMSO giving a O.OlM (10-2M) vitamin D3 solution),this solution did not require storage as all 
cells were treated on the same day for a 24 hour period. 
CH3 
Figure 2.12-2 Structure of vitamin D3 analogue used in muscle cell line experiment; 1,a-hydroxyvitamin D3 
also known as alfacalcidiol. 
Vitamin D3 used in the skeletal muscle cell lines to investigate vitamin D3 direct signalling effects and 
to verify targets from the microarray was la-hydroxyvitamin D3, structure shown in figure 2.12-2; a 
synthetic active analogue of vitamin D3. This solution was stored at -20°C in the dark between 
treatment days, and this same stock was stored for up to 7 days over the course of the myoblast 
development experiment. 
To treat cells using decreasing concentrations of l,25(OHhD3 or la(OH)-D3, a series of dilutions was 
made, the first at 10-4M was made taking 2 0 ~ 1 1 of the 10-2M vitamin D3 analogue/DMSO solution and 
diluting 10 fold into 2mls cell fusion media (DMEM with 2% v/v DHS DMEM for cell lines, 2.5% v/v 
OHS DMEM for primary cells) or in cell growth media (DMEM with 10% v/v FCS) for treating 
myoblasts. Further dilution steps were made taking 2 0 ~ 1 1 of the vitamin D3/DMEM solutions and 
diluting 10 fold into another 2mls DMEM. These steps resulted in four dilutions of vitamin 03 in 
OMEM; 10-4M, 10-6M, 10-8M and la-10M. In addition; a 6-well plate of cells was treated with 0.1% v/v 
OMSO/DMEM solution ( 2 0 ~ 1 1 DMSO added to 20mls DMEM, then 2.5mls added to cells per well) to 
be used as control samples. 
2.12.2 Treatment of primary muscle cells with Vitamin D for microarray analysis 
Three treatments were included in the microarray; DMSO/vehicle control, la,25 dihydroxyvitamin 
03 at 10-5 M, and la,25 dihydroxyvitamin D3 10-
9 M. Primary myoblasts were prepared as described 
in section 2.11.1 and were plated into gelatin coated 6-well plates at density of 2.5 X 104 cells/well 
and cultured for 4 days until 90% confluent. Cell fusion media (2.5% v/v DHS DMEM) was prepared 
with either 10-5M, 10-9 M of la,25 dihydroxyvitamin D3 (Sigma, Germany) or DMSO (0.1% 
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w/v)(preparation of vitamin D dilutions is described in section 2.12.1) and the original growth media 
on three 6-well plates was substituted for each treatment. Cells were then incubated in the 
treatment media for 24 hours. The following day cells were harvested in either protein extraction 
buffer (section 2.13.5; three replicates per treatment group) and frozen at -20°C or RLT extraction 
buffer (cell lysis buffer containing guanidinium thiocyanate, supplied with RNeasy midi kit described 
in section 2.16.1; three replicates for each treatment) and frozen at -80°C. Total RNA was prepared 
for the microarray using an RNEasy mRNA midi kit (Qiagen) and quantified on a nanodrop (ND-1000 
Nanodrop Products; Thermo Fischer Scientific, Wilmington, USA) before checking the integrity using 
a Bioanalyser (Agilent). The microarray was performed by Mr. Thomas Wilson of Pfizer (Kalamazoo, 
MI, USA), using an Affymettix Genechip Microarray for Rat V.2.0. For analysis, relative expressions 
of genes in each 1,25(OHhD3 treatment group were subtracted from the relative expression of genes 
in the DMSO control group. The genes that were then changed with each vitamin D3 treatment could 
be expressed as a fold change relative to DMSO controls. 
2.12.3 Characterisation of Myosin Heavy Chain Gene expression in skeletal muscle cells. 
To evaluate the cell lines for their use as a model to investigate vitamin D's possible effects in fibre 
type sWitching/maintenance, the expression profile of the MHC genes in each cell line as they 
differentiated was assessed. All cells were grown to 90% confluence in their respective cell growth 
media before differentiation was induced by substituting cell growth media for cell fusion media 
(2.5% v/v DHS DMEM for rat primary cells, 2% v/v DHS DMEM for cell lines). Cells were grown in 6-
well plates and at each time point three wells were used to produce replicates of total RNA and 
three wells were used for protein samples. All RNA samples from all cell types were prepared for 
analysis using TRlzol reagent (section 2.13.4) and protein samples were prepared as described in 
section 2.13.5. 
The day of addition of cell fusion media was denoted as day 0 and at this point the majority of cells 
were still myoblasts undergoing proliferation. Total RNA and protein was extracted from cells at this 
point before differentiation media was added and were denoted as Day 0 samples. Following 
addition of differentiation media, cells were allowed to differentiate into myotubes for up to 7 days 
and samples were extracted at days 2, 4 and 7 producing four time points at which the MHC 
expression could be validated. 
Extracted total mRNA, prepared as described in 2.13.4 and reverse transcribed using MMLV RT 
enzyme (section 2.7.5) and using previously published MHC primers (see Appendices E and F for rat 
and mouse primers respectively), the expression of each MHC gene was validated. All cDNA was 
amplified for each MHC gene using the semi-quantitative PCR method (section 2.8.1) and 
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electrophoresed in agarose gel before imaging, described in section 2.8.2. As a positive control, total 
RNA prepared from adult mouse or rat LD was used to demonstrate positive bands in corresponding 
cell lines. To verify the expression of the MHC genes at mRNA level, the expression at protein level 
was detected using the protein samples and the western blotting technique (section 2.10) 
identifying MHC fast and slow proteins using monoclonal antibodies developed to each isoform 
(Nova Castra) summarised in Appendix D. 
2.12.4 Treatment of Skeletal muscle cells with 1«OHD3 for gene and protein expression 
analysis 
Once the skeletal muscle cell line was chosen on the basis of MHC gene expression, a final 
experiment using laOHD3 was performed. The cells were treated directly with laOHD3 at a range of 
concentrations made up as described before in section 2.12.1. Skeletal muscle cells were treated at 
four developmental stages, the first stage was during myoblast proliferation where cells were 
treated with laOHD3 solutions made in cell growth media. Three stages during differentiation were 
then used as time points for the differentiating cells, day 0 when myoblasts were the majority of 
cells present, at day 3 when myotubes were beginning to form and finally at day 7 when 
differentiated myotubes were present (see figure 3.6-1). At all time points, laOHD3 treatment was 
added within the corresponding media and incubated for 48 hours before protein and total RNA 
extraction. Prior to harvest, cells were imaged using Leica Application Suite Software (version 2.5.0, 
Leica Microsystems, Switzerland) through a Leica DMIL microscrope (Leica Microsystems, 
Switzerland). 
2.12.4.1 Treatment of cells at proliferating myoblast stage 
Undifferentiated mouse C2C12 myoblasts grown to 75% confluence were treated with either 0.1% 
v/v DMSO or laOHD3 at decreasing concentrations in cell growth media (10% v/v FCS DMEM) for 
48hours. Cells were not induced to differentiate by addition of cell fusion media. laOHD3 solutions 
were made up as described in section 2.12.1 and cells were cultured in treated growth media for 48 
hours before total RNA and protein extraction. Each laOHD3 dose required a full 6-well plate of cells, 
giving three wells to be extracted for proteins (three biological replicates) and three for total RNA 
extraction. To treat cells with laOHD3, any media the cells had previously been incubated in was 
removed and 2.25mls fresh cell growth media was added. 225111 of the diluted laOHD3 was then 
added to the fresh media in each well giving a final 10 fold dilution and the subsequent 
concentration of laOHD3 on the cells were 10-sM, 10-7M, 10-9M and 10-
11M. Myoblasts were 
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incubated for 48hours in the treatment media before extraction of protein and total RNA as 
described in section 2.13. 
2.12.4.2 Treatment of cells at different stages of differentiation 
Skeletal muscle cells were grown in cell growth media until 90% confluent at which point cell fusion 
media was added, denoted as Day O. For each time point 5 x 6-well plates were required for each 
1aOHD3 dose and a DMSO control. For treatment of cells with 1aOHD3 at day 0, growth media was 
removed from the cells and 2.2Smls cell fusion media (2% v/v DHS DMEM) added, before 2 S 0 ~ 1 1
treatment solutions (DMSO or 1aOHD3 in cell fusion media) were added as described in section 
2.12.1. Cells were incubated in treatment media for 48hours before media was removed and total 
RNA and protein samples extracted as described in section 2.13. For cells to be treated at later 
stages of differentiation, cell fusion media was added as normal without 1aOHD3 treatment, when 
cells reached required age at either day 3 or day 7 post differentiation, media was removed and cell 
fusion media containing 1aOHD30r DMSO was added and the cells incubated for 48 hours prior to 
protein and total RNA harvest. 
2.13 Extraction of RNA and protein from cultured cells 
To determine the expression of genes and proteins in cultured cells the total RNA and protein was 
extracted. For both extractions media was removed and extraction solutions were added quickly to 
minimise cell damage. 
2.13.1 Harvest ofmRNA from Primary cells for Microarray analysiS 
Total RNA was extracted from primary cell cultures using RNeasy mini kit (Qiagen) and supplied 
buffers and consumables were used as guided by the manufacturer's instructions. Media was 
removed immediately prior to extraction and 3 S 0 ~ 1 1 of cell lysis solution, Buffer RLT, was added to 
aid cell dislodging and lysis. Removal of cells from the growth surface was further encouraged by 
repeat pipetting of Buffer RL T across the surface in addition to scratching the surface with the 
pipette tip. Samples were then frozen in Buffer RLT at -80°C until further extraction could be carried 
out, where the protocol according to manufacturer's instructions was followed. Extracted total RNA 
was dissolved in 4 0 ~ 1 1 RNAse/DNAse free water, subjected to DNAse digest (DNAse I enzyme supplied 
with RNeasy kit, Qiagen) and quantity and quality of extracted RNA was determined using an Agilent 
2100 Bioanalyzer (Agilent Technologies). 
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2.13.2 RT step with SuperScript III RT enzyme- expression ofMHC using PCR 
The 5uperscript III First-strand 5ynthesis 5ystem (55-III) for RT-PCR (Invitrogen, UK) was used to 
generate cDNA for analysis of gene expression in rat primary muscle cells. All reagents required for 
cDNA synthesis were supplied in the 55-III kit and were used at the manufacturers recommended 
proportions. All RNA was diluted to 0.111g/111 according to total RNA concentration. 
2.13.2.1 Denaturation of RNA and annealing of Primers 
1111 random hexamers (at concentration of 0.5Ilg/lll) with 1111 10mM dNTP mix was added to 5111 
total RNA in a thin-walled microcentrifuge tube and the mixture made up to 10111 with water, before 
incubating at 65°C for 5 minutes. This mixture was then immediately moved to ice for quick cooling, 
this promoted annealing of primers to denatured RNA, and the samples were left on ice for 1 minute 
and briefly centrifuged to collect at the base of the tube before addition of the RT enzyme. 
2.13.2.2 eDNA synthesis 
The following reagents were added to each sample tube; 2111 10 x RT buffer, 4111 25mM MgCI2, 2111 
O.lM Dn, 1 III RNAse Inhibitor RNAse OUT (40 units, supplied with 55-III kit) and 1 III 55-III reverse 
transcriptase enzyme (100 units), and the final volume of the reaction mix made up to 20 III with 
water. The contents of the tube were then vortex mixed for approximately 15 seconds and briefly 
centrifuged to collect at the base of the tube, before incubation at room temperature for 10 minutes 
to allow the reverse transcriptase to begin extension from the random primers. The samples were 
then incubated at 50°C for one hour to complete cDNA synthesis. The reaction was inactivated by 
heating to 85°C for 5mins before collection by centrifugation and removal to ice. The reaction 
mixtures were diluted 1:5 with water to create a 100 III stock solution of cDNA for each sample 
which was stored at -20°C. 
2.13.3 Microarray 
Total RNA prepared for the microarray was shipped to Pifzer Ltd in Kalamazoo in U5A to be analysed 
by microarray, performed by Mr. Thomas Wilson using the Affymetrix Rat 230_2.0 array. 
Briefly there are five steps to the reaction, 
1. Target preparation: double stranded cDNA is created from the mRNA. An in vitro 
transcription (IVT) reaction is then performed to create biotin-labelled cRNA from the cDNA, 
this cRNA is fragmented before the hybridization step. 
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2. Target Hybridization: A cocktail of reagents for hybridization including the fragmented 
target and the probe array controls was prepared before incubation for 16 hours to 
hybridize the reagents to the probe array. 
3. Fluidics station set up. 
4. Probe array washing and staining: the probe array was washed and stained immediately 
after hybridization. 
5. Probe array scan: the probe array must be scanned 
6. Data Analysis 
2.13.4 Microarray Analysis 
The microarray used an affymetrix Rat 2.0 chip and measured the relative expression of mRNA of 
31,099 genes. The data was analysed by Dr Neil Graham of the Arabidopsis Stock Centre, University 
of Nottingham, using Genespring software (Strand Life Sciences R&D Division, Bangalore, India). The 
relative expression of genes in each vitamin D3 treatment group were subtracted from the relative 
expression of genes in the DMSO control group, in a T-test performed in Genespring. This analysis 
gave a list of genes which had changed more than 1.5 fold, either up or down, with a significant P 
value of P<0.05). The list of changed genes was then uploaded into Ingenuity Pathway Analysis (IPA 
Version 7.1; Ingenuity Systems Inc, 2000-2008) software to determine the functions and related 
pathways of these genes to further understand the mechanism of vitamin D3 signalling in muscle 
cells. 
2.13.5 Harvest of total RNA and protein from skeletal muscle cell lines 
2.13.5.1 Harvest of total RNA 
TRlzol® Reagent (Invitrogen, UK) was used to harvest the mRNA from cultured cell lines. Media was 
removed and 1ml TRlzol® reagent added to each well; usually three wells per plate were used as 
biological replicates. The reagent was left for approximately 30 seconds and the plate rocked slightly 
to ensure coverage of all cells. To encourage removal of all cells, the surfaces of the wells were 
scraped with the pipette tip and the reagent repeat pi petted over the surface of the well. Once all 
the contents of the well were dispersed in the TRlzol® the solution was moved to a sterile l.5ml tube 
and stored on ice until all wells were harvested, at which point samples were frozen at -80°C until 
further steps of the extraction could be carried out from the phase separation stage, as described in 
section 2.7. 
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2.13.5.2 Harvest o/proteins 
lxsos-on mix (20% v/v glycerol, 12.5% v/v 1M Tris/HCI pHed to 6.8, 4% w/v SOS (Sodium Ooecyl 
Sulphate), 15.4% w/v Oithiothreitol (On), without addition of bromophenol blue) was used to 
extract the proteins and store them until further analysis. ImllxSOS mix without bromophenol blue 
was added to each well and left for approximately a minute on the cells, rocking the plate slightly to 
ensure even coverage. The plate was then scraped using a pipette tip and the mixture repeat 
pi petted, passing over whole surface area of the well to aid cell dislodging and lysis. Once all 
contents of the well were suspended the solution was transferred into a sterile l.sml tube and kept 
on ice until all samples were harvested. Protein samples were then stored at -20°C until further 
analysis. Proteins were quantified using the Plus-One 2-0 quant kit (Amersham, Buckinghamshire, 
UK) and diluted to constant protein concentration. 
2.13.6 Determination of protein concentration by 2-D Quant Kit 
Samples taken from cell cultures were extracted directly into denaturing SOS protein running buffer 
and needed to be quantified using a technique that would tolerate a high concentration of SOS and 
on in the sample. The 2-0 quant kit (Amersham Biosciences, UK Ltd., Buckinghamshire, UK) 
overcomes the interference from interfering substances as it precipitates the protein out of the 
solution containing possible interfering compounds and re-dissolves it into an alkaline solution 
containing copper ions for analysis. The copper ions bind to the protein in the solution and the 
strength of blue colour of the solution is relative to the quantity of unbound copper, measured using 
a spectrophotometer. The kit supplies all solutions required for the assay, these are BSA stock 
protein solution, precipitant, co-precipitant, copper solution and colour reagent. Colour reagent 
solution must be prepared before the assay is carried out by addition colour reagent B to colour 
reagent B at a ratio of 100:1, allowing Iml per sample. A set of Bovine Serum Albumin (BSA) protein 
standards were created by taking a set volume of a stock BSA at 2mg/ml (provided with kit)into an 
eppendorf, to give a known quantity of protein over a range from 10llg to 50llg (table 2.13-1). 
Table 2.13-1 Creation of protein standards for 2-D Quant Assay 
Standard Curve 
Volume of 2mg/ml Stock BSA Solution (Ill) 
Equivalent protein quantity, J.Ig 
o 
o 
5 
10 
10 
20 
15 
30 
20 
40 
25 
50 
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2.13.6.1 Precipitation o/the protein 
500111 Precipitant solution (provided in kit) was added to 10111 of the samples in 50S-Mix on in an 
eppendorf (each sample in duplicate). The tubes were then vortex mixed and the left to incubate at 
room temperature for 3 minutes. 500111 of the co-precipitant solution was then added and the 
contents mixed by inversion before the protein was pelleted by centrifugation at 13, 000 rpm at 4°C 
for 5 minutes. The supernatant was removed without disturbing the protein pellet before addition of 
100111 copper solution with 400111 distilled water. The contents of the tube were vortex mixed to 
encourage the precipitated protein to dissolve. Once the protein was dissolved in the copper 
solution, Iml of colour reagent was added to each sample and the samples mixed by vortex 
immediately to allow the solutions to mix rapidly. The solutions were then incubated at room 
temperature for 20 minutes before the absorbance was read at 480nm. A standard curve was 
plotted in Microsoft Excel (V. 2007) and the equation of the line was used to calculate the relative 
protein concentration of the unknown samples. 
2.13.7 Western Blotting ofC2C12 cell samples 
Two proteins were measured in the C2C12 cells using 50S-PAGE and western blotting analysis, 
described in sections 2.10.3 to 2.10.9; these were 4EBPl and MAPK ERK1/2. Product information, 
50S-PAGE conditions and development solutions for these antibodies are shown in Appendix O. Cell 
protein samples were diluted to a constant concentration of 0.25 I1g/111 so that a volume of 20111 
loaded resulted in a load of 5j.lg protein for 50S-PAGE. Both protein targets were detected using the 
total antibody before stripping and re-probing with the antibody to phosphorylated protein using 
the ECl advance detection kit. To ensure complete removal of the initial total antibody the stripped 
membranes were treated with detection reagent and hyperfilm detected as for usual luminescence 
detection, this ensured any remaining luminescence would be detected and expended. In both 
proteins the removal of the total antibody by the stripping technique described in section 2.10.8 was 
successful and so membranes could be re-probed with the phosphorylated antibody with assurance 
there would be no interference from the previous antibody. The western blots produced were 
analysed as described before (section 1.10.9) and a ratio for the level of phosphorylation was 
calculated, dividing the absorbance for phosphorylated protein by the absorbance for the total 
protein. 
2.13.8 Real Time PCR using LC480 system 
Primers and probes for MHC analysis were published by da Costa et 01. (2007; oligonucleotides 
purchased from Sigma), mRNA sequences and oligonucleotide information are summarized in 
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appendix F. Oligonucleotides purchased from Sigma were first checked using semi-quantitative PCR 
and validated by electrophoresis using agarose gel electrophoresis described in section 2.8.1 and 
2.8.2. Further targets were investigated using assay on demand kits purchased from Applied 
Biosystems (in Appendix G). A primer and probe set for Desmin was created using Primer Express 
Version 1.5, shown in Appendix F. 
In total three housekeeping genes, 7 targets of vitamin 03 signalling and 6 isoforms of MHC were 
measured by real time PCR, summarized in Table 2.13-2 (expression of neonatal mRNA was too low 
to quantify satisfactorily and was removed from analysis). 
Table 2.13-2 Summary of gene targets and their sources measured in C2C12 experiment and the standard 
curve and cDNA dilution used for analysis. 
Gene Primer/Probe Source Standard Curve Dilution 
Beta Actin da Costa et al., 2007 LD Muscle & Day 10 Cell 1:50 
Cyclophilin A ABI Assay on Demand LD Muscle & Day 10 Cell 1:50 
GAPDH ABI A s s a ~ ~ on Demand LD Muscle & D a ~ ~ 10 Cell 1:50 
Myf5 da Costa et al., 2007 Day 10 Cell 1:50 
Myogenin ABI Assay on Demand LD Muscle 1:50 
Desmin Pri mer Express V5.0 LD Muscl e 1:4 
Metallothionein 2A ABI Assay on Demand Day 10 Cell 1:50 
Parvalbumin ABI Assay on Demand LD Muscle 1:50 
C / E B P ~ ~ ABI Assay on Demand Day 10 Cell 1:50 
c - M ~ c c ABI A s s a ~ ~ on Demand D a ~ ~ 10 Cell 1:50 
Embryonic MHC da Costa et al., 2007 Day 10 Cell 1:50 
MHC I / ~ ~ da Costa et al., 2007 LD Muscle 1:4 
MHCIIA da Costa et al., 2007 LD Muscle 1:4 
MHC IIX da Costa et al., 2007 LD Muscle 1:50 
MHC liB da Costa et al., 2007 LDMuscie 1:50 
2.13.8.1 Standard curves used in analysis of C2C12 mRNA transcripts 
For each gene that was analyzed, two separate standard curves were run on the plate with the 
unknown samples allowing the possibility to quantify the results relative to either set of standards. A 
standard curve was made from pooled cDNA created from mRNA extracted from adult mouse LD 
tissue. A second standard curve was created from cDNA from C2C12 myotubes grown for 10 days 
after onset of differentiation, denoted the Day 10 standard curve. The use of two standard curves 
was necessary owing to the nature of the expression pattern of certain genes during the 
differentiation process, in particular the MHC genes. It was found that the developmental MHCs 
were not expressed highly in the LD and therefore needed a standard curve created from C2C12 
cDNA, whereas in contrast the adult MHC genes appeared over the course of differentiation and the 
result was that unknown samples did not lie in the linear range of the C2C12 cDNA curve. The 
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differences between the positions of the unknown sa mples re lat ive to eit her t he LD or day 10 
standard curve in the example of the MHC IIA gene is demonstrated in f igure 2.13-1, showing that 
sample data would need to be extrapolated should the Day 10 sta nda rd curve be used. 
Therefore, the C2C12 Day 10 standard curve al lowed the measurement of genes which were highly 
expressed in differentiating muscle cells such as the myogen ic regulatory fact or MyfS, and the 
embryonic and neonatal isoforms of MHC; whereas the LD standard curve was required for the 
measurement of genes whose expression appeared over the course of diffe rentiati on where all 
samples would not lie in the linear range of the Day 10 standard curve, such as the adult MHC 
isoforms. The comparison of the mRNA expression changes ind uced by vitamin D treatment were 
made only within each individual gene and there were no compa risons made betwee n different 
genes. All three housekeeping genes which were investigated lay on the linear range of both 
standard curves and hence all results produced could be normal ized to a housekeepe r, however 
there were significant effects of vitamin D3 treatment on these interna l standa rds and t he result s 
were not normalized to any housekeeping gene, taking the normal isat ion of total RNA pri or to RT 
step into consideration instead. The preparation of the RNA was of a high qual ity shown in Appe ndix 
H and total RNA concentration had been adjusted to a constant concentrat ion prior to t he RT step . 
MHC 2A measured using two Standard Curves 
4-5 
Y = -4 .2259x + 26.216 
.- Xc - 48 R2 = 0 .9823 
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Figure 2.13-1. Position of unknown sample MHC IIA (2A) expression when measured relative to 2 eDNA 
standard curves, mouse LD and C2C12 cell aged 10 days. 
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2.14 Statistical analysis 
All data produced in the two sheep trials were analysed by paired T-tests, except for the shear force 
data across the aging period, which was analysed by two-way ANOVA using Genstat V.l1. In the 
event of missing samples both the lost animal and its opposite treatment pair were removed from 
the analysis. For the microarray data a T-test was performed using Genespring software. For the cell 
culture work, data was analysed by either ANOVA or two-way ANOVA using Genstat V.l1. In the case 
of a significant P value result from ANOVA analysis (P<O.OS or below), a Dunnett's test (Dunnet c.w., 
1964) was performed post hoc using least significant difference values (LSD) from the Genstat 
ANOVA output and the relevant T value to calculate the treatment values which were significantly 
changed in comparison to the DMSO control. 
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Results:Vitamin D & Meat Quality Trials 
3.1 Trial 1: 4 Days Vitamin D 
Previous published work in sheep has investigated the supplementation of vitamin D immediately 
prior to slaughter as a mechanism to increase calcium levels in the muscle to activate the calpain 
proteolytic system post mortem. Neither of the two published studies fully investigated the calpain 
system to verify the mechanism of the potential effects and were inconclusive in terms of evaluating 
vitamin D's capability in activating the calpain system via increased calcium status. The first trial 
performed by Wiegand et 01. (2001) did provide data to suggest that a high dose of vitamin D at 2 x 
106 IU Vitamin Diday was sufficient to increase calcium levels, but this study focused on reducing 
the effects for the callipyge genotype on shear force, a breed with characteristically high protein 
growth through decreased protein degradation resulting in tough meat (Koohmaraie et 01., 1995), 
and this study found there was no significant effect of dietary vitamin D on shear force in this 
genotype. This study did observe a reduced shear force when comparing between the vitamin D Vs 
control diet regimes in normal genotype animals, but these results were not significant. There was 
no additional work to investigate effects on the calpain system despite finding calcium levels were 
significantly higher in the serum and numerically higher in the muscle. Work in this laboratory has 
previously investigated the effect of a short supplementation period of 4 days of vitamin D3 at 2 x 
106 IU Vitamin Diday with the additional effect of a calcium bolus on the final day. This trial did not 
observe any improvement of LD chops, nor effect on the calpastatin levels at 0 and 24 hours post 
mortem. This previous study found a significant increase in serum calcium levels by nearly 7% 
(P<O.OOl) but did not investigate further effects on muscle calcium levels or the calpain enzyme. 
The aim of this trial was to investigate the effects of supranutritionallevel of dietary vitamin D for a 
short duration immediately prior to slaughter. The hypothesis was that a short, high level of dietary 
vitamin D would cause an increase in biologically active form of vitamin D which would lead to a 
response in calcium homeostasis of the animals before, presumably, the active hormone was 
catabolised by the kidney. In addition the large dose of vitamin D would increase calcium uptake 
from the gut and this would increase calcium levels in the muscle and subsequently activate the 
calpain system post mortem. Therefore the objective of this study was to investigate any signalling 
effects that vitamin D3, and/or the change in calcium status, could have on the calpain system at the 
mRNA and protein level, as well any effect on meat quality. 
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3.1.1 Trial Outline 
Thirty six Mule X Charolais wether lambs at approximately 7 months of age were individually penned 
and allocated to two treatment groups consisting of control (n=18) and high vitamin D3 (n=18). All 
animals were housed and fed the basal diet as described in section 2.2. The basal diet period lasted 3 
weeks and allowed for acclimatisation to the housing and diet before subsequent treatment. The 
animals were weighed once a week to ensure a weekly weight gain, and feed intake was recorded 
daily. A week before the supplementation period the paired sheep were reallocated to pens 
according their size and age so that they could be slaughtered in weight order, beginning with the 
heaviest and finishing with the lightest, as described by the housing layout shown in diagram 2.2.2-
A. A period of 4 days before slaughter date the VIT D3 group (n=18) were fed the basal diet 
supplemented with vitamin D3 (Rovimix D3 500, DSM Ltd, Derbyshire UK), supplying 2 x 106 IU 
Vitamin Diday split between two feeds, whilst the control group (n=18) still received the same basal 
diet. The composition of the diets is shown in table 2.2.2.; there were no differences in the energy, 
nitrogen or calcium levels of the diets. Animals were allocated into three slaughter groups (n=12) 
according to age and size with vitamin D (n=6) and control (n=6) paired animals slaughtered 
alternately across each slaughter day (total of 12 animals/day). The start of vitamin D3 
supplementation for each group was staggered across three days, shown in the timeline of the trial 
in figure 3.1-1. Animals were slaughtered, carcass measurements taken and samples collected 
according to procedure previously described in chapter 2 of this thesis, section 2.2. LD chops were 
vacuum packed and left to age for 3, 7, 14 days at 4°C according to latin square arrangement 
presented in Appendix A, this allowed the length of the LD to be represented in each day of aging, 
this was important as tenderness across the LD can vary greatly (Kerth et 01., 2002). Due to varying 
sizes of the animals, some LD muscles did not yield 4 chops and so the first three chops of all animals 
were sampled in a latin square arrangement to assess tenderisation across the 14 day aging period. 
The LD of larger animals did yield four chops and so the extra chops, denoted chop #4, were sampled 
after 21 days of aging to assess ultimate shear force, denoted in the diagram in Appendix A. 
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3 Week 
Acclimatisati on 
3 Week 
Acciimatisation 
3 Week 
Period 
Trial Days 1 Group 1 Period 
Acclimatisation 
2 Group 2 Period 
3 Group 3 
4 Slaughter 
Post Mortem 24hrs LD Chops removed Slaughter ~ S l a u g h t e r r days: Ohr snap samples 
LD Chops removed Slaughter 4S min pH & temp 
3 Day Freeze LD Chop LD Chops rem oved ~ ~ 24 hrs Post Mortem 24 hr pH & temp 
Freeze LD Chop rem ove LD 
Freeze LD Chop 
7 day Freeze LD Chop 
Freeze LD Chop 
Freeze LD Chop 
14 day Freeze LD Chop 
Freeze LD Chop 
Freeze LD Chop 
21 day Freeze LD Chop 
I Freeze LD Chop 
I Freeze LD Chop 
Figure 3.1-1 Timeline for Trial 1: 4 days vitamin 0 immediately prior to slaughter. Shown in darker blue box 
is the duration of vitamin 0 supplementation at 2 x 106 IUjday, duration of 4 days immediately prior to 
slaughter. 
3.1.2 Meat quality results: Trial 1; 4 days vitamin D3• 
Animals were weighed weekly for the duration of the trial and the morning before slaughter. Feed 
intake was monitored by recording any refusals from the daily ration of 1.4Kg feed, and on the 
slaughter days three animals fed the vitamin D diet in each slaughter group refused less than 350g 
(25%) of their daily ration. Across the four day supplementation period, thirteen animals in total 
refused some feed, nine of these were vitamin D-supplemented animals and this amounted to 
between 2 and 17% of the total trial feed fed across the four days. Of the nine sheep which refused 
feed on the slaughter days, eight were vitamin D diet group and one was from the control group, 
although all animals ate at least 75% of their diet on this day. These refusals were not considered to 
be significant as they were not associated with effects on the liveweights, carcass weights or pH of 
the carcasses and the level of feed refusal did not associate with plasma vitamin D or serum calcium 
levels (data not shown) and all vitamin D fed animals had significantly higher plasma vitamin D than 
control animals. There were no significant differences between treatment groups in liveweight 
before and after, growth and feed conversion ratio (FCR), results shown in table 3.1-1. Carcasses 
were weighed immediately after slaughter and dressing percent calculated from final liveweight and 
hot carcass weight (taken immediately after dressing); there were no sign ificant effects of diet on 
carcass weight or dressing percent. Any differences in dressing percent would be attributed to 
changes in gut fill and so any significant effects of the feed refusals during the trial week would 
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affect the dressing percent of the carcasses, however there were no differences between the 
animals and the refusals can be considered insignificant. pH of the carcass was measured in the LD at 
the region of the initial snap sample (demonstrated in Appendix A) 45 minutes after slaughter and 
24 hours later, the change in pH (6pH) was calculated from the two values. As described in chapter 
1, muscle pH decreases post mortem as a result of anaerobic glycolysis and the extent of this pH 
change is affected by glycogen levels pre-slaughter (Poso & Puolanne; 2005). Ifthe animals had been 
stressed prior to slaughter or had been fasted then it would be expected that the development of 
muscle pH would have been affected (Peterson et 01., 1997). However, there was no effect of 
vitamin D3 supplementation for 4 days immediately prior to slaughter on carcass pH or subsequent 
pH changes (table 3.1-1); suggesting no effect of diet on pre-slaughter glycogen depletion which 
could have had detrimental effects on carcass and meat quality. 
Table 3.1-1 Effect of 4 days vitamin 0 3 supplementation on animal growth, feed intake and carcass 
characteristics, n=18. 
Control Vitamin D S.E.D. P 
Initial Lamb Weight (Kg) 35.49 35.87 0.801 0.428 
Final Lamb Weight (Liveweight) (Kg) 41.08 41.03 0.855 0.914 
Total Weight Gain (4 weeks) (Kg) 5.594 5.161 0.636 0.516 
Average Daily Gain (ADG) (Kg/Day) 0.1868 0.1725 0.0212 0.512 
Feed Conversion Ration (FCR) 13.59 12.6 1.54 0.529 
Carcass Weight (Kg) 19.14 19.13 0.514 0.966 
Dressing Percent (%) 46.59 46.61 0.774 0.978 
LDpH o Hr 6.289 6.198 0.0604 0.194 
24 Hr 5.839 5.828 0.048 0.452 
LD4pH 0.450 0.371 0.0667 0.249 
Plasma samples were analysed for 25 hydroxy-vitamin-D3 (25(OH}-D3) and -D2 levels using tandem 
mass spectrometry by Professor Bill Fraser (University of Liverpool). 25(OH)-vitamin D is routinely 
used to assess overall vitamin D status of animals as circulating l,25(OH)zD2 levels are tightly 
regulated (Li et 01., 2009). 25(OH}-Vitamin D3 levels were significantly raised (P<O.OOl) by the 4 days 
vitamin D3 supplementation, and as expected 25(OH}-Vitamin D2 levels were unaffected (table 3.1-
2). The form of vitamin D supplemented in the diet was vitamin D3, and these results demonstrate 
the changes in vitamin D status were implicated by the diet. This is evidence to show that four days 
of vitamin D3 supplementation at 2 x 106 IU Vitamin Diday was effective in altering 25(OH)-vitamin 
D3 status of the animals; increasing the treated animals circulating D3 levels by a factor greater than 
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10. Serum and muscle calcium were analysed using Atomic Absorption Spectroscopy by Dave Bozon 
(University of Nottingham) as described in section 2.5. There was no effect of 4 days vitamin D3 
supplementation on calcium levels in the serum despite the significant increase in plasma vitamin D3 
levels (table 3.1-2) and subsequently there was no effect on muscle calcium levels, results expressed 
as mg/g wet tissue. 
Table 3.1-2 Effect of 4 Days Vitamin 0 3 Supplementation on plasma Vitamin 0, serum and lO calcium levels. 
Control Vitamin 0 S.E.D. P 
03 ng/ml 27.8 319.6 18.85 < 0.001 
02 ng/ml 10.1 8.2 1.62 0.309 
Serum Calcium (mg/l) 119.4 121.7 4.479 0.633 
lO Calcium (mg/g wet tissue) 58.34 52.91 5.472 0.342 
Vitamin 0 3 and O2, n=17; serum and muscle calcium, n=18. 
LD chops were aged for 3, 7, 14 and 21 days at 4°C before shear force was determined by Warner-
Bratzler method (Wheeler et 01., 1997). Chops aged between 3 and 14 days were sampled by latin 
square arrangement as described previously (section 3.1, trial outline) and were analysed by two-
way ANOVA; chops aged for ultimate shear force after 21 days were sampled separately due to 
smaller n of samples and were analysed by t-test. Shear force of LD chops was significantly changed 
by time during the aging process as was expected (P<0.05, table 3.1-3), however, there was no 
difference between the treatment groups on shear force of LD chops. Shear force following 21 days 
of aging was not affected by diet (P=0.603). 
Table 3.1-3 Effect of 4 days vitamin 0 3 on shear force (Kg) of lO, n=18 for aging period analysed by two-way 
ANOVA, n=12 for 21 day lO chops analysed by t-test. 
Diet / Age 
Control 
Vitamin 0 
21 day shear force LD 
3 
4.87 
5.17 
Control 
4.32 
Time (days) 
7 
4.50 
4.77 
Vitamin 0 
4.50 
14 S.E.D. P 
4.30 Diet 0.201 0.351 
4.30 Age 0.247 0.017 
Diet*Age 0.349 0.808 
0.381 0.603 
Fat content of the LD was determined for a subset of 6 samples, taking two pairs from each 
slaughter group. Muscle fat was extracted by the Soxtherm Method and calculated as a percentage 
from the initial weight of muscle from which the fat was extracted as described in section 2.4. There 
was no significant effect of 4 days vitamin D3 supplementation on fat content of the LD (table 3.1-4). 
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Table 3.1-4 Effect of 4 Days Vitamin 03 Supplementation on LD Fat Content, n=6. 
Control Vitamin 0 S.E.D. p 
LD Fat Content (%) 9.02 8.39 1.614 0.568 
3.1.3 Vitamin D effects on gene expression: Trial 1; 4 days vitamin D3• 
Despite no effect of the vitamin D3 supplementation on the immediate vitamin D responses 
observed at the calcium homeostasis level, there were significant changes in the circulating 2s(OH)-
vitamin D3 levels which demonstrates an increase in vitamin D status and so there could be potential 
direct signalling effects of vitamin D on gene expression in target tissues. To determine whether the 
circulating vitamin D3 had been able to mediate effects via gene expression, specific targets were 
measured at both the mRNA and protein level using reverse-transcriptase real-time peR and western 
blotting respectively. Expression of mRNA of calbindin D-28K was measured in the kidney, a gene 
known to be up-regulated by vitamin D in its role in mineral homeostasis (Minghetti & Norman, 
1988L and the levels of mRNA of the calpain system were measured in LD to investigate whether the 
dietary vitamin D3 could modulate shear force via this mechanism. Expression of l3-actin at mRNA 
level was measured and was found to be unchanged by diet treatment in both LD and kidney tissue 
(data shown in table 2.9-3 in chapter 2), therefore all data was normalised to l3-actin mRNA and is 
expressed as a ratio of transcript mRNA: l3-actin mRNA. Expression of calpastatin at the mRNA level 
was not affected by 4 days vitamin D3 supplementation, however, expression of the calpain enzymes 
was significantly altered. There was a trend for expression of calpain I (Il-calpain) to be increased by 
3.7% (P<O.l) whereas calpain II (m-calpain) expression was significantly increased by 10% (P<O.Os) 
following 4 days vitamin D3 supplementation (table 3.1-s). The increase in both these enzymes at the 
mRNA level presents the possibility of an effect at the protein level, however, data shown in table 
3.1-5 indicated this was not translated to the protein level. It is possible that the short term vitamin 
D3 supplementation was not sufficient to cause overall changes in meat quality but was beginning to 
exert effects on the enzymes responsible for the tenderisation process by increasing their expression 
at the gene level. However, protein products from changes in gene expression take time to be 
translated and it is likely that the short period of four days prior to slaughter is not long enough to 
translate to changes at the protein level; an experiment by Antrobus et 01. (1995) reported 
responses in protein levels of kidney cells to 1,25 (OHhD3 treatment took between 1 to 3 days to be 
slightly increased but after 7 days their expression was much stronger. 
In order to further investigate the possible effects the short term supplementation of dietary vitamin 
D3 may have on gene expression, it was decided to investigate responses in the known target tissue 
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of vitamin D, the kidney. In the kidney responses to calcium homeostasis are mediated by the 
vitamin D receptor (VDR) and the calcium binding protein, calbindin D-28k and it is known that 
vitamin D3 upregulates calbindin D-28K and its receptor, the VDR (Minghetti & Norman, 1988). 
Calbindin D-28k expression at the mRNA level was measured using real-time RT-PCR and expression 
was normalised to ~ - a c t i n n mRNA, results expressed as a ratio of calbindin: ~ - a c t i n n in table 3.1-6. In 
addition the levels of calbindin D-28k and VDR were measured at the protein level using western 
blotting, data shown in table 3.1-6 and representative blots are shown in figure 3.1-2. There was no 
effect of vitamin D supplementation on the levels of calbindin D-28k at both mRNA and protein level, 
although the protein levels of VDR were approaching a trend (P=0.103) which could indicate a 
potential down-regulation of the VDR. This data suggests that a short supplementation period of 
vitamin D of four days is not sufficient to affect significant changes at either the gene or protein level 
of known vitamin D response genes. 
Table 3.1-5 Effect of 4 Days Vitamin 0 3 supplementation on mRNA and protein expression of calpain system 
in LD. 
LD mRNA Calpain Genes: Beta Actin Ratio 
Control Vitamin 0 S.E.D. P 
Calpain I 1.020 1.058 0.0260 0.099 
Calpain II 0.967 1.064 0.0376 0.014 
Calpastatin 0.956 0.987 0.0357 0.382 
Absorbance/ 100 J..lg protein 
LD protein Control Vitamin 0 S.E.D. P 
Calpain I 8.668 7.687 1.083 0.279 
Calpain II 7.784 8.121 0.550 0.785 
Calpastatin 15.79 17.99 2.553 0.339 
Desmin 5.744 6.027 0.630 0.468 
Calpain system mRNA n=17, calpain I protein n=15, calpain II, calpastatin and desmin protein n=18. 
Table 3.1-6 Effect of 4 Days Vitamin 03 supplementation on mRNA and protein expression of vitamin 0 
targets in kidney. 
Kidney mRNA Control Vitamin 0 S.E.D. P 
Calbindin : Beta Actin ratio 0.995 1.060 0.0689 0.260 
Absorbance/ 100 J..lg protein 
Kidney protein Control Vitamin 0 S.E.D. P 
Calbindin 9.468 8.889 0.822 0.504 
VDR 10.221 6.846 1.934 0.103 
Calbindin mRNA n=18, calbindin protein n=17, VDR protein n=9. 
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Figure 3.1-2 Representative blots of the calpain system in LO and vitamin 0 responsive targets in kidney 
protein extracts from sheep in trial 1: 4 Days vitamin 0 3• All protein samples were loaded with constant 
weight of 1 0 0 ~ g g protein/lane, treated (D) and control (e) samples were loaded alternately between a 
repeated standard sample (STO). Calpain I and II: 1 0 0 ~ g g LO supernatant fraction separated by SOS-PAGE 
using 10% acrylamide gel, Calpastatin and desmin: 1 0 0 ~ g g LO whole homogenate fraction separated by SOS-
PAGE using 8% acrylamide gel. Calbindin and VOR: 1 0 0 ~ g g whole homogenate kidney protein extract 
separated by 50S-PAGE using 12% acrylamide gel. Further antibody information presented in Appendix 0, 
calpain I n=15, calpain II, calpastatin and desmin n=18, calbindin n=17 and VOR n=9. 
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3.1.4 Trial Summary 
The aim of this trial was manipulate meat quality using a short supplementation period of 4 days 
vitamin D3 immediately prior to slaughter in order to maximise the effect of the supplementation 
before the vitamin D homeostasis system would be expected to begin down regulating circulating 
levels. While this supplementation regime was successful in increasing the circulating vitamin D3 
levels of the treated animals, it did not translate into a change in calcium concentration of the serum 
or muscle. In turn there was no effect on the shear force of chops from the LD and so it can be 
concluded that a 4 day vitamin D3 supplementation period immediately prior to slaughter does not 
affect meat quality in sheep. A simple hypothesis associated with the effects of supplementing feed 
with vitamin D is that high circulating levels of Vitamin D will increase body Ca2+ concentrations 
which would in turn lead to an increased activation potential for the calpain system post mortem; as 
the activity of the calpain enzymes and their affinity to bind to their inhibitor, calpastatin, is 
regulated by calcium concentration of the muscle. However in the current study there was no 
change in the calcium status of the treated sheep so, based on this hypothesis, it is not surprising 
that there was no effect on the tenderisation process in this study. 
However in addition to the Ca 2+ homeostatic effects Vitamin D is known to have effects on gene 
expression on proteins that are not associated with Ca 2+ homeostasis through the nuclear receptor 
VDR. The elevated vitamin D3 levels did have a significant effect on the expression of the calpain II 
enzyme at the mRNA leve" and indicated a trend to increase calpain I, which is evidence to suggest 
that vitamin D3 may directly moderate the expression of these enzymes which are responsible for 
the majority of post mortem proteolysis. This is in agreement with a study performed in cattle, 
whereby Cho et al. (2006) fed cows a high vitamin D (125mg/day) diet for 6 days prior to slaughter 
and reported significant increases in the mRNA of both calpain I and calpain II with significant 
decrease in calpastatin mRNA in the LD. However, effects in gene expression need to be translated 
into changes at the protein level and it is likely that 4 days was not enough time to observe 
responses at the protein level. In light of the results in this study, a second trial was conducted using 
a longer supplementation period with an additional calcium bolus. The purpose of this regime was to 
attempt to increase the calcium status of the sheep and to allow time for the vitamin D3 to mediate 
potential gene responses. 
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3.2 Trial 2: 7 Days Vitamin D & Calcium Bolus 
The hypothesis of this trial was that a longer supplementation period of vitamin D3 would produce a 
response in calcium uptake via the gut which could be further optimised as a result extra calcium 
available in the diet. The expectation was that the increase in the calcium status of the animals 
would then lead to an increase in calpain activities, causing increased proteolysis post mortem and 
subsequent improvements in the quality of the meat in terms of tenderness. Previous trials 
performed in this laboratory have used a short 4 day dose period with calcium bolus and a longer 7 
day dose period without calcium; both trials saw significant changes in calcium status but no 
significant effects on meat quality. The objective of this trial was to try to combine these treatments 
and investigate whether a longer supplementation period of dietary vitamin D3, with a calcium 
bolus, could produce significant effects in calcium status and improve meat quality via increased 
activation of the calpain system. 
3.2.1 Trial Outline 
Thirty six Mule X Charolais wether lambs at approximately 7 months of age were individually penned 
and allocated to two treatment groups consisting of control (n=18) and high vitamin D3 (n=18). All 
animals were allocated to pens and paired into treatment-control pairs according to age and weight, 
as shown in figure 2.2-2. All animals were initially fed 700g of a basal diet with no supplemented 
vitamins or minerals twice a day (half daily allowance of 1.4 kg/animaljdayL as described in section 
2.2. The basal diet period lasted around S weeks to allow for acclimatisation. A period of 7 days 
before slaughter date the VIT D3 group (n=18) were fed the basal diet supplemented with 2 x 106 IU 
Vitamin D/day (Rovimix D3 SOO, DSM Ltd, Derbyshire UK) whilst the control group (n=18) still 
received the same basal diet without vitamin D3. Due to the animals being allocated to one of three 
groups (each containing VIT D3 n=6 and control n=6) according to age and size, commencement of 
vitamin D3 supplementation was staggered slaughter days. The day before slaughter the high vitamin 
D3 animals were fed a diet with the same high vitamin D3 content plus an extra calcium bolus mixed 
into the feed to give double the calcium content compared to the control diet; as analysed by Frank 
Wright Ltd (calcium propionate suppliersL composition of the diet is shown in table 2.2.3. The 
overall timings and subsequent sample points are summarised in figure 3.2-1. 
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5 W eek 
Acclimatisation 5 Week 
Acclimatisation 5 Week Period 
Tr ial Days 1 Group 1 Period Acclimatisation 
2 Group 2 Period 
3 Group 3 
4 
5 
6 + Calcium Bolus 
7 Slaughter + Calcium Bolus 
Post Mortem 24hrs LD Ch ops rem oved Slaughter + Calcium Bolus ~ S l a u g h t e r r days: Oh r snap samples 
LD Chops removed Slaughter 45 min pH & temp 
3 Day Freeze LD Chop LD Chops removed ~ ~ 24 hrs Post Mortem 24 hr pH & temp 
Freeze LD Chop remove LD 
Freeze LD Chop Da y 1 LD chop frozen 
7 day Freeze LD Chop 
Freeze LD Chop 
Freeze LD Chop 
14 Day Freeze LD Chop 
1 Freeze LD Chop 
I Freeze LD Chop 
Figure 3.2-1 Timeline for Trial 2: 7 days vitamin D + calcium bolus immediately prior to slaughter. Shown in 
dark blue is the period of vitamin D only supplementation for 5 days before diets are supplemented with 
vitamin D and an additional calcium bolus for the final 2 days immediately prior to slaughter, shown in 
purple box. 
A group of four lambs not included in the trial , all healthy and eating 1.4kg feed/day of t he basa l diet 
were used to assess the palatability of the high vitam in D plus calc ium prop ionate diet . These 
an imals were fed the trial diet for two days to assess palatability of the high vita min D/Ca lcium 
content, specifically as anima ls had eaten the vitamin D only diet du ring t ri al 1, it was decided to 
check the calcium propionate affected palatability. There were no refusa ls fro m t his group over the 
two days and there were no ill effects seen afterwards as all animals cont inued t o eat the basal diet 
and based on these observations the study was continued using t he diet . Animal s were slaughtered, 
carcass measurements taken and samples collect ed accord ing to procedure previously mentioned in 
chapter 2, section 2.2. LD chops were vacuum packed and left to age fo r I , 3, 7 and 14 days 
according to latin square arrangement in Appendix A. Aging of sa mples w as reduced to 14 days aging 
period as the recommended aging period for lamb is between 7 and 14 days (Warris, 2000) and work 
by Dransfield (1994) states that 80% of tenderizat ion of lam b t akes place over 7.7 days. The chops 
set aside for the final aging time point of 14 days we re t ake n post erio r to the first samp le point 
along the LD (according to sample collection outlined in Appe ndix A). 
All animals were weighed twice a week to ensure wee kly weight gain and their feed intakes 
monitored. Despite the prelim inary trial , where four anim als had eaten the trial d iet without any ill 
effects, during the trial week there were varying amo unts of feed refused by the treatment group . 
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Ten animals out of a total of eighteen left from 100g up to 3kg across the course of the week (out of 
a total of 9.1kg presented to them during the weekL data shown in Appendix K. This is a significant 
amount of feed refusal when in comparison only 2 control lambs left feed (0.9kg each across the 
week). The amount of feed refused by the treatment group on calcium days was even more 
pronounced, where two animals which had always consumed 1.4kg/day left up to 1.2kg of feed. 
There were 8 animals in the treatment group who ate all food presented, compared to 16 control 
animals who did the same. 
Weights were not significantly different at the beginning of the trial, whereas on slaughter date the 
treated animals had significantly lower liveweights than controls (P<O.OlL shown in table 3.2-1. 
These reduced weights are likely to be caused by the reduced feed intakes during the trial week as 
this was the only period when animals saw weight loss between their weekly weight checks and is 
likely to be due to reduced gut fill. Overall there was no reduction in ADG and FeR over the course of 
the trial, shown in table 3.2-1, and the difference in pre-slaughter liveweight between treatment 
groups is presumed to be a result of the Vitamin D3 plus calcium diet being possibly less palatable, as 
the majority of refusals were on days when calcium was given. This is further supported by the 
carcass weight and dressing percent data, table 3.2-1, as there are no differences between the 
overall carcass weights after dressing. The dressing percent data is not significantly different but 
numerically the dressing percent is higher in the vitamin D group, due to their lower liveweights 
prior to slaughter. There was a significant difference between carcass pH at 45 minutes post mortem 
and in 8pH (P<0.05L shown in table 3.2-1. However there was no difference in final pH as measured 
at 24 hours post mortem. 
To further evaluate the effect of the feed refusal on the carcass traits and the subsequent plasma 
vitamin D3 and serum calcium levels, the data for the animals of the vitamin D treatment group was 
analysed for differences between those that ate all feed and those that refused. It was found that 
there was no effect on feed refusal on plasma D3 levels nor serum calcium, nor on the pH at 45 
minutes post mortem. There was a significant effect on the pH at 24 hours post mortem (P=O.Ol) 
and on the liveweight of the animals immediately prior to slaughter (P=0.038) however there was no 
effect on the weights of the dressed carcasses, the data is shown in appendix I. Overall this data is 
evidence to show that the differences observed in liveweight is a factor of gut fill and the actual 
carcasses were no different in size. The difference in ultimate pH 24 hours post mortem is not 
indicative of dark, firm, dry (DFD) meat as a result of reduced glycogen stores pre-slaughter as the 
values for the animals which refused feed were significantly lower than those which ate all feed. 
Overall there was no difference in the plasma levels of vitamin D3 and serum levels of calcium which 
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were the hypothesized mediators of effects in calcium and calpain activity; therefore it was decided 
to continue to include all 18 vitamin D treated animals in the analysis of the subsequent data 
presented in this section. 
Table 3.2-1 Effect of 7 days vitamin 03 + Calcium supplementation on animal growth, feed intake and carcass 
traits, n=18. 
Control Vitamin 0 S.E.D. P 
Initial Lamb Weight (Kg) 42.99 42.55 0.801 0.255 
Final Lamb Weight (Liveweight) (Kg) 49.68 48.23 0.855 0.002 
Total Weight Gain (6 weeks) (Kg) 6.683 5.678 0.636 0.120 
Average Daily Gain (ADG) (Kg/Day) 0.163 0.1386 0.021 0.120 
Feed Conversion Ration (FCR) 9.135 10.863 1.540 0.146 
Carcass We ight (Kg) 25.46 25.25 0.514 0.479 
Dressing Percent (%) 51.28 52.4 0.774 0.108 
LDpH o Hr 6.60 6.46 0.060 0.050 
24 Hr 5.50 5.51 0.048 0.664 
LD4pH 1.10 0.95 0.067 0.044 
As there was no effect on the carcass weight and pHu was not affected by the reduced feed intake in 
the final days of the trial it was decided that all animals should be included in the analysis. The 
purpose of this study was to ascertain whether a vitamin D3 and calcium supplementation regime 
immediately prior to slaughter was able to raise calcium status of the animals in both the serum and 
muscle which would serve to activate the calpain activity post mortem and subsequently improve 
the tenderisation process. Plasma samples were analysed using HPLC by Stuart Jones at Nottingham 
City Hospital and results are shown in table 3.2-2. 25(OH}-vitamin D3 levels were significantly raised 
by the treatment diet (P<O.OOl), and this equates to almost a 25 fold increase (2364%) compared to 
controls. 25(OH}-vitamin D2 levels were also changed between groups (P<O.OOl) as measured by this 
assay, with Vitamin D3 plus calcium treated animals having a 10 fold increase in their circulating 
levels of vitamin D2• Serum calcium was significantly increased by the dietary supplementation 
regime, with the treated group (P<O.OOl; table 3.2-2), with vitamin D3 plus calcium bolus giving a 
10% increase in circulating levels of calcium in the serum of sheep. In addition to significant changes 
in the serum calcium there was a significant increase in the muscle calcium levels in the treated 
group (P=0.024; table 3.2-2), with the calcium levels in the muscles of treated animals increased by 
10%. 
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Table 3.2-2 Effect of 7 Days Vitamin 0 3 + calcium bolus on plasma 25(OH)-vitamin 0, serum & LO calcium 
levels. 
Control Vitamin 0 S.E.D. P 
D3 ng/ml 49.9 1230 55.82 < 0.001 
D2 ng/ml 24.8 250.8 18.35 < 0.001 
Serum Calcium (mg/L) 129.1 142.7 3.367 <0.001 
LD Calcium (mg/g wet tissue) 44.73 49.45 1.770 0.024 
Plasma vitamin 0 3 and O2 and serum calcium n=18, LO muscle calcium n=16. 
Together, the data summarised in table 3.2-2 indicates that despite the variable feed refusal 
observed in the animals fed the treatment diet, there were still large and highly significant changes 
in the circulating levels of vitamin D3 and calcium and this was translated into changes in the calcium 
levels in the LD. This is further justification to analyse further measurements using all animals in the 
trial as the changes in vitamin D3 and calcium status were so large that any subsequent effects on 
the calpains and meat quality would be related to these parameters. 
LD chops were aged for 1, 3, 7 and 14 days at 4°C before tenderness was determined by Warner-
Bratzler method. Samples were aged at 4°C for 3, 7 and 14 days and then selected for freezing 
according to a latin- square arrangement (see appendix A), data was analysed using ANOVA. Chops 
aged for 14 days were sampled separately to provide data for shear force after 2 weeks of aging, 
shown in table 3.2-3. Shear force of all chops decreased with time (P<O.Ol) and there was no 
interaction between diet and aging period (P=0.808), however, shear force of chops taken from 
treated animals were significantly higher than those from controls (P<O.Ol). This data suggests that a 
supplemental regime of 7 days Vitamin D3 plus calcium bolus treatment has a detrimental effect on 
shear force of LD chops. 
Table 3.2-3 Effect of 7 days vitamin 0 3 + calcium bolus on shear force of LO, n=18. 
Diet / 
Control 
Vitamin 0 
Age 
14 day shear force LO 
1 
4.083 
4.338 
Control 
3.685 
TIme (days) 
3 7 
3.66 3.322 Diet 
4.09 3.82 Age 
~ i e t t * Age 
Vitamin 0 
3.944 
S.E.D. P 
0.1436 0.002 
0.1759 0.007 
0.2488 0.777 
0.191 0.133 
To ascertain whether fat content of the LD was contributing to the change in shear force, the Soxhlet 
fat content was determined for a subset of 6 samples, taking two pairs from each slaughter group. 
Muscle fat was extracted by the Soxtherm method and calculated as a percentage of muscle weight. 
There was no significant effect of 7 days vitamin D3 supplementation plus calcium bolus on the fat 
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content of LD (table 3.2-4) although numerically the vitamin D3 group had lower fat content than 
that of the control group and the P value is approaching a significant trend of P=0.121. 
Table 3.2-4 Effect of 7 Days Vitamin 0 3 Supplementation plus calcium bolus on LD Fat Content, n=6. 
Control Vitamin 0 S.E.D. P 
Extracted LD Fat Content (% per g freeze dried tissue) 12.03 9.58 1.495 0.121 
3.2.2 Vitamin D signalling results: Trial 1; 7 days vitamin D3 + calcium bolus. 
The longer supplementation of vitamin D3 for 7 days in tandem with an extra calcium bolus was able 
to produce significant changes in the vitamin D3 and calcium status of the treated sheep and it was 
hypothesised that these changes would cause changes in the calpain system and vitamin D signalling 
responses. There was a detrimental effect of this supplementation regime on the shear force of the 
LD chops and so the expression of the calpain system was measured to ascertain whether the 
increased toughness was related to their activities. 
The expression of the calpain system at the mRNA level was measured using real-time RT-PCR, as 
described in chapter 2 of this thesis (section 2.9-3). There was no effect of diet on the expression of 
~ - a c t i n n and so all data was normalised to this gene (table 2.9-3, chapter 2). Expression of calpain I or 
Il-calpain, in the LD was significantly decreased (P=0.04, table 3.2-5) in the treatment group 
compared to expression in the control animals although this difference was not apparent at the 
protein level (P=0.691, representative blots shown in figure 3.2-2). Expression of calpain II (m-
calpain), and calpastatin at the mRNA level was not affected by diet treatment; however at the 
protein level there was a significant increase in the expression of calpain II (m-calpain) by 16%. There 
was also a trend for an increase in calpastatin at the protein level (P=0.087, table 3.2-5) by 17%, 
although these changes were not apparent at the mRNA level. Given that calpastatin is the calpain-
specific endogenous inhibitor, this increase in its protein level could be responsible for the raised 
shear force observed in the LD chops from treated animals in this trial. 
As mentioned in section 3.1.3, calbindin D-28K is a gene known to be up-regulated by vitamin D and 
its mRNA and protein levels were measured to qualify the effects of dietary vitamin D3 supplement. 
There was a significant effect of 7 days dietary vitamin D3 plus calcium bolus on the mRNA 
expression of calbindin D-28k in the kidney, where the calbindin D-28K expression was increased by 
8.8% (P< 0.05, table 3.2-6). This change at the mRNA level was not translated into a change at the 
protein level as calbindin D-28k protein levels were unchanged (P=0.147) despite a higher numerical 
value in the vitamin D3 treated group. However, there was a Significant change in the VDR protein 
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levels in the kidney whereby VDR levels were significantly increased 2 fold (100%) by 7 days vitamin 
D3 + calcium treatment (P<0.001, table 3.2-6). Taken together these data show that the 
supplementation of vitamin D3 for 7 days + calcium did cause significant changes at the gene and 
protein levels and it is likely the changes in calbindin D-28k mRNA were the result of a direct 
signalling effect of vitamin D3 at a gene transcription level in the nucleus. 
Table 3.2-5 Effect of 7 Days Vitamin 0 3 + calcium on mRNA and protein expression of Calpain System in LD 
muscle. 
LO mRNA Calpain Genes: Beta Actin Ratio 
Control Vitamin 0 S.E.D. P 
Calpain I 1.004 0.951 0.0264 0.04 
Cal pain II 1.005 0.994 0.0292 0.594 
Calpastatin 1.053 1.025 0.0465 0.513 
Absorbance/ 100 Ilg protein 
LO protein Control Vitamin 0 S.E.D. P 
Calpain I 8.182 7.923 0.748 0.691 
Calpain II 4.853 5.636 0.437 0.050 
Calpastatin 11.690 13.720 2.201 0.087 
Calpain system mRNA n=18, calpain I protein n=15, calpain II protein n=16 and calpastatin protein n=17. 
Table 3.2-6 Effect of 7 Days Vitamin 0 3 + calcium on mRNA and protein expression of vitamin 0 targets in 
kidney. 
Kidney mRNA Control Vitamin 0 S.E.D. P 
Calbindin : Beta Actin ratio 1.000 1.088 0.0716 0.043 
Absorbance/ 100 j.lg protein 
Kidney protein Control Vitamin 0 S.E.D. P 
Calbindin 6.341 10.318 2.282 0.147 
VOR 3.172 6.510 0.715 <0.001 
Calbindin mRNA n=18, calbindin protein n=14, VDR protein n=17. 
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Figure 3.2-2 Representative blots of the calpain system in lO and vitamin 0 respon sive targets in kidney 
protein extracts from sheep in trial 2: 7 days vitamin 0 3 + calcium. All protein samples were loaded with 
constant weight of 100llg protein/lane, treated (0) and control (C) samples were loaded alternately 
between a repeated standard sample (STO). Note: there is no second STO on the calpastatin protein image. 
Calpain I and II: 100llg lO supernatant fraction separated by 50S-PAGE using 10% acrylamide gel, 
Calpastatin: 100llg lO whole homogenate fraction separated by 50S-PAGE using 8% acrylamide gel. 
Calbindin and VOR: lOOllg whole homogenate kidney separated by SDS-PAGE using 12% acrylamide gel . 
Further antibody information presented in Appendix D, calpain I n=15 calpain II n=16, calpastatin n=17, 
calbindin n=14 and VOR n=17 . 
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3.2.3 Trial Summary 
The aim of this trial was to manipulate meat quality using a longer supplementation period of 7 days 
vitamin D3 with an additional calcium bolus immediately prior to slaughter in order to maximise the 
changes in calcium status which would have subsequent effects on meat quality. This 
supplementation regime did confer significant changes in circulating vitamin D and calcium levels 
and subsequently calcium levels in the LD were significantly raised. Despite the changes in calcium 
status there was no improvement in the shear force of LD chops post mortem, which was instead 
increased by the dietary regime. The increase in shear force could be attributed to a number of 
parameters such as the slight reduction in fat within the LD indicated in table 3.2-4; however it is 
more likely that this increase in shear force is related to increase in the protein levels of calpastatin 
which would inhibit calpain activity. 
However, the second aim of this trial was to allow a longer supplementation of vitamin D3 with extra 
calcium which would translate into changes in gene expression as a result of direct signalling at gene 
transcription level, as it was thought 4 days of dietary vitamin D3 in the previous trial was not long 
enough to observe gene expression changes. This longer supplementation of vitamin D3 did cause an 
increase in mRNA of calbindin D-28k, a known target of vitamin D3 in the kidney, a target organ of 
the vitamin D-calcium homeostasis mechanism. This increase in calbindin D-28k mRNA was not 
translated into changes at the protein level, although the values were numerically higher with 
vitamin D3 group (P=O.147). In addition to changes in calbindin D-28k, expression of VDR at the 
protein level was significantly higher with vitamin D3 treatment (P<O.001), which demonstrated that 
the circulating vitamin D3 was having a direct signalling effect in its target organs and provides 
evidence to conclude 7 days vitamin D3 supplementation is sufficient to confer gene expression 
changes. 
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3.3 Summary of Sheep Trials 
The aim of the two trials performed in sheep in this study was to evaluate the efficacy of a pre-
slaughter vitamin D supplementation regime on its ability to improve meat quality. The proposed 
mechanism by which the vitamin D supplementation could improve the development of tenderness 
post mortem was by increasing circulating calcium levels which would lead to raised calcium levels in 
the muscles. The purpose of raising the calcium levels in the muscle would be to increase the activity 
of the calpain enzymes, in particular calpain I (l1-calpain), which was shown to be activated when 
carcasses were infused with calcium chloride post mortem (Koohmaraie et aI., 1989; Polidori et 01., 
2000). If this could be achieved by vitamin D supplementation prior to slaughter it was hypothesised 
that this regime would provide an acceptable dietary manipulation technique to promote a tender 
meat product without the need to process carcasses in the abattoir. In light of the evidence 
produced from these two meat trials and from trials performed previously (Sazili 2003, Wiegand et 
al. 2001; Boleman et 01., 2004) it can be concluded that despite some regimes being competent in 
increasing calcium status of sheep, this does not lead to an improvement in shear force of the 
muscle. In the case of trial 2 of this thesis where animals were fed vitamin D with additional calcium 
bolus in the week prior to slaughter, the increase in calcium status of was attributed to tougher LD 
chops. 
Interestingly there were changes in the expression of components of the calpain system as a result 
of 4 days vitamin D3 supplementation alone, which caused an increase in both calpains I and II at the 
mRNA level but was not translated to changes at the protein level. However, this effect was not 
observed again where 7 days vitamin D3 + calcium caused a decrease in the expression of calpain I at 
mRNA level although the protein levels of calpain II were increased. More importantly the 
detrimental effect of the 7 days vitamin D3 + calcium on shear force of LD chops was supported by an 
increase in calpastatin at the protein level. A model to explain this increase in shear force could 
possibly be that the increase in calpastatin directly inhibited the activities of the calpain enzymes 
and therefore inhibited the tenderisation process. 
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Results: Vitamin D in Muscle cells 
Introduction to muscle cell experiments 
Endo et 01. (2003) reported that knockout VDR -/- mice had abnormally raised levels of myogenic 
differentiation factors Myf5, myogenin, E2A, and the embryonic and neonatal MHC genes. In 
addition to observations in VDR -/- mice they reported that treatment of C2C12 cells with 1,25 (OHh 
vitamin D for 48 to 96 hours caused a decrease in Myf5, myogenin and neonatal MHC expression. As 
described in section 1.2 of this thesis, Myf5 is an early myogenic factor required to determine cells 
into the myogenic cell line whereas myogenin is expressed later in the process of muscle cell 
formation and is required for fusion and differentiation of myoblasts into myotubes. In light of the 
observations reported by Endo et 01. (2003) it might be concluded that vitamin D, acting via its 
receptor VDR, is required for myogenesis and regulates the process by regulating the proliferation of 
early myoblasts via affects on Myf5 expression and on the process of myotube formation via 
myogenin expression. In addition to the effects on myogenic factors Endo et 01. reported extended 
raised expression of the neonatal MHC isoform in VDR -/- mice which was down regulated in C2C12 
cells treated with 1,25 (OHh vitamin D, these findings suggest that vitamin D is able to alter the 
expression of MHC isoforms. In agreement with this are the reports that supplementation of elderly 
patients with 1,25 (OHh vitamin D resulted in an increase in the number of type II muscle fibres 
(Sato et 01./ 2005) and that supplementation with the active analogue 1a-(OH) vitamin D increased 
the number of fast oxidative fibres and decreased fast glycolytic fibre number (Sorenson et 01., 
1979). With a number of reports describing loss of type II muscle fibres associated with vitamin D 
deficiency (Bischoff et 01., 2003; Bischoff-Ferrari et 01., 2006; Snijder et 01., 2006) there is strong 
evidence for vitamin D's role in maintaining the expression profile of the MHC proteins, in particular 
the fast isoforms. 
In order to investigate vitamin D's possible role in regulating gene expression in skeletal muscle 
tissue, cell cultures were used as a model to be treated with active vitamin D3 directly. Two 
experiments were performed in this section of work; beginning with a microarray performed to 
identify novel targets of vitamin D in muscle tissue. The latter experiment was designed to test the 
hypothesis that direct treatment of vitamin D in muscle cells can perturb the growth and 
differentiation of muscle cells and alter the MHC gene expression. 
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3.4 Microarray to indentify novel targets of l,25(OH)2D3 
3.4.1 Trial outline 
Primary skeletal muscle cells prepared from hind limb muscles of neonatal male rat pups as 
described in section 2.11.1 and myoblasts were seeded at a density of 12.5 xl04 cell per well and 
cultured until 90% confluence, at which point cell growth media was substituted for cell fusion 
media supplemented with one of three treatments; either 10·sM or 10.9 M of 1a,25 
dihydroxyvitamin D3 (1,25(OHhD3) or 0.1% DM50 control. Cells were treated with the active form of 
1,25 dihydroxyvitamin D3 for 24 hours. Following treatment, three wells from a 6-well cell culture 
plate providing three replicates of total RNA were extracted using the RNeasy mini kit (QuiagenL a 
kit designed to consistently produce very high quality mRNA to prevent false discoveries. The 
microarray was performed by Thomas Wilson of Pfizer (Kalamazoo, MI, U5A) using was the rat V.2.0 
microarray chip, produced by Affymettix. The analysis was performed in two stages; firstly the raw 
data was processed using Genespring software (with kind help of Neil Graham of the Arabidopsis 
Stock Centre, University of Nottingham) before the list of up and down regulated genes were 
analysed using Ingenuity Pathway Analysis (IPA V7.1, Ingenuity 5ystems). 
3.4.2 Quality of RNA used in the microarray 
It was of extreme importance that the RNA used in the microarray was intact and of good quality in 
order to present the most reliable data from the microarray. The total RNA from the rat primary 
muscle cells was extracted as described in section 2.13.1 and the quality of the RNA was analysed 
using an Agilent 2100 Bioanalyzer (Agilent technologies) which is developed to accurately analyse 
RNA using very small sample sizes and saves the need to perform electrophoresis using an agarose 
gel, thereby reducing the amount of sample needed to check RNA integrity before it is utilised in the 
microarray. The Bioanalyzer grades the RNA out of 10, producing a Relative Integrity Number value 
(RIN valueLand transfers the interpreted integrity of the RNA into a hypothetical gel in order to 
demonstrate the intact bands of 285, 185 and tRNA as would be seen using agarose gel 
electrophoresis. For use in a microarray RNA needs to be wholly intact and to produce a RIN value of 
at least 9 out of 10. Data for the RNA prepared in this study is shown in table 3.4-1, showing that all 
samples scored 10 out of 10 except DM50 replicate 2, which still had an acceptable score of 9.2 out 
of 10. The relative band of 285 should be around twice the intensity of the 185 band, hence the ratio 
of the two bands should be as close to 2.0 as possible in good quality RNA and again all RNAs had 
acceptable 285/185 ratios The hypothetical gel showing all intact 285 and 185 ribosomal RNA and 
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tRNA bands is presented in figure 3.4-1. From th is data it can be assumed that the RNA was of high 
quality and would provide a valid template for the microa rray analysis . 
Table 3.4-1 Concentration and integrity of RNA used in microarray. 
288 ~ ~
188 ~ ~
RNA Cone Rat io rRNA RNA Integri ty No. 
Sample ng/ill 28s/18s RIN 
DMSOl 350 1.9 1.0 
DMS02 396 1.8 9.2 
DMS03 367 1.9 10.0 
lO,sM 1 109 1.9 10.0 
lO,sM 2 283 1.9 10.0 
lO,sM 3 337 2.0 10.0 
lO'9M 1 399 2.1 10.0 
lO'9M 2 478 2.0 10.0 
10'9M 3 570 2.0 10.0 
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Figure 3.4-1 Effects of 1,25 Vitamin 0 3 on quantity and quality of RNA extracted from rat primary muscle 
cells in culture. Hypothetical gel graph of band intensity of RNA produced by Agilent 2100 Bioanalyzer. 
Table 3.4-2 Effect of 1,25(OHh03 treatment on yield of RNA harvested for microarray analysis. 
DMSO S.E.D. p 
RNA cone (ng/lll) 70 0.039 
Values analysed by ANOVA, values with the same superscript are not significantly different, n=3. 
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There was a significant effect of treatment on RNA yield from rat primary myoblasts treated with 
l,25(OHhD3, P<0.039 table 3.4-2. When the values were tested using least significant difference 
values from the ANOVA output, using a T value from the Dunnett's test, there was a significant 
difference between the concentrations of RNA harvested from cells treated with either dose of 
l,25(OHhD3, but neither of these yields were significantly different to the yield of the DMSO 
controls. The effect was that RNA yields were significantly lower when cells were treated with 
l,25(OHhD3 10-sM in comparison to the yield of RNA from cells treated with the dose of 10-9M 
(P<0.05). 
3.4.3 Analysis of micro array data 
The changes affected by each dose of l,25(OHhD3 were calculated by T-tests between each vitamin 
D dose and DMSO control, performed in Genespring software, identifying genes with expression 
changes over 1.5 fold or more in either up- or down-regulation. This produced a list of genes which 
had changed 1.5 fold or more in either direction with 95% significance. The individual gene targets 
included in the lists were analysed further using Ingenuity Pathway Analysis software (IPA, V.7.1; 
Ingenuity Systems) to identify their function and role in signalling pathways. 
3.4.4 Genes changed by 1,25(OHhD3 10-5 M treatment 
Out of 31,099 targets measured by the microarray, the expression of 475 genes was significantly 
changed at least 1.5 fold (P<0.05). Of the total 475 genes changed 157 were up-regulated in 
comparison to 318 which were down-regulated. The role of these genes in cells was further analysed 
by the IPA software to identify the signalling changes that were being brought about by vitamin D at 
the highest dose of 10-sM. The software identified signalling pathways in which the changed genes 
were present and produced colour coordinated diagrams (green is down-regulated, red is up-
regulated, higher intensity of colour relates to higher fold change) of the network and the location of 
the changed molecules in those pathways. The list of the top 5 networks containing genes affected 
by l,25(OHhD3 at the 10-sM treatment is shown in table 3.4-3. The score related to each network is 
related to the number of changed genes in each network and a high score denotes a large number of 
changed genes located in the network. 
Table 3.4-3 Top 5 signalling networks containing highest number of molecules changed by 1,2S(OH)zD3 10-sM 
treatment. 
Networks Associated Network Functions Score 
1 Genetic Disorder, Ophthalmic Disease, Cellular Growth and Proliferation 
2 Cellular Growth and Proliferation, Embryonic Development, Connective Tissue Development and Functio 
3 
4 
5 
Cancer, Cell Death, Hematological Disease 
Cardiovascular System Development and Function, Cardiovascular Disease, Cell Death 
Cancer, Cellular Movement, Lipid Metabolism 
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48 
38 
35 
31 
29 
Genes which were included in these pathways are summarised in tables 3.4-4 and 3.4-5 which are 
separated for those transcripts either up-regulated or down-regulated by l,25(OHhD3 respectively. 
IPA produced diagrams for each of the top 5 networks, shown in figures 3.4-2 to 3.4-6, where known 
signalling pathways which contain or interact with those genes changed by treatment can be 
visualised. Figure 3.4.2 depicts network 1 (table 3.4-3), related to cellular growth and proliferation 
and the central signalling molecule of this pathway is the MAPK, ERK. The second network in table 
3.4-3 is depicted in figure 3.4-3, presenting molecules involved in cell growth, proliferation and 
differentiation and is focussed around the Jun and RNA polymerase molecules which are related to 
gene transcription. The transcription factors C/EBP 13 and 0 were up-regulated by 10-sM l,25(OHhD3 
treatment and are members of this network. Network 3 from table 3.4-3 is depicted in figure 3.4-4, 
showing molecules related to cell death and cancer by IPA. Signalling pathways denoted in figure 
3.4-4 are centred around the nuclear factors NFKB and NFAT which are regulators of gene 
transcription. The calcium-regulated calcineurin is part of this pathway and this presents a possible 
link between the action of l,25(OHhD3 in skeletal muscle cells and their interaction with calcium 
signalling pathways. Other proteins of interest in this pathway are calpastatin (CAST) and creatine 
kinase which were both down regulated by l,25(OHhD3 treatment at 10-sM. The fourth network in 
table 3.4-3 is depicted in figure 3.4-5 produced by IPA and shows molecules related to cell death, 
centred around the MAPK, p38, and indicating a relationship with caspase-l. The relationship to 
caspase-1 is of interest in terms of early cell growth as the caspases are apoptotic enzymes. Genes 
changed by l,25(OHhD3 at 10-sM were two MAPK signalling proteins, MEK (ERK kinase) and 
MAPKK4, and MEF2C. Finally network 5 from table 3.4-3 is shown in figure 3.4-6 and is focussed 
around the transforming growth factor TGF 13-1 and is related to cancer and cellular movement. The 
networks are useful to put the list of changed genes into related protein signalling pathways and it 
can be concluded that l,25(OHhD3 signals were mediated by a number of mechanisms, of these the 
molecules of interest are the MAPKinases and transcription factors such as C/EBP 13 and 0. 
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Table 3.4-4 List of genes up regulated with 1,2S(OH)zD3 lO,sM 
Gene Name 
Rbp4 
Mtla 
LOC682651 / / / LOC689415 
Cebpd 
Gpr68_predicted 
Hsdllbl 
Ndrg2 
Cebpb 
Fadsl 
Mme 
Agtrla 
Cebpd 
Fads2 
Notch2 
Rras2 
Nqol 
Fgfrl 
Agtrla 
Hsfl 
Dapkl_predicted 
Gadd45a 
Junb 
Srebfl 
Rab34 
Up Regulated 
Protein Name 
retinol binding protein 4, plasma 
metallothionein la 
similar to Metallothionein-2 (MT-2) (Metallothionein-II) (MT-II) 
CCAAT /enhancer binding protein (C/EBP), delta 
G protein-coupled receptor 68 (predicted) 
hydroxysteroid ll-beta dehydrogenase 1 
N-myc downstream regulated gene 2 
CCAAT/enhancer binding protein (C/EBP), beta 
fatty acid desaturase 1 
membrane metallo endopeptidase 
angiotensin II receptor, type 1 (ATlA) 
CCAAT/enhancer binding protein (C/EBP), delta 
fatty acid desaturase 2 
Notch gene homolog 2 (Drosophila) 
related RAS viral (r-ras) oncogene homolog 2 
NAD(P)H dehydrogenase, quinone 1 
Fibroblast growth factor receptor 1 
angiotensin II receptor, type 1 (ATlA) 
heat shock transcription factor 1 
death associated protein kinase 1 (predicted) 
growth arrest and DNA-damage-inducible 45 alpha 
Jun-B oncogene 
sterol regu latory element binding factor 1 
RAB34, member of RAS oncogene family 
Fold Change 
20.91 
6.79 
4.30 
2.57 
2.39 
2.32 
2.24 
2.23 
2.21 
2.10 
2.07 
1.95 
1.93 
1.92 
1.86 
1.84 
1.84 
1.83 
1.80 
1.75 
1.72 
1.69 
1.60 
1.58 
123 
Table 3.4-5 List of genes down regulated by l,25(OHhD3 lO-sM 
Gene Name 
Tnfrsfllb 
Igfbp3 
Cited2 
Pawr 
Rasillb 
Tgfb3 
Rgs2 
Rbp1 
Rgs2 
Cited2 
Wisp1 
Rxrg 
Atp1b1 
Usp13_predicted 
Cacna1s 
Tnni2 
LOC684533 
Tmod1 
Igfbp6 
Smoc2.Jlredicted 
Cdhll 
Ctsk 
Myh8 
Myh1/// Myh2 
Igfbp6 
Cast 
Capn6 
Casq2 
Map2k4 
Ndrg4 
Casq2 
Fzd2 
Atp1b1 
Mybpc1 
Rd h 5 _p red icted 
Plcb4 
Jun 
MyhlO 
Down Regulated 
Protein Name 
tumor necrosis factor receptor superfamily, member llb (osteoprotegerin) 
insulin-like growth factor binding protein 3 
Cbp/p300-interacting transactivator, with Glu/ Asp-rich carboxy-terminal domain, 2 
PRKC, apoptosis, WT1, regulator 
RAS-like family 11 member B 
transforming growth factor, beta 3 
regulator of G-protein signaling 2 
retinol binding protein 1, cellular 
regulator of G-protein signaling 2 
Cbp/p300-interacting transactivator, with Glu/ Asp-rich carboxy-terminal domain, 2 
WNTl inducible signaling pathway protein 1 
retinoid X receptor gamma 
ATPase, Na+/K+ transporting, beta 1 polypeptide 
ubiquitin specific protease 13 (isopeptidase T-3) (predicted) 
calcium channel, voltage-dependent, L type, alpha 15 subunit 
troponin I type 2 (skeletal, fast) 
similar to myosin light chain 1 slow a 
tropomodulin 1 
insulin-like growth factor binding protein 6 
SPARC related modular calcium binding 2 (predicted) 
cadherin 11 
cathepsin K 
myosin, heavy polypeptide 8, skeletal muscle, perinatal 
myosin, heavy polypeptide 1///2, skeletal muscle, adult 
insulin-like growth factor binding protein 6 
calpastatin 
calpain 6 
calsequestrin 2 
mitogen activated protein kinase kinase 4 
N-myc downstream regulated gene 4 
calsequestrin 2 
frizzled homolog 2 (Drosophila) 
ATPase, Na+/K+ transporting, beta 1 polypeptide 
myosin binding protein C, slow type 
retinol dehydrogenase 5 (predicted) 
phospholipase C, beta 4 
Jun oncogene 
myosin, heavy polypeptide 10, non-muscle 
Fold Change 
-4.24 
-3.05 
-2.68 
-2.57 
-2.54 
-2.34 
-2.30 
-2.25 
-2.15 
-2.15 
-2.13 
-2.08 
-2.01 
-1.96 
-1.92 
-1.90 
-1.88 
-1.85 
-1.82 
-1.80 
-1.79 
-1.77 
-1.77 
-1.75 
-1.71 
-1.71 
-1.68 
-1.66 
-1.63 
-1.62 
-1.61 
-1.60 
-1.55 
-1.53 
-1.53 
-1.52 
-1.52 
-1.51 
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Figure 3.4-2 Diagram of molecules included in network 1: Associated with Genetic Disorder, Opthalmic 
Disease, & Cellular Growth and Proliferation; generated by IPA from analysis of 1,25(OHhD3 10 5M data. 
Green is down regulated, red is up-regulated, higher intensity of colour relates to higher fold change. 
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Figure 3.4-3 Diagram of molecules included in network 2: Associated with Cellular Growth and Proliferation, 
Embryonic Development & Connective Tissue Development and Function; generated by IPA produced from 
analysis of 1,25(OHhD3 l O-sM data. Green is down regulated, red is up-regulated higher intensity of colour 
relates to higher fold change. 
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Figure 3.4-4 Diagram of molecules included in network 3: Associated with Cancer, Ce I Death & 
Hematological Disease; generated by IPA produced from analysis of 1,25(OH}2D3 lO-oM data. Green is down 
regulated, red is up-regulated, higher intensity of colour relates to higher fold change. 
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Development and Function, Card iovascu lar Disease & Ce ll Death; generated by IPA produced from analysis 
of 1,25(OHhD3 lO-sM data. Green is down regu lated, red is up-regulated, higher intensity of colour relates to 
higher fold change. 
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3.4.5 Genes changed by l,25(OH)zD3 10-9 M treatment 
When rat primary skeletal muscle cells were treated with l,2s(OHhD3 at a lower dose of 10-9 M, 43 
genes were changed at least 1.5 fold out of 31,099 targets measured by the microarray (P<O.Os). Out 
of the total 43 changed genes, 27 genes were up-regulated by treatment in comparison to 16 which 
were down regulated. To further understand the mechanisms of l,2s(OHhD3's action on skeletal 
muscles the changed proteins were analysed by IPA software which generated 3 networks 
associated with the changed molecules, summarised in table 3.4-6. Genes which were included in 
these pathways are summarised in tables 3.4-7 and 3.4-8 which are separated for those transcripts 
either up-regulated or down-regulated by l,2s(OHhD3 respectively. The networks generated by IPA 
listed in table 3.4-6, which contain the genes shown in tables 3.4-7 and 3.4-8, are shown in figures 
3.4-7 to 3.4-9. 
Table 3.4-6 Top 3 signalling networks containing highest number of molecules changed by l,2S(OHhD3 lO-9M 
treatment. 
Networks Associated Network Functions Score 
1 
2 
3 
Tissue Morphology, Connective Tissue Development and Function, Skeletal and Muscular System Developmer 33 
Cellular Growth and Proliferation, Cellular Development, Cancer 26 
Cell Death, DNA Replication, Recombination, and Repair, Cancer 16 
Table 3.4-7 List of genes up regulated by 1,2S(OHhD3 lO-9M 
Gene Name 
Rbp4 
Prom1 
Hsdllb1 
Fst 
Cdc42ep2 
RGD1305645_predicted 
LOC682651 III LOC689415 
Steap2_predicted 
Cebpb 
Cebpd 
Sulf2 
Crlfl_pred icted 
Spp1 
Sod2 
Fkhl18 
LOC679990 I II LOC687552 
Cct6a 
Slc1a3 
Crlf1_predicted 
Gadd45a 
Pola2 
Loxl2_predicted 
Steap2_predicted 
Syngr2 
Notch2 
Up Regulated 
Protein Name 
retinol binding protein 4, plasma 
prominin 1 
hydroxysteroid ll-beta dehydrogenase 1 
follistatin 
CDC42 effector protein (Rho GTPase binding) 2 
similar to RIKEN cDNA 9230117N10 
similar to Metallothionein-2 (MT-2) (Metallothionein-II) (MT-II) 
six transmembrane epithelial antigen of prostate 2 (predicted) 
Transcribed locus 
CCAAT/enhancer binding protein (C/EBP), beta 
CCAAT/enhancer binding protein (C/EBP), delta 
sulfatase 2 
cytokine receptor-like factor 1 (predicted) 
secreted phosphoprotein 1 
superoxide dismutase 2, mitochondrial 
forkhead-like 18 (Drosophila) 
Transcribed locus 
similar to phosphoglucomutase 5 
Chaperonin subunit 6a (zeta) 
solute carrier family 1 (glial high affinity glutamate transporter), member 3 
cytokine receptor-like factor 1 (predicted) 
growth arrest and DNA-damage-inducible 45 alpha 
polymerase (DNA directed), alpha 2 
Iysyl oxidase-like 2 (predicted) 
six transmembrane epithelial antigen of prostate 2 (predicted) 
synaptogyrin 2 
Notch gene homolog 2 (Drosophila) 
Fold Change 
12.07 
3.12 
2.82 
2.54 
2.47 
2.38 
2.15 
2.03 
2.03 
2.02 
1.99 
1.98 
1.95 
1.90 
1.89 
1.85 
1.84 
1.81 
1.79 
1.77 
1.76 
1.72 
1.67 
1.65 
1.60 
1.60 
1.55 
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Table 3.4-8 List of genes down regulated by l,2S(OHhD3 lO'9M 
Gene Name 
Tnfrsfllb 
Cd276 
LOC498564 
Osbpl2 
Pcd h 18 _pred icted 
RG D1305645_predicted 
RGD1566401_predicted 
Gramd3 
Angptl4 
Pawr 
LOC312678 
RGD1307397 
Agpat5 pred icted 
Down Regul ated 
Protein Name 
tu mor necrosis fact or receptor superfa mily, member llb (osteoprotegerin) 
(D276 antigen 
sim ilar to integrin, beta-l ike 1 
Transcribed locus 
oxysterol binding protein-l ike 2 
Transcribed locus 
protocadherin 18 (predicted ) 
similar to RI KEN cDNA 1500015010 (pred icted ) 
similar to GTL2, imp rinted mate rn ally expressed untrans lated (pred icted ) 
GRAM domain contain ing 3 
angiopoietin-like 4 
PRK(, apoptosis, WTl, regulator 
simi lar to Retinob lastoma-binding protein 2 (RBBP-2 ) 
similar to RI KEN cDNA 2810037(03 
1-acylglycerol-3-phosphate O-acyltran sferase 5 
Fold Change 
-2 .20 
-1.87 
-1.84 
-1.80 
-1.79 
-1 .77 
-1.70 
-1 .63 
-1.60 
-1.60 
-1.57 
-1. 57 
-1.57 
-1. 53 
-1. 51 
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3.4.6 Summary and discussion of micro array data 
From 31,099 interrogated sequences, 1,25(OHhD3 treatment at 10-sM caused significant changes in 
475 genes and 1,25(OHhD3 at 10-9M changed only 43 genes, meaning 1.53% and 0.14% of genes 
measured by the microarray were affected at each dose respectively. Overall there was an 
imbalance between the up-regulated and down-regulated genes changed by 10-sM, where twice as 
many genes, 318, were down-regulated compared to only 157 which were up-regulated. This was 
the opposite to the gene expression changes observed with the lower dose of 1,25(OHhD3 where 
treatment at the 10-9M concentration caused an increase in the expression of 27 genes and a 
decrease in 16. This did raise some concern that the higher dose of 10-sM was reducing transcription 
to some extent, which could be related to reduced cell proliferation or apoptosis, and the large 
number of down-regulated genes could be a result of the cells beginning to cease normal 
transcriptional activity. This hypothesis was further supported by the list of networks related to 
those changed genes whereby IPA software identified 5 signalling networks, of which 3 were related 
to cell death, and also by the effect on RNA yield shown in table 3.4-2. 
The primary aim of the microarray was to identify targets responsive to biologically active 
1,25(OHhD3 in muscle cells to be validated in the final experiments, and these are identified in table 
3.4-9. This is the first reported microarray performed to analyse 1,25(OHhD3's direct effects on 
skeletal muscle, however Latres et 01. (2005) performed an experiment in C2C12 cells using IGF-l 
and dexamethasome (a glucocorticoid) to evaluate genes which were differentially regulated 
between the two treatments. Insulin-like growth factor-l (IGF-l) is well known to promote muscle 
growth (Gerrard et 01., 1998), and on the contrary, glucocorticoids are known to promote muscle 
atrophy during sepsis and wasting and their effect in muscle is to promote muscle degradation via 
proteolysis by both the ubiquitin-proteasome pathway and the calpains (Yang et 01., 2005). There 
were some similarities between the results of the microarray performed in this thesis and the results 
reported by Latres et 01. (2005) and this supports l,25(OHhD3 acting to influence control of muscle 
growth. Genes which were significantly up-regulated by IGF-l but down-regulated by a 
glucocorticoid included metallothionein 1 and 2, both of which were found to be up-regulated in 
myoblasts treated with 1,25(OHhD3 at the 10-sM dose and metallothionein 2a was up-regulated by 
the lower dose of 10-9M 1,25(OHhD3. A second study using microarray analysis to investigate gene 
expression changes during induced skeletal muscle atrophy in rats found metallothionein 1, is and 
1L to be increased during atrophy (Lecker et 01., 2004) and does not agree with Latres et al.'s 
conclusions, but does highlight again the changes in metallothionein during changes in muscle 
growth, and it was decided to evaluate this protein as a target of vitamin D in skeletal muscle in the 
fOllowing final experiments of this thesis. 
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Table 3.4-9 Genes changed in both treatments with 1,2S(OHhD3 exhibiting dose responses. 
Gene Name 
Rbp4 
LOC682651/ / / LOC689415 
Cebpb 
Cebpd 
Notch2 
Up Regulated 
Protein Name 
retinol binding protein 4, plasma 
similar to Metallothionein-2 (MT-2) (Metallothionein-II) (MT-II) 
CCAAT/enhancer binding protein (C/EBP), beta 
CCAAT /enhancer binding protein (C/EBP), delta 
Notch gene homolog 2 (Drosophila) 
Fold Change 
lO-5M lO-9 M 
20.91 12.07 
4.3 2.15 
2.23 2.02 
2.57 1.99 
1.92 1.55 
Retinol binding protein is involved in signalling via retinoic acid which mediates gene expression in a 
similar mechanism to 1,2S(OHhD3, as the retinoic acid receptor (RAR) forms a heterodimer with RXR. 
The genes identified in table 3.4-9 had all been up-regulated by 1,2S{OHhD3 in a dose response and 
were the chosen targets for real time peR analysis in the last cell culture trial. 
Further additional targets were chosen from their relevance in literature where parvalbumin was 
found to be down-regulated by IGF-l and up-regulated by the glucocorticoid, therefore its 
expression showed association with muscle wasting {Latres et 01., (200S). Although in the 
1,2S{OHhD3 microarray of this thesis parvalbumin was not found to be affected, it is well known to 
be a gene responsive to 1,2S{OHhD3 (De Viragh et 01., 1989). Additionally, the microarray results 
indicated that 1,2S(OHhD3 was able to activate signalling pathways known to affect the maturation 
process of skeletal muscle cells. The MAPK pathways were affected by both doses of 1,2S(OHhD3 
shown by changes in genes associated with p38 MAPK and ERK 1/2. The MAPKinases are well 
documented to affect cell growth and differentiation and have been shown to be activated by 
1,2S(OHhD3 treatment in skeletal muscle cells (Losel & Wehling, 2003, Buitrago et 01.; 2001, 2006), 
described in section 1.1-4 of this thesis. 
In light of this information, additional targets were chosen to be investigated in the last experiment 
of this thesis to assess vitamin D's effects on pathways known to affect muscle cell proliferation and 
growth; these were parvalbumin and c-Myc, measured at the transcript level, and the MAPKinase, 
ERK 1/2, and 4EBPl, assessed for their extent of phosphorylation at the protein level. 
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Trial 4: Vitamin D signalling in Skeletal 
Muscle cells in Culture 
3.5 Characterisation of skeletal muscle cells for culture work 
Vitamin D deficiency is related to loss of muscle strength and fewer type II fibres in aging muscle. In 
order to investigate vitamin D's role in regulating muscle function and maintaining fast fibre type it 
was decided to treat muscle cell cultures directly with a constitutively active analogue of vitamin D, 
1a-hydroxyvitamin D (la(OH)D, known as alfacalcidiol), a substance unlikely to be degraded over the 
treatment period of 48 hours. The hypothesis of the experiment was that treatment with 1a(OH)D 
would cause a shift towards a fast muscle fibre type in muscle cells. In order to observe fibre type 
switching between the slow and fast fibre types it was important that the cell model should express, 
if at all possible, the full range of mature myosin heavy chain genes including MHC I / ~ ~ slow. In the 
event of fibre type switching, it was envisaged that the expression of MHC genes would undergo 
sequential changes from oxidative to glycolytic associated MHC gene expression in the sequence: 
MHC I / ~ ~ -7 MHC IIA -7 MHC IIX -7 MHC liB, or vice versa. Therefore it was necessary to evaluate the 
available cell lines for their MHC expression. Once characterised, the cell line which showed the 
largest range of MHC gene expression could then be used to monitor the changes in MHC 
expression, in particular it was important to find a cell line which expressed as large a range of MHC 
as possible from the slow MHC I / ~ ~ isoform to the MHCIIB fast adult isoforms. 
3.5.1 Outline of work 
Three cell types were evaluated for MHC gene expression, to determine the maturity of the cell line 
for validity in comparisons to adult animal muscle tissue. Both the rat primary muscle cells and the 
L6 Aston cell line were rat derived cells and were evaluated using rat specific primers to the MHC 
genes developed by Sanchez et 01. (2006) and Jaschinki et 01. (1998), primers shown in Appendix E. 
The mouse derived C2C12 cells were evaluated using primers designed specifically to the mouse 
isoforms of the MHC genes by da Costa et 01. (2002), shown in Appendix F. Semi-quantitative PCR 
reactions were performed using primers for each gene and products were electrophoresed in 
agarose gels before staining and imaging. Adult LD cDNA for each species was used as a positive 
control for MHC gene expression. 
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3.5.2 Expression of MHC in rat derived muscle cells (Rat Primary cells & L6 Aston cell 
line) 
cDNA produced from mRNA extracted from rat primary cells at sequential stages of development 
was used to determine MHC gene expression. Rat primary muscle cells were prepared from neonatal 
Wistar male rat pups as described in section 2.11.1 and evaluated for their use in this experiment. 
Primary cells directly harvested from animal tissue where cells are not passaged between harvest 
and treatment are useful models for animal muscle tissue in vitro, with less risk of adaptation to in 
vitro environment as can happen over time with cell lines. Cell lines tend to retain most functions of 
their parent cells but can lose them as they undergo a number of passages (Harrison & Rae, 1997). 
Cells were harvested at 4 time points from confluent myoblast phase (day O) through to fully formed 
myotubes (day 7). The primers used to characterise the MHC gene expression are summarised in 
table 3.5-1 and the positive DNA bands produced by these primers in the cDNA produced from RNA 
extracted from 3-month old rat LD are shown in figure 3.5-1. The size of DNA products produced by 
these primers correspond to the predicted product size in table 3.5-1 and so these bands were used 
as positive results with which to compare the products produced by the cells. 
Table 3.5-1 Basic PCR primers and predicted product sizes used to characterise rat-derived cells for MHC 
gene expression. 
Rat MHC Pimers for Isotyping 
MHC Gene Sequence Region of sequence Primers designed by Product Length (bp) 
Embryonic Myh 3 K02111 5' end Sanchez et 01. (2006) 181 
Neonatal Myh8 NM_012604 3' end Sanchez et 01. (2006) 103 
I / ~ ~ Myh 7 NM_Ol7240 3' end Jachinski et 01. (1998) 288 
IIa Myh 2 L1360 3' end Jachinski et 01. (1998) 310 
IIx Myh 1 XM_213345 3' end Jachinski et 01. (1998) 120 
lib Myh4 8C113948 3' end Jachinski et 01. (1998) 197 
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100 bp ladder RAT LD 
1500 ~ ~ r---:-----=..;==--=- -------. 
1 0 0 0 ~ ~
500 ~ ~
Figure 3.5-1 Expression of MHC in 3 month old rat LD verified using primers designed by Jaschinski et 0/. 
(1998) & Sanchez et 0/. (2006). PCR products electrophoresed in 1.5% agarose gel, lO1l1 of product 
synthesised from Sill cDNA template (equivalent to 0.1251lg RNA) loaded with 2111 dye, ladder is 100bp with 
major band sizes indicated. 
In rat primary skeletal muscle cell cultures both embryonic and neonatal MHC genes were expressed 
throughout differentiation and were still expressed after 7 days of development (shown in figure 3.5 
-2). Expression of MHC IIX (2X) is at a similar level to that of the neonatal and embryonic MHC genes 
and remains fairly constant throughout development, whereas expression of IIA (2A) appears to 
increase with age and liB (2B) declines. There is no expression of MHC I in these cells, although there 
is a very light band of the correct product size beginning to appear at 7 days post induction of 
differentiation. The basic PCR products produced by cDNA samples from the rat derived L6 Aston 
muscle cell line are shown in figure 3.5-3; the L6 Aston cell line is derived from the standard rat L6 
muscle cell line and the L6 Aston is a fusing derivative of this cell line. This image shows MHC 
expression is predominantly limited to the fast isoforms of MHC IIA (2A) and IIX (2X) at day 0 when 
fusion media was added to confluent myoblasts and these isoforms remain highly expressed 
throughout the course of differentiation . Around 2 days post differentiation, the cells beg in to 
express embryonic and liB (2B) MHC genes but there is no expression of neonatal or, cruc ially, MHC 
I / / . .
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Figure 3.S-2 Expression of MHC in rat primary muscle cells at four different ages post differentiation (day 0 is 
day media is substituted to cell fusion media). PCR products electrophoresed in 1.S% w/v agarose gel, l O ~ . l I I
of product synthesised from Sill cDNA template (equivalent to O.12Sllg total RNA) loaded with 2111 dye, 
ladder is lOObp with major band sizes indicated. 
lOObp ladder IOObpEmbNeo I 2A 2X 2B lOObpEmbNeo I 2A 2X 2B 
1500 ~ ~
Ill-! • 
1 0 0 0 ~ ~
500 ~ ~
Figure 3.S-3 Expression of MHC in the l6 Aston muscle cell line at four different ages post differentiation 
(day 0 is day media is substituted to cell fusion media). PCR products electrophoresed In 1.5% w/v agarose 
gel, lO1l1 of product synthesised from Sill cDNA template (equivalent to O.12Sllg total RNA) loaded with 2111 
dye, ladder is lOObp with major band sizes indicated. 
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3.5.3 Expression of MHC in Mouse Muscle cells 
Mirroring the experiment performed in rat muscle celis, mRNA from C2C12 cells was harvested at 
the same stages of differentiation and were isoform-typed using primers designed specifically to 
mouse. Primers designed by da Costa et al. (2007) were used to evaluate the MHC expression in 
C2C12 cells, summarised in table 3.5-2 along with the predicted product sizes. Positive PCR products 
were generated using cDNA extracted from mouse LD and the resulting bands produced are shown 
in figure 3.5-4. Primers for ~ - a c t i n n and Myf5 were also produced by da Costa et 01. and were tested 
in the same way to ensure they were expressed the cell line, positive products shown in figure 3.5-4 . 
Information for all these primers is presented in Appendix F. These primers were designed for real -
time PCR analysis for all of the MHC isoforms using a fluorescent probe for detection and so the 
relative intensity of the bands produced may not directly reflect the actual level of expressio n. These 
images can be assumed to be a guideline to represent the actual expression within the cell line . 
Table 3.5-2 Information for primers used to characterise MHC gene expression of C2C12 ce ll s. 
Mouse MHC primers & probes for qPCR, designed by da Costa et al. (2007) 
MHC Gene Sequence Region of sequence Product Length (bp) 
Embryonic Myh 3 XM_908146 5'end 72 
Neonatal Myh 8 NM 177369 3'end 142 
I / ~ ~ Myh 7 AY056464 3'end 116 
Iia Myh 2 NM_001039545 5' end 81 
IIx Myh 1 NM 030679 5' end 70 
lib Myh4 NM 010855 3'end 80 
Mouse LD 
lOObp ladder M P : o I ' I I i I ~ ~ ~
1 5 0 0 0 r w ~ ~ · · ·
1 0 0 0 ~ ~
500 ~ ~ ~ ~ , ,
Figure 3.5-4 Expression of MHC in Mouse lD muscle, verified using primers designed by da Costa et 01. 
(2007). PCR products electrophoresed in 1.5% agarose gel, 10111 of product synthes.ised fr.om 5111 C ~ N A A
template (equivalent to O.1251lg total RNA) loaded with 2111 dye, ladder is 100bp With major band SIZes 
indicated. 
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The basic peR produced from (2(12 cell cDNA are shown in figure 3.5-5 . From this image it can be 
seen that the (2(12 cells expressed a larger range of the M H( genes, although the band produced 
with the neonatal MH( primers was the most predom inant, bands of varying intensity can be seen 
for all the MH( isoforms. The expression of the fast isoforms IIA/2A, IIX/2X and IIB/2B appears to 
increase as the cells differentiate, whereas the MH( I / ~ ~ isoform seems to be most expressed during 
the process of differentiation at days 2 and 4. 
100 bp ladder r P i i ; ; m i i i i i r . ; j i i i ; ; r : ; : : ~ ; ; ~ ~ ~ ~ : : : : - : ~ ~ ~
1 5 0 0 ~ ~
1 0 0 0 ~ ~
500 ~ ~
100 bp ladder 
1 5 0 0 ~ ~
1 0 0 0 ~ ~
500 ~ ~
Figure 3.5-5 Expression of MHC in the C2C12 muscle cell line at four different ages post differentiation (day 0 
is day media is substituted to cell fusion media). PCR products electrophoresed in 1.5% agarose gel, lOlll of 
product synthesised from 5111 cDNA template (equivalent to O.12Sllg total RNA) loaded with 2111 dye, ladder 
is lOObp with major band sizes indicated. 
Days post Differentiation 
MHC-f,. 205kDa ~ ~
MHC-s., 205kDa ~ ~
Figure 3.5-6 Expression of MHC fast (MHC-f) and slow (MHC-s) in l6 and C2C12 cell lines at three stages post 
differentiation, where day 0 is time of substitution of media to cell fusion media., labelled 0, 2 and 4 days 
post different iation in diagram. Volume 30111 cell protein extracts (confluent cells extracted directly into 
SOOIlI SDS-mix) separated by SDS-PAGE using 8% acrylamide gel followed by western blotting, probed for 
MHC fast (MHC-f) and slow (MHC-s) (antibody information in Appendix D). 
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Following isotyping the cells at a gene leve" the expression of the fast and slow MHC isoforms was 
verified at the protein level using antibodies developed to either MHC fast, an antibody which 
detects all fast isoforms of the MHC, or MHC slow, both antibodies were optimized and verified by 
Sazili (2003). The resulting western blot produced is shown in figure 3.5-6, which demonstrates that 
there is an increasing expression of fast MHC at the protein level across differentiation in both the L6 
Aston and C2C12 cells with age. There is a similar effect seen in the expression of slow myosin at the 
protein level in the C2C12 cells whereas the MHC slow could not be detected in the L6 Aston cells at 
quantities of protein loaded. 
3.5.4 Results and Discussion: Characterisation of skeletal muscle cells for culture work 
The primary muscle cultures prepared from rat pups expressed MHC genes of a more immature fibre 
type, predominantly expressing the developmental embryonic and neonatal MHC genes and MHC IIX 
when myoblasts were induced to differentiate, but expression of MHC IIA increased as cells fused 
into myotubes. The L6 Aston rat derived cell line expressed a relatively "fast" phenotype, with MHC 
IIA and IIX predominantly expressed during the myoblast phase and the expression of embryonic and 
liB increasing as myotubes developed. The C2C12 mouse derived cell line was the only muscle cell 
type to express MHC 1/13 and expressed the largest range of adult MHC throughout the 
differentiation process. The assessment of the MHC expression was verified at the protein level for 
the L6 Aston and C2C12 cell lines, where the C2C12 cells were the only cell line to express MHC slow. 
The analysis of cell lines for their MHC expression at the mRNA level has not been reported in the L6 
Aston cell line although a study by de Arcangelis et 01. (2005) reported the L6 derivative cell line L6-
C5 expressed a similar expression of the MHC proteins using SDS-PAGE and western blotting 
techniques. The L6 cell line investigated in de Arcangelis et al.'s study was similar to the L6 Aston 
cells used in this thesis, with protein levels of MHC consisting predominantly of embryonic MHC, 
followed by neonatal MHC and MHC liB, although their study only reported the expression after 6 
days of differentiation. 
Despite the rat primary skeletal muscle cells being the model for the microarray, it was decided not 
to pursue the next experiments using these cells as they showed a high level of embryonic and 
neonatal isoforms and were only beginning to express MHC 1/13 at very low levels after 7 days of 
differentiation. The L6 Aston cells did express the more mature fast isoforms of MHC but there was 
no expression of MHC 1/13 at all and these cells were not viable for the subsequent experiment. 
The real-time qPCR primer designed to the mouse MHC genes had been used in study reported by 
da Costa et 01. (2008) who reported that the MHC profile of C2C12 cells was similar to the findings of 
the C2C12 reported in this chapter. The resolution observed with the primers used to evaluate MHC 
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gene expression in the mouse cells is quite low as the primers were designed for real time PCR using 
a probe for detection and so the products are small and are not highly visible, however, it can be 
concluded from these images that C2C12 cells have the widest expression of the MHC genes, and do 
express the MHC I / ~ ~ which was of importance to the experimental hypothesis. Therefore the C2C12 
cells were used to examine the effects of 1a(OH)D analogue on muscle cells in culture. 
3.6 Treatment of C2C12 cells with vitamin D analogue 1a(OH)D. 
Following selection of the C2C12 skeletal muscle cell line, the subsequent experiments were 
performed to investigate the effects of an active analogue of vitamin D on the differentiation of 
muscle cells. Cells were treated with the vitamin D analogue at a range of time pOints across 
differentiation so that vitamin D's effects on proliferation, the differentiation process and on MHC 
isoform expression in mature muscle cells could all be investigated. The aim of this study was to 
investigate whether a constitutively active vitamin D analogue, la-OH vitamin D (alfacalcidiol), could 
influence the expression of the MRFs and whether the time of the treatment across the 
differentiation process was a factor in the response of the cells to the vitamin D. If 1a(OH}D was to 
affect the process of differentiation then it was likely that the levels of expression of MRFs such as 
MyfS and myogenin would be altered. The process of myogenesis is regulated by the temporal 
expression of the MRFs and so measuring the changes in their expression would be an indicator of 
the progression of the cells through the myogenic programme. MyfS is expressed in the early days of 
myogenesis and is associated with the proliferation of myoblasts before they leave the cell cycle and 
begin to differentiate into myotubes. The initiation of differentiation into myotubes is then 
regulated by myogenin, which is expressed after MyfS in the myogenic programme and regulates 
the differentiation of the immature myoblasts into mature muscle cells. In their study Endo et 01. 
(2003) reported that treatment of C2C12 cells with 1,2S(OHhD3 when myoblasts were 80% confluent 
(at onset of differentiation) resulted in a decrease in MyfS and myogenin mRNA expression and 
decreased the level of expression of the MHC neonatal isoform. In addition to the changes in 
expression of the MRFs, the extent of differentiation can be evaluated by the presence of skeletal 
muscle proteins which are expressed in differentiated myotubes. Desmin is an early marker of 
muscle cell differentiation, and interacts with the sarcomeres laterally between each myofibril 
structure (see diagram 1.6-2) and therefore the expression of this protein at the mRNA level was 
measured. The second hypothesis of this investigation was that 1a(OH)D could alter the MHC 
isoform expression profile of muscle cells, and could induce cells to alter their MHC isoform 
expression. In order to assess these effects, the expression of the MHC was measured using real 
time RT-PCR. In addition, the effects of 1a(OH)D on expression of transcripts that had been 
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identified as responding to l,25(OHhD3 by the microarray experiment (described in section 3.4) was 
examined, these targets are summarised in table 3.4-9 . 
Prior to treatment with 1a(OH)D, it was important to be familiar with the cells in regards to the ir 
normal growth pattern and it was found that the cells were fully differentiated into multinucleated 
myotubes by 7 days after supplementation with cell fusion media. Figure 3.6-1 shows images of the 
(2(12 cells growing from the day before media was changed from cell growth media to cell fusion 
media, denoted day -1, up to 9 days after differentiation was induced . It was observed that 
myoblasts were beginning to elongate after 1-2 days of incubation in cell fusion media . Myotubes 
were apparent after 3 days of differentiation and by 7 days of differentiation the cells were fully 
differentiated. There was some infrequent spontaneous twitching of the cells observed at the very 
latest age of 9 days post differentiation . 
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Figure 3.6-1 Phase contrast microscopy (First image is magnification xS, all others magnification xlO) of 
(2(12 skeletal muscle cells, seeded at a density of 3 x 104 ce lls per w ell, images show cells throughout the 
process of differentiation from 80% confluence (day -1), fusion media added on day 0 and refreshed every 
48 hrs for 9 days. 
From these observations it was decided to treat cells at four different time points, the first being the 
addition of 1a(OH)D directly to the proliferating cells at 75% confluence in cell growth media, before 
adding 1a(OH)D to the cell fusion media when cells were around 90% confluent (day 0), after 3 days 
of differentiation when myotubes were beginning to appea r and after 7 days of later by which point 
mature myotubes were apparent. 
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At every time point, 1a(OH)D was supplemented at four decreasing concentrat ions; 10-sM, 10-7M, 
10-9M and 10-11M directly within the media and cells were incubated for 48 hours befo re protein and 
mRNA samples were harvested . A fifth set of cells designated as controls were treated with 0.1% 
DMSO within the media . The period of 48 hours for 1a(OH)D treatment was chosen in consideration 
of the effects observed in Endo et ol.'s (2003) study, 48 hours was the shortest treatment period 
with which they saw a response, and was also the longest period in which media could be left 
without need for change . A schematic timeline of the cell experiment is shown in figure 3.6-2 . 
riment 2 Experiment 3 eriment 4 
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Figure 3.6-2 Schematic time line of la(OH)D treatments directly on (2(12 muscle cells. Growth media in 
which cells were proliferating is depicted in grey, blue colour represents growth media treated with 
1a(OH)D. Maroon colour represents cell fu sion media, red represents cell fusion media treated with 
1a(OH)D. 
3.6.1 Results: Effects of 1u(OH)D on m ouse C2C12 muscle cell line. 
The morphology of the C2C12 cells duri ng the experim ent was imaged and the resulting 
photographs are shown in figure 3.6-3 . The photographs illust rate that the cells were able to fully 
differentiate during the experiment as had been expected . However it became apparent that the 
cells did not tolerate the highest dose of 1a(OH)D especially at the younger stages of development 
when myoblasts were st ill present. In the first two time points, 1a(OH)D at a concentration of 10-sM 
appeared to cause the cells to detach from the plate and prevented further proliferat ion, 
demonstrated by large voids across the growth surface . However, at the later stages of 
development, when myotubes had begun to appear, it seemed the cells tolerated the higher dose 
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and fewer cells detached. Following preparation of mRNA and protein there were no statistically 
significant differences found in the yield of either sample between the doses, and the mRNA 
produced from the cells is shown in Appendix H. The toxic effects of the highest dose became more 
apparent during qRT-PCR analysis when expression of certain genes were consistently low with the 
highest dose and frequently too low to measure with any confidence. As a result of these 
observations it was concluded that the highest dose was causing apoptosis to a certain extent and so 
it was decided to remove the 10-sM samples from the analysis of gene expression. 
The samples produced from the experiment essentially formed two separate experiments, the first 
investigating the effects of 1a(OH)D alone in cells which were still proliferating and the second was 
the effects of 1a(OH)D when treated with cell fusion media over the course of differentiation from 
myoblast to myotube. This course of treatment essentially produced two separate experiments, the 
first was to investigate the effects of 1a(OH)D on the onset of differentiation without the influence 
of the cell fusion media. The second experiment was designed to investigate 1a(OH)D's influence on 
the myoblasts as they grow over the full course of differentiation and in this experiment 1a(OH)D 
was administered within the cell fusion media. As a result the data collected from the two 
experiments was analysed separately, the first 1a(OH)D/cell growth media experiment was analysed 
using ANOVA while the 1a(OH)D/cell fusion media time course experiment was analysed using two-
way ANOVA. 
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Pre-confluence Myoblasts - Growth Media + Vitam in D 
Day 0 Myoblasts - Differentiation Media + Vitamin D 
Montage of Day 3 Myoblasts - Differentiat ion Media + Vitam in D 
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Day 7 Myoblasts - Differentiation Media + Vitamin D 
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Figure 3.6-3 Morphology of (2(12 ce lls fo llowing 48 hour treatment with 1a(OH)D. Myoblasts were imaged 
following 48 hour incubation in respective treatment media at X10 magnification immediately prior to 
mRNA and protein harvest. 
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3.6.2 Results: Effects of 1a(OH)D on mRNA expression of housekeeping genes during 
proliferation and differentiation of C2C12 myoblasts. 
Total RNA for qRT-PCR analysis was quantified using a Nanodrop Spectrometer, diluted to constant 
concentration and the integrity evaluated using agarose gel electrophoresis (described in sections 
2.7.3-2.7.4), the images of the electrophoresed RNA samples are shown in appendix H. The 
expression of a number of mRNA transcripts were measured using qRT-PCR and it was important to 
correct any variation in sample preparation by the measurement of a housekeeping gene which was 
expected to be unchanged by vitamin D3 treatment. ~ - a c t i n n had been used successfully as a 
housekeeping gene in the earlier work of this study performed in sheep where it had been 
unaffected by dietary vitamin D3 treatment, in addition, two other commonly used control genes, 
cyclophilin A and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were also assessed for this 
purpose. As described in section 2.13.7, two standard curves were used to evaluate changes in 
expression of transcripts. A standard curve was created from cDNA produced from the LD of a 
mature 3 month old mouse, and was used to quantify genes that were not expressed at a high level 
in the myoblast C2C12 cells, such as the adult MHC isoforms. In addition a second standard curve 
was created from cDNA produced from some C2C12 myoblasts that had been grown for 10 days in 
cell fusion media which could be used to analyse development genes such as embryonic MHC. Both 
standard curves were included in each gene expression assay for all experimental samples, and so 
each gene could be analysed using the most appropriate standard curve. As described in section 
2.13.8, it is necessary that the qRT-PCR reaction follows a linear reaction across varying 
concentrations to ensure accuracy of measurements and to achieve this, the standard curve must 
produce a linear response against which the unknown samples are compared. This meant that 
transcripts were analysed using the most suitable standard curve and all three housekeeping genes 
were analysed using both the mouse LD and the C2C12 standard curves, which provided evidence 
that the two standard curve approach produced similar data with similar responses. All comparisons 
were made within a gene and there were no comparisons made across genes, therefore the use of 
different standard curves did not affect the interpretation of results and simply provided a means to 
accurately evaluate relative changes within a gene caused by treatment. 
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3.6.2.1 Housekeeping in genes in proliferating myoblasts 
All samples had been normalized for total RNA concentration and had been checked for integrity 
using agarose electrophoresis, following these steps to ensure all total RNA samples were 
consistent; the RT step was performed at the same time to ensure variation between preparations of 
cDNA samples was minimal. It was found that mRNA expression of ~ - a c t i n n was significantly altered 
by la(OH)D treatment when proliferating C2C12 cells were treated with la(OH)D directly into their 
growth media. The effect of la(OH)D on the expression of ~ - a c t i n n was to significantly increase 
expression in cells treated with vitamin D at 10-11M compared to expression of cells treated with 10-
7M doses (table 3.6-1; P<0.05). Cyclophilin A and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) were also found to be significantly affected by vitamin D treatment (P<O.OOl and P<0.004 
respectively, table 3.6-1) with both genes showing a decreased expression with vitamin D doses 10-9 
and 10-7M in comparison to expression in the DMSO treated controls. In addition it can be seen in 
the data shown in table 3.6-1 where the relative expression of the genes in comparison to either the 
LD or C2C12 day 10 standard curves is shown, that both standard curves generate the same relative 
changes and levels of significance are similar, independent of the standard curve. 
Table 3.6-1 Expression of housekeeping genes in myoblasts treated with 1a(OH}D in growth media analysed 
using q-RT PCR. 
Oay-l Myoblasts: 48 hrs Vitamin D In Growth Media ANOVA P value 
Gene ( LD std curve) DMSO 10-7 10-9 10-11 S.E.D. Treatment 
Beta Actin 0.303 a 0.2S03abt 0.2966a 0.3S74act 0.01907 0.027 
Cyclophilin A 0.lS4a 0.0226b* 0.0443 b* 0.1169a 0.02109 <.001 
GAPDH 0.01419 a 0.00363 b* 0.006S8b* 0.0118S a 0.002127 0.004 
Oay-l Myoblasts: 48 hrs Vitamin D In Growth Media ANOVA P value 
Gene (C2C12 day 10 std curve) DMSO 10-7 10-9 10-11 S.E.D. Treatment 
Beta Actin 0.2147a 0.1824abt 0.2107a 0.2476act 0.01649 0.027 
Cyclophilin A 0.0996a 0.0131 b* 0.0261b* 0.0740a 0.01339 <.001 
GAPDH 0.0494a 0.007S b* 0.0168b* 0.0384a 0.00745 0.002 
Total RNA was diluted to constant concentration prior to cDNA synthesis, unknown samples were compared 
to standard curve generated using cDNA from either mouse LD or C2C12 cells 10 days post differentiation. 
ANOVA P value calculated with Genstat is shown in far right column. Values with the same superscript are 
not statistically different; t denotes Dunnet's test significance of P<O.OS, * denotes Dunnet's test 
significance of P<0.01. Values are arbitrary values produced in comparison to relative dilution of standard 
curves, n=3. 
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3.6.2.2 Housekeeping in genes across differentiation 
Three time points were used to investigate la(OH)D 's effects on differentiating myoblasts at 
different stages of differentiation, the identified time points were day 0 (first day of cell fusion 
media, predominantly myoblasts), day 3 (three days post induction of differentiation, myotubes 
beginning to form) and day 7 (7 days post addition of cell fusion media, fully differentiated 
myotubes). The same three genes were assessed for their possible use as housekeeping genes and 
their expression was measured across three ages of differentiation with each treatment and 
analysed as a two-way ANOVA. It was found that all three genes were significantly changed by either 
treatment or the stage of differentiation. The P values from the ANOVA are shown in the legends in 
figure 3.6-4, showing the level of significance for the effect of age (either day 2, 5 or 9 post 
differentiation), treatment and the interaction. ~ - a c t i n n was significantly changed by both age and 
treatment where expression was significantly decreased with growth post-induction of 
differentiation and the expression within the time points was affected by the treatment of vitamin 
D, demonstrated in figure 3.6-4-A. Cyclophilin A expression was not affected significantly by vitamin 
D treatment (P<O.302), however, the expression was affected by different stages of differentiation 
(P<O.002), shown in figure 3.6-4-B. GAPDH was the final gene investigated for its use as a 
housekeeping gene and was found to be affected by the time post differentiation (P<O.05) where its 
expression was higher during the appearance of myoblasts around days 3 to 5 after addition of cell 
fusion media, shown in figure 3.6-4-c' 
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Figure 3.6 4 Relative e)(pression of housekeeping genes quantified by real time RT-PCR, relative mouse lD standard curve, n=3 A) l3-actin, B) cyclophilin A and C) 
GAPHD, all at three stages post induction of differentiation with treatment of DMSO or la(OH)D at three concentrations. Error bars are SEM. 
152 
3.6.2.3 Average values of housekeeping genes 
The changes in expression of the candidate housekeeping genes were not surprising given that the 
cells were undergoing large changes over the course of differentiation and it would be difficult to 
find a gene which retained the same level of expression at all stages of myotube development with 
additional treatment. All three housekeeping genes were affected by treatment upon individual 
analysis in the pre-confluence myoblast experiment, while all three were affected by age but only 
beta actin was affected by treatment in the time course experiment. In an effort to find a value that 
was unchanged by treatment, an average of all three housekeeping gene values was taken and 
analysed for treatment and age effects. Additionally, as cyclophilin A and GAPDH were unaffected by 
treatment in the time course assay, an average of these two alone was also investigated for its 
potential as a normalisation value. It was found that both average values were still significantly 
affected by treatment in the pre-confluence myoblast experiment, shown in table 3.6-2. 
Table 3.6-2. Average values of housekeeping genes in myoblasts treated with 1a(OH)D in growth media 
analysed using q-RT PCR. 
Day -1 Myoblasts: 48 hrs Vitamin D in Growth Media ANOVA P Value 
DMSO 10-7 10-9 10-11 S.E.D. Treatment 
Average of all three Housekeeping genes 
LD Standard Curve 0.1571 0.0922 0.1158 0.1621 0.0112 <.001 
Day 10 Standard Cu rve 0.1212 0.0677 0.0845 0.12 0.00849 <.001 
Average GAPDH and Cyclophilin A 
LD Standard Curve 0.0841 0.0131 0.0254 0.0644 0.01146 <.001 
Day 10 Standard Curve 0.0745 0.0103 0.0214 0.0562 0.00988 <.001 
The same analysis for the time course experiment was performed, and average values of all three 
housekeeping genes and the average of cyclophilin A and GAPDH are shown in Appendix K, with the 
results from the two-way ANOVA analysis. Both the average of all three housekeeping values and 
the average of cyclophilin A and GAPDH were significantly affected by age (P<0.001, P<0.01 
respectively, Appendix K). The average of all three genes was also approaching a significant affect of 
treatment (P=O.058 and P=0.083 for LD and Day standard curves respectively, Appendix K) although 
the average of GAPDH and cyclophilin A was not affected by 1a(OH)D treatment (P=0.303 and 
P=0.274 for LD and Day 10 standard curves respectively, Appendix K). 
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3.6.3 Summary of Housekeeping Genes 
All three housekeeping genes were significantly changed by la(OH)D treatment in the first 
experiment where myoblasts were treated with vitamin D directly in their growth media, results 
showed that la(OH)D at the higher doses of 10-9 and 10-7M caused significant reductions in the 
expression of these genes. These results meant that none of the three potential housekeeping genes 
could be used to normalise subsequent genes of interest in this experiment. In the second 
investigation where la(OH)D was added to cell fusion media at three stages of differentiation, the 
treatment was found to have less effect on the expression of cyclophilin A and GAPDH in maturing 
cells; however f3-actin was significantly affected by la(OH)D at all three ages. When the individual 
values for each potential housekeeping gene were averaged the effects of treatment remained in 
the pre-confluence myoblast experiment, and again when the average of cyclophilin A and GAPDH 
was analysed. The effects of age and treatment remained when all three of the housekeeping genes 
were averaged in the time course experiment. There was no effect of treatment on the average of 
cyclophilin A and GAPDH but there was still a significant effect of age. 
The results reported within this section show significant effect of both la(OH)D treatment and age 
on the raw values for each housekeeping gene individually and those values obtained when the 
average of either all three, or two genes, cyclophilin A and GAPDH, were analysed. Despite efforts to 
find a value which was unaffected by age and treatment, there was no value which was unaffected, 
and in light of the nature of sample preparation whereby the variability in each step was kept to a 
minimum by: 
1. the concentration of all samples was checked using the Nanodrop spectrometer 
2. all samples were diluted to a constant concentration 
3. total RNA samples diluted to a constant concentration were then electrophoresed in agarose 
gels using a constant load of total RNA and then imaged to check visually for uniformity 
between samples 
4. the RT step on all samples was carried out at the same time using the same method and 
reagents; 
it was concluded that the cDNA produced would contain minimal variation and so subsequent gene 
expression analysis was performed without normalisation to a housekeeping gene and instead 
expression values are reported relative to the arbitrary concentration of the appropriate standard 
curves. To evaluate the variability in the real-time RT-PCR method three replicates of each individual 
sample were used, with three biological replicates for each age and treatment. 
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3.6.4 Results: Effects of 1a(08)D on mRNA expression of markers of differentiation 
during proliferation and differentiation of C2C12 myoblasts. 
The mRNA expression of two MRFs, Myf5 and myogenin were measured to evaluate the stage of 
differentiation of the C2C12 cells during the experiment. Myf5 is a regulator of the early stages of 
myogenesis when C2C12 myoblast cells are still proliferating; in comparison myogenin is expressed 
at later stages of differentiation of muscle cells when myoblasts are maturing into multinucleated 
myotubes (Dedieu et 01., 2002). It was expected that Myf5 expression would decrease when cells 
began to differentiate and that myogenin expression would become more dominant as myotubes 
appeared. As another marker of the extent of differentiation, the expression of desmin mRNA was 
also measured as its appearance would coincide with the formation of the skeletal muscle specific 
protein structures as myoblasts differentiated. 
3.6.4.1 Expression of markers of differentiation in proliferating myoblasts 
In the first experiment treating proliferating myoblasts with la(OH)D in their growth media (prior to 
differentiation, shown in figure 3.6-3), it was found that the expression of the myogenic regulatory 
factors Myf5 and myogenin were significantly affected by treatment, data shown in table 3.6-3. The 
expression of Myf 5 mRNA was decreased by 10-9 and 10-7 M doses of la(OH)D causing Myf5 
expression to be reduced by 46% and 69% respectively. Myogenin expression was decreased 
significantly by 72% with the 10-7M dose of la(OH)D. Desmin was unchanged by la(OH)D treatment 
in proliferating myoblasts (P=0.394). 
Table 3.6-3 mRNA expression of markers of differentiation in Myoblasts treated with la(OH)O in growth 
media. 
Day-l Myoblasts: 48 hrs Vitamin 0 In Growth Media 
Gene OM50 10-11 
MyfS 
Myogenin 
Desmin 
0.1054a 
0.371a 
0.218 
0.1197a 
0.321a 
0.2512 
10-9 
0.0563bt 
0.163ab 
0.2133 
ANOVA P value 
10-7 5.E.0. Treatment 
0.032b* 0.01414 <.001 
0.102bt 0.0803 0.03 
0.2256 0.02249 0.394 
Values with similar superscript are statistically the same, t denotes Ounnet's test significance of p<o.OS'. * 
denotes Ounnet's test significance of P<O.01. Values measured by qRT-PCR are arbitrary values produced In 
comparison to relative dilution of standard curves, n=3. 
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3.6.4.2 Expression ofmarkers of differentiation in differentiating muscle cells 
In the time course experiment these markers of differentiation were measured at progressive stages 
of myogenic development and it was found that expression of Myf5 and myogenin were both 
significantly changed by time during the process of myotube development (P<O.001 and P<O.01 
respectively, significance values shown in legends of figure 3.6-5, raw data shown in appendix J). 
However, there was no effect of 1a(OH)D treatment on these factors and there was no subsequent 
interaction between time after the addition of cell fusion media and the treatment given. Myf5 
expression was lowest at the earliest age of cells, 2 days post induction of differentiation, then 
increased to its highest levels at day 5 post onset of differentiation at which point myotubes were 
appearing, demonstrated in figure 3.6-5-A. Over the whole experiment, Myf5 expression was highest 
after 5 days post differentiation with 48 hour treatment with 1a(OH)D. By the final stages of 
myogenesis, after 9 days of differentiation, myotubes were predominant and the expression of Myf5 
mRNA was decreased again. The expression of myogenin followed a different spatial pattern and 
was found to start with the highest level of mRNA expression 2 days post differentiation and this 
expression was decreased with the progression of the differentiation process, shown in figure 3.6-5-
B. Finally, the expression of desmin, which had been proposed as a marker of the extent of mature 
muscle cell formation, was found to remain at a relatively constant level of expression throughout 
the process, shown in figure 3.6-5-C, and there was no significant effect of time on the relative 
mRNA expression values (P=O.988). However, the expression of desmin was affected by 1a(OH)D 
treatment (P=O.016) where expression appeared to be lower at days 2 and 9 post differentiation 
when the cells were treated with 1a(OH)D at 10-9M concentration. 
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157 
3.6.5 Results: Effects of la(OH)D on MHC gene expression. 
To investigate la(OH)D IS effects on skeletal muscle formation and fibre type of muscle cells, the 
expression of all 6 MHC genes was measured. Endo et al. (2002) had reported a decrease in the 
mRNA expression of MHC neonatal and proposed l,25(OHhD3 treatment could influence the 
differentiation of muscle cells via altering the normal expression of the MHC genes through 
development. Further, the possibility for l,25(OHhD31s ability to alter calcium status in tissues could 
simultaneously, albeit indirectly, modify fibre type of muscle tissue via mechanisms previously 
described in section 1.3.5. 
3.6.5.1 Expression of MHC genes in proliferating myoblasts 
All 6 MHC genes were measured for their expression in proliferating myoblasts and the effects of 
vitamin D alone on the MHC gene expression at this stage were minimal. Expression of neonatal 
MHC and MHC IIA were too low to be quantified accurately and no data was collected for these 
genes. Embryonic MHC and I / ~ ~ were the most predominant MHC genes to be expressed at this stage 
and was estimated at around 10 fold higher than the expression of the other adult MHCs; MHC IIX 
and MHC liB, relative expression values in arbitrary units shown in table 3.6-4. MHC liB was the only 
MHC gene to be significantly changed by la(OH)D treatment with expression decreasing with 
increasing dose of la(OH)D (P<0.05), with expression decreasing 51% and 65% with 10-9M and 10-7M 
respectively, relative to 0.1% DMSO control. It did not appear that there was any subsequent rise in 
another MHC gene to compensate for the reduction of MHC liB. 
Table 3.6-4 Expression of MHC genes in C2C12 myoblasts treated with 1a(OH)D in growth media. 
Day-1 Myoblasts: 48 hrs Vitamin 0 In Growth Media ANOVA P value 
Gene DMSO 10-11 10-9 10-7 S.E.D. Treatment 
Embryonic MHC 0.0311 0.0354 0.0268 0.0301 0.00325 0.142 
Neonatal MHC Not Expressed N/A N/A 
M H C I / ~ ~ 0.0295 0.0334 0.0268 0.0306 0.00746 0.847 
MHCIIA Not Expressed N/A N/A 
MHC IIX 0.0196 0.0198 0.0125 0.0123 0.00356 0.119 
MHX liB 0.OO1027a 0.OO1023a 0.OOO502a 0.OOO354
bt 
0.0002089 0.023 
Values with similar superscript are statistically the same, t denotes Dunnet's test significance of P<O.OS, • 
denotes Dunnet's test significance of P<O.Ol. Values analysed by real-time RT-PCR are arbitrary values 
produced in comparison to relative dilution of standard curves, n=3. 
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3.6.5.2 Expression of MHC genes in differentiating muscle cells 
All MHC genes were significantly changed throughout the course of differentiation (P<O.OOl, full 
data shown in Appendix J) with the expression of the embryonic isoform decreasing with age and 
simultaneously the adult isoforms became more predominant. Again, the expression of neonatal 
MHC was too low to detect with any certainty and data was not included for this gene. The changes 
in expression of the MHC genes over the course of differentiation are illustrated in figures 3.6-6 _ 
3.6-7, where the large decrease in embryonic MHC and the increase in the adult isoforms are 
apparent. The expression of embryonic MHC was significantly reduced with the onset of 
differentiation with the relative expression reduced by 12% and 35% after 5 and 9 days of 
differentiation in the DMSO controls. The response of the C2C12 cells in their embryonic MHC 
expression seemed to form a dose response, with the cells reacting similarly to each dose of 
la(OH)D at each progressive stage of development. At the earliest stage of development, 2 days 
post cell fusion media, the lower doses of 10-l1M and 10-9M decreased embryonic MHC expression 
by 5% and 17% respectively, there was little difference in the expression between the DMSO 
controls and the highest dose of 10-7M la(OH)D. This response was observed again at the second 
age of development, during myotube appearance, where la(OH)D at 10-l1M and 10-9M reduced 
embryonic MHC expression by 10% and 7 % respectively and there was little change with the highest 
1a(OH)D concentration. Finally, at the latest stage of differentiation, when the myotubes were most 
predominant, the effect of la(OH)D at 10-l1M and 10-9M concentrations was to reduce expression 
by 10% and 20% respectively. This significant effect of la(OH)D on the expression of embryonic MHC 
is reinforced by the lack of interaction between age and treatment (figure 3.6-6) and therefore can 
be interpreted as a stand-alone effect of la(OH)D on muscle cells. 
The expression of all four adult MHC isoforms was affected by age in this experiment, but only MHC 
I / ~ ~ was affected by vitamin D treatment. Expression of MHC IIA, IIX and liB increased with time in 
line with the appearance of multinucleated myotubes, whereas the expression of MHC I / ~ ~ declined. 
Expression of MHC 1/J3 in the DMSO controls declined with age, where expression was reduced by 
41% by 5 days post differentiation and by 50% after 9 days of differentiation in comparision to MHC 
I / ~ ~ expression after 2 days differentiation. Similar to the pattern of embryonic MHC expression, the 
effect of la(OH)D treatment was to significantly reduce the expression of MHC 1/J3 (P<0.05, figure 
3.6-7-A) in comparison to DMSO controls at day 2 and day 9 post differentiation (compare figures 
3.6-6. and 3.6-7-A). la(OH)D caused an decrease in the expression of MHC 1/J3 after 48 hours 
treatment at the onset of differentiation, with the lower doses of 10-l1M and 10-9M causing the 
largest reductions of 15% and 27% respectively. During the transitional stage of myotube formation, 
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5 days post differentiation, the highest dose of la(OH)D at 10-7M caused an increase in the 
expression of MHC I / ~ ~ of 48.5%. At the final stage of development, when mature, multinucleated 
myotubes were predominant, only the lowest dose of la(OH)D had an effect on MHC I / ~ ~ expression, 
with la(OH)D at a concentration of 10-11M causing a reduction in expression by 25.1%. The fast adult 
isoforms of the MHC genes, IIA, IIX and liB were not affected by la(OH)D treatment (P= 0.275,0.204 
and 0.431 respectively, see figures 3.6-7 B,C and D ) although these were increased significantly 
through the process of myotube formation. The expression of MHC IIA was relatively unchanged 
after 5 days post differentiation but after 9 days the expression was 6 fold higher than in the early 
differentiating myoblasts. Expression of MHC IIX mRNA was also increased throughout the course of 
differentiation, increasing by 18% after 5 days of differentiation and by 99% after 9 days 
differentiation, meaning expression of MHC IIX doubled in the mature multinucleated myotubes in 
comparison to differentiating myoblasts. Finally MHC liB expression rose by 55% after 5 days of 
differentiation and after 9 days this had increased to 3 times the expression than had been observed 
in the early differentiating myoblasts. Overall these results show that the expression profile of the 
MHC isoforms was changed throughout the course of differentiation, with the expression of the 
embryonic and MHC I / ~ ~ isoforms decreasing and the expression of the fast adult MHC isoforms 
rising in parallel. However comparisons between changes in the expression of isoforms cannot be 
made directly as they have been measured using different primers and probes with differing 
reaction efficiencies, therefore it cannot be surmised as to whether the rise in fast MHC makes up 
for the fall in embryonic MHC, and therefore isoform switching cannot be fully evaluated. The 
expression of embryonic MHC decreased by a third during differentiation and MHC I / ~ ~ by half, and 
given that relative mRNA expression of these isoforms was around 10 times that of the MHC fast 
isoforms, this reduction is the beginning of a transition. The relative expression of MHC IIA, IIX and 
liB increased by 6-, 2- and 3 fold between the early myoblast stage through to the presence of fully 
differentiated myotubes. Overall, while these changes are significant with time, it does not show a 
large change in isotype of the cells after 9 days of differentiation. 
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3.6.6 Effect of dietary vitamin D on MHC expression in sheep trials 
In light of the treatment effects observed on the MHC genes in the cell culture experiments, the 
expression of the adult MHC genes were investigated in the dietary sheep trials previously reported 
in this thesis. 
3.6.6.1 Effect of two dietary vitamin D regimes on mRNA expression of adult MHC genes in 
sheep 
There was no effect on the mRNA expression of the adult MHC isoforms in sheep fed a high dose of 
vitamin D for 4 days immediately prior to slaughter or when sheep were fed vitamin D for 7 days 
with an extra bolus on the last two days immediately prior to slaughter, data shown in table 3.6-5. 
Table 3.6-5 Effect of two vitamin 0 feeding regimes immediately prior to slaughter on relative expression of 
mRNA of adult MHC genes 
LDmRNA 4 Days Vitamin D 
MHC Genes: Beta Actin Ratio Control Vitamin D S.E.D. P 
MHCI 0.7732 0.9936 0.148 0.160 
MHCIIA 0.9522 0.8966 0.144 0.646 
MHC IIX/IIB 0.9042 0.8965 0.120 0.954 
7 Days Vitamin D + Ca 
MHCI 0.9760 1.0730 0.172 0.618 
MHCIIA 1.1550 1.0480 0.099 0.326 
MHC IIX/IIB 1.0720 0.9900 0.119 0.418 
Values are expressed as ratio of relative mRNA expression of MHC gene: f3-actin, values are arbitrary units 
produced from real-time RT-PCR analysis, n=18. 
3.6.6.2 Effect of 7 days Vitamin D3 + Ca on protein levels of MHC Genes in ovine LD 
The expression of myosin heavy chain at the protein level was measured using two antibodies, one 
developed to the slow MHC protein the other to all fast varieties of the protein, antibody data 
presented in Appendix D, verified to cross react with sheep LD by Sazili (2003). 
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Table 3.6-6. Effect of 7 days vitamin D & Ca on MHC fast and slow protein levels in ovine LD. 
7 days vitamin D + Ca Absorbance/ 3 J.Ig protein 
LD muscle protein Control Vit D S.E.D. P 
MHCSlow 2.631 2.651 0.717 0.981 
MHC Fast 7.419 7.457 0.742 0.955 
SID D C D C D C STD 
MHCFast 205 kDa .- - - ..... -
_ . 
.... ...... 
MHCSlow 205 kDa --- ' ..... 
Figure 3.6-8 Representative image of Myosin Heavy Chain fast and slow, visualized at 205kDa following SDS-
PAGE of 31lg whole homogenate fraction of LD using 8% acrylamide gel. Further antibody information 
presented in Appendix D, MHC fast n=13, MHC slow n=8. 
3.6.7 Summary of MHC gene expression 
The expression of embryonic MHC across the course of differentiation was significantly reduced and 
the effects of la(OH)D on this mRNA was consistent for each time point, with la(OH)D decreasing 
the expression of embryonic MHC when administered at the lower doses of lO-l1M and lO-9M. This 
response is convincing evidence that la(OH)D has a direct effect on the embryonic MHC isoform and 
upon treatment the cells reduce their expression of this isoform, the consequence of which is that 
the cells progress from an immature MHC isoform expression to a more adult MHC expression 
profile, which supports the notion that la(OH)D promotes muscle cell differentiation. Analysis of the 
effects of the two sheep trials did not indicate an effect of the dietary supplementation regimes on 
the expression of the mature MHC isoforms, despite significant changes in the circulating levels of 
vitamin D in both trials and of serum and muscle calcium in trial 2. 
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3.6.8 Results: Effect of lu(OH)D on transcripts up-regulated by 1,25(OH)2D3. 
The results of the microarray shown in section 3.4 highlighted a small selection of genes which were 
up-regulated by the treatment with l,25(OHhD3 in a dose response. Three of these genes were 
retinol binding protein (Rbp4), metallothionein 2A and C / E B P ~ , , all of which showed significant up-
regulation with l,25(OHhD3 treatment in comparison to controls, and the extent of the increase in 
their expression was higher with increased dose of l,25(OHhD3, see table 3.4-9. It was decided to 
measure the expression of these genes in the final la(OH)D Icell culture trial to investigate their 
validity as end-points of vitamin 0 signalling. The hypothesis was that if these genes were 
significantly changed by both concentrations of l,25(OHhD3 in the microarray then they should 
respond in the same way to the active analogue la(OH)D. To measure these genes primer and 
probes were purchased from ABI (Applied Biosystems) as "assays on demand" and the product and 
gene code are shown in Appendix G. It was found that despite large changes in Rbp4 in response to 
l,25(OHhD3 as measured by microarray in rat primary muscle cells, the expression of Rbp4 in the 
C2C12 was too low to detect with any degree of certainty and no data is shown for this gene. 
3.6.8.1 Effect of la(OH)D on mRNA expression of 1,25(OH)zD3 targets in proliferating 
myohJasts 
Three of the four l,25(OHhD3 targets were found to be significantly changed when proliferating 
myoblasts were treated with la(OH)D directly in cell growth media. C / E B P ~ ~ is a transcription factor 
which was found to show a dose response to 1,25(OHhD3 as measured by the microarray, where it 
was up-regulated in comparison to the DMSO control. In this experiment the expression of C / E B P ~ ~
was up-regulated significantly by la(OH)D at the lowest dose of 10-11M showing a 10 fold increase in 
relative expression in comparison to DMSO control (P<0.002, table 3.6-7), the higher doses of 
la(OH)D did not cause significant changes in the expression of this gene. In addition, 
metallothionein 2A was another target discovered by microarray which was shown to respond to 
l,25(OHhD3 and data from this experiment suggested a trend for changes in its mRNA expression, 
whereby metallothionein 2A expression was decreased in the highest dose of 10-7M in comparison 
to the DMSO control. Parvalbumin has been reported as a l,25(OHhD3 responsive gene in a number 
of tissues (De Viragh et 01., 1989; Antrobus et 01., 1995); however this experiment showed no effect 
of la(OH)D on the expression of parvalbumin in proliferating myoblasts. Finally c-Myc expression 
was reported to increase with vitamin 0 treatment (Drittanti et 01., 1989) and was implicated as a 
target of the IGF-l and PI3K signalling pathway (Sears et 01., 2000) which promotes muscle growth 
(Latres et 01., 2005) and was reported to be a marker of atrophy (Grounds M.D., 2002). It was found 
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that the expression of c-Myc was significantly reduced in the two higher doses of la(OH)D at lO-9M 
and lO-7M by 53% and 81% respectively. 
Table 3.6-7 Effect of 1a(OH)D on expression of 1,2S(OHhD3 targets in Myoblasts treated within growth 
media. 
Oay-1 Myoblasts: 48 hrs Vitamin 0 In Growth Media ANOVA P value 
Gene OMSO 10-11 10-9 10-7 S.E.O. Treatment 
C / E B P ~ ~ 0.064a 0.698b* 0.088a 0.0310a 0.1259 0.002 
Metallothionein 2A 0.0658 0.0508 0.0734 0.0122 0.02156 0.084 
Parvalbumin 0.0118 0.0077 0.0079 0.012 0.0041 0.595 
c-Myc 0.0663a 0.0569a 0.0309
bt 0.0148b* 0.01181 0.009 
Values with the same superscript are not statistically different, where superscript letters are different t 
denotes Ounnet's test significance of P<O.OS, * denotes Dunnet's test significance of P<O.Ol. Values analysed 
by real-time RT-PCR are arbitrary values produced in comparison to relative dilution of standard curves, n=3. 
3.6.8.2 Effect of la(OH)D on mRNA expression of l,2S(OH)2D3 targets in differentiating 
muscle cells 
All four targets of l,25(OHhD3 signalling were found to be significantly changed by treatment with 
1a(OH)D during the process of myotube formation in comparison to DMSO controls, P-values from 
two-way ANOVA analysis shown in legends of figure 3.6-9, complete data set is shown in Appendix J. 
Both targets of l,25(OHhD3 highlighted in the microarray performed in rat primary muscle cells in 
this study were found to again be affected by la(OH)D treatment in C2C12 cells when compared 
with expression in DMSO controls. C/EBPI3 was significantly increased by la(OH)D at all three time 
points, shown in figure 3.6-9-A, by all three concentrations of la(OH)D. 
The fold changes in the expression of C/EBPI3 were consistently high. At each time point in the 
development process, the largest changes in expression of C/EBPI3 were caused by the lowest 
concentration of vitamin 0 lO-l1M, giving 4.1, 7.8 and 8.4 fold increases in the expression of C/EBPI3 
at days 2, 5 and 9 post differentiation respectively, shown in table 3.6-8. 
Table 3.6-8 Fold changes in C/EBPj3 expression affected by 1a(OH)0 treatment relative to OMSO controls 
across the differentiation process. 
Fold Changes in C/EBPj3 expression in Time Course Experiment 
Days Post Differentiation 
2 
5 
9 
Vitamin 0 Concentration (M) 
10-11 10-9 10-7 
4.1 2.7 3.4 
7.8 
8.4 
5.7 
2.3 
7.3 
4.9 
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Figure 3.6-9 Relative expression of A) C/EBPJ3, B) metallothionein 2A, C) parvalbumin and D) c-Myc (all relative expression to day 10 standard Curve) at three stages 
post induction of differentiation, n- 3. Error bars are SEM. 
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Expression of metallothionein 2A mRNA was similarly affected by both la(OH)O treatment and time, 
and showed an interaction between the time and dose of la(OH)O (Figure 3.6-9-8). Expression of 
metallothionein 2A was high in the early stages of myogenesis in the OMSO controls before 
expression was significantly reduced by 75% after the appearance of myotubes. Treatment of the 
myoblasts with la(OH)O at the onset of differentiation caused a significant decrease in the 
metallothionein 2A expression, with each increasing dose of vitamin 0 10·l1M, 10·9M and 10·7M 
reducing it to 60, 78 and 73% of the expression observed in the OMSO control. This decrease in 
metallothionein 2A mRNA expression with la(OH)O treatment was enough to reduce expression to 
the same levels observed after 5 days differentiation in the OMSO control cells and this response 
may be due to la(OH)O inducing differentiation earlier than was observed in the DMSO controls. 
The response of the cells to la(OH)O at days 5 and 9 post differentiation was different again, with 
la(OH)D at the intermediate dose causing an increase in metallothionein 2A in comparison to DMSO 
controls of cells at 5 days post differentiation, and at the same dose causing a decrease in the 
expression at 9 days post differentiation. The highest and lowest concentrations of 10·7M and 10·l1M 
did not produce responses largely different to the DMSO control cells. There was a trend for 
parvalbumin expression in C2C12 cells to be affected by age (P=0.058) and treatment (P=0.076) but 
there was no interaction between the two. Expression of parvalbumin increased with appearance of 
myotubes (as observed in the DMSO controls), rising by 56% from 2 to 5 days post differentiation, 
from which point expression rose slightly again by 5% between days 5 and 9 post differentiation, see 
figure 3.6-9-C. The effect of treatment with la(OH)D on expression of parvalbumin mRNA in C2C12 
cells at 5 days post differentiation was to raise mRNA levels 1.2, 1.3 and 1.4 fold with decreasing 
la(OH)D concentration; 10·7M to 10·l1M respectively. The effects of the three doses of la(OH)O at 
either the early myoblast stage, 2 days post differentiation, and after 9 days of differentiation when 
myotubes were predominant, on parvalbumin expression was to slightly reduce expression with the 
intermediate dose of 10·9M but to raise expression with the highest concentration, 10·7M. This effect 
was greatest in the differentiated myotubes after 9 days of differentiation where the highest dose of 
la(OH)O, 10·7M, caused a 2-fold increase in parvalbumin expression in comparison to control cells at 
the same stage of development. The final target gene of l,25(OHhD3 signalling was c-Myc which was 
significantly changed with age (P<O.OOl) and showed a trend to be affected by la(OH)D treatment 
(P=0.08), and there was no interaction between age and treatment (Figure 3.6-9-D). The expression 
of c-Myc was highest after 5 days of differentiation when the myoblasts were fusing and myotubes 
were beginning to appear, see figure 3.6-9-0. C-Myc expression was 1.5 fold higher at this stage than 
after 2 days post differentiation. The expression of c-Myc was lowest after 9 days of differentiation 
where expression was 56% lower than at day 2 post differentiation. The effect of la(OH)O was 
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unclear at the earlier and later stages but there was a clear effect at the intermediate stage of 
differentiation where vitamin D at 10-9M and 10-7M cause a decrease in c-Myc expression by 31% 
and 21% respectively. 
3.6.9 Summary 1u(OH)D effects on transcripts which responded to l,25(OH)2D
3 
The transcription factor C / E B P ~ ~ was significantly increased 10-fold by 10-l1M dose administered 
within cell growth media. C-Myc was significantly decreased 53% and 77% by the 10-9 and 10-7 M 
doses of la(OH)D respectively. Binding proteins metallothionein 2A and parvalbumin were not 
changed significantly by la(OH)D treatment, although there was a trend in metallothionein 2A to be 
decreased by la(OH)D treatment (P<O.l).The data in table 3.6-7 shows that la(OH)D at the higher 
concentrations of 10-
9 
and 10-7M appeared to cause down-regulation of c-Myc mRNA expression in 
proliferating myoblasts. 
In the time course experiment all four targets of la(OH)D were significantly affected by age and 
treatment. la(OH)D treatment was most potent in increasing the expression of C / E B P ~ ~ mRNA in a 
dose response at every time point. Additionally, la(OH)D decreased expression of matellothionein 
2A with a significant interaction of age and time (P=0.005), where the effect of 1a(OH)D at the 
earlier time of 2 days post differentiation was to reduce expression of metallothionein 2A with each 
dose. 
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3.6.10 Results: Effects of la(OH)D on protein signalling. 
The effect of 1a(OH)D treatment of the extent of phosphorylation of two proteins related to cell 
growth and protein synthesis was evaluated, these were the mitogen-activated protein kinase 
(MAPK), extracellular signal-regulated kinase 1/2 (ERK 1/2), and the enzyme, eukaryotic translation 
initiation factor 4E binding protein 1 (4EBP1), respectively. 
3.6.10.1 Effects of 1a(OH)D on protein targets in proliferating C2C12 myob/asts 
The level of phosphorylation of the MAPK, ERK 1/2, was assessed using antibodies for both total and 
phosphorylated versions of the protein before the level of phosphorylation was calculated using a 
ratio of the levels of phosphorylated protein to the level of total protein; representative images of 
the protein blots are shown in figure 3.6-10, values are shown in table 3.6-9. There was a significant 
effect of 1a(OH)D on the extent of phosphorylation of ERK1/2 (P<0.002), with 1a(OH)D at 10-9M 
dose significantly decreasing the level of phosphorylation of this enzyme by 36% (P<O.Ol) and by 
21% with the 10-7M dose (P<0.05). There was no effect of 1a(OH)D treatment on level of 
phosphorylation of 4EBP1 in proliferating myoblasts, data shown in table 3.6-9. 
Table 3.6-9. Effect of la(OH)D treatment on level of phosphorylation on two protein targets in proliferating 
myoblasts 
Phosphorylation of Protein DMSO 10-11 10-9 10-7 S.E.D. P 
Ratio ERK 1/2 0.906a 0.714bt 0.571b* 0.854a 0.0585 0.002 
Ratio4EBPl 0.906 0.885 1.003 0.960 0.0591 0.259 
Values with similar superscript are statistically the same, t denotes Dunnet's test significance of P<O.OS, * 
denotes Dunnet's test significance of P<O.Ol. Values are ratio of phosphorylated protein to level of total 
protein, n=3. 
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Figure 3.6-10 Representative blot of (2(12 proteins analysed by 50S-PAGE followed with western blotting 
using antibodies for total protein before stripping the membrane and re-probing with the antibody to the 
phosphorylated protein fraction. Total MAPK ERK 1 /2 and Phosphorylated MAPK ERK 1 /2: 51lg cell (2C12 
protein separated by 50S-PAGE using 10% acrylamide gel; Total 4EBP1 and phosphorylated 4EBP1: 51lg cell 
(2C12 protein separated by 50S-PAGE using 15% acrylamide gel. Further antibody information presented in 
Appendix 0, n=3. 
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3.6.10.2 Effects of la(OH)D on protein targets in differentiating C2C12 muscle cells 
The effect of la(OH)D treatment on the level of phosphorylat ion of both ERK1/2and 4EBP1 was 
measured in muscle cell protein extracts taken from muscle cells across the course of differentiation 
following 48 hours treatment with the analogue, representative protein blots are shown in figure 
3.6-11, raw data is shown in Appendix Land P-values of two-way ANOVA shown in legends of figure 
3.6-12. The phosphorylation of ERK1/2 was found to be significantly affected by the age of the cells 
(P=0.016), with phosphorylation of ERK1/2 being highest during the transition of the cells from 
myoblasts to multinucleated myotubes, and phosphorylation of ERK1/2 remained high after 7 days 
of differentiation in comparison to the level of phosphorylation when cells were predominantly 
myoblasts, shown in figure 3.6-12-A. Treatment of the cells with 1a(OH)D was found to decrease the 
extent of phosphorylation (P<O.OOl) at all age points, and there was interaction between the age of 
the cells and dose of vitamin D (P=0.007). The decrease in extent of phosphorylation was greater 
when cells were treated at 3 days post induction of differentiation, where the 1a(OH)D treatment at 
10-11 and 10-9M reduced the extent of phosphorylation by 56% and 62% respectively . This response 
was similar again when cells were treated 7 days post induction of differentiation, where treatment 
of muscle cells which were predominantly multinucleated myotubes with 1a(OH)D again caused a 
decrease in the extent of phosphorylation of ERK 1/2 by 42% with both 10-11M and 10-9M doses and 
by 50% with 10-7M. 
The was a significant effect of differentiation on the level of phosphorylat ion of 4EBP1 (P=0.019, raw 
data in Appendix L, P-value of two-way ANOVA shown in legend of figure 3.6-11-B) where 
phosphorylation of 4EBPl was high during the early stages of differentiation when myoblasts were 
still present, and decreased after 7 days of differentiation, shown in figure 3.6-12-B. There was no 
effect la(OH)D in the level of phosphorylation of 4EBPl (P=0.852) . 
172 
-
Total 
MAPK 
ERK 
1 12 
44/42 kDa 
Phospho 
MAPK 
ERK ~ ~
1/2 
44/42kDa 
Total 
4EBPI 
18.5 kDa 
Phospho 
4EBPl 
18.5 kDa 
~ ~
la(OH)D in cell fusion media of differentiating myoblasts 
Day2 day 5 Da v 9 
Con 10-7 10-910-11 Std Con 10-7 10-9 10-11 Con 10-7 10"-9 10-11 Std 
Figure 3.6-11 Representative blot of C2C12 proteins analysed by SOS-PAGE followed with western blotting 
using antibodies for total protein before stripping the membrane and re-probing with the antibody to the 
phosphorylated protein fraction. Samples were loaded as described above bands, Con = OMSO control 
treated proteins, Std = standard sample created from pool of samples loaded repeatedly across gel to 
account for variation in electrophoresis and blotting. Total MAPK ERK 1 /2 and Phosphorylated MAPK ERK 1 
/2: 5j.1g cell C2C12 protein separated by SOS-PAGE using 10% acrylamide gel; Total 4EBP1 and 
phosphorylated 4EBP1: 5j.1g cell C2C12 protein separated by SOS-PAGE using 15% acrylamide gel. Further 
antibody information presented in Appendix 0, n=3. 
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Discussion 
The aim of the experiments performed in this thesis was to investigate the effects of vitamin D and 
its active analogues on signalling events in skeletal muscle in terms of meat quality, and factors that 
influence muscle function which might subsequently influence animal production. The hypothesis of 
the first trials was that vitamin D supplementation immediately prior to slaughter could improve the 
tenderisation of meat post mortem via increased activity of the calpain enzymes. However, the 
results indicated vitamin D's involvement in regulating the fundamental processes of muscle tissue 
gene expression which is likely to have implications for animal production in terms of muscle growth 
and development. Therefore the subsequent experiments focused on identifying novel targets of 
biologically active vitamin D in muscle tissue by microarray analysis and assessing its potential 
influence on the development of growing muscle cells. Targets identified by microarray analysis 
were verified in the final experiments of this thesis, investigating the effects of a biologically active 
form of vitamin D on muscle cells at varying stages of development. 
The main novel findings reported within this thesis are: 
• Assessment of dietary vitamin D regimes on altering 25(OH)-D3 levels, calcium concentration 
in both serum and LD muscle of sheep. 
o 4 days vitamin D: increased 25(OH)-D3 10-fold but had no effect on serum or lD 
calcium. 
o 7 days vitamin D + calcium: increased 25(OH)-D3 25-fold, increased serum and lD 
calcium 10 fold. 
• The assessment of dietary vitamin D's effects on mRNA and protein expression of lD calpain 
system genes and kidney calbindin in sheep. 
o 4 days vitamin D: increased mRNA of calpain I 3.7% and calpain II 10%, no effect on 
mRNA of calpastatin, no effects at protein level and no effect on calbindin mRNA or 
protein in the kidney. There was a trend (P=0.103) for vitamin D receptor protein 
levels to be decreased with dietary vitamin D. 
o 7 days vitamin D + calcium: decreased the mRNA of calpain I by 5.2%, but no effects 
on calpain II or calpastatin at the mRNA level. At the protein level calpain II protein 
was increased 16% and calpastatin 17% but there was no effect on calpain I protein. 
Calbindin mRNA in the kidney was increased 8.8% but there was no effect on 
calbindin protein levels. VDR levels in the kidney were significantly increased by 
100%. 
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• The first two trials of this thesis provided additional evidence to that in the literature that 
dietary vitamin D supplemented immediately prior to slaughter does not improve the shear 
force of lamb LD chops even though there were changes in calcium status. 
• The microarray performed in neonatal rat myoblasts is the first reported microarray 
performed using active 1,2S(OHhD3 in muscle cells and provided a large list of novel targets 
which are responsive to vitamin D in muscle. Of these targets, metallothionein I and 2A and 
CCAAT/enhancer binding protein ~ ~ and 6 have been previously implicated to mediate 
muscle's responses to IGF-1 during hypertrophy and to glucocorticoids during atrophy 
(Latres et al., 200SL and these findings strongly suggested that 1,25(OHhDr mediated 
effects are associated with the control of muscle growth. 
• The comparative evaluation of three cell lines for their myosin heavy chain gene expression 
has not been reported before. The experiments demonstrated that skeletal muscle cells 
differentially express MHC genes at progressive stages of differentiation in vitro. Thereby 
representing differing in vitro models for different fibre types or muscle development stages. 
o The primary muscle cultures prepared from neonatal rat pups predominantly 
expressed embryonic and neonatal MHC genes and MHC 2X, with expression of 
MHC 2A increasing during cell fusion. 
o The L6 Aston rat-derived cell line was almost exclusively a "fast" phenotype, 
expressing MHC 2A and 2X in myoblasts, and expression of embryonic and 2B 
increased as myotubes formed. 
o The C2C12 mouse derived cell line was the only muscle cell type to express MHC I / ~ , ,
and expressed the largest range of MHC genes throughout the differentiation 
process. 
o The assessment of the MHC expression was verified at the protein level for the L6 
Aston and C2C12 cell lines, the results agreeing with the semi-quantitative PCR 
whereby both cell lines expressed fast MHC at the protein level but the C2C12 cells 
were the only cell line to express MHC slow. 
• The final cell experiments were the first of their kind to be reported, treating with 1a(OH)D3 
(constitutively active vitamin D) at a range of time points across proliferation and 
differentiation in C2C12 cells. C / E B P ~ ~ was responsive to 1a(OH)D3 in muscle cells. 
Additionally the results showed that intracellular signalling of 1a(OH)D3 was mediated by the 
MAPK ERK 1/2 signal cascade. These results provide continuing evidence that activated 
vitamin D metabolites influence signalling pathways that are able to contribute to control of 
myogenesis. 
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4.1 Effects of dietary Vitamin D on meat quality in Sheep trials 
The hypothesis of the sheep trials reported in this thesis was that feed supplemented with vitamin D 
immediately prior to slaughter could promote tenderisation of meat post mortem by increasing the 
calcium levels and thereby stimulate the expression of the calpain system; the calcium-activated 
proteolytic enzymes responsible for post-mortem proteolysis. The first trial hypothesised that a 
short but high dose of feed supplemented with vitamin D immediately prior to slaughter (4 days) 
would instigate an increase in calcium absorption before the vitamin D autoregulatory axis could 
attenuate circulating levels of the active hormone. As a result of high levels of calcium before 
slaughter, post-mortem there would be an increase in calcium-mediated tenderisation. The second 
trial investigated the hypothesis that a high intake of vitamin D supplemented in the feed for 7 days 
immediately prior to slaughter combined with an added calcium bolus on the final 2 days could 
achieve greater increases in calcium levels and subsequent increase in calcium mediated 
tenderisation than supplementing vitamin D in the feed alone. 
Both trials significantly increased the circulating levels of vitamin D, as measured by circulating levels 
of 25(OH}D3 in plasma of treated animals, by a factor of 10- and 25- fold respectively (P<O.OOl). 
Previous published investigations using vitamin D supplementation to manipulate meat quality in 
sheep (Wiegand et 01., 2001; Boleman et 01., 2004) did not measure the levels of circulating vitamin 
D metabolites and the two trials described in this thesis appear to be the first to do so in sheep. 
Studies in beef steers (Montgomery et 01., 2000; Foote et 01., 2004; Montogmery et 01., 2004), cull 
dairy cows (Cho et 01., 2006) and pigs (Wilborn et 01., 2004) reported changes in 25(OH}D3 levels in 
the range of 3-13 fold increases, which were in general agreement with the findings reported in this 
thesis. Despite the significant increase in circulating levels of 25(OH}D3 in the first trial of this study, 
there was no effect on the calcium status in the circulation nor in the LD after four days of vitamin D 
supplementation (Table 3.1-2). However, the longer vitamin D supplementation with an additional 
calcium bolus in trial 2 did result in a 25 fold increase in plasma vitamin D status which was 
accompanied by significant 10% increase in serum calcium (P<O.OOl). Previous studies in sheep have 
attempted to investigate optimal dietary vitamin D supplementation in order to achieve significant 
increases in calcium status; Wiegand et 01. (2001) reported a slight, non-significant 2.5% rise in 
serum calcium following two days supplementation with 2.0 xl06 IUjday, which rose to a significant 
14.9% increase after 5 days (P<0.05), which was a greater response than that seen in trial 2 of this 
thesis using 7 days supplementation with an additional calcium bolus. Boleman et 0/., (2004) used 
lower doses of vitamin D supplementation, ranging from 0.25 x 106 to 0.75 X 106 IUjday, which were 
still at least 1100-fold higher than the normal recommended vitamin D intake for lambs (McDonald 
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et 01., 2002), and did not observe any significant increases in serum calcium; however they reported 
a trend for higher serum calcium when lambs were supplemented with the higher dose for 5 days. 
Two previous experiments performed in this laboratory have investigated the effects of two 
additional dietary regimes, the first study investigated the efficacy of 7 days vitamin 0 alone in 
improving meat quality (Sazili, 2003) while a second study investigated the effects of a short term 
vitamin 0 supplementation for 4 days with an additional calcium bolus on the final day (Smith 2003, 
unpublished data). Both these studies reported significant increases in circulating calcium levels 
(P<O.OOl) with the 7 days vitamin 0 alone providing a 15% increase in serum calcium and the short 4 
days plus calcium bolus increasing serum calcium by 6.9%. It is likely that 4 days of vitamin 0 alone at 
2.0 x 106 IU/day is not sufficient to increase circulating levels of calcium and that the significant 
increase observed in this laboratory (Smith, 2003) was due to the additional calcium bolus. 
It was hypothesised that the vitamin 0 supplementation regime would increase calcium levels in the 
muscle tissue and that this, in turn, would promote activation of the calpain system post mortem. 
Despite significant increases in plasma vitamin 0, there was no effect on serum or muscle calcium in 
the first trial (vitamin 0 for 4 days alone), however, in the second trial (vitamin 0 for 7 days with 
calcium bolus), there were significant increases in plasma vitamin 0, and a 10% increase in both 
serum and LD calcium levels. The previous trials performed in this laboratory did not report any 
increases in muscle calcium, in agreement with Wiegand et 01. (2001) who saw no changes in muscle 
calcium following vitamin 0 supplementation at 2 x 106 IU/day for 5 days, whereas Boleman et 01. 
(2004) did not measure muscle calcium levels in their study. It seems that the second trial in this 
thesis is the first experiment in sheep to report significant increases in muscle calcium levels 
following vitamin 0 supplementation; however it did involve a calcium bolus. 
The 4 day supplementation of vitamin 0 was not successful in increasing the calcium status of the 
animals and might explain the lack of effect on the tenderness of the LD chops (P=0.351, table 4.1-
1). In the second trial the effects of dietary vitamin 0 or calcium cannot be segregated from one 
another, however, it can be concluded that this feeding regime is sufficient to raise calcium levels of 
sheep. The results of the studies described above are summarised in table 4.1-1., and together these 
data demonstrate that there is an increase in effects on calcium status with increasing length of 
vitamin 0 dose. Numerous studies in beef cattle have reported positive effects of vitamin 0 
supplementation on calcium levels in the plasma (Montgomery et aI., 2000; Karges et 01., 2001; 
Scanga et 01., 2001; Montgomery et aI., 2002; Foote et 01., 2004) whilst other studies have reported 
the effects in LD (Swanek et 01., 1999; Montgomery et 01., 2002; Foote et 01., 2004; Montgomery et 
al., 2004), the data of these trials is summarised in table 4.1-2. Swanek et 01. (1999), supplemented 
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dietary vitamin D at 5 x 106 IUjday for 7 days prior to slaughter and reported significantly raised 
calcium levels in the LD by 43% (P<O.Os), and in the same publication, they report a second 
experiment supplementing 7.5 x 106 IUjday for 10 days where muscle calcium levels were raised 
50% (P<0.02). Montgomery et al. (2000), supplemented beef cattle with vitamin D at doses of 5 and 
7.5 x 106 IUjday for a period of 9 days prior to slaughter, and reported that both doses of vitamin D 
significantly raised calcium levels in the blood (P<O.Os) and the higher dose caused a 30-35% 
increase in serum calcium after 8 days. Both these studies in cattle used much higher doses of 
vitamin D for longer periods than have been used in sheep studies which might explain the 
differences in the calcium responses observed between the species, although this is not taking into 
account the large differences between the bodyweights. 
There have been studies in cattle investigating shorter (Karges et al., 2001) and lower (Montgomery 
et al., 2002) vitamin D supplementation regimes. Karges et al., 2001 investigated using a high dose of 
6 x 106 IUjday for 4 and 6 days prior to slaughter and reported that both regimes significantly 
increase blood calcium levels by 14% and 22% respectively (P<O.OOl) but that the more chronic dose 
did increase calcium levels to a greater extent (P<O.Os), however there was no measurement of 
muscle calcium in this experiment. Shorter vitamin D feeding periods did not improve tenderness of 
the LD chops in Karges et al.'s study, whereas supplementing with vitamin D for two more days did 
significantly reduce shear force of the LD (P<O.OS) after 7 and 14 days of conditioning. Although the 
level of vitamin D supplementation in Karges et al.'s trial was three times that which has been used 
in sheep, it does agree with the results presented in this thesis whereby the longer supplementation 
time period does cause significantly greater responses in calcium levels, but suggests that 4 days of 
vitamin D supplementation alone is sufficient to increase blood calcium levels in cattle. Montgomery 
et al. (2002), investigated the effects of lower doses of vitamin D in cattle (0.5 x106, 1.0 x106, 2.5 
X106, 5.0 xl06 and 7.5 xl06lUjday) for a period of 9 days prior to slaughter and reported that plasma 
calcium increased linearly in response to vitamin D dose, with increases of 5.7, 8.0, 13.8, 16.0 and 
19.5% respectively at 10 days post supplementation. However the effects on muscle calcium 
reported by Montgomery et al. (2002) found larger responses in the LD than was seen in the blood, 
where muscle calcium content was increased by 17, 60, 34, 34 and 57% with each increasing dose of 
vitamin D. In retrospect these values equate to an overly large quantity of calcium, and it is probable 
an increase in muscle calcium content by 50% in cattle would just not be feasible. In trial 2 of this 
study, the effects of vitamin D on serum and muscle calcium in sheep were lower (a 10% increase in 
both) than the effects reported in cattle (Swanek et al., 1999; Montgomery et al., 2002; 
Montgomery et al., 2004). A potential explanation is that cattle respond to the large increase in 
circulating calcium by actively sequestering the calcium into muscle resulting in larger increases in 
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that tissue, although no other study has provided an explanation for the differential responses 
between serum and muscle calcium changes observed in cattle. 
Previous studies have reported that infusion of ovine carcasses with calcium chloride solution 
improve meat tenderisation (Koohmaraie et 01., 1989; Clare et 01., 1997; Duckett et 01., 1998; 
Polidori et 01., 2000). Therefore it has been hypothesised that vitamin D-induced increases in body 
calcium levels will have a similar effect of improving meat quality. However few vitamin D/meat 
quality studies in sheep have reported clear evidence for shear force improvements nor investigated 
the levels of calpain system activity, which are believed to mediate the improved tenderisation. 
While the first trial in this thesis observed no effects on shear force values of LD chops, the second 
trial reported significant increases in the shear force of LD chops from lambs fed vitamin D plus 
calcium immediately prior to slaughter (P<0.002), and shear force values of LD chops were higher at 
all time points. In both of the previous trials performed in this laboratory, shear force of LD chops 
was performed after 14 days of conditioning, with 7 days of vitamin D supplementation alone (Sazili, 
2003) having no effect on shear force values, whereas when animals were fed the 4 days plus 
calcium diet regime (Smith, 2003) the shear force of LD chops were numerically lower, but this effect 
was not significant. Overall the data collected from the numerous trials performed by this laboratory 
do not support the hypothesis that feeding vitamin D prior to slaughter results in improvements in 
the tenderness of meat, and more importantly, only trial 2 of this thesis observed increases in 
muscle calcium and this led to an unexpected decrease in tenderness of LD chops. The available data 
in the literature on the effects of feed supplemented vitamin D on lamb meat quality is shown in 
table 4.1-1. Boleman et 01. (2004) reported no effect of 0.75 x 106 IU/day for 14 days on shear force 
of semitendinosus and semimembranosus muscles but did report a significant increase in the shear 
force of LD muscles (P<0.05) in agreement with trial 2 of this thesis. In contrast Wiegand et 01. 
(2001) reported numerically lower values for the shear force of LD chops at three aging time points 
(days 1, 14 and 21 days) and significantly lower values by 20% at 7 days aging (P<0.05), which was 
accompanied with an increase in muscle calcium concentration, but there was little analysis of the 
activities of the calpain system. 
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Table 4.1-1 Effects of vitamin D supplementation in sheep 
Study Vit 0 x 106 lUI day Serum Ca++ Muscle Ca++ LDSF 14 days 
Trial 1 this thesis 2.0/4 days f7 f7 f7 
Trial 2 this thesis 2.0/7days+Ca l' 10% (P<O.OOl) l' 10% (P<0.05) l' 7.0% (P=O.133) 
Smith, 2003 2.0 / 4 da ys + Ca l' 6.9% (P<O.OOl) not measured -J; 5.4% (P>O.OS) 
Sazili 2003 2.0/7days l' 15% (p<O.OOl) -J; 39% (P<O.05) f7 
Wiegand et 01., 2001 2.0/7 days l' 14.9% (after 5 days) l' 32% (P=O.28) -J; 35% (P>O.OS) 
Boleman et 01., 2004 0.75/14 days f7 not measured l' 11.4% (P<O.05) 
mRNA 
Protein 
Ohr Calpain System Activity 
Calpain I Cal pai n " CAST 
Measured mRNAand protein expression 
1'3.7% (P=O.099) 1'10% (P<0.05) f-7 
f-7 f-7 f-7 
Measured mRNA and protein expression 
mRNA -J;5.2% (P<O.05) f-7 f-7 
Protein f-7 1'16% (P<0.05) 1'17% (P=0.087) 
f7 
not measured measured protein expression 
-J; 9.4% (P>O.05) 
f7 l' 0.4% (P=O.055) 
Measured Troponin T degradation 
no effect 
not measured 
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Table 4.1-2. Effects of vitamin 0 supplementation in beef steers 
Study Vit 0 X 106 lUI day Serum Ca++ Muscle Ca++ lO SF 14 days 24hr Calpain System Activity 
Calpain I Calpain II CAST 
Swanek et 01., 1999 5.0/7 days l' 43.2% NS 
7.5 / 10 days l' 50% ,J" 13% (P=0.07) ,J,,66% (P=O.05) ,J,,37% (P=0.07) ,J,,15% (P=O.04) 
Montgomery et 01., 2000 5.0/9 days 1'16% ,J" 13% (P=O.0015) measured Troponin T degradation; increased 
degradation after 14 days aging with 5.0 dose 
7.5 /9 days l' 22% ,J" 14% (P=0.0015) but not 7.5 dose 
Karges et 01., 2001 6.0/4 days 1'14% ,J" 8% (P=0.0.04) 
6.0/6 days l' 22% ,J" 13% (P=0.04) 
Scanga et 01.,2001 1.0,2.0,3.0,4.0,5.0/2,4,6 or 8 days l' (P<0.05) (12 to 17%) ~ ~
2.0/2,4,6 or 8 days pi us CaC03 ~ ~ ~ ~
4.0 / 2, 4, 6 or 8 days pi us Ca C03 ~ ~ ~ ~
Montgomery et 01., 2002 0.5 /9 days l' 5.7% 1'17% ~ ~
1.0/9 days l' 8.0% l' 60% ~ ~
2.5 / 9 days 1'13.8% l' 34% ~ ~ no significant effect 
5.0/9 days 1'16.0% l' 34% ~ ~
7.5 /9 days l' 19.5% l' 57% ~ ~
Reiling & Johnson, 2003 5.0/7 not measured ~ ~
Foote et at ., 2004 5.0/9 (slaughter day 11) l' 20.9% ~ ~ Trend,J" (P<O.l) 
25(OH) 4 day prior to slaughter f-7 ~ ~ f-7 
1,25(OHhD 3 day prior to slaughter l' 24.5% ~ ~ f-7 
Montgomery et 01., 2004 0.5 /8 days l' 22% ,J,,19% (P<0.05) ,J,,54% (P<0.05) ~ ~
1.0/8 days l' 27.7% ,J" 20% (P<0.05) ,J,,59% (P<0.05) f-7 
5.0/8 days l' 23.5% ,J,,16 (P<0.05) ,J,,55% (P<0.05) f-7 
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Table 4.1-2 summarises the data on the effects of feed supplemented vitamin D on meat quality in 
cattle. When the results of these studies are considered as a whole there is little evidence which 
clearly supports vitamin D supplementation consistently improving shear force of meat. However, 
the calpain system is an essential part of the mechanism and has only been investigated in a smaller 
number of studies. The calpain system needs investigating to fully elucidate the mechanism of 
vitamin D's effects on muscle proteolysis during the post mortem period. The results of the first 
chronological eight studies to be performed in beef steers are summarised in table 4.1-2, and 
demonstrates the lack of consistency in the measurement of all aspects of the hypothesis (serum 
and muscle calcium, shear force and calpain system analysis) which could explain why the 
inconsistencies exist in the reported conclusions of the general vitamin D supplementation regimes 
on meat quality. Of the trials summarised in table 4.1-2, there are two experiments which have 
reported convincing evidence for the vitamin D dietary regimes to be able to promote tenderisation 
of meat via the calpain system, these are Swanek et al. (1999) and Montgomery et al. (2004). The 
activity of the calpain enzymes were measured in Swanek et al.'s (1999) and Montgomery et al.'s 
(2004) studies and both reported a decrease in the activity of calpain I at 24 hours post mortem in 
the LD and additionally Swanek et al. reported a decrease in calpastatin activity with vitamin D 
supplementation; both were associated with an increase in tenderness of the LD. Their work was in 
agreement with that performed in the calcium chloride carcass marination where calpain enzymes 
were reported to be activated early postmortem resulting in chops requiring less time to reach 
acceptable tenderness (Koohmaraie et al. 1989). Studies performed in sheep have not thoroughly 
investigated the effects of vitamin D supplementation on the calpain system, summarized in table 
4.1-1, and of the published trials, only Wiegand et al. (2001) measured troponin T degradation as an 
indicator of calpain enzyme activity (Huff-Lonergan et al., 1996) and found no effect. Of the trials 
performed in this laboratory, Sazili (2003) investigated the activities of the calpain system and found 
no effect on calpain enzyme activity although calpastatin activity was marginally increased (0.04% 
increase, P=0.055), and there was no effect of diet on shear force of LD chops in that study. 
Cell culture work performed by Ravid et al. (1994) demonstrated that calpain I mRNA expression was 
upregulated with l,25(OHhD3 treatment in a cancerous kidney cell line, and it was further shown 
that l,25(OHhD3 treatment of leukaemia cells caused an increase in calpain I at protein level (Berry 
& Meckling-Gill, 1999). Therefore given these apparent direct effects on the calpain system the 
experimental investigations of this thesis sought to clarify whether dietary vitamin D influenced 
calpain system expression at both mRNA and protein levels, and whether any changes could provide 
an explanation of the negative shear force effects observed in the second trial of this thesis. 
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The effect of dietary vitamin D given 4 days immediately prior to slaughter on the mRNA expression 
in sheep LD and kidney was a significant increase in LD mRNA expression of both calpains I and II by 
3.7 and 10% respectively. There was no change in the calcium concentrations in the serum or muscle 
observed in this trial suggesting that the changes were a result of vitamin D's direct signalling via the 
nuclear vitamin D receptor. The results of trial 1 of this study directly agree with a study performed 
in cull dairy cows by Cho et 01. (2006), which investigated the effects of treating cull dairy cows with 
25(OH)-vitamin D (equivalent to a single dose of 5 x 106 IU vitamin D) 6 days prior to slaughter. In 
Cho et al.'s study (2006) there was no effect of vitamin D treatment on the concentration of calcium 
in the blood, on muscle calcium levels or shear force values, despite significant increases in plasma 
25(OH)D and l,25(OHhD of 4.3 and 2.5 fold respectively (P<O.OOOl). However, there was a 
significant effect on the calpain enzymes at mRNA level, with LD calpain I and calpain II expression 
increasing by 3.97 and 4.97 fold respectively, whilst calpastatin mRNA expression was decreased by 
86%. There was also a significant increase in calpain I at the protein level by 20% but no effect on the 
protein levels of calpain " and calpastatin. Both the study by Cho et 01. (2006) and trial 1 of this 
thesis support the hypothesis that vitamin D directly up-regulates the transcription of the calpain 
enzyme genes in muscle. Four days of supplementation may not have been long enough to allow for 
translation of the mRNA transcripts into protein and therefore could explain why there were no 
changes in the calpain enzymes at the protein level. 
Trial 2 of this thesis did not agree with the two experiments reported above as mRNA expression of 
calpain I was significantly reduced by 5% (P<0.05) and calpain II and calpastatin mRNA expression 
was unchanged. However, the protein levels of calpain II and calpastatin were significantly higher in 
trial 2. A possible explanation is that changes in mRNA expression had already been translated into 
changes at the protein level and therefore mRNA that was transcribed has already degraded. The 
increase in calpastatin and the unchanged amount of calpain I at the protein level agree with the 
results of the 7 days vitamin D-alone supplementation experiment carried out in our laboratory 
(Sazili, 2003), which reported an increase in calpastatin activity at 24 hours post mortem (P=0.055) 
and numerical but not significant increases in calpastatin protein levels (P>0.05). Both trial 2 of this 
thesis and the study performed by Sazili (2003) found significant changes in serum calcium whereas 
trial 1 and Cho et 01. (2006) did not. Therefore the differences between these studies could be 
explained by interactive mechanisms between vitamin D and calcium signalling. When vitamin D was 
supplemented but did not result in changes in serum calcium, as in trial 1 and Cho et al.'s (2006) 
study, the response observed is to upregulate the expression of the calpain genes at the mRNA level, 
a result of vitamin D signalling via the VDRnuc. Conversely, when there is an increase in the calcium 
status of the animals, as reported in trial 2 of this thesis and Sazili (2003), the protein level of both 
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calpain II and calpastatin increased, whilst calpain I mRNA decreased. Despite the second trial of this 
thesis up-regulating the protein levels of calpain II, it was accompanied with increased calpastatin 
protein levels and this is likely to be responsible for the increased shear force of the meat. Although 
calpastatin protein activity in Sazili's study (2003) increased, shear force of the meat was not 
affected, in contrast, the 17% increase in calpastatin protein levels in trial 2 of this thesis was 
associated with reduced tenderness. There is a strong relationship between shear force and protein 
levels of calpastatin (Goll et 01., 1998) and so this effect may account for the shear force results of 
trial 2 of this thesis. A possible explanation for the increased calpastatin levels observed in trial 2 
could be that the animals were undergoing increased muscle hypertrophy in a response to the raised 
calcium levels observed in the vitamin D/calcium-treated animals' muscles. It is known that 
intracellular calcium activates the signalling pathways which mediate hypertrophic responses in 
muscle. Intraceullar calcium levels regulate calcineurin activity which is a crucial modulator of 
hypertrophy in skeletal muscle in vivo (Michel et 01., 2004). Calcineurin activity is modulated by 
calcium influxes induced during exercise (Meissner et 01., 2006) and by hormone treatments such as 
growth hormone (Sensky et 01., 2006), both of which are known to promote muscle hypertrophy. 
Additionally, Sensky et 01. (2006) hypothesised that l3-adrenergic agonists (BAA) could promote 
hypertrophy through protein kinase A/calcium ion signalling, and found BAA treatment significantly 
raised calpastatin expression levels by 50% in pigs. It is therefore possible that the increased 
calpastatin levels were indicative of hypertrophy, which is possibly mediated by increased 
intramuscular calcium levels, although further investigations would need to be performed to 
validate this hypothesis. 
A final investigation into dietary vitamin D's signalling effects at the nuclear level investigated the 
treatment's affects on calbindin D-28K in the kidney and on the MHC genes in the LD. Calbindin is a 
calcium binding protein which is responsible for binding calcium ions and assisting their transport 
through cells of the intestinal lining (Lee et 01., 2007) and in the kidney (Roth et 01., 1989) and is a 
known genomic target of vitamin D in cells (Norman & Collins, 2001). In trial 1, the short 4 day 
supplementation of sheep with vitamin D resulted in no changes in the level of calbindin D-28K at 
both the mRNA and protein level, which was an unexpected result in light of the effects of the same 
vitamin D supplementation regime on calpain I mRNA levels. There was however, a numerical 
decrease in the level of vitamin D receptor at the protein level measured in the whole homogenate 
fraction of the kidney protein extract (P=0.103) observed in the kidneys of treated sheep. In contrast 
there were significant effects of the 7 day vitamin D plus calcium diet, with expression of calbindin 
D-28K mRNA increasing in the kidneys of the treated animals by 8.8% (P<0.05, table 3.2-6) although 
there was no detected effect on the protein levels of calbindin D-28k (P=0.147), demonstrating the 
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vitamin D/calcium diet was able to affect expression of genes involved in calcium homeostasis. 
Again, the lack of effect observed at the protein level could be a result of the time required to 
observe changes in the circulating vitamin D levels before resulting changes in mRNA transcription 
and subsequent translation at protein level, although the same length of time was sufficient to 
observe changes in protein level of calpain II in the LD. A possible explanation for this could be that 
circulating vitamin D directly stimulated mRNA expression of calpain II within a few days from onset 
of dietary treatment, as it was shown in trial 1 that 4 days of vitamin D alone was sufficient to induce 
calpain mRNA changes, whereas the mRNA expression of calbindin D-28K was not induced until the 
calcium status of the animals had changed, which could have been a factor of either 7 days of 
vitamin D alone (Sazili's experiment was sufficient to incur increases in serum calcium) or the 
additional calcium bolus at the end of the treatment period. The expression of the VDR at protein 
level in the kidney was significantly increased by the vitamin D/calcium bolus treatment with protein 
levels being increased just over 2-fold. There is no published data on the expected vitamin D 
receptor changes in vitamin D supplemented sheep, although it is known that vitamin D binds to its 
receptor and causes a translocation to the nucleus to attenuate its own gene expression. It could be 
that the decrease in VDR levels in the first trial is the result of VDR translocation into the nucleus, 
whereas the increase in VDR protein levels observed in the second trial could be due to an increase 
in transcription of the VDR gene itself as vitamin D is known to upregulate VDR mRNA expression 
(Norman & Collins, 2001), however, the level of VDR mRNA was not measured in this study, such 
data would provide further explanation for these results. 
As reported in section 1.1.11 of this thesis, there is a large body of evidence to suggest vitamin D 
deficiency is related to a loss of fast fibre types and muscle strength in the elderly and that re-
alimentation with vitamin D supplements can reverse the effects. In addition, the study reported by 
Endo et 01. (2003) reported abnormal MHC gene expression in VDR (-/-) mice and that changes in 
MHC gene expression could be inferred with l,25(OHhD3 treatment directly onto growing muscle 
cells. However, in the trials in this thesis there was no effect of dietary vitamin D on either mRNA or 
protein levels of the MHC genes. 
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4.1.1 Conclusion of effects of dietary Vitamin D on meat quality in Sheep trials 
Neither trial reported in this thesis achieved an improvement in shear force of LD chops, but the 
results provided evidence for vitamin D's ability to alter the expression of the calpain system at both 
mRNA and protein levels. Changes in calcium status in sheep were accompanied with reduced 
tenderness of meat. This effect was attributed to an increase in calpastatin protein levels possibly as 
a result of hypertrophy of the muscle via calcium mediated signalling, although this hypothesis 
needs to be investigated further. Thus the hypothesis of increasing calcium levels ante-mortem may 
be flawed and so the addition of calcium into the muscle post mortem by mechanisms such as 
marination, injection or infusion in calcium chloride solutions might be the most effective strategy to 
decrease post mortem aging times. These trials did provide evidence for vitamin D's direct signalling 
effects within muscle, an example being the increase in calpain I and II mRNA observed in trial 1 
where there was no change in calcium status of the animals but an increase in the circulating levels 
of 25(OH)D3, suggesting a direct effect of vitamin D on gene expression in the muscle vitamin D 
supplemented animals. There is a growing body of evidence to support possible beneficial roles for 
vitamin D supplementation in affecting muscle function, as introduced in section 1.1.11 of this thesis 
and, investigated further by the final experiments of this thesis. 
4.2 Effects of direct Vitamin D treatment on muscle cells 
The hypothesis of the final experiments of this thesis was that active vitamin D administered directly 
to muscle cells could mediate a response in growth of those cells, where effects on muscle cell 
proliferation, differentiation and fibre type would be of relevance to the meat industry in terms of 
production and meat quality. The exact mechanism of vitamin D's action within muscle cells is still 
unknown but there are numerous studies providing partial insights into the signalling pathways 
involved. The purpose of the second experiment of this study was to identify novel targets of 
l,25(OHhD3 in muscle cells by microarray analysis which were subsequently validated in a second 
muscle cell experiment using an active vitamin D metabolite la(OH)D3. 
3.6.10.3 Circulating levels o/vitamin D metabolites in plasma 
It is worth noting at this point that the concentrations of active vitamin D metabolites used in both 
cell studies were similar to the concentrations achieved in the plasma of the sheep fed vitamin D 
during the first two trials of this thesis. The molecular weights of the vitamin D metabolites used in 
the cell culture experiments were 416 and 400 for l,25(OHhD3 and 1a(OH)D3 respectively. Using a 
molecular weight of 400 to convert the results of the vitamin D assays in sheep plasma, presented in 
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units of ng/ml in tables 3.1-2 and 3.2-2, the relative molar concentration of circulating vitamin D 
(250HD3) in the plasma of sheep were in the regions of 7 x 10-11M, 8 x 10-10M and 3 x 10-9M in the 
control animals, 4 days vitamin D treated sheep and 7 days vitamin D plus calcium treated sheep 
respectively. Therefore it is reasonable to assume that the concentrations used in the cell 
experiment could be achieved in vivo, although the plasma assay measured level of 25(OH)D3 as an 
indicator of total vitamin D status of the animals and levels of active metabolites are likely to be 
lower due to the tight regulation by the kidney. 
4.2.1 Effect of 1,25(OH)2D3 on muscle gene expression assessed by microarray analysis 
There were marked differences in the effects observed between the doses of 10-sM and 10-7M even 
before the microarray was analysed. Cells treated with the 10-sM l,25(OHhD3 yielded lower 
quantities of total RNA compared to those treated with 10-9M (table 3.4-2, P<0.05). This was 
considered to be the result of reduced growth and probably cell death in cells treated with the 
higher dose of l,25(OHhD3. There was a much larger response in gene changes with myoblasts 
treated with the highest dose of vitamin D for 24 hours, where, out of a total of 475 significantly 
changed genes, 318 genes were down-regulated at least 1.5 fold, (67% of the significantly changed 
genes detected). With the 10-9M l,25(OHhD3 treatment, only 43 genes changed at least 1.5 fold, of 
which 16 genes showed decreased expression amounting to 37% of the overall significantly changed 
genes detected. On the whole, the number of changed genes was small in respect of the 31,099 
genes analysed, where 1.53% and 0.14% of genes changed with the 10-sM and 10-9M doses 
respectively. The number of changed genes reported in the microarray of this thesis was similar with 
the number of genes changed in Latres et ol.'s (2005) microarray, where IGF-l treatment in C2C12 
cells caused significant 2-fold changes in 242 genes out of 22,000 genes analysed, equivalent to 
1.1%. 
Further analysis of the gene lists using the pathway analysis software showed that the higher dose of 
l,25(OHhD3 was associated with cell death and cancer signaling, where three of the five pathways 
associated with the genes were related to cancer and cell death, and in figure 3.4-5 there were a 
number of changed genes directly associated with the caspases and cytochrome C, known mediators 
of apoptosis (Cooper & Hausman, 2007). At the time it was considered that the higher l,25(OHhD3 
dose was causing toxicity in the myoblast cells and that the treatment was too high to observe 
growth responses in the muscle cells. The analysis of the genes changed when myoblasts were 
treated with 10-9M l,25(OHhD3 showed similar associations with cell death, with the last of the 
three pathways being related to DNA damage and repair. There is much evidence for vitamin D's 
role in up-regulating apoptosis and cell death in a variety of conditions including cancer, although 
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the response is not unanimous across cell types (DeHaes et 01., 2004). Figure 3.4-5 shows that the 
higher dose of l,2s(OHhD3 upregulated some of the upstream regulators of apoptosis mediated by 
caspase and cytochrome c and this contributed to the conclusion that the highest dose of 
l,2s(OHhD3 was causing cell death in this experiment. The transcription factors C / E B P ~ ~ and 6 were 
both responsive to l,2s(OHhD3 in the microarray experiment of this thesis and both transcripts 
exhibited a dose response. Interestingly both C / E B P - ~ ~ and-o have been shown to respond to 
glucocorticoid treatment in skeletal muscle (Yang et 01., 2005; Penner et 01., 2002) and it was 
hypothesised that C / E B P ~ ~ would attenuate expression of calpain I in the wasting response in light of 
the C/EBP response element in the calpain genes (Penner et 01., 2002). Hence C / E B P ~ ~ was chosen as 
another potential target for vitamin D signalling to be verified by the final experiments of this thesis. 
Additionally the mRNA expression of retinol binding protein was also highly up-regulated and was 
chosen as another target to be verified in the subsequent experiments. 
The final targets identified by the results of the microarray were retinol binding protein, C / E B P ~ , ,
metallothionein 2A, and additionally c-Myc and parvalbumin were chosen as targets at the gene 
transcript level, along with ERK 1/2 and 4EBPl as targets for events in protein phosphorylation. The 
final experiments of this thesis then were designed to assess the effects of an active form of vitamin 
D, la(OH)D3, on muscle cells undergoing proliferation through to fully differentiated myotubes. 
4.2.2 Effect of 1u(OH)D3 on muscle gene expression in proliferating C2C12 myoblasts 
The active analogue of vitamin D, la(OH)D3 or alfacalcidiol, was used in the final experiments of this 
thesis. Alfacalcidiol is biologically active and is used in the treatment of musculoskeletal disorders 
such as osteoporosis because it is already la-hydroxylated and therefore bypasses the regulatory 
step in the kidney (see figure 1.2-2) (Ringe et 01., 2005). The effect of the la(OH)D3 treatment was to 
significantly decrease the mRNA expression of a number of genes including the MRFs which are 
responsible for the control of myogenesis, the proliferation controlling c-Myc gene which is a known 
oncogene, the MHC isoform liB and the enzyme GAPDH both of which are related to fast glycolytic 
metabolism (Table 4.2-1). The only gene to be upregulated was that of the transcription factor 
C / E B P ~ , , a protein which is related to increasing the expression of cell-type specific genes (Locker, 
2001). The consequences of these expression changes will be discussed in terms of cell proliferation 
events within this section. 
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Table 4.2-1 Effect of 1a(OH)D3 on muscle gene expression in proliferating C2C12 myoblasts. Direction of 
mRNA expression change .indicated ~ y y ~ o l o u r , , yellow indicates no treatment effect, red indicates 1a(OH)D3 
caused decreased expression, green indicates 1a(OH)D3 caused increased expression. 
Effect in comparison to DMSO ANOVA P Value 
Gene Function 10-11M 10-9M 10-7M Treatment 
Beta Actin Cytoskeletal protein ~ ~
-.L- -.L- <0.05 
Cyclophilin A Basic Functional enzyme ~ ~
-.L- -.L- <0.001 
GAPDH Metabolic enzyme ~ ~ .J, 
-.L- <0.01 
Myf5 Early myogenic factor ~ ~
-.L- -.L- <0.001 
Myogenin Differentiation Factor ~ ~ ~ ~ I J, <0.05 
Desmin Cytoskeletal prote in ~ ~ ~ ~ ~ ~ 0.394 
C/EBPI3 Transcri ption Factor -cell specifi c genes ~ ~ ~ ~ <0.01 
c-Myc Proliferation - oncogene .J, 
-.L- <0.01 
Metallothionein 2A Metal Ion binding ~ ~ .J, <0.1 
Parvalbumin Calcium binding, l ,25(OHhD3 responsive ~ ~ ~ ~ ~ ~ 0.595 
Embryonic MHC Developmental MHC ~ ~ ~ ~ ~ ~ 0.142 
Neonatal MHC Developmental MHC Not Expressed N/ A 
MHC 1/13 Slow Oxidative MHC ~ ~ ~ ~ ~ ~ 0.847 
MHC IIA Fast Oxidative MHC Not Expre ssed N/ A 
MHC IIX Fast Intermediate MHC ~ ~ ~ ~ ~ ~ 0.119 
MHC liB Fast Glycolytic MHC ~ ~ ~ ~ .J, <0.05 
Treating (2(12 myoblasts with 1a(OH)D3 sign ificantly decreased mRNA expression of both MRFs, 
where MyfS was decreased by the two higher doses of 1a(OH)D3 by 46% and 69% (10-9M and 10-7M 
respectively, P<O.OOl) and myogenin was decreased by 72% when myoblasts were treated with the 
highest dose of 1a(OH)D3. This is evidence to show 1a(OH)D3 is able to cause changes in the 
expression of the myogenic regulatory factors which control muscle cell development . Endo et 01. 
(2003) performed a similar experiment treating (2(12 cells with 10-8M l ,2S(OHbD3 for 48 hours in 
the presence of fusion media and similarly reported sign ificant decreases in MyfS and myogenin . 
MyfS is thought to promote myoblast proliferation (Buckingham et 01. 2003, section 1.3 of this 
thesis), being one of the earliest MRFs to be expressed in myogenesis, and the effect of down 
regulating its expression would reduce the extent of proliferation of myoblasts present, the outcome 
being a reduced number of muscle fibres in the adult muscle . Myogenin expression was reported to 
increase in the untreated (2(12 cells in Endo et al.'s (2003) study whereas 1,2S(OHb D3 treatment 
caused a reduction in myogenin mRNA expression, as did 1a(OH)D3 treatment in this study. The 
likely outcome of reducing myogenin expression could be a reduction in the differentiation of the 
muscle cells. Myogenin expression is usually temporally up-regulated to follow MyfS and MyoD 
during normal myogenesis and is associated with the later phases of myotube differentiation and 
this has been observed during (2(12 muscle cell development (Dedeiu et 01., 2002) where an 
increase in myogenin expression was associated with the fusion of cells at arou nd 6 days after 
induction of differentiation . The reduction of myogenin expression in response to 1a(OH)D3 in this 
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thesis and by 1,25(OHhD3 in Endo et al.'s study provides evidence that vitamin D and its metabolites 
are likely to affect the process of differentiation and this is likely to have a negative effect on the 
development of myotubes. However there are two other MRFs which also playa role in myogenesis 
and their expression was not investigated in the studies of this thesis. Expression of MyoD was not 
reported to change significantly over the course of C2C12 differentiation in Dedeiu et al.'s (2002) 
study and there was no expression of MRF4, and in Endo et al.'s experiment MyoD and MRF4 
expression was not analysed, although they had reported that despite MyfS and Myogenin 
deregulation in VDR (-/-) mice there were no changes in the expression of MyoD and MRF4 between 
the knockouts and the wildtype mice. Both Dedeiu et al.'s and Endo et al.'s studies do not impart 
much relevance to the expression of MyoD and MRF4 on the process of differentiation In C2C12 
cells, but it is possible for the MRFs to show redundancies (section 1.3.2 of this thesis) and thus the 
changes in Myf5 and myogenin affected by vitamin D treatment could be compensated for by MyoD 
and possibly MRF4 to allow normal myotube formation to occur, therefore analysis of the expression 
of MyoD and MRF4 would provide further explanation of the effect of 1a(OH)D3 treatment on the 
process of myoblast differentiation. In relationship to the MRFs, the expression of embryonic MHC, 
MHC I / ~ ~ and MHC /IX were not affected by the treatment, with the exception of MHC liB which was 
significantly decreased by 10-7M 1a(OH)D3 treatment and numerically decreased by the 10-9M 
treatment (table 3.6-5, P=0.023), suggesting that the changes in MRFs examined did not have a large 
effect on the MHC expression profile. 
Of the mRNA transcripts selected for expression analysis ( C / E B P ~ , , parvalbumin, metallothionein 2A 
and c-Myc) only parvalbumin expression was unaffected by 1a(OH)D3 treatment. Expression of 
C / E B P ~ ~ was upregulated 10-fold by the lowest dose of 1a(OH)D3, but unaffected by the higher 
doses, and this is the first evidence to show that C / E B P ~ ~ responds to 1a(OH)D3 in muscle cells, the 
likely effects of its elevated expression will be discussed in the latter parts of this chapter. The 
expression of c-Myc, a well-known oncogene responsible for increasing proliferation of cells, was 
investigated owing to its known responsiveness to 1,25(OHhD3 (Simspon et 01., 1987; Simpson et 01., 
1989). These studies reported that treatment of leukemia cells with 1,25(OHhD3Ieads to a reduction 
in expression of c-Myc, thus reducing tumour proliferation and induction of differentiation (Simpson 
et 01., 1987, Simpson et 01., 1989). The mRNA expression of c-Myc was significantly down-regulated 
in myoblasts treated with 1a(OH)D3 at the 10-9M and 10-7M (P<0.009), and this is evidence to 
support that treatment with 1a(OH)D3 could be acting to reduce proliferation and promote 
differentiation in myoblasts in this experiment. However there was a significant reduction of the 
phosphorylation of ERK 1/2 when treated with 1a(OH)D3 at 10-11M and 10-9M concentrations (table 
3.6-12, P<0.05). ERK 1/2 is a MAP Kinase enzyme which is activated in a large variety of cell 
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responses and the outcome of its activation is to promote cell growth and differentiation (section 
1.1.5 of this thesis). In contrast to the data obtained for c-Myc expression the down regulation of 
ERK 1/2 in this experiment is indicative of a lack of growth and differentiation caused by la(OH)D3. 
However no direct activity measurements of this kinase or downstream factors were measured to 
confirm this effect. 
Overall these findings do not fully elucidate the effect that la(OH)D3 is eliciting on the proliferating 
myoblasts, but it is possible that proliferation is being reduced, as shown by the decrease in the 
expression of factors which would be associated with cell proliferation such as Myf5 and c-Myc, and 
the possible outcome of this would be an induction of differentiation and a reduced number of 
muscle cells leading to reduced fibre number in the mature muscle tissue. However, other factors 
that would have been expected to increase with the onset of muscle cell growth and differentiation 
were unchanged; these were desmin, the MHC genes and 4EBP1, although myogenin expression was 
decreased in line with a lack of differentiation. Further work needs to be performed to understand 
the role of la(OH)D3 at this stage of differentiation such as investigating the expression of the 
remaining MRFs, MyoD and MRF4, in addition to assessing muscle cell growth using measurements 
such as DNA/protein ratio. 
4.2.3 Effect of 1a(OH)D3 on muscle gene expression in differentiating C2C12 myoblasts 
The aim of the final experiment of this thesis was to investigate the effects of treating differentiating 
muscle cells with the active analogue la(OH)D3 at different time points across the differentiation 
process, covering induction of differentiation, formation of myotubes and hypertrophy of mature 
myotubes. The analysis of Myf5 and myogenin expression showed that these myogenic factors were 
not affected by the la(OH)D3 treatment. This was unexpected following the reduced expression 
observed after the initial myoblast experiment and the findings of Endo et 01. (2003), who reported 
that 48 hours treatment with 10-8M 1,25(OHhD3 caused a decrease in the expression of Myf5 and 
myogenin in C2C12 cells during the early phases (up to 3 days) of differentiation. There was a 
possible effect of 48 hours treatment with la(OH)D3 on the expression of myogenin during the first 
two days of differentiation which was not detected in the time course analysis. Desmin expression 
remained unchanged during the differentiation process in the control cells, but expression was 
decreased with la(OH)D3 treatment relative to the control cells at days 2 and 9, this again supports 
the idea that la(OH)D3 is affecting the differentiation of the muscle fibres, although the outcome of 
reduced desmin in terms of muscle growth would be reduced hypertrophy. 
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The expression of each MHC gene changed significantly over the course of differentiation and 
provided an insight into the development of fibre type over the myogenic process. Immature C2C12 
myoblasts expressed MHC embryonic and I / ~ ~ almost exclusively, which was succeeded by the 
expression of the fast MHC genes whose mRNA levels increased as myotubes developed, suggesting 
a switch to a faster fibre type. 1a(OH)D3 treatment significantly reduced the expression of embryonic 
and MHC I / ~ , , suggesting that 1a(OH)D3 was advancing the muscle development process as there 
was also significant changes in the mRNA expression of some ofthe fast MHC genes at differing time 
points across the differentiation process. After 5 days of differentiation, when myotubes were 
forming, the expression of MHC IIA appeared to be increased by 1a(OH)D3 treatment. At the same 
time point and at the latest stage of development when myotubes were fully formed, the expression 
of MHC liB appeared to be decreased by the treatment with 1a(OH)D3, and this decrease in 
expression of the glycolytic MHC liB was mirrored by the decrease in the expression of GAPDH. 
Taken together the effects of 1a(OH)D3 on mRNA expression appears to promote a fast-oxidative 
fibre type and decreases the glycolytic potential of the muscle fibres. 
The overall effects of 1a(OH)D3 on expression of the developmental MHC genes agrees with the 
findings of Endo et 01. (2003), who reported that VDR (-j-) mice had adversely high levels of 
embryonic and neonatal MHC, although the fast MHC genes were unaffected in this phenotype. In 
Endo et al.'s study the result of treating C2C12 cells with l,2S(OHhD3 was also a decrease in 
neonatal MHC expression. These findings support the model that vitamin D and its active 
metabolites are affecting the process of muscle development, especially during the early phases 
when myoblasts are present and that vitamin D's role is in the regulation of cell proliferation and 
regulating the time of onset of differentiation. Taken together, both the effects on the 
developmental MHC and the effects of MHC I / ~ ~ and IIA against liB indicate that there are two 
possible roles for active vitamin D metabolites in muscle tissue, the first being to reduce 
proliferation and induce differentiation, whilst the second effect is to reduce glycolytiC potential and 
increase oxidative capacity via expression of MHC I / ~ ~ and IIA. 
Finally, all four selected novel targets of 1a(OH)D3 in muscle were found to be changed by both age 
and treatment without an interaction between the two. The expression of these four proteins 
changed over the course of differentiation, C j E B P ~ ~ and metallothionein 2A expression both 
decreased over the differentiation process, whereas parvalbumin increased as myotubes formed. 
The expression of c-Myc was highest during the transition from myoblasts to myotubes and indicates 
that it is regulating cell proliferation until the myoblasts are fully differentiated, after which the 
myotubes do not divide and c-Myc expression decreases to coincide with this. The effect of 
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la(OH)D3 was to decrease c-Myc's expression at these time pOints suggests that la(OH)D3 is 
preventing cells from proliferating, indicating la(OH)D3 encourages the formation of myotubes. This 
agrees with work performed by Simpson et 01. (1989) who showed that 1,2S(OHhD3 decreases 
expression of c-Myc via induction of the protein kinase C intracellular signalling pathway in 
leukaemia cells. The idea that la(OH)D3 down regulates proliferation and induces differentiation in 
muscle cells is supported by la(OH)D3's effect on metallothionein, where treatment causes a 
profound decrease in expression after 48 hours during the early myoblast phase. Apostolova et 01. 
(1999) reported that metallothionein levels in muscle cells during the early phases of differentiation 
were necessary to prevent apoptosis, and as the muscle cells differentiated the expression of 
metallothioneins decreased. Parvalbumin was shown to respond to la(OH)D3 but effects were 
unclear, especially in the myotubes where expression decreased with the 10-9M dose but increased 
with the 10-7M dose. The hypothesis in this thesis was that parvalbumin would bind calcium in a 
protective mechanism to prevent calcium induced apoptosis, in a similar mechanism to calbindin in 
kidney cells as hypothesised by Christakos et 01. (2003). However without measuring the effect of 
la(OH)D3 on calcium and apoptosis levels, it was not possible to confirm this. 
Like in the treatment of rat primary muscle cells with 1,2S(OHhD3, the most consistent and clear 
responses to la(OH)D3 in the C2C12 myogenic process were observed in the mRNA expression of 
C / E B P ~ ~ and the phosphorylation of ERK 1/2 , where expression of C / E B P ~ ~ was consistently 
upregulated by all doses of la(OH)D3 at all ages, and ERK 1/2 phosphorylation was consistently 
down-regulated. The effects on these two targets point towards a mechanism for la(OH)D3's effects 
at both the gene expression level and in the intracellular signalling pathways of muscle, and whether 
the changes in mRNA expression observed are an effect of the VDRnuc or VDRmem is unclear. This 
information does agree with much of the literature (Buitrago & Boland, 2008; Buitrago et 01., 2006; 
Morelli et 01.,2001) in that vitamin D can mediate signals in the MAPK signalling pathways and this is 
the first evidence to show that the active vitamin D metabolite la(OH)D3 signals via this mechanism 
also. The outcome of the effects reported in this thesis show that vitamin D and its active 
metabolites do perform a role in muscle tissue and the final section of this discussion aims to 
propose the signalling pathways involved and the physical effects these signalling mechanisms have 
on muscle. It is likely that vitamin D will not have an isolated effect on one outcome but will in fact 
regulate a number of mechanisms within the muscle, in particular interest to meat quality are those 
effects on the growth of the muscle cells and the fibre type. 
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4.3 General discussion of direct Vitamin D treatment on muscle cells 
3.6.10.4 MRF expression 
Dedieu et al. (2000) report that MyoD and MyfS both mediate early myogenesis and their expression 
is followed by myogenin and then MRF4, which have higher mRNA expression in the latter phases of 
differentiation in C2C12 cells. The C2C12 results in this thesis do not agree with this as myogenin was 
relatively high all the way through, but MyfS expression did show a similar expression pattern to that 
reported by Dedeiu et al. (2000). An explanation for the differences in the expression of myogenin 
could be that our C2C12 cells were too confluent and had already begun spontaneous 
differentiation. Performing this experiment with less confluent cells might provide the best insight 
into the effects of la(OH)D3 on proliferation. In addition it would be useful to measure all four MRFs 
as it is reported in Dedieu et al.'s (2000) study that MyoD is expressed at a similar level to Myf5 
during early development and that MRF4 levels are expressed at a similar time to myogenin, thus 
this will help to clarify the developmental stage of the C2C12s throughout our experiment. 
Effects of proliferation, growth and differen tiation 
The 1a(OH)D3 treatment caused a decrease in ERK 1/2 phosphorylation, an enzyme which plays a 
number of possible roles in muscle tissue. Opinion of ERK 1/2 's role in the regulation of the 
myogenic programme is divided with some work reporting that activation of ERK 1/2 leads to 
reduced myogenesis in muscle cells (Coolican et al., 1997) and others reporting a positive action of 
ERK 1/2 activity in promoting myogenesis (Gredinger et al., 1998). However, Wu et al. (2000) 
proposed that ERK 1/2 activation served a dual purpose in the process, dependant on the extent of 
differentiation of the muscle cells. In myoblasts ERK 1/2 activation inhibited the differentiation 
process and thereby maintained the cells in the proliferation stage. After the myogenic programme 
was initiated, ERK 1/2 activation promoted the muscle growth process. In our study the effect of 
1a(OH)D3 treatment was to reduce activity of ERK 1/2 at all stages of the differentiation process. 
During the myoblast stage the effects of la(OH)D3 seemed to be to reduce proliferation and thus the 
reduced activity or ERK 1/2 could be in agreement with the Wu et al.'s hypothesis. It seems that the 
effect of la(OH)D3 in myoblasts which are proliferating is to reduce the extent of cell division, and 
possibly promote differentiation. During the later stages of myoblasts to myotube formation, the 
action of la(OH)D3 was still to reduce the ERK 1/2 activity which would reduce the differentiation 
process according to this same theory (Wu et al., 2000) but this did not seem to be the case as 
1a(OH)D3 seemed to be promoting the differentiation based on the expression of the MHC genes 
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and MRFs, where 1a(OH)D3 treatment advanced their expression towards what was observed at 
latter stages of differentiation. 
3.6.10.5 MAPK activity 
The effect of 1,2S(OHhD3 is frequently reported to be an involvement in proliferation, and the 
results reported in this thesis support the conclusions that 1a(OH)D3 may also regulate cell 
proliferation. The activity of this metabolite was to reduce ERK 1/2 activity which is opposite to the 
multiple published reports of 1,2S(OHhD3 in muscle cells (Ronda et al., 2007; Buitrago et al., 2006; 
Buitrago et al., 2008 & Morelli et al., 2001). All these studies report up-regulation of the ERK 1/2 
MAPK by action of 1,2S(OHhD3 in muscle cells, along with simultaneous activation of the MAPK P38, 
a target which was not investigated in the studies of this thesis. To further understand the effect of 
1a(OH)D3 in these experiments it would be useful to investigate the level of P38 MAPK activity as 
this would evaluate further the effects of 1a(OH)D3 on muscle cell differentiation. The signalling 
process by which 1,2S(OHhD3 activates both P38 and ERK 1/2 has been elucidated to be membrane-
receptor-mediated tyrosine activation via protein kinase C, which activates c-Src to phosphorylate 
both the MAPKKs MKK 3/6 and MEK 1/2, the upstream activators of P38 and ERK 1/2 respectively 
(Ronda et al., 2007; Buitrago et al., 2006; Buitrago et al., 2008 & Morelli et al., 2001), therefore it is 
probable that the effect of 1a(OH)D3 to reduce activity of ERK 1/2 as observed in this thesis would 
be likely to reduce activity of P38 simultaneously. 
The outcome of the effects of 1,2S(OHhD3 on MAPK activity does not appear to have been fully 
investigated but studies have reported that inhibition of P38 MAPK results in no differentiation of 
myoblasts into myotubes and a much reduced expression of MHC and myogenin as a result of this 
lack of myotube formation (Cabane, 2003). The result of P38 MAPK and ERK 1/2 signalling in C2C12 
cells was investigated by Wu et al. (2000) who reported that P38 enhanced the transcription of 
MEF2C and 2A, two transcription factors known to promote MRF signalling (see section 1.3.1 of this 
thesis) and therefore P38 activity is involved in promoting the muscle differentiation process. The 
role of ERK 1/2 in the process was not so clear and Wu et al. (2000) found the activity of this enzyme 
to be inhibitory of myotube development when muscle cells were undifferentiated myoblasts, 
where ERK 1/2 activity reduced the transcription of myogenic genes such as MyoD, MHC and 
myogenin and prevented formation of myotubes. However the effect of ERK 1/2 activation was 
different once the differentiation process had been induced and at this stage in myogenesis ERK 1/2 
activation was complimentary to P38 activity and worked to promote myotubes formation. Taken 
together, the results of the effects of P38 and ERK 1/2 on C2C12 differentiation and their activation 
by 1,2S(OHhD3 in muscle cells leads to the conclusion that 1,2S(OHhD3 will generally promote the 
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process of myotube formation and muscle growth. In light of the inhibitory effect of 1a(OH)D3 on 
ERK 1/2 in the experiments of this thesis and assuming that the myogenic process had already begun 
in the C2C12 cells, it seems reasonable to conclude that the analogue was inhibiting muscle growth 
in this experiment. 
The results of the mRNA expression of MyfS and myogenin in this experiment do not agree with this 
hypothesis as there was no clear down-regulation of these myogenic transcription factors reported 
in this study. In addition, the effect of 1a(OH)D3 to effectively advance the process of differentiation 
could be interpreted by its effects on the mRNA expression of ~ - A c t i n , , MyfS, myogenin, embryonic 
MHC, MHC 2A, metallothioenein 2A and c-Myc. The expression of these genes decreased towards 
the end of the differentiation process in the DMSO control cells, and the effect of 1a(OH)D3 at 
varying time points across differentiation was to reduce their expression and seemingly induce the 
gene expression profile to that observed in the fully differentiated muscle cells. Further work to 
support this hypothesis would need to investigate whether 1a(OH)D3 did inhibit P38 activity, and to 
further investigate the expression of the other MRFs, MyoD and MRF4. In addition the rate of 
growth of the cells could be evaluated by measuring the ratio of protein to DNA which would 
indicate hypertrophy in the latter phases of differentiation. 
Effects on Fibre Type 
Other than the effects of 1a(OH)D3 on muscle differentiation, there is another possible role for this 
compound to have been regulating the fibre type of the muscle cells as indicated by myosin heavy 
chain expression. C / E B P ~ ~ mRNA was significantly increased by 1a(OH)D3. This transcription factor is 
expressed in most cell types and its function appears to be associated with regulating expression of 
genes that are associated with cell specific responses. An example of C/EBPWs control of cell type-
specific genes is it's up-regulation of peroxisome proliferator-activated receptor gamma- coactivator 
1 alpha (PGC1a) in brown adipose tissue (Karamanlidis et 01., 2007), where PGC1a expression is 
associated with increased oxidative capacity of cells via increases in mitochondria population. 
Similarly, PGC1a expression in muscle drives conversion of muscle into a slow oxidative phenotype 
by up-regulating MHC I / ~ , , MHC IIA and mitochondria production (Lin et 01., 2002). In parallel to this, 
ERK 1/2 activation was shown to be responsible for promoting maintenance of the fast twitch fibre 
MHC genes, particularly MHC liB, and inhibiting the activity of ERK 1/2 led to expression of a slow 
oxidative fibre type, particularly leading to an increased in the expression of both MHC I / ~ ~ and MHC 
IIA. In these cell based experiments it appears that the inhibitory effect of 1a(OH)D3 on ERK 1/2 
activity and the increase in C / E B P ~ ~ expression leads to a general decrease in MHC I / ~ ~ and embryonic 
MHC and increases in MHC IIA, particularly at day 5 post differentiation, and a general decrease in 
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MHC liB. The net result of this may be a metabolic change toward an oxidative fibre type, expressing 
MHC IIA. In vivo, this change would perhaps be characterised as a movement towards an oxidative-
glycolytic fibre type, characterised as type IIA by traditional myosin ATPase histochemistry. 
Control of fibre type was described in section 1.3.6 of this thesis, and the mechanism by which the 
slow oxidative fibre type is controlled, is likely to be associated with 1,2S(OHhD3 in consideration of 
its classical role in controlling calcium influxes in muscle cells. It is known that 1,2S(OHhD3 signals at 
the membrane by production of the second messenger signals inositol triphosphate (IP3) and 
diacylglycerol (DAG) which communicate the signal intracellularly via protein kinase C (PKC) 
activation and release of calcium from the SR respectively (Morelli et al., 1993). It has been reported 
that calcineurin, activated by calcium influxes in C2C12 myotubes, activates NFAT which acts with 
other myogenic transcription factors MyoD, MEF 2-C and -D and p300 to promote transcription of 
MHC I / ~ ~ expression (Meissner et al., 2006). Similarly da Costa et al. (2007) reported that calcineurin 
upregulated MHC IIA expression via this calcineurin-NFAT pathway and simultaneously down-
regulated MHC IIX and liB expression. It is likely that this calcium-calcineurin pathway is activated by 
1,2S(OHhD3 signalling in muscle cells and therefore the increase in MHC I / ~ ~ and IIA observed with 
1a(OH)D3 treatment at 5 days post differentiation in the highest dose could have been mediated by 
this calcium-calcineurin-mediated pathway. Interestingly the same group also reported a distinct 
signalling mechanism responsible for the up-regulation of the intermediate MHC IIX gene via the P38 
MAPK signalling pathway (Meissner et al., 2007), which again was mediated by MEF-2C and also 
CREB-binding protein. ERK 1/2 activity has also been implicated in fibre type changes, where work 
done by Shi et al. (2008) reported that over-expression of ERK 1/2 promoted fast type MHC protein 
levels and that blocking the ERK 1/2 activity resulted in a promotion of the slow oxidative MHC I / ~ ~
and IIA proteins. This observation does agree with the final experiment of this thesis in that ERK 1/2 
activity was reduced with 1a(OH)D3 and that there was an increase in MHCs I / ~ ~ and IIA at day 5 post 
differentiation in highest doses. Care must be taken in this interpretation as the change in ERK 
activity was assessed indirectly through the assessment of phosphorylation ratios and not by direct 
measurement of activity and more importantly the activation of factors down-stream of this 
signalling intermediate were not assessed. Indeed treatment of muscle with 1,2S(OHhD3 has 
repeatedly been shown to up-regulate ERK 1/2 activity, and would therefore, based on the 
observations reported in the literature, promote a fast twitch phenotype. 
The strongest observations of this thesis, were in experiments using both 1a(OH)D3 and 1,2S(OHhD3 
on both primary muscle cells and muscle cell lines, was the up-regulation of the transcription factor 
C / E B P ~ . . This is a novel observation and the possible outcome in muscle cells in unclear. This 
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transcription factor is known to be involved in controlling specific patterns of gene expression. The 
transcription factor C / E B P ~ ~ has been implicated in a number of physiological processes but is 
probably best characterised in its role in adipocyte development. Karamanlidis et al. (2007) reported 
that the action of C / E B P ~ ~ in white adipocytes was to promote differentiation into brown adipocytes, 
a phenotype expressing high mitochondrial activity via C/EBPWs effect to promote PGC-la 
expression. The effect of increased PGC-la expression in muscle tissue has been reported and its 
action is to drive conversion of muscle into a slow oxidative phenotype by up-regulating 
mitochondria production and associated oxidative metabolism accompanied with associated 
changes in MHC I / ~ ~ and MHC IIA (Lin et al., 2002). Thyroid hormone has also be shown to increase 
the expression of C / E B P ~ ~ in skeletal muscle (Clement et al., 2002) and it is well established that this 
hormone has a tendency to increase type IIA muscle fibres but decrease type I substantially, as 
determined by histochemical methods (Larsson et al., 1995). Observations in C / E B P ~ ~ knock-out mice 
suggested that this transcription factor has a fundamental role in regulating genes associated with 
fat metabolism (Millward et al. 2007). Therefore a possible outcome for the la(OH)D3 mediated 
transcription of C / E B P ~ ~ is an increase in PGC-la expression which could mediate a change to a more 
oxidative muscle phenotype and, as indicated above, a potential shift toward a oxidative-glycolytic 
IIA fibre type. 
4.3.1 Conclusions of effects of lu(OH)D3 in developing myoblasts 
What can be concluded from these experiments is that the biologically active form of vitamin D is 
able to initiate intracellular signalling via cascades usually associated with membrane receptors and 
the response is to down-regulate the activity of ERK 1/2 enzyme. The likely effects on the muscle 
cells in response to reduced activity of ERK 1/2 are fibre type changes and changes in growth and 
differentiation. Likewise the effect on an increase in C / E B P ~ ~ will be to promote the differentiation of 
myotubes and modulating toward an oxidative / type IIA fibre type. The hypothesised route of the 
biologically active form of vitamin D signalling within the muscle cell is summarised in a schematic 
diagram of intracellular pathways in figure 4.3-1. Further analysis within this scheme of work to 
evaluate this hypothesis would need to investigate the genes which are thought to be upregulated 
by C / E B P ~ , , particularly PGCla, and to evaluate potential effects of this transcription factor on 
additional factors influencing fibre type as well as the effects on the calpain system, in particular 
calpain I as the expression of these genes was shown to respond to vitamin D in muscle tissue in trial 
1 of this thesis. 
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Figure 4.3-1 Hypothesised routes of the biologically active form of vitamin D signalling within the muscle cell 
at 1) the membrane receptor VDRmem, and 2) the nuclear receptor VDRnuc. 
4.4 Conclusion 
The first question addressed in this thesis was whether dietary vitamin D supple mentation 
immediately prior to slaughter improves post-mortem tenderisation of meat in the sheep species. 
The answer provided by the results of the two dietary feeding trials was that there was no positive 
effect on tenderness of the LD and that increasing the calc ium status of meat ante-mortem is likely 
to be detrimental to tenderisation. The model proposed was that calcium influxes within the muscle 
could be upregulating hypertrophy via calcium signall ing mechanisms which could mediate a 
reduction in protein degradation via an increase in calpastatin levels. Further work to prove this 
theory could begin with directly assessing the act ivity levels of the calpain system in the two trials, 
thereby comparing between the studies where an increase in calcium status was observed in the 
second trial but not the first. 
The second question to be addressed by the experiments of this thesis was whether the active 
metabolites of vitamin D were able to exert direct changes in gene expression in cultured rodent 
muscle cells. The result of the microarray and the subsequent cell culture experiments show that 
there were numerous genes which were responsive to the vitamin D metabolites in rodent-derived 
skeletal muscle cells, and thereby present a role for active vitamin D metabolites to influence muscle 
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function. Further work would need to clarify which effects are directly related to events induced via 
calcium signalling and which are vitamin D's direct signalling effects. This could be achieved by 
comparing active vitamin D metabolites against calcium ionophores in cultured muscle cells. 
The final question to be answered by this thesis was whether active vitamin D could influence the 
growth of cultured muscle cells in the early myogenic stages through to mature myotubes. The 
results in this thesis provided evidence that dietary vitamin D fed to sheep for four days prior to 
slaughter was sufficient to cause an increase in the mRNA expression of calpain I, evidence for 
vitamin D's signalling effects in mature muscle in vivo. Following this, the treatment of muscle cells 
in vitro with both 1,25(OHhD3 and 1a(OH)D3 did result in gene changes in proliferating myoblasts 
through to the development of myotubes. The implications of these changes are considered to be 
important in terms of muscle growth and development, both of which are relevant to production 
systems in their ability to affect muscle size and fibre number as controlled by the myogenic process, 
the resulting fibre type of the muscle and meat quality via levels of proteolytic enzymes such as 
calpain I. It is important to note that observations in this thesis were made using both tissues 
removed from vitamin D-supplemented sheep and in skeletal muscle cell cultures and it would be 
useful to verify all the proposed vitamin D signalling effects in one model, such as in the muscle cell 
cultures in vitro. 
Finally, the results of this thesis implicate a potential role for vitamin D metabolites which has not 
yet been fully investigated in skeletal muscle cell development, and this is vitamin D's potential to 
alter fibre type development. The published work around 1,25(OHhD3 signalling in muscle cell 
growth reports the effects in terms of proliferation and apoptosis and resulting myotube 
development, however the targets known to be stimulated by 1,25(OHhD3 in these cells are also 
known to regulate the fibre type of muscle cells. The effect of vitamin D on muscle fibre type in 
elderly patients was summarised in section 1.3.6 of this thesis and in particular it is notable that 
1a(OH)D3 supplementation in patients resulted in an increase in fast oxidative fibres and a decrease 
in fast glycolytic fibres (Sorenson et 01., 1979). The results of the final experiments in this thesis 
showed that the overall fibre type of the C2C12 cells was not greatly changed within the 48 hour 
treatment of the experiment but there were still effects on the expression of some MHC genes. 
Expression of embryonic MHC and liB was decreased with 1a(OH)D3 treatment, while MHC I / ~ ~
expression was increased. These results are important to the meat industry as slow oxidative fibre 
type, associated with expression of MHC I / ~ ~ and IIA, is linked to tender meat whereas fast glycolytic, 
associated with MHC liB, is linked to tougher meat, as observed in hypertrophy of animals 
administered with ~ - a d r e n e r g i c c agonists which leads to increased MHC liB levels and type liB fibres. 
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4.5 Further Work 
There is much further work needed to fully evaluate vitamin D's affects on these systems and it is 
possible that different active metabolites and analogues of vitamin D could promote different 
effects, as was discussed within the preceding sections of this chapter. Further work to evaluate 
differences between these vitamin D analogues could easily be performed using the C2C12 cell line 
using some of the targets considered within this thesis and would exhibit any differences and 
similarities between vitamin D metabolites. Additional mRNA targets which should be considered in 
such an experiment would be the calpains I and" and calpastatin, all four MRFs, the MHC genes, the 
transcription factors C/EBPj3 and -6 and factors which control fibre type such as PGC1-a and PGC1-j3 
and the downstream factors of the PPAR isoforms. Additionally future work should further elucidate 
the effects of metabolites in intracellular signalling pathways such as the MAPK P38, ERK 1/2 and 
JNK, as all have the potential to be affected by vitamin D signalling. Such work would involve the 
evaluation of changes in ERK 1/2 activity and activation of proteins downstream of this kinase 
signalling pathway. 
The extent of each metabolites' effect on myoblast proliferation and on myotube development 
could be further investigated using measurements to assess cell growth and hypertrophy, for 
example DNA:protein ratio could be a simple measure of hypertophic responses. Additionally work 
to evaluate whether vitamin D metabolites control proliferation by inducing apoptosis could be 
performed, for example, work reported by DeHaes et 01. (1994) found that treatment of skin cells 
with 1,2S(OHhD3 for 24 hours resulted in increased levels of the anti-apoptosis protein BcI-2 and 
decreases in the pro-apoptosis proteins Bax and Bad, a response which was mediated by increased 
phosphorylation of ERK 1/2 by Akt. Again this implies that 1a(OH)D3 decreased phosphorylation of 
ERK 1/2 could therefore regulate apoptosis and cell proliferation as seen in the final experiment of 
this thesis but analysis of the apoptotic protein levels BcI-2, Bax and Bad would provide further 
insight. 
A longer study using active metabolites of vitamin D throughout the course of differentiation in 
muscle cells over a longer period could provide further insights into the effects of 1a(OH)D3 from 
proliferation through to formed myotubes. Incubating cells in 1a(OH)D3 treated media for longer 
than 48 hours could elucidate whether there is any inhibitory effect on proliferation through the ERK 
1/2 inhibition as proposed by Wu et 01. (2000). 
Additional work investigating more of the known vitamin D signalling pathways could elucidate 
la(OH)D3's effects on muscle cells in terms of positive or negative growth responses, 1,2S(OHhD3 
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has been reported to signal using a number of intracellular pathways including the phospholipids 
PIP2 and IP3, protein kinase C, cAMP and calcium itself. 
It would be useful to elucidate which pathways are up-regulated by la(OH)D3 and 1,25(OHhD3 in a 
direct experiment comparing both metabolites. Further there is much evidence to show that 
1,25(OHhD3 also activates the MAPK P38 and analysis of the activation of this protein could 
elucidate whether the la(OH)D3 again serves to decrease P38 activation, similar to its effects on ERK 
1/2. These experiments would need to assess a number of different Signalling pathways to evaluate 
the effects of these metabolites on muscle growth and fibre type; these would need to include 
measurements of both ERK 1/2 and P38 activity and effects on calcium influx and calcineurin activity. 
Downstream targets of these pathways would additionally need to be assessed and these would be 
NFAT activation, MEF- 2C and -2D, MyoD, and p300 to assess effects on MHC I / ~ ~ and IIA via the 
calcineurin pathway; and PGC-la and mitochondrial specific gene expression to assess effects of 
C / E B P ~ ~ on MHC I / ~ , , MHC IIA and mitochondria in promotion of the slow oxidative phenotype. It is 
likely that these effects will require longer than 48 hours to be observed .The hypothesised effects in 
muscle tissue of these two metabolites are summarised in figures 4.5-1 and 4.5-2 below, taking into 
account results accumulated in this thesis and published data. 
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Intracellular Signalling in Muscle cells 
la(OH)D3 & la,25-(OHhvit 0 
Binding at 
membrane 
receptor 8 
L-__________________ ~ ( ( VDR cl_-_-_ -.. - - - - - - - - - - - - - - - - - - ~ ~
Intracellular / -
signalling IP3 \ '" & 
Protein Kinase C. r-:---. +( _____ _ 
Caz+ and c-Sn: ~ ~
/ ~ ~
-?+ 
(ERIC 1/2) ~ ~ P38 
/ 
Outcome: Outcome: 
DAG 
'--> 
Intracellular Calcium 
ions 0 
O ~ ~
~ ~ Calcineurin 
\ 
·Reduced cell proliferation 
·Increased muscle hypertrophy 
·Promote slow twitch muscle 
fibres 
·Increased muscle hypertrophy 
·Promote Type II muscle fibres 
Outcome: 
·Promote muscle 
hypertrophy 
·Promote oxidative 
fibre type 
·MHC IIA and 1/13 
·MHCIIA 
Figure 4.5-1. Proposed mechanism and outcomes of intracellular signalling of biologically active vitamin 0 
isoforms within muscle cells. 
Gene Transcription in Muscle cells 
la(OH)D3 & la,25-(OHhvit 0 
~ ~ ::cve Vitamin 0 
~ H ) ~ ~ & 1 , 2 S ( O H h ~ ~
,. 
~ , ,.. 
mRNA products; 
·C/EBPP 
·Calpain I and II 
·MRFs 
·MHCgenes 
' 9 
De Novo Protein 
Synthesis 
MRF, Calpain & MHC genes: 
-7 Proliferation 
Hypertrophy 
Fibre type 
C/EBPB -7 ?? PGC-la: 
fibre type 
l' oxidative MHC 
-,1., glycolytic M C 
Figure 4.5-2 Schematic diagram of the possib le novel gene targets of la(OH)D3 and 1,25(OHhD! discovered 
in this thesis considered to be affected t hrough the classical VDR nuclear receptor mechanism, and the 
I 
hypothesized outcomes in muscle tissue . 
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Appendix A 
WBSF Sample Procedure 
Sample procedure for snap LD sample, pH of ca rcass and remo I f LD f h . 
va 0 or s ea r force chops IS 
demonstrated in diagrams below. 
pH sample point 
Initial snap 
<E-- l ' samp e slte 
2.4" 
( ) 
r------T------T------
: I I 
I I I 
I I I 
I 
I 
I 
I 
------1 
I 
- : ' : :; ; " " " - . t t · · ' 1 1
I 
I 
I 
: 4 J 3 12 1: ~ _ _ _ _ _ _ _ _ ____ _ ~ _ _ _ _ _ _ _ _ __ _ _ _ J 
~ - - - - - - - - - - O h r s n a p p i 
sample site 
LD Divided J:to c c o p s s
2.54cm thick 
Chops samp lee. a\\"C.y 
from 1 st Snap Si:e 
Both the left and right LD muscles were sampled in this way and num be red as set out in diagram 
above. Left and right chops were vacuum packed separately but were f rozen after the same period 
of aging, allowing two replicate chops per time point; left and right. 
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Latin Square Arrangement for Shear Force LD Chop San1ples 
WBSF Sample Procedure; 4 days Vitamin 0 3 Trial 1 
Position nu mber of sample 
Animal Pair Day 3 Day 7 Day 14 Day 21 
373/208 3 1 2 4 
.-4 219/467 2 3 1 4 
Q. 333/209 1 2 3 4 j 
0 U3/178 3 1 2 4 
'-
\.!) 293/297 1 2 3 4 
330/466 3 2 1 4 
181/148 2 3 1 4 
N 251/254 1 2 3 4 
Q. 364/361 3 1 2 4 j 
0 310/263 3 1 2 4 
'-
\.!) 332/169 1 2 3 4 
377/152 2 3 1 4 
464/462 3 1 2 4 
m 475/276 1 2 3 4 
Q. 421/182 2 3 1 4 j 
0 474/258 3 1 2 4 
'-
\.!) 168/171 1 2 3 4 
386/380 2 3 1 4 
1= anterior, 4= posterior. 
Note: Some LO samples were too small to recover 4 chops and so data set for chops aged 21 days is 
smaller. 
WBSF Sample Procedure; 7 days Vitamin 0 3 = Calcium Trial 2 
Position nu mber of sample 
Animal Pair Day 1 Day 3 Day 7 Day 14 
511/246 2 3 4 1 
.-4 308/518 4 2 3 1 
Q. 158/234 3 j 4 2 1 
0 281/535 3 
'-
2 4 1 
\.!) 455/478 2 4 3 1 
145/378 4 3 2 1 
296/180 3 2 4 1 
N 228/450 4 3 2 1 
Q. 141/101 2 4 3 1 j 
0 232/137 2 3 4 1 
'-
~ ~ 144/370 4 2 3 1 
215/274 3 4 2 1 
108/490 3 2 4 1 
m 339/338 2 4 3 1 
Q. 212/220 4 j 3 2 
1 
0 522/488 3 2 4 1 
'-
\.!) 213/515 4 3 2 1 
303/409 2 4 3 1 
1= anterior, 4= posterior 
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Appendix B 
Real-time peR oligonucelotides designed in sheep 
Primers for calpains I and II and calpastat in we re designed by primer express (V1 .S) in regions 
homologous to isoform. mRNA nucleotide sequences were created f rom shee p EST databases (NCBI ) 
and aligned to known sequences of bovine mRNA. These seq uences and position of primer and dua l-
labelled probe are shown. 
Ovine Sequence for Cal pain I 
>Calpain IOv ine . 
CGGTCCGGATTCCCGGGATCCCAGTTCAAAATCCGGCTGGAGGAGACGGATGACCCAGACCCCGACGATTACGGG 
GGTCGCGAGTCAGGCTGCAGCTTCTTGCTCGCCCTCATGCAGAAGCACCGCCGTCGAGAGCGCCGATTCGGCCGT 
GACATGGAGACCATAGGTTTCGCTGTCTACGAGGTCCCTCCGGAGCTGGTGGGCCAGCCGGCCGTGCATCTGAAG 
CGAGACTTCTTCCTGGCCAATGCCTCCCGGGCCCGGTCTGAGCAGTTCATCAACCTGCGGGAGGTCAGCACCCGC 
TTCCGCCTGCCGCCCGGGGAGTACGTGGTGGTGCCCTCTACCTTCGAGCCCAACAAGGAAGGCGACTTTGTGCTG 
CGTTTCTTCTCAGAGAAGAGCGCAAGGACCCAAGAGCTGGATGACCAGGTCCAGGCCAATCTCCCTGATGAGCAA 
GTGCTCTCAGAAGAGGAGATTGATGAGAACTTCAAGTCTCTCTTCAGACAACTGGCAGGGGAGGACATGGAGATC 
AGCGTCAAGGAGCTGCGGACCATCCTCAACAGGATCATCAGCAAACACAAAGACCTGCGGACCACGGGCTTCAGC 
GTGGAGTCCTGCCGCAGCATGGTCAACCTCATGGATCGCGACGGCAATGGCAAACTGGGCCTGGTGGAGTTCAAC 
ATCCTATGGAACCGGATCCGGAATTACCTGTCCATCCTATGGAACCGGATCCGGAATTACCTGTCCATCTTCCGG 
GTTTGACCTGGA GTCGGGCAGCATGAGTGCCTACGAGATGCGGATGGCCATTGAGTTTGCAGGCTTCCAG 
TCAACAAGAAGCTGTACGAG TCATTATCACCCGCTACTCGGAGCCAGAC CTGGCCGTGGACTTCGACACTTTG 
TGTGCTGCCTGGTGCGGCTGGAGACCATGTTCCGGTTTTTCAAAACTCTGGACACCGATCTGGATGGAGTGGTGA 
CCTTTGACTTGTTTAAGTGGCTACAGCTGACCATGTTTGCATGAGGCGGGGGCTCGGGCCCCTTGCTATGCTCCT 
CTGCCCTCCTCGTCCGCCAAGCCACGCCTTCCTGCGACACCACGCCAGGCCACACCAGCTGCAAGTGCCTTCCTT 
GGAGCAGGAGGCGGCCTCGACCTCCTGTCGCCTCTCCTTTCAGCCGCTGCGGTTCGTTTGCTATGGGCAGAGCCA 
TGGGGCCCTCCCTGCCTCCAACAGGCGCACGTGGACTCCTCCAGCCCCTCCGGTCGCCAGACCAGGGAGGCAGCT 
TTCGCTAGTTCCTGCCTCAGGATGGGGCTCCCCAGGGAGCTGGGGGCCCCTGGCCTCCCCCATCCTGACGTGTCC 
TCTCTCCTGCCCCCGCAGGCCAACCATTCGCCCCCCTCCCCCACCTGCAAACTT 
Primers: 
Forward : 
Reverse : 
[Reverse Antisense: 
Probe : 
Product length : 102bp 
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Ovine Sequence for Calpain II 
>Calpain II Ovine. 
G C C T G C A G A A G C T G A T C C G C A T C C G G A A T C C C T G G G G A G A G G T G G A G T G G A C C G G G C A G T G G A A T G A C A ~ C T G G C C
CAAACTGGAACACAGTTGACCCCGAGGTGAGGGAAAGCCTGACCAGACGGCACGAGGATGGGGAATTCTGGATGT 
CTTTCAGCGACTTCCTGAGACACTATTCCCGCCTGGAGATCTGCAACCTAACCCCTGATACACTCACCAGTGACA 
CCTACAAGAAGTGGAAACTCACCAAGATGGATGGGAACTGGAGGCGAGGCTCGACCGCGGGCGGCTGCAGGAACT 
ACCCAAACACGTTCTGGATGAACCCTCAGTACCTGATCAAGCTGGAGGAAGAGGACGAGGATCAGGAGGACGGGG 
AGAGCGGCTGCACCTTCCTGGTGGGCCTCATCCAGAAGCACCGCCGGCGGCAGAGAAAGATGGGCGAGGACATGC 
C A C C A T T G G C T T C G G C A T C T A T G A A G T T C C A G A G G A A T T T A C T G G G C C G A C C A A C A T C C A C C T C A A ~ T T
TCTTCCTGACAACCAGAGCGCGGGAGCGGTCGGACACCTTCATCAACCTGCGGGAGGTGCTCAACCGCTTCAAGC 
TGCCCCCCGGGGAGTACATCGTGGTGCCCTCCACCTTCGAGCCCAACAAGGACGGCGACTTCTGCATCCGGGTCT 
TTTCTGAGAAGAAAGCCGACTACCAAGTTGTCGATGATGAAATCGAGGCCAACCTTGAGGAGATTGACATCAGCG 
AGGACGACATCGATGATGGATTCAGGAGACTGTTTGCCCAGCTAGCTGGAGAGGATGCAGAGATTTCTGCCTTTG 
AGTTGCAGACAATCCTGAGACGAGTGCTAGCAAAGCGCCAAGATATCAAGTCCGACGGCTTCAGTATTGAGACCT 
GCAAGATCATGGTGGACATGCTCGACTCGGATGGGAGTGGCAAACTGGGTCTGAAGGAGTTCTACATTCTCTGGA 
CCAAAAATCAAAAA T 
Primers: 
Forward: CGGCGGCAGAGAAAGAT 
Reverse: 
[Reverse Antisense: 
Probe: 
Product length: 101bp 
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Ovine Sequence for Calpastatin 
>Calpastatin Ovine. U66320,Ovis aries calpastatin mRNA, complete cds 
AGGGAGCGACGCAGAGAGCCTCGTGTAGGTAGCAGCGGTACCGTAAACGTTCGACCACCATGTTCTGCGTACAGT 
CATCTTCTTGGTCATCTAGCGGAAGGTTCAGTCCTCTTTTCTTTCCTAGTCTACTCTTTTTTTCGTTGTTCGGTT 
GGGAGCAGTCAGCTCTCCAGAACTCAGGCTGGTGAAAAAGCCCCGGTCACCAAGGTAACTACTTCCTCTGCTTCA 
GCCAGCAAGTCTTCCAGTATGAATCCCACAGAAGCCAAGGCTATTCCAGGCAGCAAACAGCTGGAAGGACCGCAT 
TCTCCTAACAAGAAAAGACACAAAAAACAGGCTGTAAAAACAGAACCTGAGAAGAAGTCACAATCAACTAAGCCA 
TCTGTGGTTCATGAGAAAAAAACCCAAGAAGTAAAGCCAAAGGAACACACAGAGCCAAAAAGCCAACCCAAGCAC 
CCCTCAGATACAAGAAGCAAGCATGCTCCTAAGGAAAAAGCTGTTTCCAAGTCAAGCGAGCAGCCACCATCAGAG 
AAATCAACAAAACCAAAGACCAAGTCACAGGACGAGATTTCCGGTGGTGGAAAGAGCGCTGTTCCTGCTGTTGCA 
GCTGCAGCATCTGCCGAACCAGCTGACAAGAATAAAGAAAGTAAATTGTTAACATCGGCCGTGCCAGTTGAATCC 
AAGCCAAGTAAACCTTCTGCAAAGTCAGACATGGATACTGCTCTGGATGACTTAATAGACACTTTAGGAGAACCT 
GAAGAGACAAAAGAAGATACCACAACATATACTGGACCTGAAGTTTCGGATCCAATGAGTTCTACCTACATAGAG 
GAACTGGGTAAAAGAGAAGTCACACTTCCTCCAAAATATAGGGAACTTTTGAATAAAGAAGAAGGGATCGCAGGG 
CCTCCTCCAGACTCCTCGAAACCCCTGGGGCCCAATGACGCCATCGATGCCTTGTCATCAGACTTCACCTGCAGT 
TCCCCTACAGCTGATGCAAAGAAAACTGAGAAAGAGAAATCTACAGAAGAGGCTTTAAAAGCTCAGTCAGCTGGG 
GTGATCAGAAGTGCTGCTCCACCCAAAGAGAAAAGAAGAAAAGTGGAAGAGGATACCATGACTGAGCAAGCCCTG 
GAGGCCCTGTCTGCCTCCCTGGGCACCCGGAAGCCAAGGCCAGAGCTCGACCCCAGCTCCATTAAGGAGGTCGAT 
GAGGCAAAAGCCAAAGAAGAGAAAGTAAAGAAATGTGGTGAAGATGAGGAAAGAGTCCCATCGGAGTATAGATTA 
AAGCCGGCCACAGATAAAGATGGAAAACCACTCTTGCCAGAGGCTGAAGAAAAACCCAAGCCCCTGAGTGAATCA 
GAACTCATTGATGAACTCTCAGAAGATTTTGACCGGTCTAAGTGTAAAGAAAAACAATCTAAGCCAACTGAAAAA 
AACAGAGGCATCCCCGGCCGCTGCCCCCGTGCCTGTGCGAGAGGATGTGCCTCGGACCTCCATGTGTTCTGTGCA 
GTCAGCTCCACCCACAGCAGCTCCAGCGAAGGCATGGTGCCAGACGATGCTGTGGAAGCCCTTGCTGGAAGCCTG 
GGCAAAAAGGAAGCAGATCCAGAAGACGGAAAGCCTGTGGAGGATAAAGTCAAGGAGAAAGCCAAAGAAGAGGAT 
CGTGAGAAACTTGGTGAAAGAGAAGAAACGATTCCTCCTGATTACAGATTAGAAGAGGCCAAGGATAAAGACGGA 
AAACCACTGCCGCCAAAAGAGGTCAAGGAACCGCTCCCACCCTTGAGTGAAGACTTCCTCCTCGATGCTCTGTCC 
AAGGACTTCACTGTCCCCTCAGACACGTCATCGCCTCAATTTGAAGATGCTAAACTTTCAGTCGTCGTCTCTGAA 
GTGGTTTCCCAAACCCCAGCTCCAACCACCCAGGCAGCCGGTCCACCCCGCGACTCTGCGCGTGACAACAAAGAA 
TTGACGATGCCCTGGATCAACTTTCTGACAGTCTCGGGCAAAGACAGCCTGATCCAGATGAGC AAACCTGTA 
GAGGATAAAGTCAAGGAAAAAGCCAAAGCTGAACACAGAGACAAGCTGGGAGAAAGAGATGACACCATCCCACCT 
AAATACCAGCATCTTCTGGATGATAACAAGGAGGGCACACCCGGGAAGCCAAAGCGATCAGAAAGCCCGAGGCAT 
CAGAGAAGCCCGAGGCATCAGAGAAACCTGCAGGTGCCCAGGACCCCATTGACGCCCTCTCAGGGGACTTGGACA 
GCTGTCCCTCAACTACAGAAGCCTCAACAAACACAGCAAAGGACAAAGACAAGAAGCCTGCTTCCAAGTGACAAA 
GCACCCAGGAATGGCGGGAAAGCAAAGGATTCCACAAAGGCAAAGGAGGAAACTTCCAAGCCAAAAGCTGATGGA 
AAAAGTACAAGTTAAAATTCACAGTATTTGGTTCTGCATATAAAATCTGCAGCAGGTAGATGGTGACGTCTGAAG 
AACAAAAGGCTTTGACAACAGAAACAATTCTGGGGTGGCTTCTAGACAGTGGTATTTGTTGAGTCTTTTGACATC 
CTAAACATTGTCTGTTATTCTTTTTCCTGAAAAGAAACTGAATTTGTCTGGTTC 
Primers: 
Forward: 
Reverse: 
[Reverse Antisense: 
Probe: 
Product length: 101bp 
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Ovine calbindin D-28K PCR product 
A 263bp partial length cDNA for ovine ca lbindin D-28K was obtained from a 301bp amp licon 
generated by RT-PCR from ovine kidney cD NA (Miss C. Anike-Nkweze, University of Nott ingham ). 
Th is sequence has been BLAST (NCBI) searched aga inst the human kidney calbindin D-28k cDNA and 
found to be 91% similar, thereby confirm ing the PCR amplicon as being calbind in D-28kDa from 
ovine kidney tissue. The primers used to generate this 300bp product are as follows: 
Fo rward (CaIBF) : 
Reverse (CaIBR): 
[Reverse antisense: 
CTGCTCTTCCGATGCCAGC 
CTTTCCCACACATTTTGATTCCC 
GGGAA TCAAAA TGTGTGGGAAAG] 
>Calbindin reverse complement sequence RT-PCR product. 
KTT TGCTCTTCCGATGCCAG GCTAAAGTCCTGTGAGGAATTCATGAAGACATGGAGAAAATATGATACTGAT 
CACAGTGGCTTCATAGAAACTGAGGAGCTTAAGAACTTTCTAAAGGACTTGCTGGAAAAAGCAAACAAGACTGTT 
GATGATACAAAACTAGCTGAATATACAGACCTAATGCTGAAATTGTTTGATTCAAATAATGATGGAAAGCTGGAA 
TTAACTGAGATGGCCCAGATTACTACCCGTGCTATGGA 
Primers and probe were designed within this sequence fo r use in qRT-PCR 
>Calbindin reverse complement sequenc e RT-PCR product . 
KTTCTGCTCTTCCGATGCCAGCAGCTAAAGTCCTGTGAGGAATTCATGAAGACATGGAGAAAATATGATACTGAT 
CACAGTGGCTTCATAGAAACTGAGGAGCTTAAGAACTTTCTAAAGGACTTGCTGGAAAAAGCAAACAAGACTGTT 
G A T G A T A C A A A A C T A G C T G A A T A A ~ C A G A C C T A A T G C T G A A A T T G T T T G A T T C A A A T A A T G G T G G A A A G C T G G A A A
TAACTGAGATGGC CAGATTACTACCCGTGCTATGGA 
Primers: 
Forward (Calb28F) : 
Reverse (Calb28R): 
[Reverse antisense : 
Probe: 
Product length : 101bp 
ACAAGACTGTTGATGATACAAAACTAGCT 
GGCCATCTCAGTTAATTCCAGC 
CTGGAATTAACTGAGATGGC V 
ACAGACCTAATGCTGAAATTGTTTGATTCAAATAATGA 
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Ovine Sequence for B-actin 
Primers and dual labeled probe for ovine ~ - A c t i n n were designed to the mRNA seque nce as shown 
below, by Zoe Daniel (Univers ity of Nottingham ). 
>gi ! 88097 1S !gb !AF129289.1 !AF129289 Ovis aries strain Warhill beta - actin 
mRNA, partial cds 
ACCTTCTACAACGAGCTGCGTGTGGCCCCCGAGGAGCACCCCGTGCTGCTGACGGAGGCTCCTCTGAACCCCAAG 
GCCAACCGTGAGAAGATGACCCAGATCATGTTCGAGACTTTCAACACTCCTGCCATGTATGTGGCCATCCAGGCT 
GTGCTGTCCCTGTACGCCTCTGGCCGCACCACTGGCATCGTCATGGACTCTGGGGACGGGGTCACCCACACGGTG 
CCCATCTACGAGGGGTACGCCCTCCCCCACGCCATCCTGCGTCTGGACCTGGCTGGCCGGGACCTGACGGATTAC 
CTCATGAAGATCCTCACGGAACGTGGTTACAGCTTTACCACCACAGCCGAGCGGGAAATTGTGCGTGACATCAAG 
GAGAA!GCTCTGCTACGTGGCCCTGGACTTCGAG GGAGATGGCCACTGCGGCGTCGTCCTCCTCCTTGGAGAAG 
AGCTATGAGCTGCCCGATGGTCAGGTGATCACCATCGGCAACGAGCGGTTCCGGTGTCCCGAGGCGCTCTTCCAG 
CCGTCCTTCCTGGGTATGGAGTCCTGCGGCATTCACGAGACCACCTTCAATTCCATCATGAAGTGTGACGTGGAC 
ATCCGCAAGGACCTGTACGCCAACACGGTGCTGTCTGGTGGCACCACCATGTACCCTGGCATCGCCGACAGGATG 
CAG 
Forward : 
Reverse: 
[Reverse Antisense : 
Probe: 
Product length : 67bp 
JGTGCGTGACATCAAGGAGAA 
CGCAGTGGCCATCTCCTG 
AGGAGATGGCCACTGCG 
CTGCTACGTGGCCCTGGACTTCGA 
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Ovine MHC primers Developed by Krystal Hemmings 
Primers and probes for detection of the myosin Heavy Cha in genes by real-t ime RT-PCR were 
designed to three partial cDNA sequences which were generated by RT-PCR from ovine ske letal 
muscle total RNA by Krystal Hemmings (University of Nottingham) . 
MHC lIB 
>gi 113488743 1dbj IAB058898.1 1 Ovis aries OMyHCs mRNA f o r myosin heavy chain 
slow, partial cds 
GAGCCCCTTTCCTCTCGAAGGCGCGTTTGAAAAGCCAAGCCGCAGCCATGGTGGAYGCGGAGATGGCCGCGTTTG 
GGGAGGCCGCCCCCTACCTGCGCAAGTCAGAGAAGGAGCGGCTGGAAGCCCAGACCAGGCCTTTTGACCTCAAGA 
AGGACGTCTTTGTGCCTGATGACAAAGAGGAGTTCGTCAAGGCCACAATTTTGTCTCGAGAGGGTGGCAAAGTCA 
C C G G T G A A ~ C A G A G C A T G G C A A G A C A G T G A C C G T T A A G G G GGACCAGGTGTTGCAGCA AACCCACCCAAGTTCG 
ACAAGATCGAGGACATGGCCATGCTGACCTTCCTGCACGAGCCTGCCGTGCTC 
MHC lIB Primers 
Forward: 
Reverse: 
[Reverse Antisense: 
Probe: 
Product length: lOlbp 
MHCIIA 
[iCG TCA AGG CCA CAA TIT TG 
CTG CTG CAA CAC CTG GTC CT 
!4G GAC CAG GTG TTG CAG CAGV 
CA GAG CAT GGC AAG ACA GTG ACC GTG 
>gi1134887391dbj IAB058896.1 1 Ovis aries OMyHC2a mRNA f or myosin heavy chain 
2a, partial cds 
GCAGCCATGAGTTCAGACCAAGAAATGGCAGTCTTTGGGGAGGCTGCTCCTTACCTCCGAAAGTCCGAAAAGGAG 
CGCATTGAAGCCCAGAAT GCCTTTTGATGCCAAGACATCTGTCTTTGTGGCCGAGCCCAAGGAATCTTTTGTC 
A A A G G G A C T A T C C A G A G C A G A G A A G G T G G G ~ G T G ~ ~ G G T G A A G A C C G A A G G A G G G G C G A C T C T G A C A G T G A A A A
GAGGATCAAGTCTTCCCCATGAACCCTCCCAAATTCGACAAGATCGAGGACATGGCCATGATGACCCACCTGCAC 
GAGCCCGCTGTGCTG 
MHC IIA Primers 
Forward: 
Reverse : 
[Reverse Antisense: 
Probe: 
Product length: lOlbp 
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MHC IIX/IIB 
Sequence homogeneity between MHC IIX and MHC liB was too high for rea l time primer and probes 
to be developed for these genes separately and as there is very li tt le MHC li B expressed in the 
ruminant species any expression of MHC liB would be detected by pr imers and probes. 
>g i !13488741 !dbj !AB058897 . 1 ! Ov is aries OMyHC2x mRNA f or myosin heavy chain 
2x, partial cds 
CACTTCAAGGTTACATCTCCAAGGCAGGGTCTTTGATTGGGCTGCCATCAATAACCTGCAGCCATGAGTTCAGAC 
CAGGAAATGGCTATTTTTGGGGAGGCTGCTCCTTACCTCCGAAAGTCTGAAAAGGAGCGCATCGAGGCCCAGAAT 
AAGCCTTTTGATGCCAAGACCTCAGTCTTCGTGGCGGACCCTAAGGAGTCCTTCGTGAAAGCGACCGTGCAGAGC 
GGGAAGGGGGGAAGGTGACAGCCAAGACCG GCTGGGGCGACAGTAACT TGAAAGAAGACCAAGTCTTCCCC 
ATGAACCCTCCCAAGTTTGACAAGATCGAGGACATGGCCATGATGACCCACCTGCACGAGCCCGGAGTACTG 
MHC IIX/B Primers 
Forward: 
Reverse: 
[Reverse Antisense: 
Probe : 
Product length: l02bp 
CTT CGT GGC GGA CCC T AA G 
CAG n A CTG TCG CCC CAG CT 
G eTG GGG CGA CAG TAA CTG 
f-:.GC GAC CGT GCA GAG CAG GG 
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Appendix C 
Solutions used to create denaturing protein Gels 
SDS- PAGE Acrylamide Solutions for two 20 x 10cm protein Gels 
1 MAIN GEl 8% 10% 
acrylamide (ml) 13.3 16 .7 
2M Tri s-HC L (pH 8 .8) (ml) 9.4 9.4 
10% SOS (ml) 0.5 0.5 
distilled Hp to SOm is 
Mix Solutions before addit ion of 10% AM PS & TE M ED 
10% (w/v) ammonium persulphate (AMPS) (ml) 
N,N,N'N' - tetramethyl -ethylenediamine (TEMEO) (ml ) 
2 STACK 
acrylamide (ml) 
1M Tris-HC L (pH 6.8) (ml) 
10% SOS (Ill) 
distilled H20 
0.4 
0.04 
2Sm l (for two ge ls) 
3.4 
2.52 
200 
to 20ml s 
M ix Solutions before add ition of 10% AM PS & TE MED 
10% (w/v) ammonium persulphate (AMPS) (ml) 
N,N,N'N' - tetramethyl-ethylenedia mine (TE ME 0 ) (m l) 
0 .2 
0.02 
12% 
20 
9 .4 
0.5 
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Appendix D 
Protein Antibodies 
For analysis of protein expression levels in sheep tissues the following antibodies were used using the conditions provided below. Antibodies were diluted 
in 5% (w/v) non fat dried milk- TBS-T solution at the concentration stated in the table below. Each protein required the separation of either supernatant or 
whole homogenate protein fraction by action of gels containing differing levels of acrylamide. The amount of protein loaded and the dilution of both 
primary and secondary antibodies were optimal for production of clear bands following western blotting. 
Primary Antibody Gel% Protein (Ilg) Tissue Protein Fraction Dilution Source secondary Antibody " Source 
Ca lpain I 10 100 L.D. Muscle Supernatant 1:500 Parr, to Porcine Anti -Rabbit 
Ca lpain II 10 100 L.D. Muscle Supern atant 1:1000 Parr, to Porcine Anti -Rabbit 
Ca lpastat in 8 100 L.D. Muscl e Whol e Homogenate 1:1000 Monoclonal to Clone IF7E3DlO Anti-Mouse 
Calbindin 12 100 Kidn ey Whol e Homogenate 1:1000 Monoclonal to Clone DB-955 Anti-Mou se Sigma 
VDR 12 100 Kidney Whol e Homogenate 1:500 Monoclonal to chicken i ntest i nal VDR, Abeam Ant i-Rat 
Desmin 8 100 L.D. Muscl e Whol e Homogenate 1:500 Polyclon al, Abeam Anti -Rabbit 
MHC fast 8 3 L.D. Muscl e Whole Homogenate 1: 1000 Nova Castra Anti-Mou se 
MHC slow 8 3 L.D. Muscl e Whole Homogenate 1:1000 Nova Cas tra Anti-Mou se 
• All at Dilut ion 1:5000 
Primary Antibody Gel % Protein ( ~ ) ) Source Total Protein Ab Phosporylated Protein Ab secondary Antibody Source Luminesce nce 
4EBP1 15 5 Ce ll Signalling #9452 * #9459* Ant i Ra bbit * Sigm a ECL- Advance 
MAPKinase ERK 1/2 10 5 Ce ll Signa ll ing #4695* #4370* 
* All at Dilut ion 1:5000 
215 
Appendix E 
Semi-quantitative oligonucleotides used in Rat 
Rat MHC Primers 
Primers to determine MHC expression profile of rat derived cells were used from two publi cat ions; 
primers for the neonatal and embryonic MHC were designed by Sanchez et 01. (2006) while the 
primers for the four adult MHC isoforms were designed by Jaschinski et 01. (1998) . The regions of the 
sequences to which each primer set was designed to are shown below with highlighted fo rward 
primer in green, reverse antisense of the reverse primer highlighted in purple . 
Rat Embryonic MHC Primers 
Designed by Sanchez et 01., (2006) towards the 5' end of the sequence, product is 181bp. 
Forward: ~ G C A G A G G A G G C T G A G G A A C A A T C C
Reverse: 
[Reverse antisense: 
h e a vy c hai n gene , partial 5' reg i on, mRNA 
ggctgaggaa caatccaacg t c aacc t gg c caa gttccgc 
66 1 ggaagccgag g a gcgggcag acatcgccga g tccca ggtc 
72 1 c c g c gagg t t c a c a ccaa a a tcagtgc a a gtaaacgca 
78 1 g c tgaaggaa agg c acagaa tgtgctgcc t tgggtcgctt 
84 1 tgtttacttt t ctcc c actg ctgactgaat aaaacc a caa 
Rat Neonatal MHC Primers 
Designed by Sanchez et 01., (2006) towards the 3' end of the sequence, product is 103bp. 
Forward: 
Reverse: 
[Reverse antisense: 
>NM 012 6 04 Rattus n o r v egicus myosin , heavy p o lypepti de 3, s keletal muscle, 
embryonic (My h 3) , mRNA 
576 1 aatgttcatc tcaccaagtt taga ggaggc cgaggaacgt 
582 1 gcggatattg c a g a a a c g ~ ~ c c ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
588 1 agccggatgg t g g t c c c ~ a ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
5941 atatgcagaa tgtatgtttt 
600 1 tttccacatg caataaaatt 
cttcacctct 
ggggcagaag 
acgtaacccc 
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RAT MHC I (Slow) 
Designed by Jaschinski et 01., (1998) towards the 3' end of the sequence, product is 288bp. 
Sense: 
Antisense : 
IACA GAG GAA GAC AGG AAG AAC CTA C 
GGG cn CAC AGG CAT CCT TAG 
[Reverse antisense : TA AGG ATG eeT GTG AAG ee V 
> NM 017 24 0 Rattus norv egicus myosin, heavy po l ypeptide 7, c a rd iac 
mu scle , beta (Myh7 ) , mRNA 
5461 ccgggtccgg gagctggaga atgagctgga ggctgagc a g aagcgc a atg cggagt c gg t 
5521 gaagggcatg aggaagagcg c aaggagctc accta ccaga cagaggaaga 
5581 ctac tgcgac ggtggacaag c t gc a gttaa aggtga aggc 
5641 caggctgagg acaggccaac a ccaacctgt ccaagttccg 
570 1 cacgagctgg ggagagggc g ga c a ttgccg agt c ccaggt 
5761 caa c aagctg c c g g c c r a ~ a ~ g ~ a ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
5821 ct tgtgctac 
tggcgccaag ggcctgaatg aagagtaga t 
g a cctggagc ctttgaaaca 
5881 gcaccttagg cagaaacaca ataaagcaat gccaa 
RAT MHC IIA 
Designed by Jaschinski et 01., (1998) towards the 3' end of the sequence, product is 310bp. 
Sense: AT CCT CAG GCT TCA AGA Tn G 
Antisense: 
[Reverse antisense: 
>L1 360 Rattus norvegicus skeletal muscle myosin heavy chain mRNA, 3 ' end 
241 gttgaggctg tcaaagggct tcgaaaacac gagaggc gag t ga aggagct tacttacc a g 
30 1 acagaagaag accgaaaaaa t atcctcagg cttcaa gat t tggtggataa actccaagc a 
36 1 aaagtaaaat ct tacaagag acaagctgag gaggc tgagg a acaatccaa c a caaatcta 
421 tccaagttcc gcaagctgca gcatgagc tg gaggaagccg aggagcgggc tgac at cgcc 
481 gagtcccagg t caacaagct gcgggtgaag a gccgc gagg ttcac actaa agt c ataagt 
541 gaagagtaag gcagctctga tgctgtagaa t g a ccgaaga gaggc a caaa at g tgaagcc 
60 1 tttggtca tccccatgt attctaJttt at c c t a ttgt aa 
Rat MHC IIX 
Designed by Jaschinski et 01., (1998) towards the 3' end of the sequence, product is 120bp. 
Sense: 
Antisense : 
[Reverse antisense: 
>XM 213345 Rattus norv egicus type 2X myosin heavy cha in (Myh1 ) , mRNA . 
600 1 gagctggagg aagccgagga g c gggc t gac atcgccgagt cccaggtcaa caagc tgc gg 
606 1 g t g a a g a g g c ~ g p g a g g t t c a a caccaaaa tc ataagcga ag a gtgatcgat ccaaagc agg 
6121 aaagtgac c a aagagatgag c aaaatg t ga agat c t ttgt c a c c ~ c a t t t t tgtacttacq 
618 1 lIlC't"1:t ataaaaaatt t at c t gcca 
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RAT MHC liB 
Designed by Jasch inski et 01., (1998) towa rds the 3' end of the sequence, prod uct is 197bp. 
Sense: 
Antisense : 
[Reverse ant isense : 
CTG AGG AAC AA T CCA ACG TC 
TIG TGT GAT TIC TIC TGT CAC CT 
G GTG ACA GAA GAA A TC ACA CAA ] 
> BC l13 9 4 8 Rat t us n o r v egicus myosin , heavy po l ype ptide 
ggataaatta c agac taaag tgaaagccta caagaga caa 
5761 atccaacgtc aacc tggc c a agtt ccgcaa ga tccagcac 
582 1 gcgggccgac atcgc c gagt cccaggtcaa caa gctgcgg 
588 1 caccaaagtc ataagcgaag aatagctcaa ttccttctgt 
59 41 cacaca t gt gacgttcttt gtc a ctg t cc t gt a tatcaa 
600 1 att t tgc aaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 
4 , skeletal 
gcagaggagg 
gagctggagg 
gtgaagagcc 
t g a a a g ~ t g a a
ggaaataaaa 
aaaaaaaaaa 
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Appendix F 
Oligonucleotides used in Mouse 
Mouse MHC primers 
Primers and probes designed for real time PCR to mouse MHC genes were designed by da Costa et 
01. (2007), to isotype the C2C12 cell line the primers were used in semi-quantitative RT-PCR react ions 
and products electrophoresed in a 1.5% agarose gel. The regions of the sequences to w hich each 
primer set was deigned to are shown below with highlighted forward primer in green, reverse 
antisense of the reverse primer highlighted in purple, dual labelled fluorescent probe is high lighted 
blue. 
Mouse MHC Embryonic 
Sense: 
Antisense: 
[Reverse antisense: 
rcc GAC AAC GCC TAC CAG TI 
CCC GGA TIC TCC GGT GAT 
TC ACe GGA GAA rcc G G G ~ ~
Probe: ATG CTG ACT GAT CGT GAG AAC CAG TCT ATC CT 
> XM 908146 Mus musculus 
embryonic (Myh3 ) , mRNA. 
myosin, he a vy p o l ypept i de 3, s ke letal mu s cle, 
421 t c aaccccta caaatggc tg ccagtgtac a 
48 1 ggaggct c cg cccca c at c t 
54 1 t c g t g a a ~ a ~ a ~ c ~ c ~ a ~ t ~ c ~ t ~ a ~ t ~ c ~ c ~ ~
601 caagcgggtc atc c agtac t 
MOUSE MHC Neonatal 
Sense: 
Antisense: 
[Reverse antisense: 
Probe: 
56 41 
57 01 
576 1 
582 1 at cc tac aag 
tggc gctgaa 
aaggagagg t 
atgaaag a ag 
ggctgcagga 
a gga ggc tga 
gggcggcaag 
cga aaatgaa 
agtaaaggaa 
c c t ggtggac 
ggaac a atcc 
ggtggacggc taccgaggca 
cgacaacgcc taccagttc a 
agaatccggg gccgggaa ga 
tgc a gc c a c t ggggaccttg 
8, skeletal muscle, 
aagca g a tcc agaaactgga 
c a gaaacgca atgctgaggc 
cttacctacc agac tgagga 
aaattacagg cgaaggtgaa 
aatgccaacc tggccaagtt 
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MOUSE MHC I (Slow) 
Sense : 
Antisense: 
[Reverse antisense : 
Probe: 
GCC TGG GCT TAC CTC TCT ATC AC 
cn CTC AGA cn CCG CAG GAA 
'CCTGCGGAAGTCTGAGAA 
CGT TTG AGA ATC CAA GGC TCA 
> AY0 56464 Mus musculus beta my o sin heavy chain mRNA, 
cds . 
complete 
1 
61 
12 1 
18 1 
MOUSE MHC IIA 
Sense: 
Antisense : 
[Reverse antisense: 
Probe : 
cctgc t g tt t cctta cttgc tac c ctc agg tggctccgag a a aggaagcc 
tcctacaggc ctgggcttac ctctctatca c tagacacgt 
catggcggat gcagaga tgg ctgcatttgg ggctgcagcc 
a gagg c tggaggc a c agaccaggcc ctttgacctc 
CAG CTG CAC CTT CTC GTT TG 
CCC GAA AAC GGC CAT CT 
G ATG Gce GIT ITC GGG] 
TGA GTT CAG CAG TCA TGA G 
> NM 00 1039 545 Mus mus cul u s myosin , hea vy polypept i de 2, skeletal 
mu s c l e , a dul t . 
1 t a gctagcca tataaaagag tcccgaac ga ggc tgactcg t cctgcttta aaaagctcca 
61 aggaccctct tatttcccag ctgcaccttc tcgtttgcca g taagggtct g tgagttcag 
121 cagtcatgag ctccgacgc c ga at ccg ttttcgggga ggctgcccct tacctccgga 
MOUSE MHC IIX 
Sense : GGA CCC ACG GTC GAA GTT G 
Antisense: 
[Reverse antisense : 
Probe: 
> NM 0306 7 9 Mus musculus my o sin , heavy p o l ype ptide 1, skeletal 
mus c le , adult 
1 
61 
12 1 a cc tccggaa 
~ " - - " ~ ~
ttgcatcc c t aaaggc a ggc tctctcactg 
tccgacgccg agatggccgt tttcggggag 
gagcgaatcg aggctcagaa caagcctttt 
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MOUSE MHC liB 
Sense : 
Ant isense : 
[Reverse antisense : 
Probe : 
eAA TCA GGA ACC TIC GGA ACA C 
GTC CTG GCC TCT GAG AGC AT 
TGCTCTCAGAGGCCAGGAQ 
GC TGA AGG ACA CAC AGC TGC ACC T 
> NM 01085 5 Mus mu s cul us myosin, heavy polypeptide 4, s kele tal mu scle 
(Myh4) 
4921 agcaggaa t g atgc t ctgag gattaagaag a a g a t g g _ a ~ g g ~ g ~ a ~ g ~ a _ c ~ c ~ t _ c ~ a a ~ t ~ g a g a t g g a g g
a ccatgccaa ccg ccaggct gcggaggcaa tcaggaacct tcggaacacc 
t a a g g ~ a ~ c ~ a ~ c ~ a ~ c ~ a ~ g ~ c ~ t ~ g g ~ a ~ c ~ c ~ t g g a c c a t g g ctctcaga gg ccag acgac 
a gctggcc a t gg t tgagcgc agagccaacc tgatgcaggc tgagatcgag 
4981 
5041 
5101 
Mouse real-time RT -PCR Targets 
In addition to the real-time RT-PCR primers and probes designed to the M HC genes, primers and 
probes were required for signaling factors and markers of different iat ion designed to mouse 
sequences. Primers and probes to the myogenic regulatory factor Myf5 and the inte rn al control ~ ~
actin were designed by da Costa et 01. (2007) . Primers and probes to measure desmin as a marker for 
the presence of differentiated muscle cells were designed using Primer Express V. 1.5. A f ragment of 
sequence 30 base pairs of nucleotides either side the Desmin prod uct was BLAST sea rched to detect 
any homogeneity with other sequences. The search returned on ly mouse desmin f ragments and it 
was concluded that the primers and probes were specif ic to the seque nce and we re used in real time 
qRT-PCR analysis. 
Mouse cell culture targets 
Target Protein 
myfS 
~ - A c t i n n
Desmin 
Mouse MyfS 
Sense: 
Antisense: 
[Reverse antisense: 
Probe : 
481 
541 
601 
actattacag 
ctgacggcat 
gcatctactg 
Sequence 
X56182 
NM 007393 
BC031760 
tggattgctt gtccagcatt 
Primers designed by Product Size 
da Costa et 01 ., 2007 117 
da Costa et al., 2007 72 
Pri me r Express V. 1.5 101 
cagccccacc 
aaagaacagc 
taaaagctcc 
agagccatct 
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Mouse B-actin 
Sense : 
Antisense : 
[Reverse antisense : 
Probe: 
421 
481 
54 1 ctccggagac 
Mouse Desmin 
Sense: 
Ant isense: 
[Reverse antisense: 
Probe : 
CGT GAA AAG ATG ACC CAG ATC A 
CACAGCCTGGATGGCTACGT 
CG TAG CCA TeC AGG (JiG IGQ 
iITG AGA CCT TCA ACA CCC CAG CCA TG 
gctcaccgag gcccccctga accctaaggc 
t a acc ttc aac a ccccag ccatgt a c 
ctc tggtcgt accacaggca ttgtgatgga 
catctacgag ggctatgctc tccctcacgc 
GCG CAG AAT CGA ATC CCT C 
GGA CCT GCT GTT CCT GAA GC 
C TTC AGG AAC AGC AGG reel] 
CGC GTT CCT TAA GAA AGT GCA TGA AGA GG 
> BC031760 Mus musculus desmin, mRNA 
66 1 aaatccaact aagagaagaa gcagagaaca acttggctgc cttccgagcg 
721 agctcgtatt gacctggagc gcagaatcga atccctcaac 
78 1 aaagtgcat gaagaggaga tccgtgagct tcaggccca 
84 1 ggtggagatg gacatgtcca agccggacc t c a cagctgcc 
This product was nucleotide BLAST searched against the Mouse Genomic + Transcript database and 
returned one mRNA transcript sequence, NM_010043.1 with 100% simila rity (E value : 8e-l06), this 
was a mouse desmin mRNA sequence. No other mRNA sequences were recovered with this product 
and so it was deemed specific to desmin in mouse. 
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Appendix G 
"Assay on Demand" Oligonucleotides (ABI) 
Assays on demand used on (2(12 real time peR analysis. All assays were purchased from Applied Biosystems and were mouse specific. 
Target Gene Gene Name 
Cyclophi lin A peptidylprolyl isomerase A 
GAPDH glyceraldehyde-3-phosphate dehyd rogenase 
Myogenin myogenin 
C / E B P ~ ~ CCAAT/enhancer binding protein (C/EBP), beta 
c-Myc myelocytomatosis oncogene 
Rbp4 Retino l Binding Protein 4 
M eta ll othioenin 2A metalloth ionein 2 
Pa rva lbumin parvalbumin 
Assay ID 
Mm02342430_g1 
Mm03302249_g1 
M m00446195 _gl 
MmOO843434_s 1 
MmOO487804_ml 
MmOO803266_ml 
MmOO809556_s1 
MmOO443100_ml 
Category 
Isomerase 
Oxidoreductase 
Transcription factor 
Transcription factor 
Tran scription factor 
Tran sfer/carrier protein 
Miscellaneous function 
Se lect cal cium binding protein 
Gene Group 
Other isomerase 
Dehydrogenase 
Basic helix-loop -he lix transcription factor 
Other tran scription factor 
Ba sic helix- loop-helix transcription factor 
Other- transfer/ca rrier protein 
Other misce llaneous fun ction protein 
Calmodu lin re lated protein 
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Appendix H 
C2C12 RNA agarose gel electrophoresis 
The preparation of C2C12 RNA was evaluated by both Nanodrop spect rometer and by visual 
assessment after agarose gel electrophoresis . The mRNA was diluted to a constant conce ntration of 
O.1Ilg/1l1 before O.5llg was loaded onto a 1.5% agarose gel and separated by electrop hores is and 
imaged using ethidium bromide stain and GelDoc software and equipment (Biorad , Hemel 
Hempstead, UK). These images of the mRNA provide evidence to show that all mRNA was intact for 
both 28s and 18s rRNA and for tRNA and would therefore provide a high quality temp late for cDNA 
synthesis without the need to normalise to a housekeeping gene at real-time RT-PCR level. 
Pre-Confluent Myoblasts, 48hr Vitamin D3 
lKb 100bp DMSO 10..5 10-9 10-11 
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Day 0 C2C12 Myoblasts 
1Kb 100bp DMSO 1 0 ~ ~ 103 10-9 10-11 
.. 3 _ 1 . 2 3 1 2 3 1 2 ..... 3----'''----'''''--
Day 3 C2C 12 Differentiating Myoblasts 
lKb 100bp DMSO 10-11 
22 5 
Day 7 C2C12 Myotubes 
lKb 100bp DMSO 1 0 ~ ~ 10-9 10-11 
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Appendix I 
Tria l 2 Feed Refusal Data 
Feed refusal data for vitamin D plus calcium fed animals in trial 2 and the effects of feed refusals on plasma vitamin D3, serum calcium, pH, weight at 
slaughter (liveweight ) and carcass weight . Tota l feed refused is in g, over the course of the week 9800g was presented to all animals. 
Vitamin D animals SLG Refusal vit d only diet (g) Refusal Ca diet (g) Total Refused g 
511 1 0 0 0 
308 1 0 0 0 
158 1 0 0 0 
281 1 0 0 0 
455 1 541 1384.7 1925.7 
145 1 0 211.8 211.8 
296 2 0 706.2 706.2 
228 2 0 147.3 147.3 
141 2 0 88.9 88.9 
232 2 0 0 0 
144 2 0 0 0 
215 2 1149.8 1115.3 2265.1 
108 3 0 1798.4 1798.4 
339 3 0 0 0 
212 3 764.2 1554 2318.2 
522 3 0 321.9 321.9:t 
213 3 1998.9 985.5 2984.4* 
309 3 0 0 0 
Vitamin D + Calcium Animals Plasma D3 (ng/ ml) Serum Calcium (mg/L) pH 45 mins pH 24Hrs Liveweight Carcass Wt 
Ate all f eed (n=8) 1202 145.3 6.493 5.543 49.21 25.12 
Range (min ·max ) 1045 .7 to 14 30 .8 132 .95 to 164.4 45 .3 to5 l.0 
Refu se d feed (n=10) 1252 140.6 6.436 5.483 47.44 25.36 
Ra nge (min -ma x) 728.4:j: to 14 28 .8 126 .2 to 159 .7 45 .2 to 49 .9 
5.E.O. 11 3.7 5.596 0 .122 0 .0315 0.784 0.44 
P 0 .664 OA11 0.646 0.091 0.038 0 .603 
Animal with lowest plasma vitamin D ~ ~ (728.4ng/ml) did not have the largest feed refusal (321.9g), denoted with :to Animal with highest feed refu'>al, denoted With • 
had plasma vitamin 0 , level of 1152.2ng/ml and serum calcium concentration of 148.25 mg/L. 
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Appendix J 
Real-time PCR data of C2C12 myoblasts 
mRNA extracted from (2(12 cells was quantified using Nanodrop spectrometer prior to dilution to constant concentration before samples were visually 
checked for integrity using agarose gel electrophoresis . mRNA expression data obtained for all genes measured by qRT-P(R in (2(12 cells across 
differentiation analysed by two-way AN OVA, results presented in section 2.6: 
Days post differentiation 
Gene \ Treatment 
Cyclophilin A (LD) 
Cyclophilin A (Day 10) 
GAPDH (LD) 
GAPDH (Day 10) 
Beta Actin (LD) 
Beta Actin (Day 10) 
Days po st differenti ati on 
Gene 
De smin 
Myoge nin 
Myf 5 
Me tall othi onein 2A 
Parv albumin 
C C E B P ~ ~
c-Myc 
Days po st differentiatIOn 
Gene \ Treatment 
Embryon iC MHC 
MHC I (slow) 
MHC IIA 
MHC IIX 
MHX liB 
2 
DMSO 10-11 10-9 10-7 
0 .0687 0 .0943 0.0555 0 .0828 
0.0413 0 .0591 0.0329 0 .0511 
0 .01286 0 .01484 0.0111 0 .01193 
0 .043 0 .054 1 0 .0347 0 .0389 
0 .2038 
0 .1528 
0 .2 094 
0 .1564 
2 
0 .18 0 .2047 
0 .1371 0 .1 533 
5 9 S.E.D. ANOVA P value 
DMSO 10-11 10-9 10-7 DMSO 10-11 10-9 10-7 Age Treatment A*T Age Treatment A*T 
0 .0813 0 .1006 0 .0953 0 .0784 0 .0508 0 .0568 0 .0232 0 .0422 0 .0 11 65 0 .01345 0 .0 23 29 0 .00 2 * 0 .30 2 0 .808 
0 .0498 0 .0628 0.0592 0 .0479 0.0298 0 .0341 0 .0128 0 .0248 0 .0076 3 0 .0088 1 0.0 15 27 0 .002 * 0 .294 0 .8 1 
0 .975 
0 .966 
0 .01343 0 .01498 0 .01263 0 .01236 0 .01178 0 .0105 1 0 .00786 0 .00927 0 .00135 1 0 .00156 0 .002702 0 .038* 0 .245 
0 .046 0 .0537 0.0419 0 .0408 0 .0382 0 .0325 0 .0213 0 .0284 0 .00615 0 .0071 0 .01 23 0 .044' 0 .218 
0 .1847 
0 .1404 
0 .198 0. 1734 0 .1487 0 .1279 0 .1404 0 .1128 0 .1187 0 .00613 0 .00708 0 .01 22 6 <.001' 0 .002' 0 .158 
0 .1491 0 .133 0 .1166 0 .1024 0 .1112 0 .092 0 .0959 0 .0040 4 0 .00466 0 .00807 <.001 ' 0 .00 2 ' 0 .156 
5 9 5.E.D. 
DM50 10-11 10-9 10-7 DM 50 10-11 10-9 10-7 DM50 10-11 10-9 10-7 Age Treatment A' T Age 
ANOVA P valu e 
Trea tment A' T 
04988 0473 8 0 .3922 04704 0469 2 04652 0.45 0.456 0477 04806 0 .3982 0.4912 0 .01877 0 .021 67 0 .0 3753 0 .988 0 .01 6 ' 0 .607 
2.188 1.342 146 1469 
0 .0467 0 .0626 
1.592 
0 .052 
1.547 0 .863 0 .928 0.479 0 .757 0 .1838 02122 0.3676 < 001* 0 .3 4 5 
0 .049 0 .0381 0 .0542 0 .0343 0 .0535 0 .00542 0 .00626 0 .01084 0 .001' 0 .154 
0 .65 4 
0 .8 19 
1.724 
0 .0289 
0 .08 11 
0 .01 
0 .0 8 
0 .07 0 9 
0 .0339 0 .0258 
0 .0323 0.0176 
0 .0 21 0 .0066 
0 .331 0 .218 
0 .078 1 0 .0 62 4 
1.553 
0 .03 16 
0 .0213 
0 .0114 
0 .0196 0 .0149 0 .0309 0 .0183 0 .0098 0 .0171 0 .0047 0 .0152 0 .00642 0 .00742 0 .0 128 4 0 .001* 0 .0 54 0 .005 ' 
0 .0156 0 .023 0 .0215 0 .0188 0 .0165 0 .0194 0 .0 102 0 .0 34 0 .00347 0 .0040 1 0 .00 694 0 .0 58 0 .0 76 0 .138 
2 
0.274 
0 .064 2 
0 .051 0.398 0 .289 
0 .1077 0 .1311 0 .0736 
5 
DM50 10-11 10 -9 10-7 DM SO 10-11 10-9 
0.1993 0.1896 0.165 0. 1962 0. 1744 0. 1577 0. 1622 
0.402 
0 .00427 
00481 
0.00 192 
0 .3388 0.29 19 0 .38 28 
0.00453 0.0025 0.00339 
0 .0511 0 .0444 0 .0564 
0 .00181 0 .0015 0 .00216 
0.2356 0 .2202 0.2 4 28 
0 .00458 0.00498 0.00608 
0 .0568 0 .0577 0 .0564 
0.00298 0.0025 0.00286 
0.374 0 .035 0 .2 95 0 .082 0 .17 0.0557 0 .0643 0 .11 13 0 .077 0 .001* 0 .8 89 
0 .081 0 .0455 0 .0405 0 .0399 0 .0 337 0 .00919 0 .01061 0 .01 838 <.001* 0 .08 0 .45 
9 S.E D . ANOVA P va lue 
10 -7 DM50 10- 11 10-9 10-7 Age Tr ea tment A+T Age Trea tmen t A'T 
0. 1827 0. 128 0. 11 53 0.1029 0. 129 7 0.005 7 0.00658 0.0 114 <.00 1 + 0 .002 + 0 .7 
0.3 499 0 .2 0. 1498 0.206 7 0.2232 0 .02 434 0 .028 1 0 .04867 < 001 + 0 .032 + 0 .3 4 
0.00 737 0.02588 0.022 1 0.023 71 0.02788 0.00 111 0.00 1 282 0 .00222 < 001 + 0 .275 0 .39 
0.0664 0 .096 0.0958 0 .08 18 0 .1079 0 .00629 0 .00726 0 .0 1257 <.001 + 0 .204 0974 
0.00216 0.00579 0 .005 4 7 0 .004 47 0 .00625 0 .00036 0 .00041 9 000073 < 00 1 + 0 "' 3 1 0,., 12 
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Appendix K 
Average Housekeeping gene values for real-time PCR data of C2C12 myoblasts across differentiation 
Analysis of Average Housekeeping values in timecourse experiment 
Days Post Differentiation 2 5 9 S.E.D. ANOVA P Value 
DMSO 10-11 10-9 10-7 OM SO 10-11 10-9 10-7 OM SO 10-11 10-9 10-7 Age Treatment A*T Age Treatment A* T 
Average of all three Housekeeping genes 
LD Stand ard Curve 0.095 0.106 0.082 0.1 0.093 0.1045 0.094 0.08 0.064 0.0693 0.048 0.057 0.00583 0.00673 0.01166 <.001 0.058 0.652 
Day 10 Standard Curve 0.079 0.09 0.068 0.081 0.079 0.0885 0.078 0.068 0.057 0.0593 0.042 0.05 0.00552 0.00637 0.01103 <.001 0.083 0.843 
Average GAPDH and Cyclophilin A 
LD Standard Curve 0.041 0.055 0.033 0.047 0.047 0.0578 0.054 0.045 0.031 0.0337 0.016 0.026 0.00646 0.00746 0.01293 0.003 0.303 0.843 
Day 10 Sta ndard Curve 0.042 0.057 0.034 0.045 0.048 0.0582 0.051 0.044 0.034 0.0333 0.017 0.027 0.0068 0.00786 0.01361 0.008 0.274 0.925 
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Appendix L 
Protein data of C2C12 myoblasts across differentiation 
Level of phosphorylation of two protein targets in (2(12 cells treated with 1a(OH)D at three time points post differentiation, data presented in section 
3.6.11. 
Days Post Differentiation DayO Day 3 Day7 S.E.D. P 
Protein / 1a(OH)D Dose DMSO 10-11 10-9 10-7 DMSO 10-11 10-9 10-7 DMSO 10-11 10-9 10-7 Age Treatment A*T Age Treatment A*T 
ERK 1/2Phosphorylation 0.787 0.617 0.498 0.723 1.533 0.670 0.577 1.063 1.178 0.683 0.679 0.578 0 .0469 0 .0541 0 .0937 0 .016 <.001 0 .007 
4EBP1 Phosphorylation 0.827 0.902 0.847 0.802 0.841 0.757 0.710 0.722 0.730 0.761 0.815 0.693 0 .0317 0 .0366 0.0635 0.019 0 .852 0.428 
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